Tumour necrosis factor (TNF) is an important pro-inflammatory cytokine which causes hemorrhagic necrosis of tumors and possesses other important biological activities. TNF is released by activated macrophages, activated T-lymphocytes, natural killer cells, mast cells and basophils, fibroblasts, endothelial cells and brain astrocytes among other cells.

The principal in vivo actions of TNF can be broadly classified as inflammatory and catabolic. It has been implicated as a mediator of endotoxic shock, inflammation of joints and of the airways, immune deficiency states, allograft rejection, and in the cachexia associated with malignant disease and some parasitic infections. In view of the association of high serum levels of TNF with poor prognosis in sepsis, graft versus host disease and adult respiratory distress syndrome, and its role in many other immunologic processes, this factor is regarded as an important mediator of general inflammation.

TNF primes or activates neutrophils, eosinophils, and endothelial cells to release tissue damaging mediators and increase the expression of adhesion molecules. In fibroblasts, TNF stimulates the production of collagenase, an enzyme implicated in the joint destruction in rheumatoid arthritis.

TNF also activates monocytes, macrophages and T-lymphocytes to cause the production of colony stimulating factors and other pro-inflammatory cytokines such IL-1, IL-6, IL-8 and GM-CSF, which in some cases mediate the end effects of TNF. The ability of TNF to activate T-lymphocytes, monocytes, macrophages and related cells has been implicated in the progression of Human Immunodeficiency Virus (HIV) infection. In order for these cells to become infected with HIV and for HIV replication to take place the cells must be maintained in an activated state. Cytokines such as TNF have been shown to activate HIV replication in monocytes and macrophages. Features of endotoxic shock such as fever, metabolic acidosis, hypotension and intravascular coagulation are thought to be mediated through the actions of TNF. The cachexia associated with certain disease states is mediated through indirect effects on protein catabolism.

TNF also promotes bone resorption and acute phase protein synthesis.

TNF-alpha inhibits surfactant protein C gene transcription, which may contribute to abnormalities of surfactant homeostasis associated with pulmonary injury and infection, induces

mucin hypersecretion and mediates the recruitment of neutrophils and eosinophils during airway inflammation. Although TNF-alpha inhibits collagen synthesis in fibroblasts, a number of studies point to it being pro-fibrotic in vivo. Thus, by inhibiting TNF-alpha production, the compounds of the invention have potential in suppressing the inflammation and airways remodelling that occurs in asthma.

TNF-alpha inhibits the ability of insulin to stimulate glucose uptake in adipose tissue. In obesity the overproduction of TNF is thought to cause an insulin-resistant state. Thus, by blocking TNF release the compounds of the invention have anti-diabetic potential.

TNF-alpha can induce angiogenesis in normally avascular tissue, possibly through upregulation of other pro-inflammatory cytokines, upregulation of adhesion molecules, stimulation of matrix mettalloproteinase expression and increased prostaglandin production. Thus, inhibition of TNF-alpha release by compounds of the invention will have benefit in angiogenesis dependent diseases including arthritis, diabetic retinopathies and ischemia induced diseases (myocardial infarction) and cancer.

The discussion herein relates to disease states associated with TNF including those disease states related to the production of TNF itself, and disease states associated with other cytokines, such as, but not limited to IL-1 or IL-6, that are modulated by association with TNF. For example, a IL-1 associated disease state, where IL-1 production or action is exacerbated or secreted in response to TNF, would therefore be considered a disease state associated with TNF.

TNF-alpha and TNF-beta are also herein referred to collectively as "TNF" unless specifically delineated otherwise, since there is a close structural homology between TNF-alpha (cachectin) and TNF-beta (lymphotoxin) and each of them has a capacity to induce similar biological responses and bind to the same cellular receptor.

We have now found a novel group of imidazolyl-cyclic acetals which have valuable pharmaceutical properties, in particular the ability to regulate proteins that mediate cellular activity, for example TNF.

Thus, in one aspect, the present invention is directed to compounds of general formula (I):-

wherein: - R1 is optionally substituted heteroaryl; R2 is optionally substituted aryl or optionally substituted heteroaryl; R3 represents a group -L1-R7 or -L2-R8 [where L1 represents a straight- or branched-chain alkylene linkage containing from 1 to about 6 carbon atoms optionally substituted by halogen or oxo; R7 is hydrogen, aryl, cyano, cycloalkyl, heteroaryl, heterocycloalkyl, nitro, -S(O)nR9, (where R9 is alkyl, aryl, arylalkyl, cycloalkyl, heteroaryl, heteroarylalkyl, or heterocycloalkyl and n is zero or an integer 1 or 2), -NHSO2R9, -C(=Z)OR10 (where Z is an oxygen or sulphur atom and R10 is hydrogen or R9), -C(=Z)R10, -OR10 -N(R1l)-C(=Z)R9 (where R11 is hydrogen or alkyl), -NY1Y2 (where y1 and Y2 are independently hydrogen, alkenyl, alkyl, alkynyl, aryl, arylalkyl, cycloalkenyl, cycloalkyl, heteroaryl or heteroarylalkyl, or the group -NY1Y2 may form a 5-7 membered cyclic amine which may optionally contain a further heteroatom selected from 0, S, or NY3 (where Y3 is hydrogen, alkyl, aryl, arylalkyl, -CHO, -C(=Z)R9 or -S02R9), or which may also be fused to additional aryl, heteroaryl, heterocycloalkyl or cycloalkyl rings to form a bicyclic or tricyclic ring system}, -S02-NY1Y2, -C(=Z)-NY1Y2, -N(R11)- C(=Z)-NY1Y2, N(OR10)-C(=Z)-NYlY2 -N(OR10)-C(=Z)R10, C(=NOR10)Rl0 -C(=Z)NR100R12 (where R12 is hydrogen, alkyl, aryl or arylalkyl), -N(R11)-C(=NR13)-NY1Y2 (where R13 is hydrogen, cyano, alkyl, cycloalkyl or aryl), or -N(R1l)-C(=Z)ORll; L2 represents a direct bond or a straight- or branched-carbon chain comprising from 2 to about 6 carbon atoms and contains a double or triple carbon-carbon bond; and R8 is hydrogen , aryl, cycloalkenyl, cycloalkyl, heteroaryl or heterocycloalkyl]; R4 represents a group -L3-R14 [where L3 represents a direct bond or a straight- or branched-chain alkylene linkage containing from 1 to about 6 carbon atoms (optionally substituted by halogen, hydroxy, alkoxy or oxo); and

R14 is hydrogen, alkyl, azido, hydroxy, alkoxy, aryl, arylalkyloxy, aryloxy, carboxy (or an acid bioisostere), cycloalkyloxy, heteroaryl, heteroarylalkyloxy, heteroaryloxy, heterocycloalkyl, heterocycloalkyloxy, nitro, -NY4Y5, (where Y4 and Y5 are independently hydrogen, aryl, cycloalkyl, heterocycloalkyl, heteroaryl or alkyl optionally substituted by alkoxy, aryl, cyano, cycloalkyl, heteroaryl, heterocycloalkyl, hydroxy, oxo, -CO2R10, -CONY1Y2 or -NY1Y2, or the group -NY4Y5 may form a 5-7 membered cyclic amine which (i) may be optionally substituted with one or more substituents selected from alkoxy, carboxamido, carboxy, hydroxy, oxo (or a 5, 6,or 7 membered cyclic acetal derivative thereof), R9 or alkyl substituted by carboxy, carboxamido or hydroxy (ii) may also contain a further heteroatom selected from 0, S, S02 or NY6 (where V6 is hydrogen, alkyl, aryl, arylalkyl, -C(=Z)R9, -C(=Z)OR9 or -S02R9) and (iii) may also be fused to additional aryl, heteroaryl, heterocycloalkyl or cycloalkyl rings to form a bicyclic or tricyclic ring system, -N(R10)-C(=Z)-Rl5 (where R15 is alkyl, alkoxy, aryl, arylalkyloxy, cycloalkyl, heteroaryl, heteroarylalkoxy or heterocycloalkyl); -N(R10)-C(=Z)-L4-R16 (where R16 is alkoxy, aryl, arylalkyloxy, arylalkyloxycarbonylamino, carboxy (or an acid bioisostere), cycloalkyl, cyano, halo, heteroaryl, heteroarylalkoxy, heterocycloalkyl, hydroxy or -NY1Y2, and L4 is a straight- or branched-chain alkylene linkage containing from 1 to about 6 carbon atoms), -NH-C(=Z)-NH-R15, -NH-C(=Z)-NH-L4-R16, -N(R10)-SO2-Rl5, -N(R10)-S02-L4-R16, -S(O)nR9, -C(=Z)-NY4Y5 or -C(=Z)-OR9] R5 represents hydrogen, alkyl or hydroxyalkyl; or R4 and R5, when attached to the same carbon atom, may form with the said carbon atom a cycloalkyl, cycloalkenyl or heterocycloalkyl ring or a group C=CH2; R6 represents hydrogen or alkyl; and m is zero or an integer 1 or 2; and N-oxides thereof, and their prodrugs; and pharmaceutically acceptable salts and solvates (e.g. hydrates) of compounds of formula (I) and N-oxides thereof, and their prodrugs.

In the present specification, the term "compounds of the invention", and equivalent expressions, are meant to embrace compounds of general formula (I) as hereinbefore described, which expression includes the N-oxides, the prodrugs, the pharmaceutically acceptable salts, and the solvates, e.g. hydrates, where the context so permits. Similarly, reference to intermediates, whether or not they themselves are claimed, is meant to embrace their N-oxides, salts, and solvates, where the context so permits. For the sake of clarity, particular instances when the

context so permits are sometimes indicated in the text, but these instances are purely illustrative and it is not intended to exclude other instances when the context so permits.

It will be appreciated that when m is zero the cyclic acetal system in formula (I) represents a 1,3-dioxolane ring; when m is 1 the cyclic acetal system in formula (I) represents a 1,3-dioxane; and when m is 2 the cyclic acetal system in formula (I) represents a 1,3-dioxepane.

As used above, and throughout the description of the invention, the following terms, unless otherwise indicated, shall be understood to have the following meanings:- "Patient" includes both human and other mammals.

"Acid bioisostere" means a group which has chemical and physical similarities producing broadly similar biological properties to a carboxy group (see Lipinski, Annual Reports in Medicinal Chemistry, 1986, 21, page 283 "Bioisosterism In Drug Design"; Vun, Hwahak Sekye, 1993, 33, pages 576-579 "Application Of Bioisosterism To New Drug Design"; Zhao, Huaxue Tongbao, 1995, pages 34-38 "Bioisosteric Replacement And Development Of Lead Compounds In Drug Design"; Graham, Theochem, 1995, 343, pages 105-109 "Theoretical Studies Applied To Drug Design:ab initio Electronic Distributions In Bioisosteres"). Examples of suitable acid bioisosteres include: -C(=O)-NHOH, -C(=O)-CH2OH, -C(=O)-CH2SH, -C(=O)-NH-CN, sulpho, phosphono, alkylsulphonylcarbamoyl, tetrazolyl, arylsulphonylcarbamoyl, heteroarylsulphonylcarbamoyl, N-methoxycarbamoyl, 3-hydroxy-3-cyclobutene-1,2-dione, 3,5-dioxo-1,2,4-oxadiazolidinyl or heterocyclic phenols such as 3-hydroxyisoxazolyl and 3-hydoxy-1 -methylpyrazolyl.

"Acyl" means an H-CO- or alkyl-CO- group in which the alkyl group is as described herein.

"Acylamino" is an acyl-NH- group wherein acyl is as defined herein.

"Alkenyl" means an aliphatic hydrocarbon group containing a carbon-carbon double bond and which may be straight or branched having about 2 to about 15 carbon atoms in the chain.

Preferred alkenyl groups have 2 to about 12 carbon atoms in the chain; and more preferably about 2 to about 4 carbon atoms in the chain. "Branched", as used herein and throughout the text, means that one or more lower alkyl groups such as methyl, ethyl or propyl are attached to a linear chain; here a linear alkenyl chain. "Lower alkenyl" means about 2 to about 4 carbon atoms in the chain which may be straight or branched. Exemplary alkenyl groups include

ethenyl, propenyl, n-butenyl, i-butenyl, 3-methylbut-2-enyl, n-pentenyl, heptenyl, octenyl, cyclohexylbutenyl and decenyl.

"Alkoxy" means an alkyl-O- group in which the alkyl group is as described herein. Exemplary alkoxy groups include methoxy, ethoxy, n-propoxy, i-propoxy, n-butoxy and heptoxy.

"Alkoxymethyl" means an alkyl-O-CH2- group in which the alkyl group is as described herein.

Exemplary alkoxymethyl groups include methoxymethyl and ethoxymethyl.

"Alkoxycarbonyl" means an alkyl-O-CO- group in which the alkyl group is as described herein.

Exemplary alkoxycarbonyl groups include methoxy- and ethoxycarbonyl.

"Alkyl" means, unless otherwise specified, an aliphatic hydrocarbon group which may be straight or branched having about 1 to about 15 carbon atoms in the chain, optionally substituted by one or more halogen atoms. Particular alkyl groups have from 1 to about 6 carbon atoms. Exemplary alkyl groups for R5, R6 and within R4 include C1 4alkyl groups such as methyl, ethyl, n-propyl and i-propyl.

"Alkylene" means a straight or branched bivalent hydrocarbon chain having from 1 to about 15 carbon atoms. Particular alkylene groups are the lower alkylene groups having from 1 to about 6 carbon atoms. Exemplary groups include methylene and ethylene.

"Alkylsulphinyl" means an alkyl-SO- group in which the alkyl group is as previously described.

Preferred groups are those in which the alkyl group is C1 4alkyl.

"Alkylsulphonyl" means an alkyl-SO2- group in which the alkyl group is as previously described. Preferred groups are those in which the alkyl group is C1 4alkyl.

"Alkylsulphonylcarbamoyl" means an alkyl-SO2-NH-C(=O)- group in which the alkyl group is as previously described. Preferred alkylsulphonylcarbamoyl groups are those in which the alkyl group is C1 4alkyl.

"Alkylthio" means an alkyl-S- group in which the alkyl group is as previously described.

Exemplary alkylthio groups include methylthio, ethylthio, isopropylthio and heptylthio.

"Alkynyl" means an aliphatic hydrocarbon group containing a carbon-carbon triple bond and which may be straight or branched having about 2 to about 15 carbon atoms in the chain.

Preferred alkynyl groups have 2 to about 12 carbon atoms in the chain; and more preferably about 2 to about 4 carbon atoms in the chain. Exemplary alkynyl groups include ethynyl, propynyl, n-butynyl, i-butynyl, 3-methylbut-2-ynyl, and n-pentynyl.

"Aroyl" means an aryl-CO- group in which the aryl group is as described herein. Exemplary groups include benzoyl and 1- and 2-naphthoyl.

"Aroylamino" is an aroyl-NH- group wherein aroyl is as previously defined.

"Aryl" as a group or part of a group denotes: (i) an optionally substituted monocyclic or multicyclic aromatic carbocyclic moiety of about 6 to about 14 carbon atoms, such as phenyl or naphthyl; or (ii) an optionally substituted partially saturated multicyclic aromatic carbocyclic moiety in which an aryl and a cycloalkyl or cycloalkenyl group are fused together to form a cyclic structure, such as a tetrahydronaphthyl, indenyl or indanyl ring. Aryl groups may be substituted with one or more aryl group substituents which may be the same or different, where "aryl group substituent" includes, for example, acyl, acylamino, alkoxy, alkoxycarbonyl, alkylenedioxy, alkylsulphinyl, alkylsulphonyl, alkylthio, aroyl, aroylamino, aryl, arylalkyloxy, arylalkyloxycarbonyl, arylalkylthio, aryloxy, aryloxycarbonyl, arylsulphinyl, arylsulphonyl, arylthio, carboxy, cyano, halo, heteroaroyl, heteroaryl, heteroarylalkyloxy, heteroaroylamino, heteroaryloxy, hydroxy, nitro, trifluoromethyl, Y7V8N-, Y7V8NCO-, V7V8NSO2-(where Y7 and y8 are independently hydrogen, alkyl, aryl, arylalkyl, heteroaryl and heteroarylalkyl), Y7Y8N-C2,6alkylene-Z2- (where z2 is O, NR5 or S(O)n) alkylC(=O)-Y7N-, alkylSO2-V7N- or alkyl optionally substituted with aryl, heteroaryl, hydroxy, or Y7Y8N-. Preferred aryl group substituents within R2 include halogen, alkoxy, trifluoromethyl, alkylthio, alkylsulphinyl, V7V8N-, alkylC(=O)-V7N- or alkylSO2-V7N-, more preferably fluoro.

"Arylalkyl" means an aryl-alkyl- group in which the aryl and alkyl moieties are as previously described. Preferred arylalkyl groups contain a C1 4alkyl moiety. Exemplary arylalkyl groups include benzyl, 2-phenethyl and naphthlenemethyl.

"Arylalkyloxy" means an arylalkyl-O- group in which the arylalkyl groups is as previously described. Exemplary arylalkyloxy groups include benzyloxy and 1- or 2-naphthalenemethoxy.

"Arylalkyloxycarbonyl" means an arylalkyl-O-CO- group in which the arylalkyl groups is as previously described. An exemplary arylalkyloxycarbonyl group is benzyloxycarbonyl.

"Arylalkylthio" means an arylalkyl-S- group in which the arylalkyl group is as previously described. An exemplary arylalkylthio group is benzylthio.

"Aryloxy" means an aryl-O- group in which the aryl group is as previously described.

Exemplary aryloxy groups include optionally substituted phenoxy and naphthoxy.

"Aryloxycarbonyl" means an aryl-O-CO- group in which the aryl group is as previously described. Exemplary aryloxycarbonyl groups include phenoxycarbonyl and naphthoxycarbonyl.

"Arylsulphinyl" means an aryl-SO- group in which the aryl group is as previously described.

"Arylsulphonyl" means an aryl-SO2- group in which the aryl group is as previously described.

"Arylsulphonylcarbamoyl" means an aryl-SO2-NH-C(=O)- group in which the aryl group is as previously described.

"Arylthio" means an aryl-S- group in which the aryl group is as previously described.

Exemplary arylthio groups include phenylthio and naphthylthio.

"Azaheteroaryl" means an aromatic carbocyclic moiety of about 5 to about 10 ring members in which one of the ring members is nitrogen and the other ring members are chosen from carbon, oxygen, sulphur, or nitrogen. Examples of optionally substituted azaheteroaryl groups include pyridyl, pyrimidinyl, quinolinyl, isoquinolinyl, quinazolinyl, imidazolyl, and benzimidazolyl, optionally substituted with one or more "heteroaryl group substituents". Preferred azaheteroaryl groups within R1 include optionally substituted pyridyl and pyrimidinyl.

Preferred heteroaryl group substituents when R1 is pyrimidinyl include R17Z3- [where R17 is alkyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, or alkyl substituted by alkoxy, aryl, cyano, cycloalkyl, heteroaryl, heterocycloalkyl, hydroxy, oxo, -CO2R10, -CONY1Y2 or-NV4V5 and Z3 is O or S(O)n] and Y4Y5N-.

"Cycloalkenyl" means an optionally substituted non-aromatic monocyclic or multicyclic ring system containing at least one carbon-carbon double bond and having about 5 to about 10 carbon atoms. Exemplary monocyclic cycloalkenyl rings include cyclopentenyl, cyclohexenyl and cyclopentenyl. Exemplary multicyclic cycloalkenyl ring include norbornenyl. The cycloalkenyl group may be substituted by one or more substituents chosen from, for example, halo, or alkyl.

"Cycloalkoxymethyl" means a cycloalkyl-O-CH2-group in which the cycloalkyl group is as described hereinafter. Exemplary cycloalkoxymethyl groups include cyclopropyloxymethyl and cyclopentyloxymethyl.

"Cycloalkyl" means an optionally substituted non-aromatic monocyclic or multicyclic ring system of about 3 to about 10 carbon atoms. Exemplary monocyclic cycloalkyl rings include cyclopropyl, cyclopentyl, cyclohexyl and cycloheptyl. Exemplary multicyclic cycloalkyl rings include perhydronaphthyl, adamant-(1- or 2-)yl and norbornyl and spirocyclic groups e.g. spiro[4,4]non-2yl. When R3 is, or contains, a cycloalkyl ring this may particularly represent a 3 to 7 membered monocyclic ring, especially cyclohexyl. The cycloalkyl group may be substituted by one or more (e.g. 1, 2, or 3) substituents chosen from, for example, alkyl, aryl, arylalkyl, halo, halo substituted alkyl (such as trifluoromethyl), hydroxyalkyl, hydroxy, alkoxy, -S(O)n-alkyl, -NV1V2 or -CO2R12.

"Cycloalkylalkyl" means a cycloalkyl-alkyl- group in which the cycloalkyl and alkyl moieties are as previously described. Exemplary monocyclic cycloalkylalkyl groups include cyclopropylmethyl, cyclopentylmethyl, cyclohexylmethyl and cycloheptylmethyl.

"Cycloalkyloxy" means a cycloalkyl-O- group in which the cycloalkyl group is as described herein. Exemplary cycloalkyloxy groups include cyclopropyloxy, cyclopentyloxy, cyclohexyloxy and cycloheptyloxy.

"Halo" or "halogen" means fluoro, chloro, bromo, or iodo. Preferred are fluoro or chloro.

"Heteroaroyl" means a heteroaryl-CO- group in which the heteroaryl group is as described herein. Exemplary groups include pyridylcarbonyl.

"Heteroaroylamino" means a heteroaroyl-NH- group in which the heteroaroyl moiety is as previously described.

"Heteroaryl" as a group or part of a group denotes an optionally substituted aromatic monocyclic or multicyclic organic moiety of about 5 to about 10 ring members in which one or more of the ring members is/are element(s) other than carbon, for example nitrogen, oxygen or sulphur. Examples of suitable optionally substituted heteroaryl groups include benzimidazolyl, furyl, imidazolyl, isoxazolyl, isoquinolinyl, isothiazolyl, oxadiazolyl, pyrazinyl, pyridazinyl, pyrazolyl, pyridyl, pyrimidinyl, pyrrolyl, quinazolinyl, quinolinyl, 1,3,4-thiadiazolyl, thiazolyl, thienyl and triazolyl groups. When R1 is an optionally substituted heteroaryl group this may particularly represent an optionally substituted "azaheteroaryl" group. Heteroaryl groups may be substituted with one or more heteroaryl group substituents which may be the same or different, where "heteroaryl group substituent" includes, for example acyl, acylamino, alkoxycarbonyl, alkylenedioxy, aroyl, aroylamino, aryl, arylalkyloxycarbonyl, aryloxycarbonyl, carboxy, cyano, halo, heteroaroyl, heteroaryl, heteroaroylamino, hydroxy, nitro, trifluoromethyl, R17Z3-, V4V5N-, V4V5N-CO-, V4V5NSO2-, alkylSO2-V4N- or alkyl optionally substituted with aryl, heteroaryl, hydroxy, oxo, -CO2R10, -CONV1V2 or Y4Y5N-.

"Heteroarylalkyl" means a heteroaryl-alkyl- group in which the heteroaryl and alkyl moieties are as previously described. Preferred heteroarylalkyl groups contain a C1 4alkyl moiety.

Exemplary heteroarylalkyl groups include pyridylmethyl.

"Heteroarylalkyloxy" means an heteroarylalkyl-O- group in which the heteroarylalkyl group is as previously described. Exemplary heteroaryloxy groups include optionally substituted pyridylmethoxy.

"Heteroaryloxy" means an heteroaryl-O- group in which the heteroaryl group is as previously described. Exemplary heteroaryloxy groups include optionally substituted pyridyloxy.

"Heteroarylsulphonylcarbamoyl" means a heteroaryl-SO2-NH- C(=O)- group in which the heteroaryl group is as previously described.

"Heterocycloalkyl" means a cycloalkyl group of about 3 to 7 ring members which contains one or more heteroatoms selected from 0, S or NY3. Exemplary heterocycloalkyl groups include 5-7 membered cyclic ethers such as tetrahydrofuran and perhydropyran.

"Heterocycloalkylalkyl" means a heterocycloalkyl-alkyl- group in which the heterocycloalkyl and alkyl moieties are as previously described.

"Heterocycloalkyloxy" means a heterocycloalkyl-O- group in which the heterocycloalkyl is as previously defined.

"Hydroxyalkyl" means a HO-alkyl- group in which alkyl is as previously defined. Preferred hydroxyalkyl groups contain C1 4alkyl. Exemplary hydroxyalkyl groups include hydroxymethyl and 2-hydroxyethyl.

"V7V8N-" means a substituted or unsubstituted amino group, wherein Y7 and V8 are as previously described. Exemplary groups include amino (H2N-), methylamino, ethylmethylamino, dimethylamino and diethylamino.

"V7V8NCO-" means a substituted or unsubstituted carbamoyl group, wherein Y7 and V8 are as previously described. Exemplary groups are carbamoyl (H2NCO-) and dimethylcarbamoyl (Me2NCO-).

" Y7Y8NSo2-" means a substituted or unsubstituted sulphamoyl group, wherein Y7 and V8 are as previously described. Exemplary groups are sulphamoyl (H2NSO2-) and dimethylsulphamoyl (Me2NSO2-).

"Prodrug" means a compound which is convertible in vivo by metabolic means (e.g. by hydrolysis) to a compound of formula (I), including N-oxides thereof. For example an ester of a compound of formula (I) containing a hydroxy group may be convertible by hydrolysis in vivo to the parent molecule. Alternatively an ester of a compound of formula (I) containing a carboxy group may be convertible by hydrolysis in vivo to the parent molecule.

"Solvate" means a physical association of a compound of this invention with one or more solvent molecules. This physical association includes hydrogen bonding. In certain instances the solvate will be capable of isolation, for example when one or more solvent molecules are incorporated in the crystal lattice of the crystalline solid. "Solvate" encompasses both solution-phase and isolable solvates. Representative solvates include hydrates, ethanolates, methanolates, and the like.

Suitable esters of compounds of formula (I) containing a hydroxy group, are for example acetates, citrates, lactates, tartrates, malonates, oxalates, salicylates, propionates, succinates, fumarates, maleates, methylene-bis-b-hydroxynaphthoates, gentisates, isethionates, di-p-toluoyltartrates, methanesulphonates, ethanesulphonates, benzenesulphonates, p-toluenesulphonates, cyclohexylsulphamates and quinates.

Suitable esters of compounds of formula (I) containing a carboxy group, are for example those described by F.J.Leinweber, Drug Metab. Res., 1987 18, page 379.

An especially useful class of esters of compounds of formula (I) containing a hydroxy group, may be formed from acid moieties selected from those described by Bundgaard et. al., J. Med. Chem., 1989, 32, page 2503-2507, and include substituted (aminomethyl)-benzoates, for example dialkylamino-methylbenzoates in which the two alkyl groups may be joined together and/or interrupted by an oxygen atom or by an optionally substituted nitrogen atom, e.g. an alkylated nitrogen atom, more especially (morpholino-methyl)benzoates, e.g. 3- or 4-(morpholinomethyl)-benzoates, and (4-alkylpiperazin-1-yl)benzoates, e.g. 3- or 4-(4-alkylpiperazin- 1-yl)benzoates.

Some of the compounds of the present invention are basic, and such compounds are useful in the form of the free base or in the form of a pharmaceutically acceptable acid addition salt thereof.

Acid addition salts are a more convenient form for use; and in practice, use of the salt form inherently amounts to use of the free base form. The acids which can be used to prepare the acid addition salts include preferably those which produce, when combined with the free base, pharmaceutically acceptable salts, that is, salts whose anions are non-toxic to the patient in pharmaceutical doses of the salts, so that the beneficial inhibitory effects inherent in the free base are not vitiated by side effects ascribable to the anions. Although pharmaceutically acceptable salts of said basic compounds are preferred, all acid addition salts are useful as sources of the free base form even if the particular salt, per se, is desired only as an intermediate product as, for example, when the salt is formed only for purposes of purification, and identification, or when it is used as intermediate in preparing a pharmaceutically acceptable salt by ion exchange procedures. Pharmaceutically acceptable salts within the scope of the invention include those derived from mineral acids and organic acids, and include hydrohalides, e.g. hydrochlorides and hydrobromides, sulphates, phosphates, nitrates, sulphamates, acetates, citrates, lactates, tartrates, malonates, oxalates, salicylates, propionates, succinates, fumarates,

maleates, methylene-bis-b-hydroxynaphthoates, gentisates, isethionates, di-p-toluoyltartrates, methane-sulphonates, ethanesulphonates, benzenesulphonates, p-toluenesulphonates, cyclohexylsulphamates and quinates.

Where the compound of the invention is substituted with an acidic moiety, base addition salts may be formed and are simply a more convenient form for use; and in practice, use of the salt form inherently amounts to use of the free acid form. The bases which can be used to prepare the base addition salts include preferably those which produce, when combined with the free acid, pharmaceutically acceptable salts, that is, salts whose cations are non-toxic to the patient in pharmaceutical doses of the salts, so that the beneficial inhibitory effects inherent in the free base are not vitiated by side effects ascribable to the cations. Pharmaceutically acceptable salts, including those derived from alkali and alkaline earth metal salts, within the scope of the invention include those derived from the following bases: sodium hydride, sodium hydroxide, potassium hydroxide, calcium hydroxide, aluminium hydroxide, lithium hydroxide, magnesium hydroxide, zinc hydroxide, ammonia, ethylenediamine, N-methyl-glucamine, lysine, arginine, ornithine, choline, N,N'-dibenzylethylenediamine, chloroprocaine, diethanolamine, procaine, N-benzylphenethylamine, diethylamine, piperazine, tris(hydroxymethyl)aminomethane, tetramethylammonium hydroxide, and the like.

As well as being useful in themselves as active compounds, salts of compounds of the invention are useful for the purposes of purification of the compounds, for example by exploitation of the solubility differences between the salts and the parent compounds, side products and/or starting materials by techniques well known to those skilled in the art.

With reference to formula (I) above, the following are particular and preferred groupings: R1 may particularly represent optionally substituted azaheteroaryl such as optionally substituted pyridyl, pyrimidinyl, quinolinyl, isoquinolinyl, quinazolinyl, imidazolyl or benzimidazolyl (for example optionally substituted 4-pyridyl, 4-pyrimidinyl, 4-quinolinyl, 6-isoquinolinyl, 4-quinazolinyl, 1-imidazolyl or 1-benzimidazolyl). R1 is preferably optionally substituted 4-pyridyl or 4-pyrimidinyl, especially unsubstituted 4-pyridyl or 2-substituted 4-pyrimidinyl. Preferred substituents include C1 4alkyl, especially methyl, -NY4Y5 (especially where at least one of Y4 and Y5 is hydrogen) or -OR17(especially where R17 is cycloalkyl).

R2 is preferably optionally substituted phenyl, particularly when substituted by halogen, especially fluoro and chloro, or an alkylthio or alkylsulphinyl group, especially methylthio or methysulphinyl, or a trifluoromethyl group. R2 is more preferably phenyl substituted by a halogen (e.g. fluorine) atom, especially in the 4-position.

R3 may particularly represent hydrogen or C1 4alkyl, preferably hydrogen.

R4 may particularly represent a group -L3-R14 where L3 is a direct bond and R14 is -NY4Y5, where Y4 and Y5 are as defined hereinbefore, especially where Y4 and Y5 are hydrogen.

R4 may also particularly represent a group -L3-R14 where L3 is a direct bond and R14 is -N(R10)-C(=Z)-Rl5, in which Z, R10 and R15 are as defined hereinbefore, especially where Z is oxygen, R10 is hydrogen and R15 is alkyl (especially methyl), aryl (e.g. substituted or more preferably, unsubstituted phenyl) or heteroaryl.

R4 may also particularly represent a group -L3-R14 where L3 is a direct bond and R14 is -N(R10)-C(=Z)-L4-Rl6, in which Z, L4, R10 and R16 are as defined hereinbefore, especially where Z is oxygen, L4 is methylene, R10 is hydrogen, and R16 is aryl (e.g. substituted or more preferably, unsubstituted phenyl) or heteroaryl.

R4 may also particularly represent a group -L3-R14 where L3 is a direct bond and R14 is -C(=Z)-NV4Y5, in which Z is as defined hereinbefore, especially oxygen, and Y4 and Y5 are as defined hereinbefore, especially where Y4 and Y5 are hydrogen or where Y4 is hydrogen and Y5 is aryl, arylalkyl, heteroaryl or heteroarylalkyl.

R4 may also particularly represent a group -L3-R14 where L3 is a direct bond and R14 is -C(=Z)-NV4Y5, in which Z is as defined hereinbefore, especially oxygen, and the group -NY4Y5 forms a 5-7 membered cyclic amine [which may optionally contain a further heteroatom selected from 0, S or NV6 (where V6 is as defined hereinbefore)], preferably a 5-7 membered cyclic amine optionally containing oxygen, especially a morpholine ring.

R4 may also particularly represent a group -L3-R14 where L3 is a direct bond and R14 is -C(=Z)-OR9, in which Z and R9 are as defined hereinbefore, especially where Z is oxygen and R9 is C1-4alkyl, preferably methyl.

R4 may also particularly represent a group -L3-R14 where L3 is a direct bond, especially methylene or ethylene, and R14 is alkyl, especially methyl.

R4 may also particularly represent a group -L3-R14 where L3isCl6alkylene, especially methylene, and R14 is hydroxy.

R4 may also particularly represent a group -L3-R14 where L3isCl6alkylene, especially methylene, and R14 is -N(R10)-C(=Z)-R15, in which Z, R10 and R15 are as defined hereinbefore, especially where Z is oxygen, R10 is hydrogen and R15 is alkyl, aryl or heteroaryl.

R4 may also particularly represent a group -L3-R14 where L3isCl6alkylene, especially methylene, and R14 is -N(R10)-C(=Z)-L4-R16, in which Z, L4, R10 and R15 are as defined hereinbefore, especially where Z is oxygen, L4isCl6alkylene, especially methylene, R10 is hydrogen and R16 is aryl or heteroaryl.

R4 may also particularly represent a group -L3-R14 where L is C1-6alkylene, especially methylene, and R14 is -NHC(=Z)-NH-R15, in which Z and R15 are as defined hereinbefore, especially where R15 is alkyl, aryl or heteroaryl.

R4 may also particularly represent a group -L3-R14 where L is C1-6alkylene, especially methylene, and R14 is -NH-C(=Z)-NH-L4-R16, in which Z, L4 and R16 are as defined hereinbefore, especially where L4 is methylene and R15 is aryl or heteroaryl.

R4 may also particularly represent a group -L3-R14 where L is C1-6alkylene, especially C1-3alkylene, preferably methylene, and R14 is -NY4Y5, where Y4 and Y5 are as defined hereinbefore, especially where Y4 and V5 are hydrogen.

R4 may also particularly represent a group -L3-R14 where L3 is C1 6alkylene, especially methylene or ethylene, and R14 is aryl or heteroaryl.

R4 may also particularly represent a group -L3-R14 where L3 is C1 6alkylene, especially methylene, and R14 is -N(R10)-502-R15, in which R10 and R15 are as defined hereinbefore, especially where R10 is hydrogen and R15 is alkyl, aryl or heteroaryl.

R4 may also particularly represent a group -L3-R14 where L3 is C1 6alkylene, especially methylene, and R14 is -N(R10)-So2-L4-Rl5, in which L4, R10 and R15 are as defined hereinbefore, especially where L4 is methylene, R10 is hydrogen and R15 is alkyl, aryl or heteroaryl.

R5 may particularly represent hydrogen or C1 4alkyl, especially methyl.

R5 may also particularly represent hydroxyalkyl, especially hydroxymethyl.

R4 and R5 together with the carbon atom to which they are attached may particularly represent a group C=CH2 or a 5-7 membered cyclic ether such as tetrahydrofuran-2-yl or perhydropyran-2-yl.

R6 may particularly represent hydrogen or C1 4alkyl, especially hydrogen. m is preferably an integer 1.

It is to be understood that this invention covers all appropriate combinations of the particular and preferred groupings referred to herein.

A particular group of compounds of the invention are compounds of formula (Ia):-

in which R4 and R5 are as hereinbefore defined, and N-oxides thereof, and their prodrugs; and pharmaceutically acceptable salts and solvates (e.g. hydrates) of compounds of formula (Ia) and N-oxides thereof, and their prodrugs.

Compounds of formula (Ia) in which R4 represents a group -L3-R14 where L3 is a direct bond and R14 is -NY4Y5, where Y4 and Y5 are as defined hereinbefore, especially where Y4 and Y5 are hydrogen, are preferred.

Compounds of formula (Ia) in which R4 represents a group -L3-R14 where L3 is a direct bond and R14 is -N(R10)-C(=Z)-Rl5, in which Z, R10 and R15 are as defined hereinbefore, especially where Z is oxygen, R10 is hydrogen and R15 is alkyl (especially methyl), aryl (e.g. substituted or more preferably, unsubstituted phenyl) or heteroaryl, are also preferred.

Compounds of formula (Ia) in which R4 represents a group -L3-R14 where L3 is a direct bond and R14 is -N(R10)-C(=Z)-L4-Rl6, in which Z, L4, R10 and R16 are as defined hereinbefore, especially where Z is oxygen, L4 is methylene, R10 is hydrogen, and R16 is aryl (e.g. substituted or more preferably, unsubstituted phenyl) or heteroaryl, are also preferred.

Compounds of formula (Ia) in which R4 represents a group -L3-R14 where L3 is a direct bond and R14 is -C(=Z)-NV4V5, in which Z is as defined hereinbefore, especially oxygen, and Y4 and V5 are as defined hereinbefore, especially where Y4 and Y5 are hydrogen or where Y4 is hydrogen and Y5 is aryl, heteroaryl or heteroarylalkyl, are also preferred.

Compounds of formula (Ia) in which R4 represents a group -L3-R14 where L3 is a direct bond and R14 is -C(=Z)-NV4V5, in which Z is as defined hereinbefore, especially oxygen, and the

group -NY4Y5 forms a 5-7 membered cyclic amine [which may optionally contain a further heteroatom selected from 0, S or NV6 (where V6 is as defined hereinbefore)], preferably a 5-7 membered cyclic amine optionally containing oxygen, especially a morpholine ring, are also preferred.

Compounds of formula (Ia) in which R4 represents a group -L3-R14 where L3 is a direct bond and R14 is -C(=Z)-OR9, in which Z and R9 are as defined hereinbefore, especially where Z is oxygen and R9 is C1-4alkyl, preferably methyl, are also preferred.

Compounds of formula (Ia) in which R4 represents a group -L3-R14 where L3 is a direct bond, especially methylene or ethylene, and R14 is alkyl, especially methyl, are also preferred.

Compounds of formula (Ia) in which R4 represents a group -L3-R14 where L3isCl6alkylene, especially methylene, and R14 is hydroxy, are also preferred.

Compounds of formula (Ia) in which R4 represents a group -L3-R14 where L3isCl6alkylene, especially methylene, and R14 is -N(R10)-C(=Z)-R15, in which Z, R10 and R15 are as defined hereinbefore, especially where Z is oxygen, R10 is hydrogen and R15 is alkyl, aryl or heteroaryl, are also preferred.

Compounds of formula (Ia) in which R4 represents a group -L3-R14 where L3isCl6alkylene, especially methylene, and R14 is -N(R10)-C(=Z)-L4-R16, in which Z, L4, R10 and R15 are as defined hereinbefore, especially where Z is oxygen, L4 is C1.6alkylene, especially methylene, R10 is hydrogen and R16 is aryl or heteroaryl, are also preferred.

Compounds of formula (Ia) in which R4 represents a group -L3-R14 where L3isCl6alkylene, especially methylene, and R14 is -NH-C(=Z)-NH-R15, in which Z and R15 are as defined hereinbefore, especially where R15 is alkyl, aryl or heteroaryl, are also preferred.

Compounds of formula (Ia) in which R4 represents a group -L3-R14 where L3isCl6alkylene, especially methylene, and R14 is -NH-C(=Z)-NH-L4-R16, in which Z, L4 and R16 are as defined hereinbefore, especially where L4 is methylene and R15 is aryl or heteroaryl, are also preferred.

Compounds of formula (Ia) in which R4 represents a group -L3-R14 where L3 is C1 6alkylene, especially C1,3alkylene, preferably methylene, and R14 is -NV4V5, where Y4 and Y5 are as defined hereinbefore, especially where Y4 and Y5 are hydrogen, are also preferred.

Compounds of formula (Ia) in which R4 represents a group -L3-R14 where L3 is C1 6alkylene, especially methylene or ethylene, and R14 is aryl or heteroaryl, are also preferred.

Compounds of formula (Ia) in which R4 represents a group -L3-R14 where L3 is C1 6alkylene, especially methylene, and R14 is -N(R10)-So2-Rl5 in which R10 and R15 are as defined hereinbefore, especially where R10 is hydrogen and R15 is alkyl, aryl or heteroaryl, are also preferred.

Compounds of formula (Ia) in which R4 represents a group -L3-R14 where L3 is C1 6alkylene, especially methylene, and R14 is -N(R10)-502-L4-R15, in which L4, R10 and R15 are as defined hereinbefore, especially where L4 is methylene, R10 is hydrogen and R15 is alkyl, aryl or heteroaryl, are also preferred.

Compounds of formula (Ia) in which R5 represents hydrogen, C1 4alkyl (e.g. methyl) or hydroxyC1 4alkyl (e.g. hydroxymethyl), especially methyl, are preferred.

Compounds of formula (Ia) in which R4 and R5 together with the carbon atom to which they are attached represent a group C=CH2 or a 5-7 membered cyclic ether such as tetrahydrofuran-2-yl or perhydropyran-2-yl are also preferred.

A preferred group of compounds of the invention are compounds of formula (Ia) in which R4 is a group -L3-R14 (where L3 is a direct bond and R14 is (i) -NY4Y5, preferably -NH2; (ii) -N(R10)-C(=Z)-Rl5, preferably -NH-C(=O)-alkyl, -NH-C(=O)-aryl or -NH-C(=O)-heteroaryl, especially -NH-C(=O)-aryl, particularly where aryl is substituted, or more preferably, unsubstituted phenyl; (iii) -N(R10)-C(=Z)-L4-R16, preferably -NH-C(=O)-CH2-aryl or -NH-C(=O)-CH2-heteroaryl, particularly where aryl is substituted, or more preferably,

unsubstituted phenyl; (iv) -C(=Z)-NV4V5, preferably -C(=O)-NH2; (v) -C(=Z)-NV4V5, preferably -C(=O)-NV4V5 where the group -NY4Y5 forms a 5-7 membered cyclic amine [which may optionally contain a further heteroatom selected from 0, S or NV6 (where V6 is as defined hereinbefore), preferably a 5-7 membered cyclic amine optionally containing oxygen, especially a morpholine ring]; (vi) -C(=Z)OR9, particularly -CO2Me; or (vii) alkyl, especially methyl) and R5 represents hydrogen, C1 4alkyl (e.g. methyl) or hydroxyC1 4alkyl (e.g. hydroxymethyl), especially methyl; and N-oxides thereof, and their prodrugs; and pharmaceutically acceptable salts and solvates (e.g. hydrates) of compounds of formula (Ia) herein and N-oxides thereof, and their prodrugs.

A further preferred group of compounds of formula (Ia) are compounds in which R4 is a group -L3-R14 (where L3 is a methylene linkage and R14 is (i) hydroxy; (ii) -N(R10)-C(=Z)-Rl5, preferably -NH-C(=O)-alkyl, -NH-C(=O)-aryl or -NH-C(=O)-heteroaryl ; (iii) -N(R10)-C(=Z)-L4-R16, preferably -NH-C(=O)-CH2-aryl or -NH-C(=O)-CH2-heteroaryl; (iv) -NH-C(=Z)-NH-R15 preferably -NH-C(=O)-NH-alkyl, -NH-C(=O)-NH-aryl or -NH-C(=O)-NH-heteroaryl; (v) NH-C(=Z)-NH-L4-R16 preferably -NH-C(=O)-NH-CH2-alkyl, -NH-C(=O)-NH-CH2-aryl or -NH-C(=O)-NH-CH2-heteroaryl; (vi) -NY4Y5, preferably -NH2; (vii) aryl; (viii) heteroaryl; (ix) -N(R10)-5O2-R15, preferably -NH-SO2-alkyl, NH-SO2-aryl or -NH-SO2-heteroaryl} and R5 represents hydrogen, C1 4alkyl (e.g. methyl) or hydroxyC1 4alkyl (e.g. hydroxymethyl), especially methyl; and N-oxides thereof and their prodrugs; and pharmaceutically acceptable salts and solvates (e.g. hydrates) of compounds of formula (Ia) herein and N-oxides thereof, and their prodrugs.

A further particular group of compounds of the invention are compounds of formula (Ib):-

in which R4 and R5 are as hereinbefore defined, and R18 is R17Z3- or V4V5N- (in which R17, Y4, V5 and Z3 are as hereinbefore defined), and N-oxides thereof, and their prodrugs; and pharmaceutically acceptable salts and solvates (e.g. hydrates) of compounds of formula (Ib) and N-oxides thereof, and their prodrugs.

Compounds of formula (Ib) in which R4 represents a group -L3-R14 where L3 is a direct bond and R14 is -NY4Y5, where Y4 and Y5 are as defined hereinbefore, especially where Y4 and Y5 are hydrogen, are preferred.

Compounds of formula (Ib) in which R4 represents a group -L3-R14 where L3 is a direct bond and R14 is -N(R10)-C(=Z)-R15, in which Z, R10 and R15 are as defined hereinbefore, especially where Z is oxygen, R10 is hydrogen and R15 is alkyl (especially methyl), aryl (e.g. substituted or more preferably, unsubstituted phenyl) or heteroaryl, are also preferred.

Compounds of formula (Ib) in which R4 represents a group -L3-R14 where L3 is a direct bond and R14 is -N(R10)-C(=Z)-L4-R16, in which Z, L4, R10 and R16 are as defined hereinbefore, especially where Z is oxygen, L4 is methylene, R10 is hydrogen, and R16 is aryl (e.g. substituted or more preferably, unsubstituted phenyl) or heteroaryl, are also preferred.

Compounds of formula (Ib) in which R4 represents a group -L3-R14 where L3 is a direct bond and R14 is -C(=Z)-NV4V5, in which Z is as defined hereinbefore, especially oxygen, and Y4 and V5 are as defined hereinbefore, especially where Y4 and Y5 are hydrogen or where Y4 is hydrogen and Y5 is aryl, heteroaryl or heteroarylalkyl, are also preferred.

Compounds of formula (Ib) in which R4 represents a group -L3-R14 where L3 is a direct bond and R14 is -C(=Z)-NV4V5, in which Z is as defined hereinbefore, especially oxygen, and the group -NY4Y5 forms a 5-7 membered cyclic amine [which may optionally contain a further heteroatom selected from 0, S or NY6 (where V6 is as defined hereinbefore)], preferably a 5-7 membered cyclic amine optionally containing oxygen, especially a morpholine ring, are also preferred.

Compounds of formula (Ib) in which R4 represents a group -L3-R14 where L3 is a direct bond and R14 is -C(=Z)-OR9, in which Z and R9 are as defined hereinbefore, especially where Z is oxygen and R9 is C1-4alkyl, preferably methyl, are also preferred.

Compounds of formula (Ib) in which R4 represents a group -L3-R14 where L3 is a direct bond, especially methylene or ethylene, and R14 is alkyl, especially methyl, are also preferred.

Compounds of formula (Ib) in which R4 represents a group -L3-R14 where L3isCl6alkylene, especially methylene, and R14 is hydroxy, are also preferred.

Compounds of formula (Ib) in which R4 represents a group -L3-R14 where L3isCl6alkylene, especially methylene, and R14 is -N(R10)-C(=Z)-Rl5, in which Z, R10 and R15 are as defined hereinbefore, especially where Z is oxygen, R10 is hydrogen and R15 is alkyl, aryl or heteroaryl, are also preferred.

Compounds of formula (Ib) in which R4 represents a group -L3-R14 where L3isCl6alkylene, especially methylene, and R14 is -N(R10)-C(=Z)-L4-R16, in which Z, L4, R10 and R15 are as defined hereinbefore, especially where Z is oxygen, L4 is C1.6alkylene, especially methylene, R10 is hydrogen and R16 is aryl or heteroaryl, are also preferred.

Compounds of formula (Ib) in which R4 represents a group -L3-R14 where L3isCl6alkylene, especially methylene, and R14 is -NH-C(=Z)-NH-R15, in which Z and R15 are as defined hereinbefore, especially where R15 is alkyl, aryl or heteroaryl, are also preferred.

Compounds of formula (Ib) in which R4 represents a group -L3-R14 where L3isCl6alkylene, especially methylene, and R14 is -NH-C(=Z)-NH-L4-R16, in which Z, L4 and R16 are as defined hereinbefore, especially where L4 is methylene and R15 is aryl or heteroaryl, are also preferred.

Compounds of formula (Ib) in which R4 represents a group -L3-R14 where L3isCl6alkylene, especially C1-3alkylene, preferably methylene, and R14 is -NV4V5, where Y4 and Y5 are as defined hereinbefore, especially where Y4 and Y5 are hydrogen, are also preferred.

Compounds of formula (Ib) in which R4 represents a group -L3-R14 where L3isCl6alkylene, especially methylene or ethylene, and R14 is aryl or heteroaryl, are also preferred.

Compounds of formula (Ib) in which R4 represents a group -L3-R14 where L is C1-6alkylene, especially methylene, and R14 is -N(R10)-SO2-R15, in which R10 and R15 are as defined hereinbefore, especially where R10 is hydrogen and R15 is alkyl, aryl or heteroaryl, are also preferred.

Compounds of formula (Ib) in which R4 represents a group -L3-R14 where L is C1-6alkylene, especially methylene, and R14 is -N(R10)-SO2-L4-R15, in which L4, R10 and R15 are as defined hereinbefore, especially where L4 is methylene, R10 is hydrogen and R15 is alkyl, aryl or heteroaryl, are also preferred.

Compounds of formula (Ib) in which R5 represents hydrogen, C1 4alkyl (e.g. methyl) or hydroxyC1-4alkyl (e.g. hydroxymethyl), especially methyl, are preferred.

Compounds of formula (Ib) in which R4 and R5 together with the carbon atom to which they are attached represent a group C=CH2 or a 5-7 membered cyclic ether such as tetrahydrofuran- 2-yl or perhydropyran-2-yl are also preferred.

Compounds of formula (Ib) in which R18 is -NY4Y5, where Y4 and Y5 are as hereinbefore defined, especially where V4 is hydrogen and Y5 is (i) arylalkyl, particularly optionally substituted benzyl or optionally substituted a-methylbenzyl (in which the phenyl group may be

optionally substituted by one or more aryl group substituents, especially halo, methoxy, trifluoromethyl, methyl and methylenedioxy); (ii) heteroarylalkyl, particularly azaheteroaryl-alkyl, more particularly azaheteroaryl-CH2-; (iii) C2.6alkyl substituted by alkoxy, particularly C2 6alkyl substituted by methoxy; (iv) C2 6alkyl substituted by -NY1Y2, particularly C2 6alkyl substituted by -NMe2; (v) C2 6alkyl substituted by hydroxy; (vi) cycloalkyl or (vii) aryl, especially phenyl optionally substituted by one or more aryl group substituents, especially halo, methoxy, trifluoromethyl, methyl or methylenedioxy; are preferred.

Compounds of formula (Ib) in which R18 is -OR17, where R17 is as hereinbefore defined, especially where R17 is alkyl, aryl (especially phenyl optionally substituted by one or more aryl group substituents, especially halo, methoxy, trifluoromethyl, methyl or methylenedioxy) or cycloalkyl, are also preferred.

A preferred group of compounds of the invention are compounds of formula (Ib) in which R4 is a group -L3-R14 (where L3 is a direct bond and R14 is (i) -NY4Y5, preferably -NH2; (ii) -N(R10)-C(=Z)-Rl5, preferably -NH-C(=O)-alkyl, -NH-C(=O)-aryl or -NH-C(=O)-heteroaryl, especially -NH-C(=O)-aryl, particularly where aryl is substituted, or more preferably, unsubstituted phenyl; (iii) -N(R10)-C(=Z)-L4-R16, preferably -NH-C(=O)-CH2-aryl or -NH-C(=O)-CH2-heteroaryl, particularly where aryl is substituted, or more preferably, unsubstituted phenyl; (iv) -C(=Z)-NV4V5, preferably -C(=O)-NH2; (v) -C(=Z)-NV4V5, preferably -C(=O)-NV4V5 where the group -NY4Y5 forms a 5-7 membered cyclic amine [which may optionally contain a further heteroatom selected from 0, S or NV6 (where V6 is as defined hereinbefore), preferably a 5-7 membered cyclic amine optionally containing oxygen, especially a morpholine ring]; (vi) -C(=Z)OR9, particularly -CO2Me; or (vii) alkyl, especially methyl) R5 represents hydrogen, C1 4alkyl (e.g. methyl) or hydroxyC1 4alkyl (e.g. hydroxymethyl), especially methyl and R18 represents -NY4Y5 (where Y4 and Y5 are as hereinbefore defined, especially where Y4 is hydrogen and Y5 is (i) arylalkyl, particularly benzyl or a-methylbenzyl; (ii) heteroarylalkyl, particularly azaheteroaryl-alkyl, more particularly azaheteroaryl-CH2-; (iii) C2 6alkyl substituted by alkoxy, particularly C2.6alkyl substituted by methoxy; (iv) C2.6alkyl substituted by -NY1Y2, particularly C2.6alkyl substituted by -NMe2; (v) C2 6alkyl substituted by hydroxy; (vi) cycloalkyl or (vii) aryl, especially phenyl optionally substituted by one or more aryl group substituents, especially halo, methoxy, trifluoromethyl, methyl or methylenedioxy) or

-OR17, where R17 is alkyl or cycloalkyl; and N-oxides thereof, and their prodrugs; and pharmaceutically acceptable salts and solvates (e.g. hydrates) of compounds of formula (Ia) herein and N-oxides thereof, and their prodrugs.

A further preferred group of compounds of formula (Ib) are compounds in which R4 is a group -L3-R14 (where L3 is a methylene linkage and R14 is (i) hydroxy; (ii) -N(R10)-C(=Z)-Rl5, preferably -NH-C(=O)-alkyl, -NH-C(=O)-aryl or -NH-C(=O)-heteroaryl; (iii) -N(R10)-C(=Z)-L4-R16, preferably -NH-C(=O)-CH2-aryl or -NH-C(=O)-CH2-heteroaryl; (iv) -NH-C(=Z)-NH-R15 preferably -NH-C(=O)-NH-alkyl, -NH-C(=O)-NH-aryl or -NH-C(=O)-NH-heteroaryi;(v) NH-C(=Z)-NH-L4-R16 preferably -NH-C(=O)-NH-CH2-alkyl, -NH-C(=O)-NH-CH2-aryl or -NH-C(=O)-NH-CH2-heteroaryl; (vi) -NY4Y5, preferably -NH2; (vii) aryl; (viii) heteroaryl; (ix) -N(R10)-SO2-R15, preferably -NH-SO2-alkyl, NH-SO2-aryl or -NH-SO2-heteroaryl} and R5 represents hydrogen, C1 4alkyl (e.g. methyl) or hydroxyC1 4alkyl (e.g. hydroxymethyl), especially methyl and R18 represents -NY4Y5 (where Y4 and Y5 are as hereinbefore defined, especially where Y4 is hydrogen and Y5 is (i) arylalkyl, particularly benzyl or a-methylbenzyl; (ii) heteroarylalkyl, particularly azaheteroarylalkyl, more particularly azaheteroaryl-CH2-; (iii) C2 6alkyl substituted by alkoxy, particularly C2 6alkyl substituted by methoxy; (iv) C2 6alkyl substituted by -NY1Y2, particularly C2 6alkyl substituted by -NMe2; (v) C2 6alkyl substituted by hydroxy; or (vi) cycloalkyl) or -OR17, where R17 is alkyl or cycloalkyl; and N-oxides thereof, and their prodrugs; and pharmaceutically acceptable salts and solvates (e.g. hydrates) of compounds of formula (Ia) herein and N-oxides thereof, and their prodrugs.

A particular group of compounds of the invention are those selected from the following: (2-[5-(4-fluoro-phenyl)-4-pyridin-4-yl-1H-imidazol-2-yl]-5-m ethyl-[1,3]dioxan-5-yl }-methanol, cis-isomer, (Compound A); (2- [5-(4-fluoro-phenyl)-4-pyridin-4-yl- lH-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl )-methanol, trans-isomer, (Compound B); 4-[2-(5,5-dimethyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)- lH-imidazol-4-yl]-pyridine, (Compound C); C-[5-methyl-2-{5-(4-fluoro-phenyl)-4-pyridin-4-yl-1H-imidazo l-2-yl}-[1,3]dioxan-5-yl]- methylamine, cis- and trans-isomers, (Compound D);

2,2,2-trifluoro-N- [5-methyl-2-{5-(4-fluoro-phenyl)-4-pyridin-4-yl- lH-imidazol-2-yl}- [1,3]dioxan- 5-yl]-acetamide, cis- and trans-isomers, (Compound E); <BR> <BR> <BR> 2,2,2-trifluoro-N-[5-methyl-2-{5-(4-fluoro-phenyl)-4-pyridin -4-yl-1H-imidazol-2-yl)-[1,3]dioxan 5-yl]-acetamide, cis-isomer, (Compound F); <BR> <BR> <BR> 2,2,2-trifluoro-N-[5-methyl-2-{5-(4-fluoro-phenyl)-4-pyridin -4-yl-lH-imidazol-2-yl}-[1,3]dioxan- 5-yl]-acetamide, trans-isomer, (Compound G); <BR> <BR> <BR> 4-[2-(5-azidomethyl-5-methyl-[1,3]dioxan-2-yl)-5-(4-fluoro-p henyl)-lH-imidazol-4-yl]-pyridine, cis- and trans-isomers, (Compound H); 4-[2-(5-benzyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)-1H-imid azol-4-yl]-pyridine, cis- and trans-isomers, (Compound I); 2-[5-(4-fluoro-phenyl)-4-pyridin-4-yl-lH-imidazol-2-yl]-5-me thyl-[1,3]dioxane-5-carboxylic acid methyl ester, cis- and trans-isomers, (Compound J); 4-[5-(4-fluoro-phenyl)-2-(1,8,10-trioxa-spiro[5.5]undec-9-yl )-lH-imidazol-4-yl]-pyridine, (Compound K); 4-[5-(4-fluoro-phenyl)-2-(1,7,9-trioxa-spiro[4.5]dec-8-yl)- 1H-imidazol-4-yl]-pyridine, (Compound L); 4-[2-(5-methyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)-3H-imid azol-4-yl]-pyridine, (Compound M); 4-[5-(4-fluoro-phenyl)-2-(5.methylene-[1,3]dioxan-2-yl)-3H-i midazol-4-yl]-pyridine, (Compound N); 4-[2-[1,3]dioxan-2-yl-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]- pyridine, (Compound O); 4-[5-(4-fluoro-phenyl)-2-(4-methyl-[1,3]dioxan-2-yl)-3H-imid azol-4-yl]-pyridine, (R/S)(R/S) isomers, (Compound P); 4-[2-(4,6-dimethyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)-3H- imidazol-4-yl]-pyridine, (R/S)(R/S)(R/S) isomers, (Compound Q); 4-[2-(5-benzyloxy-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)-3H-i midazol-4-yl]-pyridine, cis- and trans-isomers, (Compound R); 4-[5-(4-fluoro-phenyl)-2-(5-phenyl-[1,3]dioxan-2-yl)-3H-imid azol-4-yl]-pyridine, cis- and trans-isomers, (Compound S); <BR> <BR> <BR> 4-[5-(4-fluoro.phenyl)-2-(4-isopropyl-5,5-dimethyl-[1,3]diox an-2-yl)-3H-imidazol-4-yl]-pyridine, (R/S)(R/S) isomers, (Compound T); 4-[2-(5,5-diethyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)-3H-i midazol-4-yl]-pyridine, (Compound U); 4-[2-(2,4-dioxa-spiro[5.5]undec-8-en-3-yl)-5-(4-fluoro-pheny l).3H-imidazol-4-yl]-pyridine, cis- and trans-isomers, (Compound V); N-{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-lH-imidazol-2-yl]-5 -methyl-[1,3]dioxan-5-yl}- benzamide, cis- and trans-isomers, (Compound W);

1-(4-fluoro-phenyl)-3-{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl - 1H-imidazol-2-yl]-5-methyl- [1,3]dioxan-5-yl}-thiourea, cis- and trans-isomers, (Compound X); 1-(2,6-dimethyl-phenyl)-3-{2-[4-(4-fluoro-phenyl)-5-pyridin- 4-yl-lH-imidazol-2-yl]-5-methyl- [1,3]dioxan-5-yl)-thiourea, cis- and trans-isomers, (Compound Y); <BR> <BR> <BR> 4-[5-(4-fluoro-phenyl)-2-(5-methyl-5-pyrrol-1-yl-[1,3]dioxan -2-yl)-3H-imidazol-4-yl]-pyridine, cis- and trans-isomer, (Compound Z); C-[5-methyl-2-(5-(4-fluoro-phenyl)-4-pyridin-4-yl-1H-imidazo l-2-yl)-[1,3]dioxan-5-yl]- methylamine, trans-isomer, (Compound AA); C-[5-methyl-2-j5-(4-fluoro-phenyl)-4-pyridin-4-yl-1H-imidazo l-2-yl}-[1,3]dioxan-5-yl]- methylamine, cis-isomer, (Compound AB); 2,2,2-trifluoro-N-[5-methyl-2-{5-(4-fluoro-phenyl)-4-pyridin -4-yl-1H-imidazol-2-yl}-[1,3]dioxan- 5-ylmethyl]-acetamide, trans-isomer, (Compound AC); 2,2,2-trifluoro-N-[5-methyl-2-{5-(4-fluoro-phenyl)-4-pyridin -4-yl-1H-imidazol-2-yl}-[1,3]dioxan- 5-ylmethyl]-acetamide, cis-isomer, (Compound AD); 5-methyl-2-{5-(4-fluoro-phenyl)-4-pyridin-4-yl-1H-imidazol-2 -yl}-[1,3]dioxan-5-ylamine, cis- isomer, (Compound AE); 5-methyl-2-(5-(4-fluoro-phenyl)-4-pyridin-4-yl.1H-imidazol-2 -yl)-[1,3]dioxan-5-ylamine, trans- isomer, (Compound AF); 5-methyl-2-{5-(4-fluoro-phenyl)-4-pyridin-4-yl-1H-imidazol-2 -yl }-[1,3]dioxan-5-ylamine, cis- and trans-isomers, (Compound AG); 2-[5-(4-fluoro-phenyl)-4-pyridin-4-yl-1H-imidazol-2-yl]-5-me thyl-[1,3]dioxane-5-carboxylic acid, trans-isomer, (Compound AH); 2-[5-(4-fluoro-phenyl)-4-pyridin-4-yl-1H-imidazol-2-yl]-5-me thyl-[1,3]dioxane-5-carboxylic acid, cis-isomer, (Compound AI); 2-t4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-me thyl- [1,3]dioxane-5-carboxylic acid benzylamide, cis-isomer, (Compound AJ); 2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-me thyl-[1,3]dioxane-5-carboxylic acid benzylamide, trans-isomer, (Compound AK); 2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl- 1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylic acid (2-hydroxy-ethyl)-amide, trans-isomer, (Compound AL); 2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-me thyl-[1,3]dioxane-5-carboxylic acid (2-methoxy-ethyl)-amide, trans-isomer, (Compound AM); 2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-me thyl [1,3]dioxane-5-carboxylic acid amide, trans-isomer, (Compound AN); 2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-me thyl-[1,3]dioxane-5-carboxylic acid (pyridin-2-ylmethyl)-amide, trans-isomer, (Compound AO);

2-[4-(4-fluoro.phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-me thyl-[1,3]dioxane-5-carboxylic acid (pyridin-3-ylmethyl) -amide, trans-isomer, (Compound AP); 2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-lH-imidazol-2-yl]-5-me thyl-[1,3]dioxane-5-carboxylic acid (pyridin-4-ylmethyl)-amide, trans-isomer, (Compound AQ); <BR> <BR> <BR> {2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-lH-imidazol-2-yl]-5-m ethyl-[1,3]dioxan-5-yl}-(4-methyl- piperazin-1-yl)-methanone, trans-isomer, (Compound AR); 2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-lH-imidazol-2-yl]-5-me thyl-[1,3]dioxane-5-carboxylic acid (3-dimethylamino-propyl)-amide, trans-isomer, (Compound AS); 2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-lH-imidazol-2-yl]-5-me thyl-[1,3]dioxane-5-carboxylic acid [2-(1H-indol-3-yl)-ethyl]-amide, trans-isomer, (Compound AT); 2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-lH-imidazol-2-yl]-5-me thyl-[1,3]dioxane-5-carboxylic acid (3-hydroxy-propyl)-amide, trans-isomer, (Compound AU); 2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-lH-imidazol-2-yl]-5-me thyl-[1,3]dioxane-5-carboxylic acid (tetrahydro-furan-2-ylmethyl)-amide, trans-isomer, (Compound AV); {2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-m ethyl-[1,3]dioxan-5-yl}-morpholin- 4-yl-methanone, trans-isomer, (Compound AW); {2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-m ethyl-[1,3]dioxan-5-yl}-pyrrolidin-1- yl-methanone, trans-isomer, (Compound AX); 2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-me thyl-[1,3]dioxane-5-carboxylic acid butylamide, trans-isomer, (Compound AY); 2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-me thyl-[1,3]dioxane-5-carboxylic acid dipropylamide, trans-isomer, (Compound AZ); 2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-me thyl-[1,3]dioxane-5-carboxylic acid (3-methoxy-propyl)-amide, trans-isomer, (Compound BA); 2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-me thyl-[1,3]dioxane-5-carboxylic acid phenethyl-amide, trans-isomer, (Compound BB); 2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-me thyl-[1,3]dioxane-5-carboxylic acid (2-pyridin-2-yl-ethyl)-amide, trans-isomer, (Compound BC); 2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-me thyl-[1,3]dioxane-5-carboxylic acid (furan-2-ylmethyl)-amide, trans-isomer, (Compound BD); (2-[4-(4-fluoro-pheny1) -5-pyridin-4-yl- 1H-imidazol-2-yl]-5-methyl- [1,3]dioxan-5-yl )-morpholin- 4-yl-methanone, trans-isomer, (Compound BE); 2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl- lH-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylic acid dimethylamide, trans-isomer, (Compound BF); 2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-me thyl-[1,3]dioxane-5-carboxylic acid propylamide, trans-isomer, (Compound BG);

2-[4-(4-fluoro-phenyi)-5-pyridin-4-yl- lH-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylic acid cyclopropylamide, trans-isomer, (Compound BH); 2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-lH-imidazol-2-yl]-5-me thyl-[1,3]dioxane-5-carboxylic acid cyclopentylamide, trans-isomer, Compound BI); 2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-lH-imidazol-2-yl]-5-me thyl-[1,3]dioxane-5-carboxylic acid cyclohexylamide, trans-isomer, (Compound BJ); 2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-lH-imidazol-2-yl]-5-me thyl-[1,3]dioxane-5-carboxylic acid (2-methoxy-ethyl)-amide, cis-isomer, (Compound BK); 2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-me thyl-[1,3]dioxane-5-carboxylic acid (2-hydroxy-ethyl)-amide, cis-isomer, (Compound BL); 2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl- 1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylic acid amide, cis-isomer, (Compound BM); 2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-lH-imidazol-2-yl]-5-me thyl-[1,3]dioxane-5-carboxylic acid (pyridin-2-ylmethyl)-amide, cis-isomer, (Compound BN); 2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-lH-imidazol-2-yl]-5-me thyl-[1,3]dioxane-5-carboxylic acid (pyridin-3-ylmethyl)-amide, cis-isomer, (Compound BO); 2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-lH-imidazol-2-yl]-5-me thyl-[1,3]dioxane-5-carboxylic acid (pyridin-4-ylmethyl)-amide, cis-isomer, (Compound BP); <BR> <BR> <BR> {2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-lH-imidazol-2-yl]-5-m ethyl-[1,3]dioxan-5-yl}-morpholin- 4-yl-methanone, cis-isomer, (Compound BQ); {2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-m ethyl-[1,3]dioxane-5-yl}-(4-methyl- piperazin-1-yl)-methanone, cis-isomer, (Compound BR); 2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-me thyl-[1,3]dioxane-5-carboxylic acid (3-dimethylamino-propyl)-amide, cis-isomer, (Compound BS); 2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-me thyl-[1,3]dioxane-5-carboxylic acid [2-(1H-indol-3-yl)-ethyl]-amide, cis-isomer, (Compound BT); 2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-me thyl-[1,3]dioxane-5-carboxylic acid (3-hydroxy-propyl)-amide, cis-isomer, (Compound BU); 2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-me thyl-[1,3]dioxane5carboxylic acid phenethyl-amide, cis-isomer, (Compound BV); 2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-me thyl-[1,3]dioxane-5-carboxylic acid (3-methoxy-propyl)-amide, cis-isomer, (Compound BW); 2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl- lH-imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid (2-pyridin-2-yl-ethyl)-amide, cis-isomer, (Compound BX); 2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl- lH-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylic acid (furan-2-ylmethyl)-amide, cis-isomer, (Compound BY);

2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl- 1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylic acid (tetrahydro-furan-2-ylmethyl)-amide, cis-isomer, (Compound BZ); <BR> <BR> <BR> <BR> <BR> {2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-m ethyl-[1,3]dioxan-5-yl }-pyrrolidin-1- yl-methanone, cis-isomer, (Compound CA); <BR> <BR> <BR> <BR> <BR> {2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-lH-imidazol-2-yl]-5-m ethyl-[1,3]dioxan-5-yl}-piperidin-1- yl-methanone, cis-isomer, (Compound CB); 2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-lH-imidazol-2-yl]-5-me thyl-[1,3]dioxane-5-carboxylic acid propylamide, cis-isomer, (Compound CC); 2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-lH-imidazol-2-yl]-5-me thyl-[1,3]dioxane-5-carboxylic acid butylamide, cis-isomer, (Compound CD); 2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-lH-imidazol-2-yl]-5-me thyl-[1,3]dioxane-5-carboxylic acid cyclopropylamide, cis-isomer, (Compound CE); 2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-lH-imidazol-2-yl]-5-me thyl-[1,3]dioxane-5-carboxylic acid cyclopentylamide, cis-isomer, (Compound CF); 2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-lH-imidazol-2-yl]-5-me thyl-[1,3]dioxane-5-carboxylic acid cyclohexylamide, cis-isomer, (Compound CG); 2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-me thyl-[1,3]dioxane-5-carboxylic acid methylamide, cis-isomer, (Compound CH); 2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-lH-imidazol-2-yl]-5-me thyl-[1,3]dioxane-5-carboxylic acid (2-dimethylamino-ethyl)-amide, cis-isomer, (Compound CI); 2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-me thyl-[1,3]dioxane-5-carboxylic acid dimethylamide, cis-isomer, (Compound CJ); 2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl- 1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylic acid dipropylamide, cis-isomer, (Compound CK); 2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-me thyl-[1,3]dioxane-5-carboxylic acid ethylamide, cis-isomer, (Compound CL); 2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-me thyl-[1,3]dioxane-5-carboxylic acid methylamide, trans-isomer, (Compound CM); 2-[4-(4-fluoro-phenyl)-5-pyfldin-4-yl-1H-imidazol-2-yl]-5-me thyl-[1,3]dioxane5carboxylic acid (2-dimethylamino-ethyl)-amide, trans-isomer, (Compound CN); 2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidaWl-2-yl]-5-met hyl-[1,3]dioxane5carboxylic acid ethylamide, trans-isomer, (Compound CO); 1-{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl- lH-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-3-phenyl- urea, cis-isomer, (Compound CP); 1-ethyl-3-{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol -2-yl]-5-methyl-[1,3]dioxan-5-yl}- urea, cis-isomer, (Compound CQ);

1-(3,5-dimethyl-isoxazol-4-yl)- 3- (2- [4-(4-fluoro-phenyl)-5- pyridin-4-yl- 1H-imidazol-2-yl]-5- methyl-[1,3]dioxan-5-yl)-urea, cis-isomer, (Compound CR); <BR> <BR> <BR> <BR> 1-benzyl-3-{2-[4-(4-fluoro-phenyl)-5-pyndin-4-yl-1H-imidazol -2-yl]-5-methyl-[1,3]dioxan-5-yl}- urea, cis-isomer, (Compound CS); 1-{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5 -methyl-[1,3]dioxan-5-yl)-3-(2- thiophen-2-yl-ethyl)-urea, cis-isomer, (Compound CT); I-(3-acetyl-phenyl)-3-(2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl -1H-imidazol-2-yl]-5-methyl- [1,3]dioxan-5-yl)-urea, cis-isomer, (Compound CU); <BR> <BR> <BR> <BR> 1-{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-lH-imidazol-2-yl]-5 -methyl-[1,3]dioxan-5-yl}-3-phenyl- urea, trans-isomer, (Compound CV); <BR> <BR> <BR> <BR> 3-(3-{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-lH-imidazol-2-yl ]-5-methyl-[1,3]dioxan-5-yl}-ureido)- benzoic acid, trans-isomer, (Compound CW); <BR> <BR> <BR> <BR> 1-benzyl-3-{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-lH-imidazo l-2-yl]-5-methyl-[1,3]dioxan-5-yl}- urea, trans-isomer, (Compound CX); <BR> <BR> <BR> <BR> 1-ethyl-3-{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol -2-yl]-5-methyl-[1,3]dioxan-5-yl}- urea, trans-isomer, (Compound CY); 1-{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5 -methyl-[1,3]dioxan-5-yl)-3-(2- thiophen-2-yl-ethyl)-urea, trans-isomer, (Compound CZ); 1-benzyl-3-{3-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazo l-2-yl]-5-methyl-[1,3]dioxan-5- ylmethyl)-urea, cis-isomer, (Compound DA); 1-ethyl-3-{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol -2-yl]-5-methyl-[1,3]dioxan-5- ylmethyl)-urea, cis-isomer, (Compound DB); <BR> <BR> <BR> <BR> 1-{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-lH-imidazol-2-yl]-5 -methyl-[1,3]dioxan-5-ylmethyl}-3- phenyl-urea, cis-isomer, (Compound DC); 1-{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl- 1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-ylmethyl)-3- phenyl-urea, trans-isomer, (Compound DD); 1-benzyl-3-(2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazo l-2-yl]-5-methyl-[1,3]dioxan-5- ylmethyl}-urea, trans-isomer, (Compound DE); 1-ethyl-3-{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol -2-yl]-5-methyl-[1,3]dioxan-5- ylmethyl}-urea, trans-isomer, (Compound DF); 1-(2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5 -methyl-[1,3]dioxan-5-yl)-3-(2- morpholin-4-yl-ethyl)-thiourea, cis-isomer, (Compound DG); 1-{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl- 1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-3-furan-3- ylmethyl-thiourea, cis-isomer, (Compound DH); <BR> <BR> <BR> <BR> 1-{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-lH-imidazol-2-yl]-5 -methyl-[1,3]dioxan-5-yl}-3-pyridin- 3-yl-thiourea, cis-isomer, (Compound DI);

1-benzo1,3]dioxol-5-yl-3- {2- [4- (4-fluoro-phenyl)-5-pyridin-4-yl- lH-imidazol-2-yl]-5-methyl- [1,3]dioxan-5-yl)-thiourea, cis-isomer, (Compound DJ); 1-benzo[1,3]dioxol-5-ylmethyl-3-{2-[4-(4-fluoro-phenyl)-5-py ridin-4-yl-1H-imidazol-2-yl]-5- methyl-[1,3]dioxan-5-yl)-thiourea, cis-isomer, (Compound DK); <BR> <BR> <BR> 1-{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-lH-imidazol-2-yl]-5 -methyl-[1,3]dioxan-5-ylmethyl}-3- pyridin-3-yl-thiourea, trans-isomer, (Compound DL); <BR> <BR> <BR> 1-{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-lH-imidazol-2-yl]-5 -methyl-[1,3]dioxan-5-ylmethyl}-3- (2-morpholin-4-yl-ethyl)-thiourea, trans-isomer, (Compound DM); <BR> <BR> <BR> 1-{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-lH-imidazol-2-yl]-5 -methyl-[1,3]dioxan-5-ylmethyl}-3- furan-2-ylmethyl-thiourea, trans-isomer, (Compound DN); 1-benzo[1,3]dioxol-5-ylmethyl-3-(2-[4-(4-fluoro-phenyl)-5-py ridin-4-yl-1H-imidazol-2-yl]-5- methyl-[1,3]dioxan-5-ylmethyll-thiourea, trans-isomer, (Compound DO); 1-benzo[1,3]dioxol-5-yl-3-{2-[4-(4-fluoro-phenyl)-5-pyridin- 4-yl-1H-imidazol-2-yl]-5-methyl- [1,3]dioxan-5-ylmethyl}-thiourea, cis-isomer, (Compound DP); 1-{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5 -methyl-[1,3]dioxan-5-ylmethyl}-3- furan-2-ylmethyl-thiourea, cis-isomer, (Compound DQ); 3-(3-{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl ]-5-methyl-[1,3]dioxan-5-ylmethyl}- thioureido)-benzoic acid, cis-isomer, (Compound DR); 1-{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5 -methyl-[1,3]dioxan-5-ylmethyl}-3- pyridin-3-yl-thiourea, cis-isomer, (Compound DS); 1-{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5 -methyl-[1,3]dioxan-5-ylmethyl}-3- (2-morpholin-4-yl-ethyl)-thiourea, cis-isomer, (Compound DT); 1-benzo[1,3]dioxol-5-ylmethyl-3-{2-[4-(4-fluoro-phenyl)-5-py ridin-4-yl-1H-imidazol-2-yl]-5- methyl-[1,3]dioxan-5-ylmethyl )-thiourea, cis-isomer, (Compound DU); N-(2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl- 1H-imidazol-2-yl]-5-methyl-[l ,3]dioxan-5-yl)- acetamide, cis-isomer, (Compound DV); N-{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5 -methyl-[1,3]dioxan-5-yl}-2-phenyl- acetamide, cis-isomer, (Compound DW); cyclohexanecarboxylic acid (2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-m ethyl- [1,3]dioxan-5-yl )-amide, cis-isomer, (Compound DX); 2-benzyloxy-N-{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imid azol-2-yl]-5-methyl-[1,3]dioxan-5- yl}-acetamide, trans-isomer, (Compound DY); 2-benzyloxy-N-{2- [4-(4-fluoro-phenyl)-5-pyridin-4-yl- 1H-imidazol-2-yl]-5-methyl- [1,3]dioxan-5- yl}-acetamide, cis-isomer, (Compound DZ); N-(2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl- 1H-imidazol-2-yl]-5-methyl- [1,3]dioxan-5-yl)- acetamide, trans-isomer, (Compound EA);

N-{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5 -methyl-[1,3]dioxan-5-yl}-2-phenyl- acetamide, trans-isomer, (Compound EB); cyclohexanecarboxylic acid {2- [4-(4-fluoro-phenyl)-5-pyridin-4-yl- 1H-imidazol-2-yl]-5-methyl- [1,3]dioxan-5-yl}-amide, trans-isomer, (Compound EC); <BR> <BR> <BR> N-(2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl- 1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5 )-2-phenyl- acetamide, cis-isomer, (Compound ED); 2-benzyloxy-N-{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imid azol-2-yl]-5-methyl-[1,3]dioxan-5- ylmethyl}-acetamide, cis-isomer, (Compound EE); <BR> <BR> <BR> N-{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5 -methyl-[1,3]dioxan-5-ylmethyl}-2- phenyl-acetamide, cis-isomer, (Compound EF); <BR> <BR> <BR> N-{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-lH-imidazol-2-yl]-5 -methyl-[1,3]dioxan-5-ylmethyl}- acetamide, cis-isomer, (Compound EG); <BR> <BR> <BR> N-{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5 -methyl-[1,3]dioxan-5-ylmethyl}-2- phenyl-acetamide, cis-isomer, (Compound EH); cyclohexanecarboxylic acid {2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-m ethyl- [1,3]dioxan-5-ylmethyl)-amide, cis-isomer, (Compound EI); N-{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-lH-imidazol-2-yl]-5 -methyl-[1,3]dioxan-5-ylmethyl}- acetamide, trans-isomer, (Compound EJ); N-{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5 -methyl-[1,3]dioxan-5-ylmethyl}-2- phenyl-acetamide, trans-isomer, (Compound EK); cyclohexanecarboxylic acid {2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-m ethyl- [1,3]dioxan-5-ylmethyl}-amide, trans-isomer, (Compound EL); N-{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5 -methyl-[1,3]dioxan-5-ylmethyl}-2- phenyl-acetamide, trans-isomer, (Compound EM); 4-{2-[5-(4-fluoro-phenyl)-4-pyridin-4-yl-1H-imidazol-2-yl]-5 -methyl-[1,3]dioxan-5-ylcarbamoyl}- butyric acid, cis-isomer, (Compound EN); 4-({2-[5-(4-fluoro-phenyl)-4-pyridin-4-yl-1H-imidazol-2-yl]- 5-methyl-[1,3]dioxan-5-ylmethyl}- carbamoyl)-butyric acid, cis-isomer, (Compound EO); <BR> <BR> <BR> 4-{2-[5-(4-fluoro-phenyl)-4-pyridin-4-yl- lH-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-ylcarbamoyl}- propionic acid, cis-isomer, (Compound EP); 4-({2-[5-(4-fluoro-phenyl)-4-pyridin-4-yl-1H-imidazol-2-yl]- 5-methyl-[1,3]dioxan-5-ylmethyl}- carbamoyl)-propionic acid, cis-isomer, (Compound EQ); 4-({2-[5-(4-fluoro-phenyl)-4-pyridin-4-yl-1H-imidazol-2-yl]- 5-methyl-[1,3]dioxan-5-ylmethyl}- carbamoyl)-propionic acid, trans-isomer, (Compound ER); N-{2-[5-(4-fluoro-phenyl)-4-pyridin-4-yl-1H-imidazol-2-yl]-5 -methyl-[1,3]dioxan-5-yl}- methanesulphonamide, cis-isomer, (Compound ES);

N-{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-lH-imidazol-2-yl]-5 -methyl-[1,3]dioxan-5-ylmethyl}- methanesulphonamide, cis-isomer, (Compound ET); N-{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5 -methyl-[1,3]dioxan-5-ylmethyl}- benzenesulphonamide, cis-isomer, (Compound EU); N-{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl- lH-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-ylmethyl}-C- phenyl-methanesulphonamide, cis-isomer, (Compound EV); thiophene-2-sulphonic acid {2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-m ethyl- [1,3]dioxan-5-ylmethyl)-amide, cis-isomer, (Compound EW); 3,5-dimethyl-isoxazole-4-sulphonic acid (2-[4-(4-fluoro-phenyl)-5-pyndin-4-yl-1H-imidazol-2yl]- 5-methyl-[1,3]dioxan-5-ylmethyl}-amide, cis-isomer, (Compound EX); N-{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5 -methyl-[1,3]dioxan-5-ylmethyl}- methanesulphonamide, trans-isomer, (Compound EY); N-{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5 -methyl-[1,3]dioxan-5-ylmethyl}- benzenesulphonamide, trans-isomer, (Compound EZ); thiophene-2-sulphonic acid {2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-lH-imidazol-2-yl]-5-m ethyl- [1,3]dioxan-5-ylmethylj-amide, trans-isomer, (Compound FA); 3,5-dimethyl-isoxazole-4-sulphonic acid (2- [4-(4-fl uoro- phenyl)-5-pyridin -4-yl-1 H-imidazol-2- yl]-5-methyl-[1,3]dioxan-5-ylmethyl}-amide, trans-isomer, (Compound FB); 3-amino-N-{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol -2-yl]-5-methyl-[1,3]dioxan-5-yl}- propionamide, trans-isomer, (Compound FC); 3-amino-N-{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol -2-yl]-5-methyl-[1,3]dioxan-5-yl}- propionamide, cis-isomer, (Compound FD); 4-amino-N-{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol -2-yl]-5-methyl-[1,3]dioxan-5-yl}- butyramide, trans-isomer, (Compound FE); 4-amino-N-{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol -2-yl]-5-methyl-[1,3]dioxan-5-yl}- butyramide, cis-isomer, (Compound FF); 2-amino-N-{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol -2-yl]-5-methyl-[1,3]dioxan-5-yl}- acetamide, trans-isomer, (Compound FG); 2-amino-N-{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol -2-yl]-5-methyl-[1,3]dioxan-5-yl}- acetamide, cis-isomer, (Compound FH); (3-{2- [4-(4-fluoro-phenyl)-5-pyridin-4-yl- lH-imidazol-2-yl]-5-methyl-[1,3]dioxan-5- ylcarbamoyl)-ethyl)-carbamic acid benzyl ester, trans-isomer, (Compound FI); (3-{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]- 5-methyl-[1,3]dioxan-5- ylcarbamoyl}-ethyl)-carbamic acid benzyl ester, cis-isomer, (Compound FJ); (3-{2-[4-(4-fluoro-phenyl)5-pyridin-4-yl-1H-imidazol-2-yl]-5 -methyl-[1,3]dioxan-5- ylcarbamoyl}-propyl)-carbamic acid benzyl ester, trans-isomer, (Compound FK);

(3-{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-lH-imidazol-2-yl]- 5-methyl-[1,3]dioxan-5- ylcarbamoyl}-propyl)-carbamic acid benzyl ester, cis-isomer, (Compound FL); (3-{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]- 5-methyl-[1,3]dioxan-5- ylcarbamoyl}-methyl)-carbamic acid benzyl ester, trans-isomer, (Compound FM); (3-{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-111-imidazol-2-yl] -5-methyl-[1,3]dioxan-5- ylcarbamoyl}-methyl)-carbamic acid benzyl ester, cis-isomer, (Compound FN); 4-dimethylamino-N-(2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H- imidazol-2-yl]-5-methyl- [1,3]dioxan-5-yl}-butyramide, cis- and trans-isomers, (Compound FO); N-{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-lH-imidazol-2-yl]-5 -methyl-[1,3]dioxan-5-yl}- benzamide, trans-isomer, (Compound FR); {2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-m ethyl-[1,3]dioxan-5-yl}-(4-hydroxy- piperidin-1-yl)-methanone, trans isomer, (Compound FS); <BR> <BR> <BR> (1,4-dioxa-8-aza-spiro[4.5]dec-8-yl)-(2-[4-(4-fluoro-phenyl) -5-pyridin-4-yl-1H-imidazol-2-yl]-5- methyl-[1,3]dioxan-5-yl}-methanone, trans isomer, (Compound FT); <BR> <BR> <BR> 1-{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-lH-imidazol-2-yl]-5 -methyl-[1,3]dioxane-5-carbonyl}- piperidine-4-carboxylic acid ethyl ester, trans isomer, (Compound FU); 1-{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5 -methyl-[1,3]dioxane-5-carbonyl}- piperidine-4-carboxylic acid, trans isomer, (Compound FV); {2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-lH-imidazol-2-yl]-5-m ethyl-[1,3]dioxan-5-yl}- thiomorpholin-4-yl-methanone, trans isomer, (Compound FW); (1,1-dioxothiomorpholin-4-yl)-{2-[4-(4-fluoro-phenyl)-5-pyri din-4-yl-1H-imidazol-2-yl]-5-methyl- [1,3]dioxan-5-yl}-methanone, trans isomer, (Compound FX); {2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-m ethyl-[1,3]dioxan-5-yl}-(3- hydroxymethyl-piperidin-1-yl)-methanone, trans isomer, (Compound FY); {2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-m ethyl-[1,3]dioxan-5-yl}-(3-hydroxy- piperidin-1-yl)-methanone, trans isomer, (Compound FZ); (2,6-dimethyl-morpholin-4-yl)-{2-[4-(4-fluoro-phenyl)-5-pyri dn-4-yl-1H-imidazol-2-yl]-5- methyl-[1,3]dioxan-5-yl}-methanone, trans isomer, (Compound GA); {2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-m ethyl-[1,3]dioxan-5-yl}-(3-hydroxy- pyrrolidin-1-yl)-methanone, trans isomer, (Compound GB); {2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-m ethyl-[1,3]dioxan-5-yl}-(4-methoxy- piperidin-1-yl)-methanone, trans isomer, (Compound GC); {2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-m ethyl-[1,3]dioxan-5-yl}-[4-(2- hydroxy-ethyl)-piperidin- 1-yl]-methanone, trans isomer, (Compound GD); {5-Amino-2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2 -yl]-[1,3]dioxan-5-yl}-methanol, cis isomer, (Compound LE);

{5-Amino-2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-lH-imidazol-2 -yl]-[1,3]dioxan-5-yl}-methanol, trans isomer, (Compound LF); {2-[4-(4-Fluoro-phenyl)-5-pyridin-4-yl- lH-imidazol-2-yl]-5-nitro- [1,3]dioxan-5-yl)-methanol, cis isomer, (Compound LG); {2-[4-(4-Fluoro-phenyl)-5-pyridin-4-yl-lH-imidazol-2-yl]-5-n itro-[1,3]dioxan-5-yl}-methanol, trans isomer,(Compound LH); C-{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5 ,5-dimethyl-[1,3]dioxan-4-yl}- methylamine (Compound LI); 4-[2-(5,5-dimethyl-4-nitromethyl-[1,3]dioxan-2-yl)-5-(4-fluo ro-phenyl)-3H-imidazol-4-yl]- pyridine (Compound LJ); and the corresponding N-oxides, and their prodrugs; and pharmaceutically acceptable salts and solvates (e.g. hydrates) of such compounds and their N- oxides and prodrugs.

A further particular group of compounds of the invention are those selected from the following: {2-[5-(2-cyclopropylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl )-1H-imidazol-2-yl]-5-methyl- [1,3]dioxan-5-yl}-morpholin-4-yl-methanone, trans isomer, (Compound GE); <BR> <BR> <BR> <BR> 2-[5-(2-Amino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-lH-imidazo l-2-yl]-5-methyl-[1,3]dioxan-5-yl}- morpholin-4-yl-methanone, trans-isomer, (Compound GI); {2-[5-(2-Dimethylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1 H-imidazol-2-yl]-5-methyl- [1,3]dioxan-5-yl )-morpholin-4-yl-methanone, trans-isomer, (Compound GJ); (2-{4-(4-Fluoro-phenyl)-5-[2-(3-hydroxy-propylamino)-pyrimid in-4-yl]-lH-imidazol-2-yl}-5- methyl-[1,3]dioxan-5-yl)-morpholin-4-yl-methanone , trans-isomer, (Compound GK); (2-{4-(4-Fluoro-phenyl)-5-[2-(2-methoxy-ethylamino)-pyrimidi n-4-yl]-1H-imidazol-2-yl}-5- methyl-[1,3]dioxan-5-yl)-morpholin-4-yl-methanone, trans-isomer, (Compound GL); {2-[4-(4-Fluoro-phenyl)-5-(2-methylamino-pyrimidin-4-yl)-1H- imidazol-2-yl]-5-methyl- [1,3]dioxan-5-yl }-morpholin-4-yl-methanone, trans-isomer, (Compound GM); (2-(4- (4-Fluoro-phenyl)-5 -[2-(1- ethoxycarbonylpiperidin-4-ylamino) -pyrimidin4-yl]-1H- imidazol-2-yl}-5-methyl-[1,3]dioxan-5-yl)-morpholin-4-yl-met hanone, trans-isomer, (Compound GN); {2-[5-(2-Cyclohexylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl) -1H-imidazol-2-yl]-5-methyl- [1,3]dioxan-5-yl}-morpholin-4-yl-methanone, trans-isomer, (Compound GO); (2-{4-(4-Fluoro-phenyl)-5-[2-(2-hydroxy-ethylamino)-pyrimidi n-4-yl]-1H-imidazol-2-yl}-5- methyl-[1,3]dioxan-5-yl)-morpholin-4-yl-methanone, trans-isomer, (Compound GP); {2-[5-[2-(2-Amino-ethylamino)-pyrimidin-4-yl]-4-(4-fluoro-ph enyl)-1H-imidazol-2-yl]-5-methyl [1,3]dioxan-5-yl}-morpholin-4-yl-methanone, trans-isomer, (Compound GQ);

[2-(4-(4-Fluoro-phenyl)-5-{2- [3-(5H-imidazol- l-yl)-propyiamino ]-pyrimidin-4-yl)-l H-imidazol-2- yl)-5-methyl-[1,3]dioxan-5-yl]-morpholin-4-yl-methanone, trans-isomer, (Compound GR); <BR> <BR> <BR> <BR> (2-{4-(4-Fluoro-phenyl)-5-[2-(3-morpholin-4-yl-propylamino)- pyrimidin-4-yl]-lH-imidazol-2-yl}- 5-methyl-[1,3]dioxan-5-yl)-morpholin-4-yl-methanone, trans-isomer, (Compound GS); 2-[5-(2-Benzylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-i midazol-2-yl]-5-methyl- [1,3]dioxan-5-yl)-morpholin-4-yl-methanone, trans-isomer, (Compound GT); (2-{4-(4-Fluoro-phenyl)-5-[2-(1-phenyl-ethylamino)-pyrimidin -4-yl]-1H-imidazol-2-yl}-5-methyl- [1,3]dioxan-5-yl)-morpholin-4-yl-methanone, R isomer, trans-isomer, (Compound GU); <BR> <BR> <BR> <BR> (2-{4-(4-Fluoro-phenyl)-5-[2-(1-phenyl-ethylamino)-pyrimidin -4-yl]-lH-imidazol-2-yl}-5-methyl- [1,3]dioxan-5-yl)-morpholin-4-yl-methanone, S isomer, trans-isomer, (Compound GV); {2-[4-(4-Fluoro-phenyl)-5-(2-phenylamino-pyrimidin-4-yl)-1H- imidazol-2-yl]-5-methyl- [1,3]dioxan-5-yl}-morpholin-4-yl-methanone, trans-isomer, (Compound GW); {2-[4-(4-Fluoro-phenyl)-5-(2-piperidin-1-yl-pyrimidin-4-yl)- 1H-imidazol-2-yl]-5-methyl- [1,3]dioxan-5-yl}-morpholin-4-yl-methanone, trans-isomer, (Compound GX); [2-(4-(4-Fluoro-phenyl)-5-{2-[(pyridin-4-ylmethyl)-amino]-py rimidin-4-yl}-1H-imidazol-2-yl)-5- methyl-[1,3]dioxan-5-yl]-morpholin-4-yl-methanone, trans-isomer, (Compound GY); <BR> <BR> <BR> <BR> [2-(4-(4-Fluoro-phenyl)-5-{2-[(pyridin-2-ylmethyl)-amino]-py rimidin-4-ylj-1H-imidazol-2-yl)-5- methyl-[1,3]dioxan-5-yl]-morpholin-4-yl-methanone, trans-isomer, (Compound GZ); <BR> <BR> <BR> [2-(4-(4-Fluoro-phenyl)-5-(2-[(pyridin-3-ylmethyl)-amino]-py rimidin-4-yl}-1H-imidazol-2-yl)-5- methyl-[1,3]dioxan-5-yl]-morpholin-4-yl-methanone, trans-isomer, (Compound HA); [2-(4-(4-Fluoro-phenyl)-5-(2- [(furan-2-ylmethyl)-amino]-pyrimidin-4-ylj- lH-imidazol-2-yl)-5- methyl-[1,3]dioxan-5-yl]-morpholin-4-yl-methanone, trans-isomer, (Compound HB); [2-(4-(4-Fluoro-phenyl)-5-{2-[(thiophen-2-ylmethyl)-amino]-p yrimidin-4-yl}-1H-imidazol-2-yl)-5- methyl-[1,3]dioxan-5-yl]-morpholin-4-yl-methanone, trans-isomer, (Compound HC); [2-(4-(4-Fluoro-phenyl)-5-{2-[(tetrahydro-furan-2-ylmethyl)- amino]-pyrimidin-4-yl}-1H- imidazol-2-yl)-5-methyl-[1,3]dioxan-5-yl]-morpholin-4-yl-met hanone, trans-isomer, (Compound HD); (2-{4-(4-Fluoro-phenyl)-5-[2-(4-methyl-piperazin-1-yl)-pyrim idin-4-yl]-1H-imidazol-2-yl}-5- methyl-[1,3]dioxan-5-yl)-morpholin-4-yl-methanone, trans-isomer, (Compound HE); {2-[4-(4-Fluoro-phenyl)-5-(2-morpholin-4-yl-pyrimidin-4-yl)- 1H-imidazol-2-yl]-5-methyl- [1,3]dioxan-5-yl}-morpholin-4-yl-methanone, trans-isomer, (Compound HF); (2-{4-(4-Fluoro-phenyl)-5-[2-(3-methoxy-propylamino)-pyrimid in-4-yl]-1H-imidazol-2-yl}-5- methyl- [1,3]dioxan-5-yl)-morpholin-4-yl-methanone, trans-isomer, (Compound FG); {2-[5-[2-(3-Dimethylamino-propylamino)-pyrimidin-4-yl]-4-(4- fluoro-phenyl)-1H-imidazol-2-yl]- 5-methyl-[1,3]dioxan-5-yl}-morpholin-4-yl-methanone, trans-isomer, (Compound HH);

{2-[5- [2-(2-Dimethylamino-ethylamino)-pyrimidin-4-yl]-4-(4-fluoro- phenyl)-1H-imidazol-2-yl]-5- methyl-[1,3]dioxan-5-yl)-morpholin-4-yl-methanone, trans-isomer, (Compound HI); (4-{5-(4-Fluoro-phenyl)-2- [5-methyl-5-(morpholine-4-carbonyl)- [1,3]dioxan-2-yl]-3H-imidazol-4- yl}-pyrimidin-2-ylamino)-acetic acid, trans-isomer, (Compound HJ); <BR> <BR> <BR> <BR> 3-(4-{5-(4-Fluoro-phenyl)-2-[5-methyl-5-(morpholine-4-carbon yl)-[1,3]dioxan-2-yl]-3H-imidazol- 4-yl}-pyrimidin-2-ylamino)-propionic acid, trans-isomer, (Compound HK); <BR> <BR> <BR> <BR> 4-[2-(5,5-dimethyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)-3H- imidazol-4-yl]-pyrimidin-2-ylamine, (Compound HL); {4-[2-(5,5-dimethyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)-3H -imidazol-4-yl]-pyrimidin-2-yl}- methyl-amine, (Compound HM); {4-[2-(5,5-dimethyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)-3H -imidazol-4-yl]-pyrimidin-2-yl}- dimethyl-amine, (Compound HN); cyclopropyl-(4-[2-(5,5-dimethyl-[1,3]dioxan-2-yl)-5-(4-fluor o-phenyl)-3H-imidazol-4-yl]- pyrimidin-2-yl}-amine, (Compound HO); cycloheXyl-{4-[2-(5,5-dimethyl-[1,3]dioxan-2-yl)-5-(4-fluoro -phenyl)-3H-imidazol-4-yl]- pyrimidin-2-yl)-amine, (Compound HQ); 2-{4-[2-(5,5-dimethyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)- 3H-imidazol-4-yl]-pyrimidin-2- ylamino}-ethanol, (Compound HR); N1-{4-[2-(5,5-dimethyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl) -3H-imidazol-4-yl]-pyrimidin-2-yl}- ethane-1,2-diamine, (Compound HS); <BR> <BR> <BR> <BR> {4-[2-(5,5-dimethyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)-3H -imidazol-4-yl]-pyrimidin-2-yl}-[3- (5H-imidazol-1-yl)-propyl]-amine, (Compound HT); <BR> <BR> <BR> <BR> {4-[2-(5,5-dimethyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)-3H -imidazol-4-yl]-pyrimidin-2-yl}-(3- morpholin-4-yl-propyl)-amine, (Compound HU); 3-{4-[2-(5,5-dimethyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)- 3H-imidazol-4-yl]-pyrimidin-2- ylamino}-propan-1-ol, (Compound HV); <BR> <BR> <BR> <BR> benzyl-{4-[2-(5,5-dimethyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phe nyl)-3H-imidazol-4-yl]-pyrimidin-2- yl}-amine, (Compound HW); {4- [2-(5,5-dimethyl- [1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-pyri midin-2-yl}-(1- phenyl-ethyl)-amine, R-isomer, (Compound HX); {4-[2-(5,5-dimethyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)-3H -imidazol-4-yl]-pyrimidin-2-yl}-(1- phenyl-ethyl)-amine, S-isomer, (Compound HY); {4-[2-(5,5-dimethyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)-3H -imidazol-4-yl]-pyrimidin-2-yl}- phenyl-amine, (Compound HZ); 4-[2-(5,5-dimethyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)-3H- imidazol-4-yl]-2-piperidin-1-yl- pyrimidine, (Compound IA);

{4-[2-(5,5-dimethyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)-3H -imidazol-4-yl]-pyrimidin-2-yl}- pyridin-4-ylmethyl-amine, (Compound IB); (4- [2-(5,5-dimethyl- [1,3]dioxan-2-yl)-5-(4-fluoro-phenyl) -3H-imidazol-4-yl]-pyrimidin-2-yl)- pyridin-2-ylmethyl-amine, (Compound IC); {4-[2-(5,5-dimethyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)-3H -imidazol-4-yl]-pyrimidin-2-yl}- pyridin-3-ylmethyl-amine, (Compound ID); {4-[2-(5,5-dimethyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)-3H -imidazol-4-yl]-pyrimidin-2-yl}- (furan-2-ylmethyl)-amine, (Compound IE); {4-[2-(5,5-dimethyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)-3H -imidazol-4-yl]-pyrimidin-2-yl}- (thiophen-2-ylmethyl)-amine, (Compound IF); {4-[2-(5,5-dimethyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)-3H -imidazol-4-yl]-pyrimidin-2-yl}- (tetrahydro-furan-2-ylmethyl)-amine, (Compound IG); 4-[2-(5,5-dimethyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)-3H- imidazol-4-yl]-2-(4-methyl- piperazin-1-yl)-pyrimidine, (Compound IH); 4-{4-[2-(5,5-dimethyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)- 3H-imidazol-4-yl]-pyrimidin-2-yl}- morpholine, (Compound IJ); {4-[2-(5,5-dimethyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)-3H -imidazol-4-yl]-pyrimidin-2-yl}-(3- methoxy-propyl)-amine, (Compound IK); {4-[2-(5,5-dimethyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)-3H -imidazol-4-yl]-pyrimidin-2-yl}-(2- methoxy-ethyl)-amine, (Compound IL); N-{4-[2-(5,5-dimethyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)- 3H-imidazol-4-yl]-pyrimidin-2-yl}- N',N'-dimethyl-propane-1,3-diamine, (Compound IM); N-{4-[2-(5,5-dimethyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)- 3H-imidazol-4-yl]-pyrimidin-2-yl}- N',N'-dimethyl-ethane-1,2-diamine, (Compound IN); {2-[5-(2-amino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidaz ol-2-yl]-5-methyl-[1,3]dioxan-5- yl}-methanol, trans-isomer, (Compound IO) {2-[4-(4-Fluoro-phenyl)-5-(2-methoxy-pyrimidin-4-yl)-1H-imid azol-2-yl]-5-methyl-[1,3]dioxan-5- yl}-morpholin-4-yl-methanone, trans-isomer, (Compound IP); {2-[5-(2-Benzyloxy-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-im idazol-2-yl]-5-methyl-[1,3]dioxan- 5-yl}-morpholin-4-yl-methanone, trans-isomer, (Compound IQ); {2-[4-(4-Fluoro-phenyl)-5-(2-phenoxy-pyrimidin-4-yl)-1H-imid azol-2-yl]-5-methyl-[1,3]dioxan-5- yl}-morpholin-4-yl-methanone, trans-isomer, (Compound IR); (2-{4-(4-Fluoro-phenyl)-5-[2-(2-methoxy-ethoxy)-pyrimidin-4- yl]-1H-imidazol-2-yl}-5-methyl- [1,3]dioxan-5-yl)-morpholin-4-yl-methanone, trans-isomer, (Compound IS); {2-[5-[2-(2-Dimethylamino-ethoxy)-pyrimidin-4-yl]-4-(4-fluor o-phenyl)-1H-imidazol-2-yl]-5- methyl-[1,3]dioxan-5-yl}-morpholin-4-yl-methanone, trans-isomer, (Compound IT);

{2-[5-(2-Cyclohexyloxy-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1 H-imidazol-2-yl]-5-methyl- [1,3]dioxan-5-yl}-morpholin-4-yl-methanone, trans-isomer, (Compound IU); {2-[5-(2-Isopropoxy-pyrimidin-4-yl)-4-(4-fluoro-phenyl)- lH-imidazol-2-yl]-5-methyl-[1,3]dioxan- 5-yl}-morpholin-4-yl-methanone, trans-isomer, (Compound IW); 4-[2-(5,5-dimethyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)-3H- imidazol-4-yl]-2-methoxy- pyrimidine, (Compound IY); 2-benzyloxy-4-[2-(5,5-dimethyl-[1,3]dioxan-2-yl)-5-(4-fluoro -phenyl)-3H-imidazol-4-yl]- pyrimidine, (Compound IZ); 4-[2-(5,5-dimethyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)-3H- imidazol-4-yl]-2-phenoxy- pyrimidine, (Compound JA); <BR> <BR> <BR> 4-[2-(5,5-dimethyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)-3H- imidazol-4-yl]-2-(2-methoxy-ethoxy)- pyrimidine, (Compound JB); (2-{4-[2-(5,5-dimethyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl) -3H-imidazol-4-yl]-pyrimidin-2- yloxy)-ethyl)-dimethyl-amine, (Compound JC); 2-cyclohexyloxy-4-[2-(5,5-dimethyl-[1,3]dioxan-2-yl)-5-(4-fl uoro-phenyl)-3H-imidazol-4-yl]- pyrimidine, (Compound JD); 2-isopropoxy-4-[2-(5,5-dimethyl-[1,3]dioxan-2-yl)-5-(4-fluor o-phenyl)-3H-imidazol-4-yl]- pyrimidine, (Compound JE); 4-[2-(5-amino-5-methyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl) -3H-imidazol-4-yl]-pyrimidin-2- ylamine, cis-isomer, (Compound JF); <BR> <BR> <BR> <BR> {4-[2-(5-amino-5-methyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl )-3H-imidazol-4-yl]-pyrimidin-2- yl}-methyl-amine, cis-isomer, (Compound JG); {4-[2-(5-amino-5-methyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl )-3H-imidazol-4-yl]-pyrimidin-2- yl}-dimethyl-amine, cis-isomer, (Compound JH); <BR> <BR> <BR> <BR> {4-[2-(5-amino-5-methyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl )-3H-imidazol-4-yl]-pyrimidin-2- yl}-cyclopropyl-amine, cis-isomer, (Compound JI); {4-[2-(5-amino-5-methyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl )-3H-imidazol-4-yl]-pyrimidin-2- yl}-piperidin-4-yl-amine, cis-isomer, (Compound JJ); {4-[2-(5-amino-5-methyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl )-3H-imidazol-4-yl]-pyrimidin-2- yl}-cyclohexyl-amine, cis-isomer, (Compound JK); <BR> <BR> <BR> <BR> 2-{4-(2-(5-amino-5-methyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phen yl)-3H-imidazol-4-yl]-pyrimidin-2- ylamino}-ethanol, cis-isomer, (Compound JL); <BR> <BR> <BR> <BR> N1-{4-[2-(5-amino-5-methyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phe nyl)-3H-imidazol-4-yl]-pyrimidin- 2-yl}-ethane-1,2-diamine, cis-isomer, (Compound JM); {4-[2-(5-amino-5-methyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl )-3H-imidazol-4-yl]-pyrimidin-2- yl}-[3-(5H-imidazol-1-yl)-propyl]-amine, cis-isomer, (Compound JN);

{4-[2-(5-amino-5-methyl-[1,3]dioxan-2-yl)-5-84-fluoro-phenyl )-3H-imidazol-4-yl]-pyrimidin-2- yl}-(3-morpholin-4-yl-propyl)-amine, cis-isomer, (Compound JO); <BR> <BR> <BR> <BR> 3-{4-12-(5-amino-5-methyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phen yl)-3H-imidazol-4-yl]-pyrimidin-2- ylamino}-propan-1-ol, cis-isomer, (Compound JP); <BR> <BR> <BR> <BR> {4-[2-(5-amino-5-methyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl )-3H-imidazol-4-yl]-pyrimidin-2- yl)-benzyl-amine,, cis-isomer, (Compound JQ); <BR> <BR> <BR> <BR> {4-[2-(5-amino-5-methyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl )-3H-imidazol-4-yl]-pyrimidin-2- yl}-(1-phenyl-ethyl)-amine, R isomer, cis-isomer, (Compound JR); <BR> <BR> <BR> <BR> <BR> {4-[2-(5-amino-5-meThyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl )-3H-imidazol-4-yl]-pydmidin-2- yl)-(1-phenyl-ethyl)-amine, S isomer, cis-isomer, (Compound JS); <BR> <BR> <BR> <BR> {4-[2-(5-amino-5-methyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl )-3H-imidazol-4-yl]-pyrimidin-2- yl}-phenyl-amine, cis-isomer, (Compound JT); 2-[4-(4-fluoro-phenyl)-5-(2-piperidin- 1-yl-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl- [1,3]dioxan-5-ylamine, cis-isomer, (Compound JU); <BR> <BR> <BR> <BR> {4-[2-(5-amino-5-methyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl )-3H-imidazol-4-yl]-pyrimidin-2- yl}-pyridin-4-ylmethyl-amine, cis-isomer, (Compound JV); {4-[2-(5-amino-5-methyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl )-3H-imidazol-4-yl]-pyrimidin-2- yl}-pyridin-2-ylmethyl-amine, cis-isomer, (Compound JW); {4-[2-(5-amino-5-methyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl )-3H-imidazol-4-yl]-pyrimidin-2- yl}-pyridin-3-ylmethyl-amine, cis-isomer, (Compound JX); {4-[2-(5-amino-5-methyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl )-3H-imidazol-4-yl]-pyrimidin-2- ylj-(furan-2-ylmethyl)-amine , cis-isomer, (Compound JY); {4-[2-(5-amino-5-methyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl )-3H-imidazol-4-yl]-pyrimidin-2- yl}-(thiophen-2-ylmethyl)-amine, cis-isomer, (Compound JZ); <BR> <BR> <BR> <BR> {4-[2-(5-amino-5-methyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl )-3H-imidazol-4-yl]-pyrimidin-2- yl}-(tetrahydro-furan-2-ylmethyl)-amine, cis-isomer, (Compound KA); 2-{4-(4-fluoro-phenyl)-5-[2-(4-methyl-piperazin-1-yl)-pyrimi din-4-yl]-1H-imidazol-2-yl}-5- methyl-[1,3]dioxan-5-ylamine, cis-isomer, (Compound KB); 2-[4-(4-fluoro-phenyl)-5-(2-morpholin-4-yl-pyrimidin-4-yl)- 1H-imidazol-2-yl]-5-methyl- [1,3]dioxan-5-ylamine, cis-isomer, (Compound KC); <BR> <BR> <BR> <BR> {4-[2-(5-amino-5-methyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl )-3H-imidazol-4-yl]-pyrimidin-2- yl}-(3-methoxy-propyl)-amine, cis-isomer, (Compound KD); {4-[2-(5-amino-5-methyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl )-3H-imidazol-4-yl]-pyrimidin-2- yl}-(2-methoxy-ethyl)-amine, cis-isomer, (Compound KE); N-{4-[2-(5-amino-5-methyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phen yl)-3H-imidazol-4-yl]-pyrimidin-2- yl)-N',N'-dimethyl-propane-1,3-diamine, cis-isomer, (Compound KF);

N-{4-[2-(5-amino-5-methyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phen yl)-3H-imidazol-4-yl]-pyrimidin-2- yl}- N',N'-dimethyl-ethane-1,2-diamine, cis-isomer, (Compound KG); {2- [4-(4-fluoro-phenyl)-5-(2-methylsulphonylpyrimidin-4-yl)- 1H-imidazol-2-yl]-5-methyl- [1,3]dioxan-5-yl}-morpholin-4-yl-methanone, trans isomer, (Compound KH); 2-[4-(4-fluoro-phenyl)-5-(2-methylsulphonylpyrimidin-4-yl)-1 H-imidazol-2-yl]-5,5-dimethyl [1,3]dioxane (Compound KI); {2-[4-(4-fluoro-phenyl)-5-(2-methylsulphonyl-pyrimidin-4-yl) -lH-imidazol-2-yl]-5-methyl- [1,3]dioxan-5-yl)-methanol, trans-isomer (Compound KJ); (2- [4-(4-fluoro-phenyl)-5 -(2-methylsulphonyl-pyrimidin-4-yl)- 1H-imidazol-2-yl]-5-methyl- [1,3]dioxan-5-yl}-methanol, cis-isomer (Compound KK); 2-[4-(4-fluoro-phenyl)-5-(2-methylsulphonylpyrimidin-4-yl)-1 H-imidazol-2-yl]-5-methylene- [1,3]dioxane (Compound KL).

4-[2-[1,3]dioxan-2-yl-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]- 2-methylsulphonyl-pyrimidine (Compound KM); <BR> <BR> <BR> {2-[4-(4-fluoro-phenyl)-5-(2-methylSulphonyl-pyrimidin-4-yl) -lH-imidazol-2-yl]-[1,3]dioxan-5- yl}-methanol, trans-isomer (Compound KN); {2-[4-(4-fluoro-phenyl)-5-(2-methylsulphonyl-pyrimidin-4-yl) -1H-imidazol-2-yl].[1,3]dioxan-5- yl}-methanol, cis-isomer (Compound KO); 2,2,2-trifluoro-N-[2-{4-(4-fluoro-phenyl)-5-(2-methanesulpho nylpyrimidin-4-yl)-1H-imidazol-2- yl}-5-methyl-[1,3]dioxan-5-yl]acetamide, cis-isomer (Compound KP); {2-[4-(4-fluoro-phenyl)-5-(2-methylsulphanylpyrimidin-4-yl)- 1H-imidazol-2-yl]-5-methyl- [1,3]dioxan-5-yl)-morpholin-4-yl-methanone, trans isomer, (Compound KQ); 2-[4-(4-fluoro-phenyl)-5-(2-methylsulphanylpyrimidin-4-yl)-1 H-imidazol-2-yl]-5,5-dimethyl- [1,3]dioxane (Compound KR); <BR> <BR> <BR> 2,2,2-trifluoro-N-[2-{4-(4-fluoro-phenyl)-5-(2-methylSulphan yl-pyrimidin-4-yl)-lH-imidazol-2- yl}-5-methyl-[1,3]dioxan-5-yl]acetamide, cis-isomer, (Compound KS); {2-[4-(4-fluoro-phenyl)-5-(2-methylsulphanyl-pyrimidin-4-yl) -1H-imidazol-2-yl]-5-methyl- [1,3]dioxan-5-yl}-methanol, cis isomer (Compound KT); {2-[4-(4-fluoro-phenyl)-5-(2-methylsulphanyl-pyrimidin-4-yl) -1H-imidazol-2-yl]-5-methyl- [1,3]dioxan-5-yl}-methanol, trans isomer (Compound KU); 4-[5-(4-fluoro-phenyl)-2-(5-methylene-[1,3]dioxan-2-yl)-3H-i midazol-4-yl]-2-methylsulfanyl- pyrimidine (Compound KV); 4-[2-[1,3]dioxan-2-yl-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]- 2-methylsulphanyl-pyrimidine (Compound KW); {2-[4-(4-fluoro-phenyl)-5-(2-methylsulphanyl-pyrimidin-4-yl) -1H-imidazol-2-yl]-[1,3]dioxan-5- yl}-methanol, trans-isomer (Compound KX);

{2-[4-(4-fluoro-phenyl)-5-(2-methylsulphanyl-pyrimidin-4-yl) -1H-imidazol-2-yl]-[1,3]dioxan-5 yl}-methanol, cis-isomer (Compound KY); C-(2- [4-(4-fluoro-phenyl)-5- (2-methylsulfanyl-pyrimidin-4-yl)- 1H-imidazol-2-yl]-5-methyl- [1,3]dioxan-5-yl)-methylamine, cis isomer (Compound KZ); 2-[4-(4-fluoro-phenyl)-5-(2-methylsulfanyl-pyrimidin-4-yl)-1 H-imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid amide, cis isomer Compound LA); 2-[4-(4-fluoro-phenyl)-5-(2-methylSulfanyl-pyrimidin-4-yl)-l H-imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid, cis isomer (Compound LB); 2-[4-(4-fluorophenyl)-5-(2-methylsulphanylpyrimidin-4-yl)-lH -imidazol-2-yl]-5-methyl- [1,3]dioxan-5-carboxylic acid methyl ester, trans isomer, (Compound LC); 2-[4-(4-fluorophenyl)-5-(2-methylSulphanylpyrimidin-4-yl)-lH -imidazol-2-yl]-5-methyl- [1,3]dioxan-5-carboxylic acid methyl ester, cis isomer, (Compound LD); <BR> <BR> <BR> <BR> 2,2,2-trifluoro-N-{2-[5-(2-methylsulphonyl-pyrimidin-4-yl)-4 -(4-fluoro-phenyl)- 1H-imidazol-2- yl]-5-methyl-[1,3]dioxan-5-ylmethyl)-acetamide, cis isomer, (Compound LK); <BR> <BR> <BR> <BR> 2,2,2-trifluoro-N-{2-[5-(2-methylsulphonyl-pyrimidin-4-yl)-4 -(4-fluoro-phenyl)-1H-imidazol-2- yl]-5-methyl-[1,3]dioxan-5-ylmethyl}-acetamide, trans isomer,(Compound LL); 2-[4-(4-fluorophenyl)-5-(2-methylsulphonylpyrimidin-4-yl)-lH -imidazol-2-yl]-5-methyl- [1,3]dioxan-5-carboxylic acid methyl ester, trans isomer, (Compound LM); 2-[4-(4-fluorophenyl)-5-(2-methylenesulphonylpyrimidin-4-yl) -1H-imidazol-2-yl]-5-methyl- [1,3]dioxan-5-carboxylic acid methyl ester, cis isomer (Compound LN); and the corresponding N-oxides, and their prodrugs; and pharmaceutically acceptable salts and solvates (e.g. hydrates) of such compounds and their N-oxides and prodrugs.

Preferred compounds of the invention include: <BR> <BR> <BR> <BR> (2-[5-(4-fluoro-phenyl)-4-pyridin-4-yl-1H-imidazol-2-yl]-5-m ethyl-[1,3]dioxan-5-yl)-methanol, cis-isomer, (Compound A); C-[5-methyl-2-{5-(4-fluoro-phenyl)-4-pyridin-4-yl-1H-imidazo l-2-ylj-[1,3]dioxan-5-yl]- methylamine, cis- and trans-isomers, (Compound D); <BR> <BR> <BR> <BR> 4-[5-(4-fluoro-phenyl)-2-(4-isopropyl-5,5-dimethyl-[1,3]diox an-2-yl)-3H-imidazol-4-yl]-pyridine, (R/S)(R/S) isomers, (Compound T); C-[5-methyl-2-(5-phenyl-4-pyridin-4-yl-lH-imidazol-2-yl)-[1, 3]dioxan-5-yl]-methylamine, trans-isomer, (Compound AA); C-[methyl-2-(5-phenyl-4-pyridin-4-yl-1H-imidazol-2-yl)-[1,3] dioxan-5-yl]-methylamine, cis-isomer, (Compound AB); 5-methyl-2-{5-(4-fluoro-phenyl)-4-pyridin-4-yl-1H-imidazol-2 -yl}-[1,3]dioxan-5-ylamine, cis-isomer, (Compound AE);

5-methyl-2-{5-(4-fluoro-phenyl)-4-pyridin-4-yl- lH-imidazol-2-yl}- [1,3]dioxan-5-ylamine, trans-isomer, (Compound AF); 5-methyl-2-{5-(4-fluoro-phenyl)-4-pyridin-4-yl- 1H-imidazol-2-yli- [1,3]dioxan-5-ylamine, cis- and trans-isomers, (Compound AG); 2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-lH-imidazol-2-yl]-5-me thyl-[1,3]dioxane-5-carboxylic acid amide, trans-isomer, (Compound AN); <BR> <BR> <BR> <BR> {2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-m ethyl-[1,3]dioxan-5-yl}-morpholin- 4-yl-methanone, trans-isomer, (Compound AW); 2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-lH-imidazol-2-yl]-5-me thyl-[1,3]dioxane-5-carboxylic acid amide, cis-isomer, (Compound BM); amino-N-{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2 -yl]-5-methyl-[1,3]dioxan-5-yl}- acetamide, trans-isomer, (Compound FC); amino-N-{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2 -yl]-5-methyl-[1,3]dioxan-5-yl}- acetamide, cis-isomer, (Compound FD); N-{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-lH-imidazol-2-yl]-5 -methyl-[1,3]dioxan-5-yl}- benzamide, trans-isomer, (Compound FR); and the corresponding N-oxides, and their prodrugs; and pharmaceutically acceptable salts and solvates (e.g. hydrates) of such compounds and their N-oxides and prodrugs.

Further preferred compounds of the invention include: {2-[5-(2-cyclopropylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl )-lH-imidazol-2-yl]-5-methyl- [1,3]dioxan-5-yl}-morpholin-4-yl-methanone, trans isomer, (Compound GE); (2-{4-(4-fluoro-phenyl)-5-[2-(methoxy-ethylamino)-pyrimidin- 4-yl]-1H-imidazol-2-yl}-5- methyl-[1,3]dioxan-5-yl)-morpholin-4-yl-methanone, trans isomer, (Compound GI); 2-{4-(4-fluoro-phenyl)-5-[2-(1-ethoxycarbonylpiperidin-4-yla mino)-pyrimidin-4-yl]-1H-imidazol- 2-yl}-5-methyl-[1,3]dioxan-5-yl)-morpholin-4-yl-methanone, trans isomer, (Compound GK); {2-[5-(2-cyclohexylamino-pyflmidin-4-yl)-4-(4.fluoro-phenyl) -1H-imidazol-2-yl]-5-methyl.

[1,3]dioxan-5-yl}-morpholin-4-yl-methanone, trans isomer, (Compound GL); and the corresponding N-oxides, and their prodrugs; and pharmaceutically acceptable salts and solvates (e.g. hydrates) of such compounds and their N-oxides and prodrugs.

A particularly preferred compound of the invention is (2-[4-(4-fluoro-phenyl)-5.pyridin-4-yl-1H- imidazol-2-yl]-5-methyl-[1,3]dioxane-5-yl}morpholin-4-yl-met hanone, trans-isomer, (Compound AW); and the corresponding N-oxide, and its prodrugs; and pharmaceutically acceptable salts and solvates (e.g. hydrates) of this compound and its N-oxide and prodrugs, especially its methane sulphonic acid salt as depicted by Compound FP.

The compounds of the invention exhibit useful pharmacological activity and accordingly are incorporated into pharmaceutical compositions and used in the treatment of patients suffering from certain medical disorders. The present invention thus provides, according to a further aspect, compounds of the invention and compositions containing compounds of the invention for use in therapy.

Compounds within the scope of the present invention are inhibitors of the generation of tumour necrosis factor (TNF), especially TNF-alpha, according to tests described in the literature and described in vitro and in vivo procedures hereinafter, and which tests results are believed to correlate to pharmacological activity in humans and other mammals. Thus, in a further embodiment, the present invention provides compounds of the invention and compositions containing compounds of the invention for use in the treatment of a patient suffering from, or subject to, conditions which can be ameliorated by the administration of an inhibitor of TNF, especially of TNF-alpha. For example, compounds of the present invention are useful in the treatment of joint inflammation, including arthritis, rheumatoid arthritis and other arthritic conditions such as rheumatoid spondylitis, gouty arthritis, traumatic arthritis, rubella arthritis, psoriatic arthritis and osteoarthritis. Additionally, the compounds are useful in the treatment of acute synovitis, tuberculosis, atherosclerosis, muscle degeneration, cachexia, Reiter's syndrome, endotoxaemia, sepsis, septic shock, endotoxic shock, gram negative sepsis, gout, toxic shock syndrome, chronic pulmonary inflammatory diseases including asthma and adult respiratory distress syndrome, silicosis, pulmonary sarcoidosis, bone resorption diseases, osteoporosis, restenosis, heart failure and myocardial ischaemic syndromes, cardiac and renal reperfusion injury, thrombosis, glomerularnephritis, graft vs. host reaction, allograft rejection and leprosy.

Furthermore, the compounds are useful in the treatment of infections such as viral infections, for example HIV, cytomegalovirus (CMV), influenza, adenovirus and the Herpes group of viruses, parasitic infections, for example malaria such as cerebral malaria, and yeast and fungal infections, for example fungal meningitis; fever and myalgias due to infection; AIDS; AIDS related complex (ARC); cachexia secondary to infection or malignancy; cachexia secondary to acquired immune deficiency syndrome (AIDS) or to cancer; keloid and scar tissue formation; pyresis; diabetes; inflammatory bowel diseases such as Crohn's disease and ulcerative colitis; eczema; contact dermititis; psoriasis; sunburn and conjunctivitis.

Compounds of the invention are also useful in the treatment of diseases of, or injury to, the brain in which over-production of TNF-alpha has been implicated, such as multiple sclerosis, Alzheimers disease, trauma, stroke and other ischaemic conditions.

Compounds of the invention may also be useful in inhibiting diseases associated with over-production of other pro-inflammatory cytokines, IL-1, IL-6 and IL-8.

A special embodiment of the therapeutic methods of the present invention is the treating of asthma.

Another special embodiment of the therapeutic methods of the present invention is the treating of joint inflammation.

According to a further feature of the invention there is provided a method for the treatment of a human or animal patient suffering from, or subject to, conditions which can be ameliorated by the administration of an inhibitor of TNF, especially TNF-alpha, for example conditions as hereinbefore described, which comprises the administration to the patient of an effective amount of compound of the invention or a composition containing a compound of the invention.

"Effective amount" is meant to describe an amount of compound of the present invention effective in inhibiting TNF and thus producing the desired therapeutic effect.

References herein to treatment should be understood to include prophylactic therapy as well as treatment of established conditions.

The present invention also includes within its scope pharmaceutical compositions comprising at least one of the compounds of the invention in association with a pharmaceutically acceptable carrier or excipient.

Compounds of the invention may be administered by any suitable means. In practice compounds of the present invention may generally be administered parenterally, topically, rectally, orally or by inhalation, especially by the oral route.

Compositions according to the invention may be prepared according to the customary methods, using one or more pharmaceutically acceptable adjuvants or excipients. The adjuvants comprise, inter alia, diluents, sterile aqueous media and the various non-toxic organic solvents.

The compositions may be presented in the form of tablets, pills, granules, powders, aqueous solutions or suspensions, injectable solutions, elixirs or syrups, and can contain one or more agents chosen from the group comprising sweeteners, flavorings, colorings, or stabilizers in order to obtain pharmaceutically acceptable preparations. The choice of vehicle and the content

of active substance in the vehicle are generally determined in accordance with the solubility and chemical properties of the active compound, the particular mode of administration and the provisions to be observed in pharmaceutical practice. For example, excipients such as lactose, sodium citrate, calcium carbonate, dicalcium phosphate and disintegrating agents such as starch, alginic acids and certain complex silicates combined with lubricants such as magnesium stearate, sodium lauryl sulphate and talc may be used for preparing tablets. To prepare a capsule, it is advantageous to use lactose and high molecular weight polyethylene glycols. When aqueous suspensions are used they can contain emulsifying agents or agents which facilitate suspension. Diluents such as sucrose, ethanol, polyethylene glycol, propylene glycol, glycerol and chloroform or mixtures thereof may also be used.

For parenteral administration, emulsions, suspensions or solutions of the products according to the invention in vegetable oil, for example sesame oil, groundnut oil or olive oil, or aqueous-organic solutions such as water and propylene glycol, injectable organic esters such as ethyl oleate, as well as sterile aqueous solutions of the pharmaceutically acceptable salts, are used. The solutions of the salts of the products according to the invention are especially useful for administration by intramuscular or subcutaneous injection. The aqueous solutions, also comprising solutions of the salts in pure distilled water, may be used for intravenous administration with the proviso that their pH is suitably adjusted, that they are judiciously buffered and rendered isotonic with a sufficient quantity of glucose or sodium chloride and that they are sterilized by heating, irradiation or microfiltration.

For topical administration, gels (water or alcohol based), creams or ointments containing compounds of the invention may be used. Compounds of the invention may also be incorporated in a gel or matrix base for application in a patch, which would allow a controlled release of compound through the transdermal barrier.

For administration by inhalation compounds of the invention may be dissolved or suspended in a suitable carrier for use in a nebulizer or a suspension or solution aerosol, or may be absorbed or adsorbed onto a suitable solid carrier for use in a dry powder inhaler.

Solid compositions for rectal administration include suppositories formulated in accordance with known methods and containing at least one compound of the invention.

The percentage of active ingredient in the compositions of the invention may be varied, it being necessary that it should constitute a proportion such that a suitable dosage shall be obtained.

Obviously, several unit dosage forms may be administered at about the same time. The dose employed will be determined by the physician, and depends upon the desired therapeutic effect, the route of administration and the duration of the treatment, and the condition of the patient.

In the adult, the doses are generally from about 0.001 to about 50, preferably about 0.001 to about 5, mg/kg body weight per day by inhalation, from about 0.01 to about 100, preferably 0.1 to 70, more especially 0.5 to 10, mg/kg body weight per day by oral administration, and from about 0.001 to about 10, preferably 0.01 to 1, mg/kg body weight per day by intravenous administration. In each particular case, the doses will be determined in accordance with the factors distinctive to the subject to be treated, such as age, weight, general state of health and other characteristics which can influence the efficacy of the medicinal product.

The compounds according to the invention may be administered as frequently as necessary in order to obtain the desired therapeutic effect. Some patients may respond rapidly to a higher or lower dose and may find much weaker maintenance doses adequate. For other patients, it may be necessary to have long-term treatments at the rate of 1 to 4 doses per day, in accordance with the physiological requirements of each particular patient. Generally, the active product may be administered orally 1 to 4 times per day. Of course, for some patients, it will be necessary to prescribe not more than one or two doses per day.

Compounds of the invention may be prepared by the application or adaptation of known methods, by which is meant methods used heretofore or described in the literature.

Compounds of the invention may be prepared by methods similar to those described in EP424195 and EP506437.

In the reactions described hereinafter it may be necessary to protect reactive functional groups, for example hydroxy, amino, imino, thio or carboxy groups, where these are desired in the final product, to avoid their unwanted participation in the reactions. Conventional protecting groups may be used in accordance with standard practice, for examples see T.W.Greene and P.G.M.Wuts in "Protective Groups in Organic Chemistry" John Wiley and Sons, 1991.

Compounds of this invention may be represented by the formula (Ic):-

wherein R4, R5, R6 and m are as hereinbefore defined and T1 represents a group of the formula:- wherein R1, R2 and R3 are as hereinbefore defined.

In a process (A), compounds of formula (I), wherein R1, R2, R4, R5 R6 and m are as hereinbefore defined and R3 is hydrogen, may be prepared by reaction of compounds of formula (Il):- wherein R1 and R2 are as hereinbefore defined, R19 is hydrogen or a suitable protecting group, such as 2-trimethylsilanyl-ethoxymethyl, which is subsequently removed under the acidic reaction conditions and R20 is -CHO or -CH(OMe)2, with compounds of formula (III):-

wherein R4, R5, R6 and m are as hereinbefore defined. The reaction may conveniently be carried out in the presence of an acid catalyst, such as pyridinium 4-toluene sulphonate or 4-toluene sulphonic acid, in an inert solvent, such as toluene, at reflux temperature, with azeotropic removal of the water formed in the reaction.

Compounds of formula (I), wherein R1, R2, R4, R5, R6 and m are as hereinbefore defined and R3 represents a group -L1-R7 (where L1 and R7 are as hereinbefore defined) or -L2-R8 (where L2 is as hereinbefore defined and R8 is aryl, cycloalkenyl, cycloalkyl, heteroaryl, heterocycloalkyl) may be similarly prepared by reaction of compounds of formula (II), wherein R1, R2 are as hereinbefore defined, R19 represents a group -L1-R7 (where L1 and R7 are as hereinbefore defined) or -L2-R8 (where L2 is as hereinbefore defined and R8 is aryl, cycloalkenyl, cycloalkyl, heteroaryl, heterocycloalkyl) and R20 is -CHO or -CH(OMe)2, with compounds of formula (III) wherein R4, R5, R6 and m are as hereinbefore defined.

In a process B, compounds of formula (I), wherein R2, R3, R4, R5, R6 and m are as hereinbefore defined, and R1 represents a group (IV):- wherein R18 is Y4Y5N- (in which Y4 and Y5 are as hereinbefore defined), may be prepared by:-

(i) treating Merrifield resin (chloromethylpolystyrene resin) with potassium thioacetate in an inert solvent, such as dimethylformamide, at a temperature at about room temperature, to give Resin A; Merrifield Resin Resin A (ii) reaction of Resin A with lithium borohydride in an inert solvent, such as tetrahydrofuran, and at a temperature at about room temperature, to give Resin B; Resin B (iii) reaction of Resin B with an alkali metal hydride, such as sodium hydride, in an inert solvent, such as dimethylformamide, at a temperature at about room temperature, followed by treatment with compounds of formula (V); wherein R2, R3, R4, R5, R6 and m are as hereinbefore defined, at a temperature from about room temperature to about 80"C, to give Resin C;

Resin C in which R2, R3, R4, R5, R6 and m are as hereinbefore defined; followed by appropriate functional group interconversions, for example those described hereinafter.

(iv) reaction of Resin C, in which R2, R3, R4, R5, R6 and m are as hereinbefore defined, with m-chloroperoxybenzoic acid, in an inert solvent or preferably in a mixture of inert solvents, such as a mixture of dichloromethane and methanol, to give resin D, in which R2, R3, R4, R5, R6 and m are as hereinbefore defined; Resin D (v) reaction of Resin D, wherein R2, R3, R4, R5, R6 and m are as hereinbefore defined, with amines of formula HNY4Y5, wherein Y4 and Y5 are as hereinbefore defined, in an inert solvent, such as dimethoxyethane, and at a temperature at about 70"C.

Compounds of formula (I), wherein R2, R3, R4, R5, R6 and m are as hereinbefore defined and R1 represents a group (IV), wherein R18 is a -OR17 or -SR17 group (in which R17 is as

hereinbefore defined), may be prepared by reaction of Resin D, wherein R2, R3, R4, R5, R6 and m are as hereinbefore defined, with compounds of formula R17OH or R17SH (in which R17 is as hereinbefore defined), in the presence of an alkali metal hydride, such as sodium hydride, in an inert solvent, such as dimethylformamide, and at a temperature from about room temperature to about 80"C.

According to a further feature of the present invention, compounds of the invention may be prepared by interconversion of other compounds of the invention.

For example compounds of formula (I), wherein R1, R2, R4, R5, R6 and m are as hereinbefore defined and R3 is a group -L1-R7 (in which L1 represents a straight- or branched-chain alkylene linkage containing from 1 to about 6 carbon atoms and R7 is as hereinbefore defined), may be prepared by alkylation of compounds of formula (I) wherein R1, R2, R4, R5, R6 and m are as hereinbefore defined and R3 is hydrogen, with an alkyl halide of formula (IV):- X1-L1-R7 (IV) wherein L1 and R7 are as hereinbefore defined immediately above and X1 is a halogen atom, preferably a bromine atom. The alkylation may for example be carried out in the presence of a base, such as an alkali metal hydride, e.g. sodium hydride, in dimethylformamide, or dimethyl sulphoxide, at a temperature from about 0~C to about 100"C.

As another example of the interconversion process, compounds of formula (I), wherein R1, R2, R4, R5, R6 and m are as hereinbefore defined and R3 is a group -L2-R8 (in which L2 represents a straight- or branched-carbon chain comprising from 2 to about 6 carbon atoms and contains a double or triple carbon-carbon bond, and R8 is aryl, cycloalkenyl, cycloalkyl, heteroaryl, heterocycloalkyl), may be similarly prepared by alkylation of compounds of formula (I), wherein R1, R2, R4, R5, R6 and m are as hereinbefore defined and R3 is hydrogen, with compounds of formula (V):- X1 L2 R8 (V) wherein L2 and R8 are as hereinbefore defined immediately above and X1 is a halogen atom, preferably a bromine atom.

As another example of the interconversion process, compounds of formula (Ic), wherein T1, R5, R6 and m are as hereinbefore defined and R4 contains a -NH2 group, may be prepared by reaction of compounds of formula (Ic) wherein T1, R5, R6 and m are as hereinbefore defined, and R4 contains a -NHC(=O)CF3 group, with a base such as potassium or ammonium carbonate in methanol, or a mixture of methanol and water, at a temperature at about reflux temperature.

As another example of the interconversion process, compounds of formula (Ic), wherein T1, R5, R6 and m are as hereinbefore defined and R4 contains a -N(R10)-C(=O)-R15 or -N(R10)-C(=O)-L4-R16 group (in which R10, R15, R16 and L4 are as hereinbefore defined), may be prepared by reaction of compounds of formula (Ic) wherein T1, R5, R6 and m are as hereinbefore defined, and R4 contains a -NHR10 group (in which R10 is as hereinbefore defined), with the appropriately substituted acid chloride Cl-C(=O)-R15 or Cl-C(=O)-L4-R16 (in which R15, R16 and L4 are as herein before defined) in the presence of triethylamine in an inert solvent such as tetrahydrofuran and at a temperature at about room temperature.

As another example of the interconversion process, compounds of formula (Ic), wherein T1, R5, R6 and m are as hereinbefore defined, and R4 contains a -NH-C(=O)-R15 or -NH-C(=o)-L4-R16 group (in which R15, R16 and L4 are as hereinbefore defined), may be prepared by reaction of compounds of formula (Ic), wherein T1, R5, R6 and m are as hereinbefore defined, and R4 contains a -NH2 group, with the appropriately substituted acid HO-C(=O)-R15 or HO-C(=O)-L4-R16 (in which R15, R16 and L4 are as hereinbefore defined) respectively, in the presence of O-(7-azabenzotriazol- 1-yl)-I,1,3,3-tetramethyluronium hexafluorophosphate and diisopropylethylamine in dimethylformamide, at room temperature. Other standard peptide coupling procedures may be employed for the reaction, such as treatment with a carbodiimide, for example dicyclohexylcarbodiimide, in the presence of triethylamine, or treatment with 1-hydroxybenzotriazole and a carbodiimide, such as 1-(3-dimethylaminopropyl)-3- ethylcarbodiimide, in an inert solvent such as dimethylformamide and at a temperature at about room temperature.

As another example of the interconversion process, compounds of formula (Ic), wherein T1, R5, R6 and m are as herein before defined and R4 contains a -NH-C(=O)-R15 or a

-NH-C(=o)-L4-R16 group (in which R15, R16 and L4 are as hereinbefore defined), may be prepared by reaction of compounds of formula (Ic), wherein T1, R5, R6 and m are as hereinbefore defined and R4contains a -NH2 group, with the appropriately substituted acid anhydride R15-C(=O)-O-C(=O)-R15 or R16-L4-C(=O)-O-C(=O)-L4-R16 (in which R15, R16 and L4 are as hereinbefore defined) in the presence of triethylamine or pyridine, in an inert solvent, such as tetrahydrofuran, and at a temperature at about room temperature As another example of the interconversion process compounds of formula (Ic), wherein T1, R5, R6 and m are as hereinbefore defined and R4 contains a -NH-C(=O)-NH-R15 or -NH-C(=O)-NH-L4-R16 group (in which Rl5, R16 and L4 are as hereinbefore defined), may be prepared by reaction of compounds of formula (Ic) wherein T1, R5, R6 and m are as hereinbefore defined and R4contains a -NH2 group, with the appropriately substituted isocyanate O=C=N-R15 or O=C=N-L4-R16 (in which R15, R16 and L4 are as hereinbefore defined), in an inert solvent, such as tetrahydrofuran, and at a temperature at about room temperature.

As another example of the interconversion process, compounds of formula (Ic) wherein T1, R5, R6 and m are as hereinbefore defined, and R4 contains a -NH-(C=S)-NH-R15 or -NH-(C=S)-NH-L4-R16 group (in which R15, R16 and L4 are as hereinbefore defined), may prepared by reaction of compounds of formula (Ic) wherein T1, R5, R6 and m are as hereinbefore defined, and R4contains a -NH2 group, with the appropriately substituted isothiocyanate S=C=N-R15 or S=C=N-L4-R16 (in which R15, R16 and L4 are as hereinbefore defined), in an inert solvent, such as tetrahydrofuran, and at a temperature at about reflux temperature.

As another example of the interconversion process, compounds of formula (Ic), wherein T1, R5, R6 and m are as hereinbefore defined and R4 contains a -CO2H group, may be prepared by hydrolysis of corresponding compounds of formula (Ic), wherein T1, R5, R6 and m are as hereinbefore defined and R4 contains a -CO2R21 group (in which R21 is as hereinbefore defined). The hydrolysis may conveniently be carried out by alkaline hydrolysis using a base, such as an alkali metal hydroxide or carbonate, in the presence of an aqueous/organic solvent mixture, using organic solvents such as dioxan, tetrahydrofuran or methanol, at a temperature

from about ambient to about reflux. The hydrolysis may also be carried out by acid hydrolysis using an inorganic acid, such as hydrochloric acid, in the presence of an aqueous/inert organic solvent mixture, using organic solvents such as dioxan or tetrahydrofuran, at a temperature from about 50"C to about 80~C.

As another example of the interconversion process, compounds of formula (Ic), wherein T1, R5, R6 and m are as hereinbefore defined and R4 contains a -C(=O)-NV4Y5 group (in which Y4 and V5 are as hereinbefore defined), may be prepared by reaction of compounds of formula (Ic), wherein T1, R5, R6 and m are as hereinbefore defined and R4 contains a -CO2H group, with an appropriately substituted amine of formula HNY4Y5 (in which Y4 and Y5 are as hereinbefore defined). The coupling reaction may conveniently be carried out in the presence of 1- hydroxybenzotriazole and a carbodiimide such as 1-(3-dimethylaminopropyl)-3- ethylcarbodiimide in an inert solvent such as dimethylformamide and at a temperature at about room temperature. Alternatively the reaction may be carried out by initial conversion of the acid of formula (Ic), wherein R4 contains a -CO2H group, to the corresponding acid chloride (for example by reaction with thionyl chloride or oxalyl chloride at room temperature) followed by treatment with an appropriately substituted amine of formula HNY4Y5.

As another example of the interconversion process, compounds of formula (I) containing sulphoxide linkages may be prepared by the oxidation of corresponding compounds containing -S- linkages. For example, the oxidation may conveniently be carried out by means of reaction with a peroxyacid, e.g. 3-chloroperbenzoic acid, preferably in an inert solvent, e.g. dichloromethane, preferably at or near room temperature, or alternatively by means of potassium hydrogen peroxomonosulphate in a medium such as aqueous methanol, buffered to about pH5, at temperatures between about 0~C and room temperature. This latter method is preferred for compounds containing an acid-labile group.

As another example of the interconversion process, compounds of formula (Ic), wherein T1, R5, R6 and m are as hereinbefore defined and R4 contains a -N(R10)-SO2-R15 or -N(R10)-S02-L4-R16 group (in which R10, R15, R16 and L4 are as hereinbefore defined), may be prepared from the corresponding compounds of of formula (Ic) wherein T1, R5, R6 and m are as hereinbefore defined and R4 contains a -NH2 group by treatment with the appropriately substituted acid chloride Cl-SO2-R15 or Cl-S02-L4-R16 (in which R15, R16 and L4 are as

hereinbefore defined), in the presence of a suitable base, such as triethylamine, in an inert solvent, such as tetrahydrofuran, and at a temperature at about room temperature.

As another example of the interconversion process, compounds of formula (I) containing sulphone linkages may be prepared by the oxidation of corresponding compounds containing -S- or sulphoxide linkages. For example, compounds of formula (Ib) where R18 is -SO2Me may conveniently be prepared by means of reaction of compounds of formula (Ib) where R18 is -SMe with a peroxyacid, e.g. 3-chloroperbenzoic acid, preferably in an inert solvent, such as dichloromethane, at a temperature from about 0~C to about room temperature.

As another example of the interconversion process, compounds of formula (Ib), wherein R4 and R5 are as hereinbefore defined and R18 is a -NY4Y5 group (in which Y4 is hydrogen and Y5 is as hereinbefore defined), may be prepared by reaction of compounds of formula (Ib), where R18 is a -SO2Me group, with an appropriately substituted amine of formula Y5NH2 (in which Y5 is as hereinbefore defined). The reaction may conveniently be carried out in an inert solvent such as dimethylformamide at a temperature up to about 100"C. When Y5 is hydrogen the reaction may be conveniently carried out in a sealed vessel. When Y5 is aryl, for example phenyl, the reaction may be conveniently carried out with the lithio-anion of the amine.

As another example of the interconversion process, compounds of formula (Ib), wherein R4 and R5 are as hereinbefore defined and R18 is a -OR17 group (in which R17 is as hereinbefore defined), may be prepared by reaction of compounds of formula (Ib), where R18 is a -SO2Me group, with an appropriately substituted alcohol of formula R17OH (in which R17 is as hereinbefore defined). The reaction may conveniently be carried out in the presence of an alkali metal hydride, such as sodium hydride, in a mixture of inert solvents, for example tetrahydrofuran and dimethylformamide, and at a temperature at about room temperature.

It will be appreciated that compounds of the present invention may contain asymmetric centres.

These asymmetric centres may independently be in either the R or S configuration. It will be apparent to those skilled in the art that certain compounds of the invention may also exhibit geometrical isomerism. It is to be understood that the present invention includes individual geometrical isomers and stereoisomers and mixtures thereof, including racemic mixtures, of compounds of formula (I) hereinabove. Such isomers can be separated from their mixtures, by the application or adaptation of known methods, for example chromatographic techniques and

recrystallisation techniques, or they are separately prepared from the appropriate isomers of their intermediates. Additionally, in situations where tautomers of the compounds of formula (I) are possible, the present invention is intended to include all tautomeric forms of the compounds.

According to a further feature of the invention, acid addition salts of the compounds of this invention may be prepared by reaction of the free base with the appropriate acid, by the application or adaptation of known methods. For example, the acid addition salts of the compounds of this invention may be prepared either by dissolving the free base in water or an aqueous alcohol solution or other suitable solvents containing the appropriate acid and isolating the salt by evaporating the solution, or by reacting the free base and acid in an organic solvent, such as tetrahydrofuran, in which case the salt separates directly or can be obtained by concentration of the solution.

Compounds of this invention can be regenerated from their acid addition salts by the application or adaptation of known methods. For example, parent compounds of the invention can be regenerated from their acid addition salts by treatment with an alkali, e.g. aqueous sodium bicarbonate solution or aqueous ammonia solution.

According to a further feature of the invention, base addition salts of the compounds of this invention may be prepared by reaction of the free acid with the appropriate base, by the application or adaptation of known methods. For example, the base addition salts of the compounds of this invention may be prepared either by dissolving the free acid in water or aqueous alcohol solution or other suitable solvents containing the appropriate base and isolating the salt by evaporating the solution, or by reacting the free acid and base in an organic solvent, in which case the salt separates directly or can be obtained by concentration of the solution.

Compounds of this invention can be regenerated from their base addition salts by the application or adaptation of known methods. For example, parent compounds of the invention can be regenerated from their base addition salts by treatment with an acid, e.g. hydrochloric acid.

Compounds of the present invention may be conveniently prepared, or formed during the process of the invention, as solvates (e.g. hydrates). Hydrates of compounds of the present invention may be conveniently prepared by recrystallisation from water.

The starting materials and intermediates may be prepared by the application or adaptation of known methods, for example methods as described in the Reference Examples or their obvious chemical equivalents.

Intermediates of formula (II), wherein R1 and R2 are as hereinbefore defined, R19 is a 2-trimethylsilanyl-ethoxymethyl group and R20 is -CH(OMe)2, may be prepared by reaction of compounds of formula (II), wherein R1 and R2 are as hereinbefore defined, R19 is a 2-trimethylsilanyl-ethoxymethyl group and R20 is -CHO, with trimethylorthoformate in the presence of an acid catalyst, such as 4-toluene sulphonic acid, in methanol at reflux temperature.

Intermediates of formula (II), wherein R1 and R2 are as hereinbefore defined, R19 is a 2-trimethylsilanyl-ethoxymethyl group and R20 is -CHO, may be prepared by reaction of compounds of formula (1):- wherein R1 and R2 are as hereinbefore defined, R19 is a 2-trimethylsilanyl-ethoxymethyl group, with an alkyllithium, such as butyllithium or lithium diisopropylamide, in an inert solvent, such as tetrahydrofuran, at a temperature at about -780C, followed by reaction with N-formylmorpholine.

Intermediates of formula (II), wherein R1 and R2 are as hereinbefore defined, R19 is hydrogen and R20 is -CH(OMe)2, may be prepared by reaction of compounds of formula (2):-

wherein R1 and R2 are as hereinbefore defined, with glyoxal 1,1-dimethylacetal and ammonium acetate. The reaction may conveniently be carried out in a mixture of inert solvents, such as tert-butylmethyl ether and methanol, and at a temperature at about room temperature.

Intermediates of formula (II), wherein R1, R2 are as hereinbefore defined, R19 represents a -L1-R7Or -L2-R8 group (in which R7, L1 and L2 is as hereinbefore defined and R8 is aryl, cycloalkenyl, cycloalkyl, heteroaryl, heterocycloalkyl) and R20 is -CHO, may be similarly prepared by reaction of compounds of formula (1), wherein R1, R2 and R19 are as defined immediately above, with butyl lithium followed by reaction with N-formylmorpholine.

Intermediate 1,3-propanediols of formula (III), wherein R4 is an azidomethyl group, R5 is a methyl group, R6 is hydrogen and m is 1, and where both R4 and R5 are attached in the 2-position, may be prepared by reaction of 5-azidomethyl-2,5-dimethyl-1,3-dioxane (prepared according to the procedure in J.Org.Chem., 1992, 57, page 6080) with a mineral acid, for example hydrochloric acid, in an aqueous organic solvent mixture such as tetrahydrofuran and water, at reflux temperature.

Intermediate 1,3-propanediols of formula (III), wherein R4 is an -NHC(=O)CF3 group, R5 is a methyl group, R6 is hydrogen and m is 1, and where both R4 and R5 are attached in the 2-position, may be prepared by reaction of 2-amino-2-methyl-1,3-propanediol with trifluoroacetic acid in the presence of a base, such as potassium carbonate, in an inert solvent, such as dimethylformamide, and at a temperature at about room temperature.

Intermediate 1,3-propanediols of formula (III), wherein R4 is a -C(=O)-NV4V5 group (in which V4 and Y5 are as hereinbefore defined), R5 is a methyl group, R6 is hydrogen and m is 1, and where both R4 and R5 are attached in the 2-position, may be prepared by reaction of 2-carboxy- 2-methyl-1,3-propanediol with an amine of formula HNY4Y5, wherein Y4 and Y5 are as hereinbefore defined. The coupling may conveniently be carried out with a carbodiimide, such as dicyclohexylcarbodiimide, in the presence of 1-hydroxybenzotriazole and disisopropylethylamine, in an inert solvent, such as acetonitrile, and at a temperature from room temperature to about 55"C. Other standard peptide coupling procedures may be employed for the reaction, such as those described hereinbefore.

Resins of formula Resin C in which R3, R5, R6 and m are as hereinbefore defined, and R4 contains a -C(=O)-NV4V5 group may be prepared from the corresponding Resin C, in which R3, R5, R6 and m are as hereinbefore defined and R4 contains a -C(=O)-OR21 group (in which R21 is alkyl, aryl or arylalkyl), by:- (i) treatment with an alkali metal hydroxide, such as sodium hydroxide, in a mixture of water and a water miscible inert organic solvent, such as tetrahydrofuran,and at a temperature from about room temperature to about 70"C; (ii) treatment of the resulting resin in which R4 contains a -C(=O)-OH group with oxalyl chloride solution in an inert solvent, such as dichloromethane, at a temperature at about room temperature; (iii) treatment of the resulting resin in which R4 contains a -C(=O)-CI group with an amine of formula HNY4Y5 in an inert solvent, such as dichloromethane, at a temperature at about room temperature.

Resins of formula Resin C in which R3, R5, R6 and m are as hereinbefore defined, and R4 contains a -N(R10)-C(=O)-R15 or -N(R10)-C(=O)-L4-R16 group (in which R10, R15, R16 and L4 are as hereinbefore defined), may be prepared from the corresponding Resin C, in which R3, R5, R6 and m are as hereinbefore defined and R4 contains a -NH2 group by treatment with the appropriately substituted acid chloride Cl-C(=O)-R15 or Cl-C(=O)-L4-R16 (in which R15, R16 and L4 are as hereinbefore defined), in the presence of triethylamine, in an inert solvent, such as tetrahydrofuran, and at a temperature at about room temperature.

Resins of formula Resin C in which R3, R5, R6 and m are as hereinbefore defined, and R4 contains a -N(R10)-SO2-R15 or -N(R10)-S02-L4-R16 group (in which R10, R15, R16 and L4 are as hereinbefore defined), may be prepared from the corresponding Resin C, in which R3, R5, R6 and m are as hereinbefore defined and R4 contains a -NH2 group by treatment with the appropriately substituted acid chloride Cl-SO2-R15 or Cl-SO2-L4-R16 (in which R15, R16 and L4 are as hereinbefore defined), in the presence of triethylamine, in an inert solvent, such as tetrahydrofuran, and at a temperature at about room temperature.

Compounds of formula (1), wherein R1 and R2 are as hereinbefore defined, R19 is a 2-trimethylsilanyl-ethoxymethyl group, may be prepared by reaction of compounds of formula (1), wherein R1 and R2 are as hereinbefore defined, R19 is a hydrogen atom, with

2-(trimethylsilyl)ethoxymethyl chloride in the presence of sodium hydride, in an inert solvent such as dimethylformamide, and at a temperature at about room temperature.

Compounds of formula (1) wherein R1 and R2 are as hereinbefore defined, R19 represents a group -L1-R7 (where L1 and R7 are as hereinbefore defined) or -L2-R8 (where L2 is as hereinbefore defined and R8 is aryl, cycloalkenyl, cycloalkyl, heteroaryl, heterocycloalkyl) may be similarly prepared by reaction of compounds of formula (1), wherein R1 and R2 are as hereinbefore defined, R19 is a hydrogen atom, with an alkyl halide of formula (V) or (VI) respectively, in the presence of sodium hydride.

Compounds of formula (1), wherein R1 and R2 are as hereinbefore defined, R19 is a hydrogen atom, may be prepared by the application or adaptation of known literature methods, for example Boehm et. al., J.Med.Chem., 1996, 39, page 3829.

Intermediates of formulae (II), (III), (IV), Resin C and Resin D are novel compounds and, as such, they and their processes described herein for their preparation constitute further features of the present invention.

The present invention is further Exemplified but not limited by the following illustrative Examples and Reference Examples.

EXAMPLE 1 Compounds A, B and C A solution of 4-[5(4)-(4-fluoro-phenyl)-2-formyl-1-[(2-(trimethylsilyl)eth oxy)methyl]-lH- imidazol-4(5)-yl]-pyridine (1.log, Reference Example 1), 1,1,1-tris(hydroxymethyl)-ethane (1.66g) and pyridinium-4-toluenesulphonate (0.13g) in dry toluene (20ml) was gently refluxed for 20 hours with azeotropic removal of water. After cooling to room temperature the reaction mixture was treated with ethyl acetate (100ml), then washed three times with water (20ml), then dried over magnesium sulphate and then evaporated. The residual oil was subjected to flash chromatography, on silica, eluting with a mixture of dichloromethane and methanol (24:1, v/v) to give {2-r5-(4-fluoro-Phenyl)-4-Pvridin-4-vl-1H-imidazol-2-vll-5-m ethvl-r1.3ldioxan-5-vll methanol, cis-isomer, (Compound A) as a white solid, m.p. 270-272"C. [Elemental analysis:- C,64.22; H,5.71; N,10.81; F,4.91%. Calculated for C2oH20FN303-H20:-C,64.67; H,5.97; N,1 1.31; F,5.1 1%]; and {2-r5-(4-fluoro-Phenvl)-4-Pvridin-4-vl-1H-imidazol-2-vll-5-m etht- 11,3ldioxan-5-vl}-methanol trans-isomer, (Compound B) as a buff-coloured solid, m.p. 250-

2550C. [Elemental analysis:- C,64.22; H,5.71; N,10.81; F,4.91 %. Calculated:- C,65.03; H,5.46; N,11.38; F,5.14%].

By proceeding in a similar manner but using 2,2-dimethyl-1,3-propanediol there was prepared 4-[2-(5,t-dimethyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)-1H- imidazol-4-yl]-pyridine, (Compound C) as a cream solid, m.p. 248-249"C (with decomposition). [Elemental analysis:- C,66.75; H,5.74; N,11.42%. Calculated for C20H20FN302*o.5H20 :- C,66.28; H,5.84; N,11.59%].

EXAMPLE 2 Compound D A solution of 4-[5-azidomethyl-5-methyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phen yl)-1H-imidazol-4- yl]-pyridine, cis- and trans-isomers [1.56g, Compound H] in methanol (lOOml) was treated with ammonium formate (1g), then with 10% palladium on activated carbon (0.15g). After stirring for 3.5 hours the reaction mixture was filtered through diatomaceous earth then evaporated.

The residual orange solid was subjected to flash chromatography on silica eluting with a mixture of dichloromethane, pentane, methanol and concentrated ammonia (55:25:18:2 v/v/v/v) to give C-[5-methyl-2-{5-(4-fluoro-phenyl)-4-pyridin-4-yl1H-imidazol -2-yl}-[1,3]dioxan-5-yl]- methvlamine cis- and trans-isomers, Compound D, (0.68g) as a yellow solid.

EXAMPLE 3 Compounds E to Z A stirred solution of 4-[2-dimethoxymethyl-5(4)-(4-fluoro-phenyl)-lH-imidazol-4(5) -yl]-pyridine (5.75g, Reference Example 3), and 2-methyl-2-trifluoroacetamido-1,3-propanediol (7.38g, Reference Example 4) and 4-toluenesulphonic acid (8.03g) in dry tetrahydrofuran (200ml) was heated at reflux for 6 hours. After cooling the mixture was stood at room temperature for 4 days then partitioned between ethyl acetate and saturated sodium bicarbonate solution. The organic phase was washed twice with water (100ml), then with brine (lOOml), then dried over magnesium sulphate and then evaporated to give 2.2 2-trifluoro-N-[5-methvl-2-85-(4-fluoro-Phenvl)-4- pyridin-4-vl-1H-imidazol-2-vl}-11.3ldioxan-5-vll-acetamide, cis- and trans-isomers (Compound E). The residue was subjected to flash chromatography on silica eluting with a mixture of dichloromethane and methanol (95:5, v/v) to give: 2,2,2-trifluoro-N-[5-methyl-2-{5-methyl-2-{5-(4-fluoro- phenyl)-4-pyridin-4-yl-1H-imidazol-2-yl}-[1 3ldioxan-5-vll-acetamide. cis-isomer (Compound F); MH+ 451; and 2,2,2-trifluoro-N-[5-methyl-2-{5-(4-fluoro-phenyl)-4-pyridin -4-yl-1H-imidazol-2- vl-rl,3ldioxan-5-vll-acetamide. trans-isomer (Compound G). MH+ 451.

By proceeding in a similar manner but using 2-azidomethyl-2-methyl-1,3-propanediol (Reference Example 5) there was prepared 4- F2-(5-azidomethvl-5-methyl- Fl 3ldioxan-2-vl-5-(4-fluoro- phenvl)-lH-imidazol-4-vll-pvridine cis- and trans-isomers (Compound H) as a white solid.

By proceeding in a similar manner but using 2-benzyl-1,3-propanediol and subjecting the crude product to preparative thick layer chromatography on silica eluting with a mixture of dichloromethane and methanol (9:1, v/v) there was prepared 4-12-(5-benzvl-T1,31dioxan-2-vl)-5- (4-fluoro-phenyl)-1H-imidazol-4-yl]-pyridine cis- and trans-isomers (Compound I). RF 0.46 using a mixture of dichloromethane and methanol (9:1, v/v). MH+ 416.

By proceeding in a similar manner but using methyl 2,2-bis(hydroxymethyl)propionate and subjecting the crude product to preparative thick layer chromatography on silica eluting with a mixture of dichloromethane and methanol (9:1, v/v) there was prepared 2-F5-(4-fluoro-phenvl)-4- pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carbo xylic acid methvl ester cis- and trans-isomers (Compound J). RF 0.71 using a mixture of dichloromethane and methanol (9:1, v/v). MH+ 398.

By proceeding in a similar manner but using 2,2-bis(hydroxymethyl)-tetrahydropyran, carrying out the reaction in dimethylformamide at 500C and subjecting the crude product to preparative thick layer chromatography on silica eluting twice with a mixture of dichloromethane and methanol (19:1, v/v) there was prepared 4-15-(4-fluoro-Phenvl)-2-(1 8,10-trioxa-sPirof5.5lundec- 9-vl)-1H-imidazol-4-vll-pvridine, (Compound K), as a mixture of isomers. RF 0.45 and 0.48 using a mixture of dichloromethane and methanol (19:1, v/v) as eluent. MH+ 396.

By proceeding in a similar manner but using 2,2-bis(hydroxymethyl)-tetrahydrofuran, carrying out the reaction in dimethylformamide at 50"C and subjecting the crude product to preparative thick layer chromatography on silica eluting twice with a mixture of dichloromethane and methanol (19:1, v/v) there was prepared 4-F5-(4-fluoro-nhenvl)-2-(1 79-tn.oxa-sniro.5ldee-8- vl)-1H-imidazol-4-vll-vridine, (Compound L), as a mixture of isomers. RF 0.39 and 0.45 using a mixture of dichloromethane and methanol (19:1, v/v) as eluent. MH+ 382.

By proceeding in a similar manner but using the appropriately substituted 1,3-propanediols, carrying out the reaction in dichloromethane at room temperature over 3 days, and subjecting the crude product to preparative thick layer chromatography on silica, there were prepared the Compounds M to Z depicted in Table 1. For Compounds M to V and Compound Z the eluent

used was a mixture of dichloromethane and methanol (9:1, v/v); for Compound W the eluent used was ethyl acetate then a mixture of dichloromethane and methanol (14:1, v/v); and for Compounds X and Y the eluent used was a mixture of dichloromethane and methanol (14:1, v/v).

TABLE 1 STRUCTURE STRUCTURE substituted MOLECULAR MH+ and 1,3-propanediol RF FORMULA (intensity) Compound number used in the reaction ( (MS-ESI) 0.41 C19H18FN302 340 (100%) N Compound M 0.40 0.40 C19H16FN302 338 (100%) 43 Compound N 0.37 C18H16FN302 326 HOffi HH) (100%) go N O Compound O 0.40 C19H18FN302 340 - W~S f (100%) ~ Compound P ~ N, n 0.44 C20H20FN302 354 ,9 / oa HOX 5~6f9 ) (looa) Compound Q 0.47 0.47 C25H22FN303 432 XN o} HO} 0.31 (100%) HO 0.31 F Compound R Tis\ 0.20 C24H20FN302 402 sr (100%) HOyM 0.18 HO Compound S N 0.43 C23H26FN302 396 F/ gIt i cloo, HO- Compound T N 0.30 C22H24FN302 382 k'i .m -V (100%) XN oX HOx ( 100 % ) p/ Compound U 0.30 0.30 C23H22FN302 392 N10 (100%) L Bo- pr Compound V 0.14 C26H23FN403 459 N10 S k (100%) 1/ HO Compound W ~;iwy HO F Compound X I p 0.25 C28H28FN502S 518 NIO & (100%) HO 0.18 w HO HH Y Compound V

0.31 C23H21FN402 405 NIO (100%) 1/ HO~ F\~NO HO Com oundZ EXAMPLE 4 Compounds AA and AB A solution of 2,2,2-trifluoro-N-[5-methyl-2-t5-(4-fluoro-phenyl)-4-pyridin -4-yl-lH-imidazol-2- yl}-[1,3]dioxan-5-ylmethyl]-acetamide, trans-isomer [1.04g, Compound AC] and potassium carbonate (1.55g) in methanol (150ml) was heated at reflux for 24 hours. After cooling to room temperature the mixture was partitioned between ethyl acetate and water. The aqueous layer was treated with sodium chloride then extracted three times with ethyl acetate (50ml). The combined organic phases were evaporated. The residual oil was subjected to flash chromatography on silica eluting with a mixture of dichloromethane, pentane, methanol and concentrated ammonia (55:25:18:2, v/v/v/v) to give C-[5-methvl-2-(5-(4-fluoro-Phenyl)-4-pvridin- 4-vl-lH-imidazol-2-vl)- Fl 31dioxan-5-vll-methvlamine. trans-isomer (0.51g, Compound AA).

MH+ 369.

By proceeding in a similar manner but using 2,2,2-trifluoro-N-[5-methyl-2-{5-(4-fluoro-phenyl)- 4-pyridin-4-yl-1H-imidazol-2-yl )- [l,3]dioxan-5-ylmethyl]-acetamide, trans-isomer, [Compound AD] there was prepared C-[5-methyl-2-{5-(4-fluoro-phenyl)-4-pyridin-4-yl-1H-imidazo l-2-yl}-[1,3]dioxan- r1.3ldioxan-5-vll-methvlamine. cis-isomer (Compound AB). MH+ 369.

EXAMPLE 5 Compounds AC and AD A suspension of C-[5-methyl-2-{5-(4-fluoro-phenyl)-4-pyridin-4-yl- 1H-imidazol-2-yl)- [1,3]dioxan-5-yl]-methylamine (0.68g, cis- and trans-isomers, Compound D) in dichloromethane (35ml) was treated with triethylamine (0.72ml) then with trifluoroacetic anhydride (0.72ml).

After stirring at room temperature for 4.5 hours the reaction mixture was partitioned between ethyl acetate and water. The organic phase was washed with water, then with brine, then dried over magnesium sulphate and then evaporated. The residue was subjected to flash chromatography on silica eluting with a mixture of ethyl acetate and methanol (9:1, v/v) to give 2,2,2-trifluoro-N-[5-methyl-2-{5-(4-fluoro-phenyl)-4-pyridin -4-yl-1H-imidazol-2-yl}-[1,3]dioxan- 5-ylmethyl]-acetamide, cis- and trans-isomers. The mixture was subjected to preparative HPLC, using methanol and water 40/60 to 5/95 v/v over 20 minutes to give 2*2*2-trifluoro-Nîf5-methvl-2

{5-(4-fluoro-phenyl)-4-pyridin-4-yl-1H-imidazol-2-yl}-[1,3]d ioxan-5-ylmenthyl]-acetamide, trans- isomer (0.75g, Compound AC, RT=11.99,) and 2,2,2-trifluoro-N-[5-methyl-2-{5-(4-fluoro- phenyl)-4-pyridin-4-yl-1H-imidazol-2-yl T-l l ,3ldioxan-5-vlmethvil-acetamide, cis-isomer (0.3g, Compound AD, RT=10.8).

EXAMPLE 6 Compounds AE, AF and AG A stirred solution of 2,2,2-trifluoro-N-[5-methyl-2-{5-(4-fluoro-phenyl)-4-pyridin -4-yl-1H- imidazol-2-yl}-[1,3]dioxan-5-yl]-acetamide, cis-isomer (1.75g, Compound F) and potassium carbonate (1.07g) in a mixture of methanol (200ml) and water (5ml) was heated at reflux for 8 hours. After cooling to room temperature the mixture evaporated and then azeotroped with toluene. The residue was treated with silica and filtered through a pad of silica washing with a mixture of dichloromethane and methanole (4:1,v/v) to give 5-methyl-2-{5-(4-flouro-phenyl)-4- pvridin-4-vl-1H-imidazol-2-vl - Fl 3ldioxan-5-vlamine. cis-isomer (1.3g, Compound AE) as a yellow solid.

By proceeding in a similar manner but using Compound G there was prepared 5-methvl-2-45-(4- fluoro-phenyl)-4-pyridin-4-yl-1H-imidazol-2-yl}-[1 31dioxan-5-vlamine. trans-isomer (Compound AF).

By proceeding in a similar manner but using Compound E there was prepared 5-methyl-2-{5-(4- fluoro-phenvl)4- Pvridin-4-vl-l H-imidazol-2-vl)-T1 3ldioxan-5-vlamine. cis- and trans-isomers (Compound AG).

EXAMPLE 7 Compounds AH and AI A solution of 2-[5-(4-fluoro-phenyl)-4-pyridin-4-yl-1H-imidazol-2-yl]-5-me thyl-[1,3]dioxane-5- carboxylic acid methyl ester, cis- and trans-isomers (0.34g, Compound J) in methanol (15ml) was treated with aqueous sodium hydroxide solution (1.71ml, 1N) then heated at reflux for 7 hours.

After cooling to room temperature the reaction mixture was evaporated. The residual cream powder was dissolved in methanol (lOml) and the solution acidified to pH 5-6 by addition of glacial acetic acid. The resulting white precipitate was filtered and washed with pentane to give 2-[5-(4-fluoro-phenyl)-4-pyridin-4-yl-1H-imidazol-2-yl]-5-me thyl-[1,3]dioxane-5-carboxylic acid, trans-isomer (0.11g, Compound AH). RF 0.15 (CH2Cl2/CH30H, 9:1 developed five times), MH+ 384. The filtrate plus washings were absorbed onto silica and subjected to flash chromatography on silica eluting with a mixture of dichloromethane and methanol (9:1, v/v) to

give 2-r5-(4-fluoro-phenvl)-4-pvridin-4-vl-1H-imidazol-2-vll-5-me thyl-11 3ldioxane-5-carboxvlic acid. cis-isomer (0.14g, Compound AI,) as a white solid. RF 0.25 (CH2Cl2/CH30H, 9:1, developed five times), MH+ 384.

EXAMPLE 8 Compounds AT to CO and FS to GD A solution of 2-[5-(4-fluoro-phenyl)-4-pyridin-4-yl-1H-imidazol-2-yl]-5-me thyl-[1,3]dioxane-5- carboxylic acid, cis- or trans-isomer (1 equivalent, Compound AH or AI) an appropriately substituted amine of formula HNY4Y5 [1.1 equivalents, see table 2 ], l-(3-dimethylamino- propyl)-3-ethylcarbodiimide [1.1 equivalents], 1-hydroxybenzotriazol hydrate [1.1 equivalents] and N,N-diisopropylethylamine [3 equivalents] in dry dimethylformamide was stirred at room temperature for 18 hours. The reaction mixture was evaporated and the residue was partitioned between ethyl acetate and water. The organic phase was washed with brine then evaporated to give Compounds AJ to GD and FS to GD depicted in Table 2 (Compound FV was obtained following alkaline hydrolysis of the intermediate ester). The RF values indicated were determined using a mixture of dichloromethane and methanol (9:1, v/v) as eluent [* in one case a mixture of ethyl acetate and methanol (9:1, v/v) was used].

TABLE2 STRUCTURE HNY4V5 RF MOLECULAR MH+ and FORMULA (Intensity) Compound number NIA o H2Nm 0.33 C27H25FN403 473 Na~<OXNC WJ 0.33 C27H25FN4O3 (70%) 418 (100%) Compound AJ N )NHO H2Nffi% 0.35 C27H25FN403 473 1)N/Oj)rHH\/ 418 F (100%) F Compound AK NOH 0.13 C22H23FN404 427 X N 1 0.13 % ) O OH ComDound AL H2N0N 0.28 C23H25FN404 441 /"-t0 384 o o (100%) Com ound AM NA NH3 0.14 C20H19FN403 383 oAtN~2 (100 % ) O F Compound AN NA NA 0.29 C26H24FN503 474 N X HNo) (100%) O N F \+ Compound AO Compound AO 0.18 C26H24FN503 474 H1NI (100%) NA nN 0.16 C26H24FN503 474 H2N®® 0.16 C26H24FN5O3 (100%) F Compound AQ N 77 N 0.09 C25H28FN503 466 +t~N ,jr \ (100%) j)H/O 0 F Com oundAR N l 0.14 C25H30FN503 468 H'HH (100%) Compound AS N H2N 0.25 C30H28FN503 526 IO BB (100%) F N O- H Compound AT H2HOH 0.09 C23H25FN4O4 441 /0,.. (100%) NO"K"'\~OH Compound AU F C25H27FN4O4 467 Compound AU 0.32 C25H27FN404 467 H1NL (100%) Q~J (100%) .k3 Compound AV 77 0.32 C24H25FN404 453 The (so%) Compound AW 0.39 C24H25FN403 437 (so> 3 384 p/-0 o (100%) Compound AX 0.33 C24H27FN403 439 ~ F Compound / 0.41 C26H31FN403 467 XH o H > (100%) Compound AZ Compound AZ H,NzOz 0.29 C24H27FN404 455 /) / H < N ~N O @ o 384 F4J 384 (100%) Compound BA Compound BA N )i:Hi#(:m/,, N WJ 0.33 C28H27FN4O3 (100%) o )/ N o \>t F Compound BB N 2N wNa 0.24 C27H26FN503 488 eo@N\~-t (100%) F Compound BC 0 Ni; H,N \ NH H2N#) 0.32 C25H23FN404 4 O O Compound BD Compound BD - 0.36 C25H27FN403 451 FX (100 % ) 384 Ne F/4r (100%) I 384 F (100%) Compound BF H2H 0.29 C23H25FN403 425 UC(70%) 384 (100%) (100%) Com ound BG P HIN-a H H,NX 0.22 C23H23FN403 423 Y (25 %) F)N Or~ (100%) Compound BH toNX H,Ne 0.32 C25H27FN403 451 vN o) N F4J X Compound BI tl,N--0 0.36 C26H29FN403 465 H2N (100%) I Compound BJ 441 H,N~Oo 0.29 C23H25FN404 441 IsJ\ AN 0.29 C231125FN4O4 (100%) XN oJis Fw Corn ound BK P N 0 OH H2HOH 0.18 C22H23FN404 427 R Na~4O $N~ 2 (100%) .N C F/-0 Compound BL NH, 0.16 C20H19FN403 383 >c' 8- (loo 46) NA NH3 0.16 C20H19FN403 383 + N 034NH (100 % ) Compound BM N N 0.25 C26H24FN503 474 HN/1 (loo) NA Nt 0.25 C26H24FN503 474 llu>l N>(OXNt HNszU (100%) Compound BN 0.13 C26H24FN503 474 vzNn 0.13 C26H24FN503 474 < /H H,Nx) H F Compound BO 0.10 C26H24FN503 474 W Na~<o9~N~ )N (100%) [N O F Compound BP 77 /7 0.36 C24H25FN404 453 0 o. HN wO<< HNwO (100 % ) F Compound BQ 0.08 C25H28FN503 466 HNH- BNJN- (100%) F Compound BR A / 0.13 C25H30FN503 468 O ~> N 0.13 C25H30FN5O3 468 .ISJN\ (00%) S N O Compound BS H,N 0.28 C30H28FN503 526 H O ~ -> t3 (100%) X N/8OX t0~ Compound wOH oundBT H1NOH 0.08 C23H25FN404 941 (loo4b) Fw Compound BU Corn H,N oundBU o S" bJ ( 100 % ) Compound BV N 0 1 0.28 C24H27FN404 455 o 9~ H,N ZO ( 100 % ) Compound BW N no 0.25 C27H26FN503 488 (100%) 1 (100%) Compound BX % > NHX H,Nm 0.33 C25H23FN404 463 vN O Compound BY ~o\ 0.34 C25H27FN404 467 0 tN (100%) Fw Compound BZ N 0 HN 0.38 C24H25FN403 437 NHO ®' (10%) 384 F (100%) ComPound CA cI>S- -C> 0.40 C25H27FN403 (Oo) A / \ 0.40 C25H27FN403 451 64N O 384 384 Compound CB NA O ~ H,N~ 0.26 C23H25FN403 425 Compound CB a,N 0.26 C23H25FN403 425 Com ound CC I J o- 384 WJ\ N O )~ (100%) Compound CC SN O Compound CD NlA O /\ H2NX 0.24 C23H23FN403 423 (15%) 384 FJ\ ( 100 % ) Compound CE N ,Sx+P t 4 032 0.32 C251127FN4O3 451 H2 (35%) H 0 4 384 (100%) Corn ound C F I)S-If3 HN-0 0.32 C26H29FN403 465 (loo) iC. o | ( ) H [/9N O Compound CG N 0 I,N-CH, .HC1 0.22 C21H21FN403 397 ca >S- (so%) g N O 384 Fw (100 % ) Compound CH \ I O.11 C24H28FN503 454 >9N H,N~Ns (100 % ) Compound CI Compound CI WrCH .HCI 0.33 C22H23FN403 411 X />4 Y \ 384 Fw (100 % ) 384 NA / 0.40 C26H31FN403 467 Compound CJ / 0.40 C26H31FN403 467 C -t (100%) {io 384 (loos) Corn ound CL H2NCH Hcl 0.15 C21H21FN4O3 397 H H2NCH3 . HC1 )HHO C21H21FN403 397 W N O (45 %) (100%) and (100 %) Compound CM H2H 454 H.NN/ 0.07 C24H28FN503 N l (40Ne) o (100 % ) F (100%) Compound CN N 0.23 C22H23FN403 411 )HHO H,Nv .HCl (34 % ) H NIN/O,N 384 F (100 % ) Compound CO 0.55 C27H29FN405 467 v NC Hw~OH (100%) ffiN/O [W F Compound FS Nt O\ 0.71 C25H27FN404 509 (loo4ro) < XX9. (N lO(oD (100%) P Compound 1"1 QI ~ 0.73 C28H31FN405 523 . Nt O 0.73 C28H31FN405 523 | Xose E (lo0%) F Compound FU f 0.29 C26H27FN405 495 ® OOH 0 (100%) 'I " d F Compound FV 0.76 C24H25FN403S 469 (100%) -nr o Compound FW 0.4 C24H25FN405S 501 . o Compound FX 0.62 C26H29FN404 481 II( (loo46) *I/OH -bl HM Corn ound FV 0.59 C25H27FN404 467 ® SX>FNQ OH H-N (100%) OH F pound FZ 0.71 C26H29FN404 481 /y (100%) r H--N HN/) 0.53 C24H25FN404 453 Compound GA a A- 0.53 C24H25FN404 453 F Corn ound GB H- 0.58+ 0.58* C26H29FN404 481 0 ® \llO..NO\ (100%) C/ \\ O F Compound GC 0.72 C27H31FN404 495 Wl9X,N HOH (100%) y\HOO F Compound GD EXAMPLE 9 Compounds CP to DF A solution of 5-methyl-2-{5-(4-fluoro-phenyl)-4-pyridin-4-yl-1H-imidazol-2 -yl}-[1,3]dioxan-5- ylamine, cis- or trans-isomer (1 equivalent, Compound AE or AF), and an appropriately substituted isocyanate of formula O=C=N-R15 or O=C=N-L4-R16 [1 equivalent, see Table 3] in dry tetrahydrofuran was stirred at room temperature for 30 minutes. The reaction mixture was evaporated in vacuo to give Compounds CP to CZ depicted in Table 3. The RF values indicated were determined using a mixture of dichloromethane and methanol (9:1,v/v) as eluent.

By proceeding in a similar manner but using Compound AA or Compound AB, there were prepared Compounds DA to DF depicted in Table 3. The RF values indicated were determined using a mixture of dichloromethane and methanol (9:1,v/v) as eluent.

TABLE 3 STRUCTURE O=C=N-R15 or RF MOLECULAR MH+ and Compound number O=C=N-L4-R16 FORMULA (Intensity) 0.46 C26H23FN503 474 o=c=N-- (looa) Compound CP C261123FN5O3 (100%) Corn / ound C22H24FN503 CP " H 0 O=C=Nv 0.41 C22H24FN503 (140206%) l)NO P7P" F Compound CQ D=C=N- \ 0.41 0A1 C2SH25FN604 493 , z 0X~t~ O=C=NS (100%) O Few / Compound CR D=C=N-- 0.50 C27H26FN503 488 aoX HN ) (7402~e ) F b (100%) Compound CS F Corn oundCS Sq (104023%) p/ ;I <,+ HN 0.50 C26H26FN5O3S 9 (100%) ,# iY Q I 0.51 C28H26FN504 516 D=C=N- 5 (100%) 11 1 X F 0 Compound CU

N13N ~ o o=C=NX,3 0.40 C26H24FN503 (100 Se) / D N O H NX C26H24FN5O3 (10404%) F Compound CV ® 0 0.36 C27H24FN505 MH 516 X (loo 4ro) F/iB 'N o- o Compound CW O=C=N-- 0.39 C27H26FN503 488 b (100%) Compound 0=c=y 0.39 " "e H Compound CX O=C=N / 0.24 C22H24FN503 426 P7l o (loO%) NAl vS) 0.40 C26H26FN503S 508 Compound CY S 0.40 C26H26FN503S 508 FJt; H S F Compound CZ O=C=N-- 0.46 C28H28FN503 502 HHNH Compound DA Corn ound DA H 0 ~~~~~ 0.39 C23H26FN5O3 440 ;19 X^N H (100%) H FI)N Compound DB <\ < 0.48 C27H26FN503 489 < O=C=N=vR (100 % ) ;<N O Compound DC

0.42 D=C=N e OA2 C27H26FN503 488 O=C=N O~4%oNHy F Compound DD x9 O=C=Na 0.40 C28H28FN503 502 F\%IN/H1O "VN ompound DE O=C=N---/ 023 C23H26FN503 440 H (100%) , /8 B+oNgN (100%) N O- \I F Compound DF EXAMPLE 10 Compounds DG to DU A solution of 5-methyl-2-(5-(4-fluoro-phenyl)-4-pyridin-4-yl-1H-imidazol-2 -yl)-[1,3]dioxan-5- ylamine, cis- or trans-isomer (1 equivalent, Compound AE or AF), an appropriately substituted isothiocyanate of formula S=C=N-R15 or S=C=N-L4-R16 [1 equivalent, see Table 3] [1 equivalent] in dry tetrahydrofuran was heated to reflux for 18 hours. After cooling the reaction mixture was evaporated in vacuo and purified by preparative chromatography on silica gel, eluting with a mixture of dichloromethane and methanol (9:1 v/v) to give Compounds DG to DK depicted in Table 4. The RF values indicated were determined using a mixture of dichloromethane and methanol (9:1,v/v) as eluent.

By proceeding in a similar manner but using Compound AA or Compound AB, there were prepared Compounds DL to DU depicted in Table 4. The RF values indicated were determined using a mixture of dichloromethane and methanol (9:1,v/v) as eluent.

TABLE 4 STRUCTURE S=C=N-R15 or RF MOLECULAR MH+ and Compound number ~ NA S=C=Nn 77 0.46 C26H31FN603S 527 H S NO (100%) I)N04 ®NM F Compound DG 0.46 C25H24FN503S 494 ><o3"N 45 S=C=Nx (100%) F Compound DH His 0.32 C25H23FN602S 491 p/ S=C=N-- (loo %) Of Corn DI NO S=C=Na 0.50 C28H26FN504S 548 H S /\)O (100%) I)IN/#kO% (100%) F X \oJ Compound DJ 0.24 C27H24FN504S 534 XN ~~? S=C=N<O (100 % ) F Compound DK S=C=N S 0.23 C26H25FN6O2S 505(100%) F Compound DL Nt S=C=Nm n 0.16 C27H33FN603S 541 +X/NYN C NwO (100 % ) sgf N S F Compound DM X S=C=Nn 0.37 C26H26FN503S 508 NHyNHTh NI/\HHN)AA/ S=C=N 0.37 (100%) F P Compound DN 01 0.40 C29H28FN504S 562 < S O F Compound DO .~ 5 ,o 0.48 C29H28FN504S 562 s=c=N- > XN H4JO S=C=N4~ (100%) Compound DP Na S o S=C=N @n 0.46 C26H26FN503S 508 < o (100 %) v N O P- Corn ound DQ 0 S=C=N-- 0.13 C281126FN5O4S 548 Of S=C=N<OH " (100%) Nllt H o N 0 NH f N oJ FI)N0 4 Compound DR S=C=N j- 0.28 C26H25FN602S 505 r-c H C26H25FN6O2S >/ N H Compound DS

:=C=N- 7 0,35 C27H33FN603S - 1 Compound DT N 0.50 C28H26FN504S 548 S=C=N -0 (100%) P/0 Compound DU EXAMPLE 11 Compounds DV to EM A stirred solution of 5-methyl:2-{5-(4-fluoro-phenyl)-4-pyridin-4-yl-lH-imidazol-2 -yl}- [1,3]dioxan-5-ylamine, cis- or trans-isomer (1 equivalent, Compound AE or AF) and triethylamine [1 equivalent] in dry tetrahydrofuran was treated with an appropriately substituted acid chloride of formula Cl-C(=O)-R15 or Cl-C(=O)-L4-R16[1 equivalent, see Table 4]. After stirring at room temperature for 18 hours the reaction mixture was evaporated to give Compounds DV to ED depicted in Table 5. The RF values indicated were determined using a mixture of dichloromethane and methanol (9:1,v/v) as eluent.

By proceeding in a similar manner using Compound AA or AA, there were prepared Compounds EF to EM depicted in Table 4. The RF values indicated were determined using a mixture of dichloromethane and methanol (9:1,v/v) as eluent.

TABLE 5 STRUCTURE Cl-C(=O)-R15 or RF MOLECULAR MH+ and Compound number ~ NA 8 0.41 C21H21FN403 397 Cl C1t (100%) ri (ioo%) P Compound DV N~l 9 oundDV HAy C C27H25FN4O3 (loop) F Compound DW 0.46 C26H29FN403 465 0 (100%) Compound DX Compound DX Z ,ZXo) ~< k ci~o~ 0.58 C28H27FN4O4 MW501 F Compound DV NA o < 0.52 C28H27FN404 503 ;?î>9on 0%) ComPound DZ Corn ound DZ ® 0 34 C21H21FN403 397 Cl o)+ C1 < ( (100%) >cc1( > o <\ 0.49 C27H25FN403 473 F/0-" " '' F C1 .51 C261129FN4O3 (104065%) 0.51 C26H29FN403 465 oA %) f Compound EC NA u8 0.52 C26H23FN403 459 +~3 t C1 > (100%) )i"kP ":? (10409%) Corn ound ED 0.55 o < 0.55 C29H29FN404 517 -0 0.55 C29H29FN404 517 %~ \ \, N 64N OS (100%) ound EE Comp Ciffi (100%) F Compound EF 0 N O 8 0.22 C22H23FN403 411 (100%) 1/ H ® O F Compound EG cl- 0.30 C28H27FN403 486 0 (100%) > N O F Compound EH N ® o 1~l 0.29 C27H31FN403 479 NHON)~ Cl < Cl<O (100%) /N o t Q3X- P/ N o Compound EI Y;IH/O H Corn oundEJ

0.45 0.45 C28H27FN403 487 H ~ : (100%) ps Ni H I Compound EK o 1~ 0.45 C27H31FN403 479 N1 < H 1 (100%) O . Compound EL j Bn 0.45 C27H25FN403 473 X /8 3""o NX C 1 < ( 100 % ) o P Compound EM EXAMPLE 12 Compounds EN to ER A solution of 5-methyl-2-{5-(4-fluoro-phenyl)-4-pyridin-4-yl-1H-imidazol-2 -yl}-[1,3]dioxan-5- ylamine, cis-isomer (1 equivalent, Compound AE), triethylamine (1.2 equivalents) and glutaric anhydride (1 equivalent) in dry tetrahydrofuran was heated to reflux for 8 hours. The reaction mixture was evaporated to give 4-{2-[5-(4-fluoro-phenyl)-4-pyridin-4-yl-1H-imidazol-2-yl]-5 - methyl-[1,3]dioxan-5-ylcarbamoyl}-butyric acid cis-isomer (Compound EN). MH+ 469. RF 0.12 (determined using a mixture of dichloromethane and methanol (9:1,v/v) as eluent}.

By proceeding in a similar manner but using Compound AB and glutaric anhydride, there was prepared 4-({2-[5-(4-fluoro-phenyl)-4-pyridin-4-yl-1H-imidazol-2-yl]- 5-methyl-[1,3]dioxan-5- vlmethvl)-carbamovl)-butvric acid. cis-isomer (Compound EO). MH+ 483. RF 0.10 (determined using a mixture of dichloromethane, pentane, methanol and ammonia (55:25:18:2,v/v) as eluenti.

By proceeding in a similar manner but using Compound AE and succinic anhydride there was prepared 4-f 2-F5-(4-fluoro-nhenvl)-4-Pvridin-4-vl- 1H-imidazol-2-vll-5-methvl-11 3ldioxan-5- vlcarbamovl}-ProPionic acid. cis-isomer (Compound EP). MH+ 455. RF 0.18 (determined using a mixture of dichloromethane and methanol (9:1,v/v) as eluent}.

By proceeding in a similar manner but using Compound AB and succinic anhydride there was prepared 4-({2-[5-(4-fluoro-phenyl)-4-pyridin-4-yl-1H-imidazol-2-yl]- 5-methyl-[1,3]dioxan-5- vlmethvl-carbamovl)-nronionic acid. cis-isomer (Compound EQ). MH+ 469. RF 0.10 (determined using a mixture of dichloromethane, pentane, methanol and ammonia (55:25:18:2,v/v) as eluent).

By proceeding in a similar manner but using Compound AA and succinic anhydride there was prepared 4-({2-[5-(4-fluoro-phenyl)-4-pyridin-4-yl-1H-imidazol-2-yl]- 5-methyl-[1,3]dioxan-5- vlmethvll-carbamovl)-ProPionic acid. trans-isomer (Compound ER). MH+ 469. RF 0.11 (determined using a mixture of dichloromethane, pentane, methanol and ammonia (55:25:18:2,v/v) as eluent}.

EXAMPLE 13 Compounds ES to FB A solution of 5-methyl-2-{5-(4-fluoro-phenyl)-4-pyridin-4-yl-1H-imidazol-2 -yl}-[1,3]dioxan-5- ylarnine, cis-isomer [1 equivalent, Compound AE], and triethylamine [1 equivalent] in tetrahydrofuran was treated with methane suiphonyl chloride [1 equivalent]. After stirring at room temperature for 48 hours the reaction mixture was evaporated and the residue was subjected to preparative thick chromatography on silica, eluting with a mixture of dichloromethane and methanol (9:1, v/v), to give N-{2-[5-(4-fluoro-phenyl)-4-pyridin-4-yl-1H- imidazol-2-vll-5-methvl-r1.3ldioxan-5-vll-methanesulPhonamid e. cis-isomer (Compound ES).

MH+ 433. RF 0.42 (determined using a mixture of dichloromethane and methanol (9: 1,v/v) as eluent}.

By proceeding in a similar manner but using Compound AA or Compound AB and an appropriately substituted sulphonyl chloride of formula Cl-S02-R15 or Cl-S02-L4-R15 there was prepared Compounds ET to FB depicted in Table 6. The RF values indicated were determined using a mixture of dichloromethane and methanol (9:1,v/v) as eluent.

TABLE 6 STRUCTURE Cl-S02-R15 or RF MOLECULAR MH+ and EXAMPLE NUMBER Cl-S02-L - NA ox ,O 0.21 C21H23FN404S 447 H ® N On (100%) P/Q Compound ET N> Ou /> 1~ 0.28 C26H25FN40S 509 N X okcl (100%) 0 C/ o '\)NHO %!? ~) (100%) Fl) iWo Compound EV P/0 ~t0' o C24HZ FFN404S25 515 N Compound EW NA Cl C ~ | 0.30 C25H26FN505S 528 b H / N H ~ Ks3 (100%) Compound EX Compound EX cl 0.32 C21H23FN404S 447 Compound EY N®INHO H Compound EZ Corn ound EZ F Compound EZ

o "o 0.50 C24H23FN404S2 515 N 0 H H (100%) t 9 (100%) F Corn oundFA ,, ' 0.50 0.SOC25H2I ~ (100%) EXAMPLE 14 Compounds FC to FJ A solution of ({2-[5-(4-fluoro-phenyl)-4-pyridin-4-yl-1H-imidazol-2-yl]-5- methyl-[1,3]dioxan-5- ylcarbamoyl}-ethyl)-carbamic acid benzyl ester, trans-isomer (Compound FI) was treated with palladium, 5% activated on carbon and stirred at room temperature under a hydrogen atmosphere for 8 hours. The reaction mixture was filtered through a pad of diatomaceous earth and evaporated to dryness. The residue was subjected to preparative thick layer chromatography on silica, eluting with dichloromethane and methanol (7:3 v/v) to give 3-amino- N-{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5 -methyl-[1,3]dioxan-5-yl}- pronionarnide trans-isomer (Compound FC). MH+ 426. RF 0.04 determined using a mixture of dichloromethane and methanol (7:3, v/v) as eluent.

By proceeding in a similar manner but using Compound FJ there was prepared 3-amino-N-{2- [4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-meth yl-[1,3]dioxan-5-yl}-propionamide, cis-isomer (Compound FD). MH+ 426. RF 0.04 determined using a mixture of dichloromethane and methanol (7:3, v/v) as eluent.

By proceeding in a similar manner but using Compound FK there was prepared 4-amino-N-{2- [4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-meth yl-[1,3]dioxan-5-yl}-butyramide, trans-isomer (Compound FE). MH+ 440. RF 0.03 determined using a mixture of dichloromethane and methanol (7:3, v/v) as eluent.

By proceeding in a similar manner but using Compound FL there was prepared 4-amino-N-{2- [4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-meth yl-[1,3]dioxan-5-yl}-butyramide,

cis-isomer (Compound FF). MH+ 440. RF 0.03 determined using a mixture of dichloromethane and methanol (7:3, v/v) as eluent.

By proceeding in a similar manner but using Compound FM there was prepared 2-amino-N-82- [4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-meth yl-[1,3]dioxan-5-yl}-acetamide, trans-isomer (Compound FG). MH+ 412. RF 0.01 determined using a mixture of dichloromethane and methanol (9:1, v/v) as eluent with two developments.

By proceeding in a similar manner but using Compound FN there was prepared 2-amino-N-f2- [4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-meth yl-[1,3]dioxan-5-yl}-acetamide,cis- isomer (Compound FH). MH+ 412. RF 0.03 determined using a mixture of dichloromethane and methanol (9:1, v/v) as eluent with two developments.

EXAMPLE 15 Compounds Fl to FP A solution of 5-methyl-2-{5-(4-fluoro-phenyl)-4-pyridin-4-yl-1H-imidazol-2 -yl}-[1,3]dioxan-5- ylamine, cis- and trans-isomers [1 equivalent, Compound AG], N-benzyloxycarbonyl- -alanine, [1 equivalent], 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride [1.1 equivalents], N,N-diisopropylethylamine [3 equivalents] and 1-hydroxybenzotriazole hydrate [1.1 equivalents] in dry dimethylformamide was heated at 900C for 2.5 hours. The reaction mixture was cooled to room temperature, then evaporated. The residue was partitioned between ethyl acetate (12ml) and water (12ml). The organic phase was separated and allowed to stand at room temperature.

The solid which crystallised was filtered to give (3-{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H- imidazol-2-yl]-5-methyl-[1,3]dioxan-5-ylcarbamoyl}ethyl)carb amic acid benzvl ester trans- isomer (Compound FI). The filtrate was subjected to preparative chromatography on silica, eluting with a mixture of dichloromethane and pentane (9:1, v/v) to give (3-{2-[4-(4-fluoro- phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxa n-5-ylcarbamoyl}-ethyl)-carbamic acid benzvl ester. cis-isomer (Compound FJ).

By proceeding in a similar manner but using N-benzyloxycarbonyl-4-aminobutyric acid there was prepared (3-{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]- 5-methyl-[1,3]dioxan- 5-vlcarbamovi)-propvl)-carbamic acid benzvl ester. trans-isomer, (Compound FK) and (3-f2-14- 4-fluoro-phenvl)-5-Pvridin-4-vl-lH-imidazol-2-vll-5-methvl-r l*31dioxan-5-vlcarbamovl}- propyl)-carbamic acid benzvl ester. cis-isomer (Compound FL).

By proceeding in a similar manner but using N-benzyloxycarbonylglycine there was prepared (3- {2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-m ethyl-[1,3]dioxan-5-ylcarbamoyl}- methvl)-carbamic acid beuzyl ester. trans-isomer (Compound FM) and (3-{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]- 5-methyl-[1,3]dioxan-5- vlcarbamovl}-methvl)-carbamic acid benzvl ester. cis-isomer (Compound FN).

By proceeding in a similar manner but using 3-dimethylamino-propionic acid there was prepared 4-dimethvlamino-N-82-r4-(4-fluoro-Phenvl)-5-Pvridin-4-vl-1H- imidazol-2-vll-5-methyl- F1.3idioxan-5-vl}-butvramide. cis- and trans-isomers Compound FO. MH+ 468. RF 0.32 determined using a mixture of dichloromethane and methanol (7:3, v/v) as eluent.

EXAMPLE 16 Compound FP A solution of {2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-m ethyl-[1,3]dioxan-5-yl}- morpholin-4-yl-methanone, trans-isomer (7.43g, Compound AW) in hot tetrahydrofuran (500ml) was treated with a solution of methane sulphonic acid (1.578g) in tetrahydrofuran. After standing at room temperature for 18 hours the reaction mixture was filtered and the solid recrystallised from acetonitrile with hot filtration through celite to give {2-F4-(4-fluoro-phenvl)-5-pvridin-4-vl- 1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-yl}-morpholin-4-yl-me thanone methane sulphonic acid salt. trans-isomer (6.00g, Compound FP) as a pale yellow crystalline solid, m.p. 242-246"C (with decomposition). [Elemental analysis:- C,54.76; H,5.25; N,10.44; S, 5.89%. Calculated for C24H25FN404-CH3S03H:- C,54.73; H,5.32; N,10.21; S,5.84%].

EXAMPLE 17 Compound FO A solution of N-{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5 -methyl-[1,3]dioxan-5- yl)-benzamide, trans-isomer (0.85g, Compound FR) in tetrahydrofuran (100ml) was treated with methane sulphonic acid (0.178g). The reaction mixture was agitated for 5 minutes then evaporated to dryness and dried under high vacuum. The residual solid was recrystallised from ethyl acetate containing a minimum volume of acetonitrile to give N-f2-14-(4-tluoro-phenvl)-5- pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-(1,3)dioxan-5-yl}-be nzamide, methane sulphonic acid salt. trans-isomer (1.20g, Compound FQ) as a yellow crystalline solid, m.p. 165-169"C. [Elemental analysis:- C,57.93; H,5.41; N,8.73%. Calculated for C26H23FN403 CH3S03H CH3C02C2H5:- C,52.94; H,5.123; N,9.88%].

EXAMPLE 18 Compound FR A stirred suspension of 5-methyl-2-{5-(4-fluoro-phenyl)-4-pyridin-4-yl-1H-imidazol-2 -yl}- [1,3]dioxan-5-ylamine, trans isomer (1.76g, Compound AF), benzoic acid (0.67g) and diisopropylethylamine (1.39ml) in dry dimethylformamide (50ml) was treated with (O-(7-Azabenzotriazo1- l-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate) (1.88g) under a nitrogen atmosphere. After stirring at room temperature for 2 hours the reaction mixture was evaporated to dryness. The residue was partitioned between ethyl acetate (70ml) and saturated sodium bicarbonate (50ml). The organic phase was washed twice with water (50ml), then with brine (30ml) and then evaporated. The residue was subjected to flash chromatography on silica eluting with ethyl acetate to give N-f2-14-(4-fluoro-Phensl)-5-Pvridin-4-vl-1H-imidazol-2-vll-5 - methvl-11.3ldioxan-5-vlT-benzamide. trans-isomer (0.85g, Compound FR) as a cream coloured solid, m.p. 235-236"C. RF: 0.42 determined using a mixture of dichloromethane and methanol (9:1, v/v) as eluent. MH+ 459.

EXAMPLE 19 ComPound AW Method A: 2-[5-(4-fluoro-phenyl)-4-pyridin-4-yl-1H-imidazol-2-yl]-5-me thyl-[1,3]dioxane-5- carboxylic acid, trans-isomer (7.70g, Compound AH) was added portionwise to stirred thionyl chloride. The reaction mixture was stirred at room temperature for 1.25 hours then evaporated.

The residue was azeotroped with dry toluene to yield the crude acid chloride. This was treated with dry dichloromethane (150ml) followed by morpholine (30ml) under nitrogen. The mixture was stirred at room temperature for 2.5 hours then evaporated. The residue was partitioned between ethyl acetate (250ml) and saturated sodium bicarbonate (200ml). The insoluble product at the interface was filtered off and washed with methanol (lOml), then with water (20ml) and then with diethyl ether (20ml) to give {2-r4-(4-fluoro-nhenvl)-5-Pvridin-4-vl-1H-imidazol-2-vll-5- methvl-[1 3ldioxan-5-vll-morpholin-4-vl-methanone. trans-isomer (7.63g, Compound AW), m.p.

288-291"C. MH+ 453.

Method B: 4-[e-Dimethoxymethyl)-5-(4-fluorophenyl)-1H-4-imidazolyl]pyr idine (62.7g) and 3-hydroxy-2-(hydroxymethyl)-2-methyl-1-morpholino-1-propanon e (44.8g, Reference Example 6) were added to toluene (440ml), under nitrogen. The mixture was stirred and heated to reflux under a Dean and Stark trap for 20 minutes. N,N-dimethylformamide (160ml) and methanesulphonic acid (2ml) were added and the mixture heated to a gentle reflux over 4hours, removing a total of 150ml distillate at a fairly uniform rate. The reaction mixture was then evaporated in vacuo to remove as much toluene as possible. The resulting suspension was

treated with triethylamine (8ml) and then water (600ml) was added dropwise over 1hour. The mixture was filtered to give a damp, crude solid mixture of cis- and trans-isomers after washing with water and allowing the cake to suck on the filter for lhour. This material was stirred in methanol (350ml), then the mixture was heated to reflux for 15 minutes and then cooled to 50C.

The solid was filtered and then washed with methanol to give 2-F4-(4-fluoro-henvl)-5-vridin- 4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-morpholin- 4-yl-methanone, trans-isomer (46.4g, Compound AW), m.p. 214~C (with decomposition). 1H NMR (5, CDCl3): 8.52 (d, 0.6H); 8.39 (d, 1.4H); 7.32-7.49 (m, 4H); 7.29 (t, 1.4H); 7.13 (t, 0.6H); 5.59 (s, 1H); 4.07 (s, 4H); 3.51 (bd, 8H); 1.56 (s, 3H).

EXAMPLE 20 Compound GE A stirred suspension of {2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-m ethyl- [1,3]dioxan-5-yl}-morpholin-4-yl-methanone, trans-isomer (4.52g, Compound AW) in a mixture of ethanol and methanol (45ml, 95:5, v/v) was treated with aqueous hydrobromic acid (1.2ml, 48%).

The mixture was heated to reflux, then water (15ml) was added and then the mixture was heated again to reflux. The solution formed was allowed to cool to room temperature then filtered. The solid was washed three times with a mixture of ethanol and methanol (10ml, 95:5, v/v) to give {2- <BR> <BR> <BR> <BR> r4-(4-fluoro-phenvl)-5- pvridin4-vl-l H-imidazol-2-vll-5-methvl- F13ldioxand -vl)-morpholin4-vl- methanone monohvdrobromide dihvdrate. trans-isomer (4.5g, Compound GE) as an off-white crystalline solid, m.p. 276-277"C (with decomposition). 1H NMR (CD3)2SO: 61.53 (s, 3H), 3.49 (bd, 8H), 4.08 (s, 4H), 5.64 (s, 1H), 7.36 (t, 2H), 7.53-7.58 (m, 2H), 7.84 (d, 2H), 8.63 (d, 2H).

EXAMPLE 21 Compound GF {2-[4-(4-Fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-m ethyl-[1,3]dioxan-5-yl}-morpholin- 4-yl-methanone, trans-isomer (25.2g, Compound AW), stirred in isopropanol (300ml), was treated with concentrated hydrochloric acid (5ml) and water (440ml) and the mixture was heated to reflux for 15 minutes. The mixture was cooled to room temperature and then filtered.

The solid was washed with isopropanol to give f2-F4-(4-fluoro-phenvl)-5-pvridin-4-vl-1H- imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-morpholin-4-yl-met hanone monohydrochloride dihvdrate, trans-isomer (22.5g, Compound GF) as an off-white solid, m.p. 245-248"C (with decomposition). 1H NMR (CD3)2SO: 61.58 (s, 3H), 3.55 (bd, 8H), 4.12 (s, 4H), 5.68 (s, 1H), 7.49 (t, 2H), 7.58-7.62 (m, 2H), 7.89 (d, 2H), 8.68 (d, 2H).

EXAMPLE 22 ComPound GG {2-[4-(4-Fluoro-phenyl)-5-pyridin-4-yl- lH-imidazol-2-yl]-5-methyl- [1,3]dioxan-5-yl}-morpholin 4-yl-methanone, trans-isomer (4.52g, Compound AW), stirred in a mixture of ethanol and methanol (45ml, 95:5, v/v), was treated with d-10-camphorsulphonic acid (2.55g). The mixture was heated to reflux and the resulting solution allowed to cool to room-temperature. The resulting solid was collected by filtration and washed three times with a mixture of ethanol and methanol (lOml, 95:5, v/v) to give {2-r4-(4-fluoro-Phenvl)-5-Pvridin-4-vl-1H-imidazol-2-vll-5- methvl-f1.3ldioxan-5-vl1-morPholin-4-vl-methanone d-10-camnhorsulphonic acid salt. trans- isomer (6.0g, Compound GG) as pale yellow crystals, m.p. 265-267"C (with decomposition). 1H NMR (CD3)2SO: 60.74 (s, 3H), 1.05 (s, 3H), 1.33-1.43 (m, 2H), 1.58 (s, 3H), 1.80 (d, 1H), 1.81- 1.89 (m, 1H), 1.94 (t, 1H), 2.24 (dt, 1H), 2.49 (d, 1H), 2.64-2.72 (m, 1H), 2.89 (d, 1H), 33.53 (d, 8H), 4.12 (s, 4H), 5.69 (s, 1H), 7.40 (t, 2H), 7.57-7.63 (m, 2H), 7.90 (d, 2H), 8.68 (d, 2H).

EXAMPLE 23 Compounds GH to HK (a) A solution of (2- [4-(4-fluoro-phenyl)-5-(2-methanesulphonylpyrimidin-4-yl)-11 1-imidazol-2- yl]-5-methyl-[1,3]dioxan-5-yl}-morpholin-4-yl-methanone, trans isomer (1 equivalent, Compound KH) and cyclopropylamine (5 equivalents ) in dry dimethylformamide was heated at 100"C for 16 hours. The solvent was evaporated and the residue subjected to high pressure liquid chromatography on a C18 Dynamax 60A column using gradient elution with a mixture of acetonitrile and water as the mobile phase (0-2 minutes 20% acetonitrile; 3-16 minutes ramp up to 80% acetonitrile; 17 minutes to end of run 80% acetonitrile) and UV detection at 238nm to give {2-[5-(2-cyclopropylaminopyrimidin-4-yl)-4-(4-fluoro-phenyl) -1H-imidazol-2- vll-5-methvl-Fl.3ldioxan-5-vll-morpholin-4-vl-methanone. trans isomer (Compound GH), HPLC retention time = 8.0 minutes. MH+ 509.

(b) By proceeding in a similar manner to Example 23 (a), but replacing cyclopropylamine with an appropriately substituted amine of formula HNY4Y5 [5 equivalents, see Table 7], there were prepared Compounds GI to HK in Table 7. For Compound GI the reaction was carried out in the absence of dimethylformamide in a sealed vessel. For Compound GW the lithio-anion of the aniline (generated by reaction of aniline with butyl lithium in tetrahydrofuran according to standard reaction conditions) was used to replace the cyclopropylamine. Compounds GI to GL were obtained as solids on treating the crude reaction product with acetonitrile. The RT values indicated in Table 7 refer to high pressure

liquid chromatography retention times determined on a C18 Dynamax 60A column using gradient elution with a mixture of acetonitrile and water as the mobile phase (0-12 minutes 5% acetonitrile ramp up to 80% acetonitrile; 12 minutes to end of run 80% acetonitrile). The RF values indicated in Table 7 were determined using a mixture of ethyl acetate and methanol (19:1, v/v) [the eluant for Compounds HJ and HK was a mixture of dichloromethane and methanol (9:1, v/v)].

TABLE7 STRUCTURE HNV4Y5 RT RF MOLECULAR MH+ and FORMULA (Intensity) Compound number Nl il, 9 C23H25FN604 469 NH2 9 C231125FN6O4 469 (100%) NI3 o F Compound GI 0.5 0.5 C25H29FN604 497 (100%) Compound GJ Who 0.07 C26H31FN605 527 AN H2NOH (100%) î NO II Fw Compound GK 0.19 C26H31FN605 527 )HH (100%) A 2 B Compound oundGL 9 9 C24H27FN604 483 \SHZr a,N- Compound GM ~ o 10 C31H38FN706 624 NN OEt (100 % ) a7|rNO H,N 0 F Compound GN 11 C29H35FN604 551 (100%) t) (100%) ® F Compound GO HO 8 C25H29FN605 513 7 (looa) A <17 NO H N~OH il Qr ' NOH Compound GP qnr, 6 C25H30FN704 512 NI g 6 C25H30FN704 512 T X . ll,o Corn oundG 7 7 C29H33FN804 577 r (100%) HiN t K,lw Corn ound GR P 77 7 C30H38FN705 596 /MN®iO (100%) HIN N4N iy ' H,n 11 1 0 p/JC Compound GS 11 C30H31FN604 559 1 (100%) ar Fw Compound GT 11 11 11 C31H33FN604 573 ruhr h (100%) > ,NO H,NX P/ N Compound GU Ph 11 C31H33FN604 573 . ~ MI: (100%) Ph H2NY Ph Com ound GV N 11.5 C29H29FN604 545 (100%) Compound GW Compound GW 10 C28H33FN604 537 '2wcc F Com ound GX rN< 7 C29H30FN704 560 (100%) NH Compound GY ® HN 7 C29H30FN704 560 NSjH NhJ (100%) NH N "N Corn ound GZ ComPound GZ H2N®) 7 C29H30FN704 560 NH P7/ /\o F Corn oundlIA H2N%ft0 10.5 C28H29FN605 (105409 NH NtN H .e F/jl/l O F Compound HB H2N 13 1 C28H29FN6O45 565 NH NN H I I Compound HC I N H 0 "\/ Compound oundHD i /7 7 C28H34FN704 552 $N) HN N- N N H > N O 3 0 11 1 0 Fv Compound HE (9 /n 9 C27H31FN605 539 \z (100%) r o rC Corn ound HF 1 H2No' 8 C27H33FN605 541 ~ (100%) N XNH H Compound HG N H2NAN 7 C28H36FN704 554 N, ) I (100%) N N H o F ~ Compound HH 1 7 C27H34FN704 540 Fd 0 Compound HI HOO to OH 0.22 C25H27FN606 527 kNH HN O (100%) N N H Compound HJ HOotO 0.24 C26H29FN606 541 ~ (100%) XH H2NXOH N N H ,N' O Corn oundHK

(c) By proceeding in the same manner to Example 23 (b) and using the appropriately substituted amine of formula HNY4Y5 there are prepared Compounds Al to A16.

{2-[4-(4-fluoro-phenyl)-5-(2-isopropylamino-pyrimidin-4-yl)- lH-imidazol-2-yl]-5-methyl- [1,3]dioxan-5-yl }-morpholin-4-yl-methanone, trans-isomer, (Compound Al); <BR> <BR> <BR> <BR> {2-[5-(2-allylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-lH-i midazol-2-yl]-5-methyl-[1,3]dioxan- 5-yll-morpholin-4-yl-methanone, trans-isomer, trans-isomer, (Compound A2); {2-[5-[2-(cyclopropylmethyl-amino)-pyrimidin-4-yl]-4-(4-fluo ro-phenyl)-lH-imidazol-2-yl]-5- methyl-[1,3]dioxan-5-yl}-morpholin-4-yl-methanone, trans-isomer, (Compound A3); <BR> <BR> <BR> <BR> (4-(5-(4-fluoro-phenyl)-2-[5-methyl-5-(morpholine-4-carbonyl )-[1,3]dioxan-2-yl]-311-imidazol-4 yl}-pyrimidin-2-ylamino)-acetonitrile, trans-isomer, (Compound A4); 3-(4-{5-(4-fluoro-phenyl)-2-[5-methyl-5-(morpholine-4-carbon yl)-[1,3]dioxan-2-yl]-3H-imidazol- 4-yl}-pyrimidin-2-ylamino)-propionitrile, trans-isomer, (Compound A5); (2-{4-(4-fluoro-phenyl)-5-[2-(pyridin-3-ylamino)-pyrimidin-4 -yl]-1H-imidazol-2-yl}-5-methyl- [1,3]dioxan-5-yl)-morpholin-4-yl-methanone, trans-isomer, (Compound A6); (2-{4-(4-fluoro-phenyl)-5-[2-(pyridin-3-ylamino)-pyrimidin-4 -yl]-1H-imidazol-2-yl}-5-methyl- [1,3]dioxan-5-yl)-morpholin-4-yl-methanone, trans-isomer, (Compound A7); 2-(4-{5-(4-fluoro-phenyl)-2-[5-methyl-5-(morpholine-4-carbon yl)-[1,3]dioxan-2-yl]-3H-imidazol 4-yl)-pyrimidin-2-ylamino)-acetamide, trans-isomer, (Compound A8); 3-(4-{5-(4-fluoro-phenyl)-2-[5-methyl-5-(morpholine-4-carbon yl)-[1,3]dioxan-2-yl]-3H-imidazol- 4-yl}-pyrimidin-2-ylamino)-propionamide, trans-isomer, (Compound A9); {2-[4-(4-fluoro-phenyl)-5-(2-propylamino-pyrimidin-4-yl)-1H- imidazol-2-yl]-5-methyl- [1,3]dioxan-5-yl )-morpholin-4-yl-methanone, trans-isomer, (Compound A10); {2-[4-(4-fluoro-phenyl)-5-(2-pyrrolidin-1-yl-pyrimidin-4-yl) -1H-imidazol-2-yl]-5-methyl- [1,3]dioxan-5-yl )-morpholin-4-yl-methanone, trans-isomer, (Compound All); <BR> <BR> <BR> 2-[5-(2-(4-fluorobenzyl)amino-pyrimidin-4-yl)-4-(4-fluoro-ph enyl)-lH-imidazol-2-yl]-5-methyl- [1,3]dioxan-5-yl)-morpholin-4-yl-methanone, trans-isomer, (Compound A12); 2-[5-(2-(4-methoxybenzyl)amino-pyrimidin-4-yl)-4-(4-fluoro-p henyl)- lH-imidazol-2-yl]-5- methyl-[1,3]dioxan-5-yl )-morpholin-4-yl-methanone, trans-isomer, (Compound A13); {2-[4-(4-fluoro-phenyl)-5-(2-(4-fluorophenyl)amino-pyrimidin -4-yl)-1H-imidazol-2-yl]-5-methyl- [1,3]dioxan-5-yl)-morpholin-4-yl-methanone, trans-isomer, (Compound A14); {2-[4-(4-fluoro-phenyl)-5-(2-(3,4-difluorophenyl)amino-pyrim idin-4-yl)-1H-imidazol-2-yl]-5- methyl-[1,3]dioxan-5-yl)-morpholin-4-yl-methanone, trans-isomer, (Compound A15); {2-[4-(4-fluoro-phenyl)-5-(2-(3-methoxyphenyl)amino-pyrimidi n-4-yl)-1H-imidazol-2-yl]-5- methyl-[1,3]dioxan-5-yl}-morpholin-4-yl-methanone, trans-isomer, (Compound A16);

(d) By proceeding in a similar manner to Example 23 (b) but using 2-[4-(4-fluoro-phenyl)-5-(2- methylsulphonylpyrimidin-4-yl)-lH-imidazol-2-yl]-5,5-dimethy l-[l,3]dioxane (Compound KI) there were prepared Compounds HL to IN in Table 7a.

TABLE 7a STRUCTURE HNY4Y5 RT MOLECULAR MH+ and FORMULA (Intensity) COMPOUND NUMBER NH2 NH3 10.31 C19H20FN502 370 NN H (100%) fI 2 (100%) H /N O Fw Compound HM HN' 10.88 C21H24FN502 1 398 N N H (100%) H I XH (100 % ) Compound HN toy Fw Corn ound HO P 12.7 C25H30FN502 452 N9NHN H2Nt (100 % ) NI~Ho H Fi)NO Compound HQ HO 414 H2N oH 9.76 C211124FN5O3 (100%) NH N N H of N O ComPound HR Compound HR rH2 H2NNH, 8.85 C21H25FN602 413 N N H 0 9 N O 3 Compound HS H2N H NNn .16 C25H25FN702 478 (100%) N H H o ~kg H2NN) 9.15 C26H33FN603 497 N N Compound HU 428 HO) H2N~OH 9.68 C22H26FN502 428 N 4 N (100 H X NwO 3 F Compound HV Ph7 HzN9Ph 12.4 C26H26FN502 446 N4N H (100%) < NwO 3 {<N O Compound HW Ph Ph 13.01 C27H28FN502 474 H2N H,N--( (100%) N N H ~0y, Compound HX Ph\l,, Ph 13.01 C27H28FN502 474 N 4 N H H2N (100 % ) NH -, (loo) F~®120O~ Corn HY 12.53 C25H24FN502 446 H2N (100%) NH N H >/ N O Compound HZ (j) 12.23 C24H28FN502 438 HN X N O 3 Compound IA NA H H2Nm 8.97 C25H25FN602 461 I N (100%) N4N H H XN O Compound IB I HN 8.87 C25H25FN602 461 N 2N (100%) Iv ,H o H Compound IC H2N m 8.94 C25H25FN602 461 NtN XHN iN (100 % ) N H rv N O 7 FU N O F CompoundID N N H toy Compound IE S HNS 12.3 C24H24FN502S 466 iI (100%) XH N N H H NH2 FI)N Compound IF 0 H2N®ffi0 11.29 C241128FN5O3 454 CO H, I I (100%) N4N H 9 N O 7 ComPound IG Compound IG 1 /7 9.43 C24H29FN602 453 fN' HN N- N N H ef N O F4J Compound IH Koo 11.1 C23H26FN503 440 (loos) X N O 3 Compound IJ

0 H2NO 11.1 C23H28FN503 442 (100%) N H H F)N 0 Compound H2N0 10.78 C22H26FN5O3 428 I (loo) N XNH -N O F I YN/\/\N/ 907 C24H31FN602 455 N I (100%) ,Nx H2NNI 9.07 C24H31FN602 (14005eXe) H Fj run 0 Compound IM 1 l 9.14 C23H29FN602 441 H,NN (100%) N4N H tl IsNO F Compound IN (e) By proceeding in a similar manner to Example 23 (d) and using the appropriately substituted amine of formula HNY4Y5 there are prepared Compounds A17 to A35.

{4-[2-(5,5-dimethyl-[1 ,3]dioxan-2-yl)-5-(4-fluoro-phenyl)-311-imidazol-4-yl]-pyrim idin-2- ylamino}-acetic acid, (Compound A17); 3-{4-[2-(5,5-dimethyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)- 3H-imidazol-4-yl]-pyrimidin-2 ylamino}-propionic acid, (Compound A18); {4-[2-(5,5-dimethyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)-3H -imidazol-4-yl]-pyrimidin-2 piperidin-4-yl-amine, (Compound A19);

{4-[2-(5,5-dimethyl- [1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-pyri midin-2-yl}- isopropyl-amine, (Compound A20); <BR> <BR> <BR> <BR> allyl-{4-[2-(5,5-dimethyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phen yl)-311-imidazol-4-yl]-pyrimidin-2-yl}- amine, (Compound A21); cyclopropylmethyl-{4-[2-(5,5-dimethyl-[1,3]dioxan-2-yl)-5-(4 -fluoro-phenyl)-3H-imidazol-4-yl]- pyrimidin-2-yl}-amine, (Compound A22); {4-[2-(5,5-dimethyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)-31 1-imidazol-4-yl]-pyrimidin-2- ylamino)-acetonitrile, (Compound A23); 3-{4-[2-(5,5-dimethyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)- 3H-imidazol-4-yl]-pyrimidin-2- ylamino}-propionitrile, (Compound A24); (4-[2-(5,5-dimethyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)-3H -imidazol-4-ylj-pyrirnidin-2-yli- pyridin-3-yl-amine, (Compound A25); (4-[2-(5,5-dimethyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)-31 1-imidazol-4-yl]-pyrimidin-2-yl)- pyridin-4-yl-amine, (Compound A26); 2-{4-[2-(5,5-dimethyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)- 3H-imidazol-4-yl]-pyrimidin-2- ylamino)-acetamide, (Compound A27); 3-{4-[2-(5,5-dimethyl-[1 ,3]dioxan-2-yl)-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-pyrimi din-2- ylamino}-propionamide, (Compound A28); {4-[2-(5,5-dimethyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)-31 1-imidazol-4-yl]-pyrimidin-2.yl)- propyl-amine, (Compound A29); 4-[2-(5,5-dimethyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)-3H- imidazol-4-yl]-2-pyrrolidin-1-yl- pyrimidine, (Compound A30); 4-fluorobenzyl-(4-[2-(5,5-dimethyl-[1,3]dioxan-2-yl)-5-(4-fl uoro-phenyl)-311-imidazol-4-yl]- pyrimidin-2-yl}-amine, (Compound A31); 4-methyoxybenzyl-{4-[2-(5,5-dimethyl-[1,3]dioxan-2-yl)-5-(4- fluoro-phenyl)-3H-imidazol-4-yl]- pyrimidin-2-yl}-amine, (Compound A32); {4-[2-(5,5-dimethyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)-3H -imidazol-4-yl]-4- fluorophenyl-amine, (Compound A33); <BR> <BR> <BR> <BR> (4-[2-(5,5-dimethyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)-31 1-imidazol-4-yl]-pyrimidin-2-yl)-3,4- difluorophenyl-amine, (Compound A34); {4-[2-(5,5-dimethyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)-3H -imidazol-4-yl]-3- methoxyphenyl-amine, (Compound A35); (f) By proceeding in a similar manner to Example 23 (a), but using {2-[4-(4-fluoro-phenyl)- 5-(2-methylsulphonyl-pyrimidin-4-yl)- lH-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl }-methanol, trans isomer, (Compound KJ) and replacing cyclopropylamine with liquid ammonia and

carrying out the reaction under pressure for 2 days, there was prepared following preparative thin layer chromatography on silica gel [eluting with a mixture of dichloromethane, methanol and ammonia (90:10:2, v/v/v)] {2-r5-(2-amino-pvrimidin-4-vl)-4-(4-fluoro-Phenyl)-1H-imidaz ol- 2-yl]-5-methyl-[1,3]dioxan-5-yl}-methanol, trans-isomer (Compound IO) as a white solid. MH+ 386. RF: 0.41 (solvent as described immediately above).

(g) By proceeding in a similar manner to Example 23 (b) but using (2-[4-(4-fluoro-phenyl)-5- (2-methylsulphonyl-pyrimidin-4-yl)-111-imidazol-2-yl]-5-meth yl-[1,3]dioxan-5-yl)-methanol, trans isomer, (Compound KJ) there are prepared Compounds A36 to A79:- {2-[4-(4-fluoro-phenyl)-5-(2-methylamino-pyrimidin-4-yl)-1H- imidazol-2-xl]-5-methyl- [1,3]dioxan-5-yl}-methanol, trans-isomer, (Compound A36); {2-[5-(5-dimethylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1 H-imidazol-2-yl]-5-methyl- [1,3]dioxan-5-yl}-methanol, trans-isomer, (Compound A37); {2-[5-(2-cyclopropylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl )-1H-imidazol-2-yl]-5-methyl- [1,3]dioxan-5-yl)-methanol, trans-isomer, (Compound A38); <BR> <BR> <BR> (2-{4-(4-fluoro-phenyl)-5-[2-(piperidin-4-ylamino)-pyrimidin -4-yl]-lH-imidazol-2-yl}-5-methyl- [1,3]dioxan-5-yl)-methanol, trans-isomer, (Compound A39); {2-[5-(2-cyclohexylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl) -1H-imidazol-2-yl]-5-methyl- [1,3]dioxan-5-yl}-methanol, trans-isomer, (Compound A40); 2-{4-[5-(4-fluoro-phenyl)-2-(5-hydroxymethyl-5-methyl-[1,3]d ioxan-2-yl)-3H-imidazol-4-yl]- pyrimidin-2-ylamino}-ethanol, trans-isomer, (Compound A41); {2-[5-(2-amino-ethylamino)-pyrimidin-4-yl)-4-(4-fluoro-pheny l)-1H-imidazol-2-yl]-5-methyl- [1,3]dioxan-5-yl}-methanol, trans-isomer, (Compound A42); [2-(4-(4-fluoro-phenyl)-5-{2-[3-(5H-imidazol-1-yl)-propylami no]-pyrimidin-4-yl}-1H-imidazol-2- yl)-5-methyl-[1,3]dioxan-5-yl]-methanol, trans-isomer, (Compound A43); <BR> <BR> <BR> (2-{4-(4-fluoro-phenyl)-5-[2-(3-morpholin-4-yl-propylamino)- pyrimidin-4-yl]-lH-imidazol-2-yl}- 5-methyl-[1,3]dioxan-5-yl)-methanol, trans-isomer, (Compound A44); 3-{4-[5-(4-fluoro-phenyl)-2-(5-hydroxymethyl-5-methyl-[1,3]d ioxan-2-yl)-3H-imidazol-4-yl]- pyrimidin-2.ylamino)-propan- 1-ol, trans-isomer, (Compound A45); {2-[5-(2-benzylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H- imidazol-2-yl]-5-methyl- [1,3]dioxan-5-yl)-methanol, trans-isomer, (Compound A46); {2-[5-(2-(4-fluorobenzyl)amino-pyrimidin-4-yl)-4-(4-fluoro-p henyl)-1H-imidazol-2-yl]-5-methyl- [1,3]dioxan-5-yl i-methanol, trans-isomer, (Compound A47); {2-[5-(2-(4-methoxbenzyl)amino-pyrimidin-4-yl)-4-(4-fluoro-p henyl)-1H-imidazol-2-yl]-5- methyl-[1,3]dioxan-5-yl }-methanol, trans-isomer, (Compound A48);

(2-{4-(4-fluoro-phenyl)-5- [2-(1-phenyl-ethylamino)-pyrimidin-4-yl]-111-imidazol-2-yl)- 5-methyl [1,3]dioxan-5-yl)-methanol, R isomer, trans-isomer, (Compound A49); <BR> <BR> <BR> <BR> (2-{4-(4-fluoro-phenyl)-5-[2-(1-phenyl-ethylamino)-pyrimidin -4-yl]-111-imidazol-2-yl)-5-methyl- [1,3]dioxan-5-yl)-methanol, S isomer, trans-isomer, (Compound A50); {2-[4-(4-fluoro-phenyl)-5-(2-phenylamino-pyrimidin-4-yl)- 111-imidazol-2-yl]-5-methyl- [1,3]dioxan-5-yl}-methanol, trans-isomer, (Compound A51); {2-[4-(4-fluoro-phenyl)-5-(2-(4-fluorophenyl)amino-pyrimidin -4-yl)-1H-imidazol-2-yl]-5-methyl- [1,3]dioxan-5-yl}-methanol, trans-isomer, (Compound A52); {2-[4-(4-fluoro-phenyl)-5-(2-(3,4-difluorophenyl)amino-pyrim idin-4-yl)-1H-imidazol-2-yl]-5- methyl-[1,3]dioxan-5-yl}-methanol, trans-isomer, (Compound A53); {2-[4-(4-fluoro-phenyl)-5-(2-(3-methoxyphenyl)amino-pyrimidi n-4-yl)-1H-imidazol-2-yl]-5- methyl-[1,3]dioxan-5-yl)-methanol, trans-isomer, (Compound A54); {2-[4-(4-fluoro-phenyl)-5-(2-piperidin-1-pyrimidin-4-yl)-1H- imidazol-2-yl]-5-methyl- [1,3]dioxan-5-yl}-methanol, trans-isomer, (Compound A55); [2-(4-(4-fluoro-phenyl)-5-{2-[(pyridin-4-ylmethyl)amino]-pyr imidin-4-yl}-1H-imidazol-2-yl]-5- methyl-[1,3]dioxan-5-yl]-methanol, trans-isomer, (Compound A56); <BR> <BR> <BR> <BR> [2-(4-(4-fluoro-pheny1)-5- (2-[(pyridin-3-ylmethyl)-amino] -pyrimidin4-yl)-l H-imidazol-2-yl)-5- methyl-[1,3]dioxan-5-yl]-methanol, trans-isomer, (Compound A57); [2-(4-(4-fluoro-phenyl)-5-{2-[(pyridin-2-ylmethyl)amino]-pyr imidin-4-yl}-1H-imidazol-2-yl]-5- methyl-[1,3]dioxan-5-yl]-methanol, trans-isomer, (Compound A58); [2-(4-(4-fluoro-phenyl)-5-{2-[(furan-4-ylmethyl)amino]-pyrim idin-4-yl}-1H-imidazol-2-yl]-5- methyl- [1,3]dioxan-5-yl]-methanol, trans-isomer, (Compound A59); [2-(4-(4-fluoro-phenyl)-5-{2-[(thiophen-4-ylmethyl)amino]-py rimidin-4-yl}-1H-imidazol-2-yl]-5- methyl-[1,3]dioxan-5-yl]-methanol, trans-isomer, (Compound A60); [2-(4-(4-fluoro-phenyl)-5-{2-[(tetrahydro-furan-2-ylmethyl)a mino]-pyrimidin-4-yl}-1H- imidazol-2-yl)-5-mehtyl-[1,3]dioxan-5-yl]-methanol, trans-isomer, (Compound A61); (2-{4-(4-fluoro-phenyl)-5-[2-(4-methyl-piperazin-1-yl)-pyrim idin-4-yl}-1H-imidazol-2-yl}-5- methyl-[1,3]dioxan-5-yl)-methanol, trans-isomer, (Compound A62); {2-[4-(4-fluoro-phenyl)-5-(2-morpholin-4-yl-pyrimidin-4-yl)- lH-imidazol-2-yl]-5-methyl- [1,3]dioxan-5-yl)-methanol, trans-isomer, (Compound A63); (2-(4-(4-fluoro-phenyl)-5-[2-(3-methoxy-propylamino)-pyrimid in-4-yl]-111-imidazol-2-yl}-5- methyl-[1,3]dioxan-5-yl)-methanol, trans-isomer, (Compound A64); (2-{4-(4-fluoro-phenyl)-5-[2-(2-methoxy-ethylamino)-pyrimidi n-4-yl]-1H-imidazol-2-yl}-5- methyl-[1,3]dioxan-5-yl)-methanol, trans-isomer, (Compound A65); {2-[5-[2-(3-dimethylamino-propylamino)-pyrimidin-4-yl]-4-(4- fluoro-phenyl)-1H-imidazol-2-yl]- 5-methyl- [1,3]dioxan-5-yl }-methanol, trans-isomer, (Compound A66);

{2-[5-[2-(2-dimethylamino-ethylamino)-pyrimidin-4-yl]-4-(4-f luoro-phenyl)-111-imidazol-2-yl]-5- methyl-[1,3]dioxan-5-yl)-methanol, trans-isomer, (Compound A67); (4-[5-(4-fluoro-phenyl)-2-(5-hydroxymethyl-5-methyl-[1,3]dio xan-2-yl)-311-imidazol-4-yl]- pyrimidin-2-ylamino}-acetic acid, trans-isomer, (Compound A68); 3-{4-[5-(4-fluoro-phenyl)-2-(5-hydroxymethyl-5-methyl-[1,3]d ioxan-2-yl)-311-imidazol-4-yl]- pyrimidin-2-ylamino}-propionic acid, trans-isomer, (Compound A69); {2-[4-(4-fluoro-phenyl)-5-(2-isopropylamino-pyrimidin-4-yl)- lH-imidazol-2-yl]-5-methyl- [1,3]dioxan-5-yl)-methanol, trans-isomer, (Compound A70); <BR> <BR> <BR> (2-[5-(2-allylamino-pyrimidin-4-yl) -4-(4-fluoro-phenyl)- 1H-imidazol-2-yl]-5-methyl-[l ,3]dioxan- 5-yl}-methanol, trans-isomer, (Compound A71); <BR> <BR> <BR> <BR> (2-[5-[2-(cyclopropylmethyl-amino)-pyrimidin-4-yl]-4-(4-fluo ro-phenyl)-111-imidazol-2-yl]-5- methyl-[1,3]dioxan-5-yl}-methanol, trans-isomer, (Compound A72); (4-[5-(4-fluoro-phenyl)-2-(5-hydroxymethyl-5-methyl-[1,3]dio xan-2-yl)-311-imidazol-4-yl]- pyrimidin-2-ylamino)-acetonitrile, trans-isomer, (Compound A73); 3-{4-[5-(4-fluoro-phenyl)-2-(5-hydroxymethyl-5-methyl-[1,3]d ioxan-2-yl)-3H-imidazol-4-yl]- pyrimidin-2-ylamino)-propionitrile, trans-isomer, (Compound A74); (2-{4-(4-fluoro-phenyl)-5- [2-(pyridin-3-ylamino)-pyrimidin-4-yl]- 1H-imidazol-2-yl)- 5-methyl- [1,3]dioxan-5-yl)-methanol, trans-isomer, (Compound A75); (2-{4-(4-fluoro-phenyl)-2-[2-(pyridin-4-ylamino)-pyrimidin-4 -yl]-1H-imidazol-2-yl]-5-methyl- [1,3]dioxan-5-yl)-methanol, trans-isomer, (Compound A76); 2-{4-[5-(4-fluoro-phenyl)-2-(5-hydroxymethyl-5-methyl-[1,3]d ioxan-2-yl)-3H-imidazol-4-yl]- pyrimidin-2-ylamino}-acetamide, trans-isomer, (Compound A77); 3-(4-[5-(4-fluoro-phenyl)-2-(5-hydroxymethyl-5-methyl-[1,3]d ioxan-2-yl)-311-imidazol-4-yl]- pyrimidin-2-ylamino}-propionamide, trans-isomer, (Compound A78); {2-[4-(4-fluoro-phenyl)-5-(2-propylamino-pyrimidin-4-yl)-1H- imidazol-2-yl]-5-methyl- [1,3]dioxan-5-yl}-methanol, trans-isomer, (Compound A79); (h) By proceeding in a similar manner to Example 23 (g) but using {2-[4-(4-fluoro-phenyl)-5- (2-methylsulphonyl-pyrimidin-4-yl)- lH-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-methanol, cis- isomer, (Compound KK) there are prepared the corresponding cis-isomers of Compounds A36 to A79.

(i) By proceeding in a similar manner to Example 23 (b) but using 2-[4-84-fluoro-phenyl)-5- (2-methylsulphonylpyrimidin-4-yl)-1H-imidazol-2-yl]-5-mehtyl ene-[1,3]dioxane (Compound KL) there are prepared compounds A80 to A125:-

4-[5-(4-fluoro-phenyl)-2-(5-methylene-[1,3]dioxan-2-yl)-3H-i midazol-4-yl]-pyrimidin-2-ylamine, (Compound A80); {4-[5-(4-fluoro-phenyl)-2-(5-methylene-[1,3]dioxan-2-yl)-3H- imidazol-4-yl]-pyrimidin-2-yl}- methyl-amine, (Compound A81); {4-[5-(4-fluoro-phenyl)-2-(5-methylene-[1,3]dioxan-2-yl)-3H- imidazol-4-yl]-pyrimidin-2-yl}- dimethyl-amine, (Compound A82); cyclopropyl-{4-[5-(4-fluoro-phenyl)-2-(5-methylene-[1,3]diox an-2-yl)-3H-imidazol-4-yl]- pyrimidin-2-yl}-amine, (Compound A83); {4-[5-(4-fluoro-phenyl)-2-(5-methylene-[1,3]dioxan-2-yl)-3H- imidazol-4-yl]-pyrimidin-2-yl}- piperidin-4-yl-amine, (Compound A84); cyclohexyl-{4-[5-(4-fluoro-phenyl)-2-(5-methylene-[1,3]dioxa n-2-yl)-3H-imidazol-4-yl]- pyrimidin-2-yl)-amine, (Compound A85); 2-{4-[5-(4-fluoro-phenyl)-2-(5-methylene-[1,3]dioxan-2-yl)-3 H-imidazol-4-yl]-pyrimidin-2- ylamino}-ethanol, (Compound A86); N1-{4-[5-(4-fluoro-phenyl)-2-(5-methylene-[1,3]dioxan-2-yl)- 3H-imidazol-4-yl]-pyrimidin-2-yl}- ethane-1,2-diamine, (Compound A87); {4-[5-(4-fluoro-phenyl)-2-(5-methylene-[1,3]dioxan-2-yl)-3H- imidazol-4-yl]-pyrimidin-2-yl}-[3- (SH-imidazol-l-yl)-propyl]-amine, (Compound A88); {4-[5-(4-fluoro-phenyl)-2-(5-methylene-[1,3]dioxan-2-yl)-3H- imidazol-4-yl]-pyrimidin-2-yl}-(3- morpholin-4-yl-propyl)-amine, (Compound A89); 3-{4-[5-(4-fluoro-phenyl)-2-(5-methylene- [1,3]dioxan-2-yl)-3H-imidazol-4-yl]-pyrimidin-2- ylamino)-propan-1-ol, (Compound A90); benzyl-{4-[5-(4-fluoro-phenyl)-2-(5-methylene-[1,3]dioxan-2- yl)-3H-imidazol-4-yl]-pyrimidin-2- yl)-amine, (Compound A91); 4-fluorobenzyl-{4-[5-(4-fluoro-phenyl)-2-(5-methylene-[1,3]d ioxan-2-yl)-3H-imidazol-4-yl]- pyrimidin-2-yl)-amine , (Compound A92); 4-methoxybenzyl-{4-[5-(4-fluoro-phenyl)-2-(5-methylene-[1,3] dioxan-2-yl)-3H-imidazol-4-yl]- pyrimidin-2-yl)-amine, (Compound A93); {4-[5-(4-fluoro-phenyl)-2-(5-methylene-[1,3]dioxan-2-yl)-3H- imidazol-4-yl]-pyrimidin-2-yl}-(1- phenyl-ethyl)-amine, R isomer, (Compound A94); {4-[5-(4-fluoro-phenyl)-2-(5-methylene- [1,3]dioxan-2-yl)-3H-imidazol-4-yl]-pyrimidin-2-yl}-(1- phenyl-ethyl)-amine, S isomer, (Compound A95); (4-[5-(4-fluoro-phenyl)-2-(5-methylene-[1 ,3]dioxan-2-yl)-311-imidazol-4-yl]-pyrimidin2yl} phenyl-amine, (Compound A96); {4-[5-(4-fluoro-phenyl)-2-(5-methylene-[1,3]dioxan-2-yl)-3H- imidazol-4-yl]-pyrimidin-2-yl}-4- fluorophenyl-amine, (Compound A97);

{4-[5-(4-fluoro-phenyl)-2-(5-methylene-[1,3]dioxan-2-yl)-3H- imidazol-4-yl]-pyrimidin-2-yl}-3,4- difluorophenyl-amine, (Compound A98); (4-[5-(4-fluoro-phenyl)-2-(5-methylene-[1,3]dioxan-2-yl)-3H- imidazol-4-yl]-pyrimidin-2-yl)-3 methoxyphenyi-amine, (Compound A99); 4-[5-(4-fluoro-phenyl)-2-(5-methylene-[1,3]dioxan-2-yl)-3H-i midazol-4-yl]-2-piperidin-1-yl- pyrimidine, (Compound A100); (4-[5-(4-fluoro-phenyl)-2-(5-methylene-[1 ,3]dioxan-2-yl)-311-imidazol-4-yl]-pyrimidin-2-yl) pyridin-4-ylmethyl-amine, (Compound A101); {4-[5-(4-fluoro-phenyl)-2-(5-methylene-[1,3]dioxan-2-yl)-3H- imidazol-4-yl]-pyrimidin-2-yl}- pyridin-3-ylmethyl-amine, (Compound A102); {4-[5-(4-fluoro-phenyl)-2-(5-methylene-[1,3]dioxan-2-yl)-3H- imidazol-4-yl]-pyrimidin-2-yl}- pyridin-2-ylmethyl-amine, (Compound A103); {4-[5-(4-fluoro-phenyl)-2-(5-methylene-[1,3]dioxan-2-yl)-3H- imidazol-4-yl]-pyrimidin-2-yl}- (furan-2-ylmethyl)-amine, (Compound A104); {4-[5-(4-fluoro-phenyl)-2-(5-methylene-[1,3]dioxan-2-yl)-3H- imidazol-4-yl]-pyrimidin-2-yl) (thiophen-2-ylmethyl)-amine, (Compound A105); {4-[5-(4-fluoro-phenyl)-2-(5-methylene-[1,3]dioxan-2-yl)-3H- imidazol-4-yl]-pyrimidin-2-yl}- (tetrahydro-furan-2-ylmethyl)-amine, (Compound A106); 4-[5-(4-fluoro-phenyl)-2-(5-methylene-[1,3]dioxan-2-yl)-3H-i midazol-4-yl]-2-(4-methyl-piperazin- 1-yl)-pyrimidine, (Compound A107); 4-{4-[5-(4-fluoro-phenyl)-2-(5-methylene-[1,3]dioxan-2-yl)-3 H-imidazol-4-yl]-pyrimidin-2-yl}- morpholine, (Compound A108); {4-[5-(4-fluoro-phenyl)-2-(5-methylene-[1,3]dioxan-2-yl)-3H- imidazol-4-yl]-pyrimidin-2-yl}-(3- methoxy-propyl)-amine, (Compound A109); {4-[5-(4-fluoro-phenyl)-2-(5-methylene-[1,3]dioxan-2-yl)-3H- imidazol-4-yl]-pyrimidin-2-yl}-(2- methoxy-ethyl)-amine, (Compound A110); N-{4-[5-(4-fluoro-phenyl)-2-(5-methylene-[1,3]dioxan-2-yl)-3 H-imidazol-4-yl]-pyrimidin-2-yl}- N',N'-dimethyl-propane- 1,3-diamine, (Compound All); N-{4-[5-(4-fluoro-phenyl)-2-(5-methylene-[1,3]dioxan-2-yl)-3 H-imidazol-4-yl]-pyrimidin-2-yl}- N',N'-dimethyl-ethane- 1,2-diamine, (Compound A112); {4-[5-(4-fluoro-phenyl)-2-(5-methylene-[1,3]dioxan-2-yl)-3H- imidazol-4-yl]-pyrimidin-2- ylamino}-acetic acid, (Compound A113); 3-{4-[5-(4-fluoro-phenyl)-2-(5-methylene-[1,3]dioxan-2-yl)-3 H-imidazol-4-yl]-pyrimidin-2- ylamino}-propionic acid, (Compound A114); {4-[5-(4-fluoro-phenyl)-2-(5-methylene-[1,3]dioxan-2-yl)-3H- imidazol-4-yl]-pyrimidin-2-yl}- isopropyl-amine, (Compound A115);

allyl-{4-[5-(4-fluoro-phenyl)-2-(5-methylene-[1,3]dioxan-2-y l)-3H-imidazol-4-yl]-pyrimidin-2-yl}- amine, (Compound A116); <BR> <BR> <BR> <BR> cyclopropylmethyl-(4-[5-(4-fluoro-phenyl)-2-(5-methylene-[1, 3]dioxan-2-yl)-311-imidazol-4-yl]- pyrimidin-2-yl)-amine, (Compound A117); (4-[5-(4-fluoro-phenyl)-2-(5-methylene-[1,3]dioxan-2-yl)-3H- imidazol-4-yl]-pyrimidin-2 ylamino}-acetonitrile, (Compound A118); 3-{4-[5-(4-fluoro-phenyl)-2-(5-methylene-[1,3]dioxan-2-yl)-3 H-imidazol-4-yl]-pyrimidin-2- ylamino)-propionitrile, (Compound A119); {4-[5-(4-fluoro-phenyl)-2-(5-methylene-[1,3]dioxan-2-yl)-3H- imidazol-4-yl]-pyrimidin-2-yl}- pyridin-3-yl-amine, (Compound A120); {4-[5-(4-fluoro-phenyl)-2-(5-methylene-[1,3]dioxan-2-yl)-3H- imidazol-4-yl]-pyrimidin-2-yl}- pyridin-4-yl-amine, (Compound A121); 2-(4-[5-(4-fluoro-phenyl)-2-(5-methylene-[1,3]dioxan-2-yl)-3 H-imidazol-4-yl]-pyrimidin-2- ylamino}-acetamide, (Compound A122); 3-{4-[5-(4-fluoro-phenyl)-2-(5-methylene- [1,3]dioxan-2-yl)-3H-imidazol-4-yl]-pyrimidin-2- ylamino)-propionamide, (Compound A123); {4-[5-(4-fluoro-phenyl)-2-(5-methylene-[1,3]dioxan-2-yl)-3H- imidazol-4-yl]-pyrimidin-2-yl}- propyl-amine, (Compound A124); 4-[5-(4-fluoro-phenyl)-2-(5-methylene-[1,3]dioxan-2-yl)-3H-i midazol-4-yl]-pyrrolidin-1-yl- pyrimidine, (Compound A125); (j) By proceeding in a similar manner to Example 23 (b) but using 4-[2-[1,3]dioxan-2-yl-5-(4- fluoro-phenyl)-3H-imidazol-4-yl]-2-methylsulphonyl-pyrimidin e (Compound KM) there are prepared Compounds A126 to A170:- 4-[2-[1,3]dioxan-2-yl-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]- pyrimidin-2-ylamine, (Compound A126); 4-[2-[1,3]dioxan-2-yl-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]- pyrimidin-2-yl}-methyl-amine, (Compound A127); {4-[2-[1,3]dioxan-2-yl-5-(4-fluoro-phenyl)-311-imidazol-4-yl ]-pyrimidin-2-yl}-dimethyl-amine, (Compound A128); <BR> <BR> <BR> <BR> cyclopropyl-(4-[2-[1,3]dioxan-2-yl-5-(4-fluoro-phenyl)-311-i midazol-4-yl]-pyrimidin-2-yl)-amine, (Compound A129); 4-[2-[1,3]dioxan-2-yl-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]- pyrimidin-2-yl}-piperidin-4-yl- amine, (Compound A130); cyclohexyl-{4-[2-[1,3]dioxan-2-yl-5-(4-fluoro-phenyl)-3H-imi dazol-4-yl]-pyrimidin-2-yl}-amine, (Compound A131);

2-{4- [2- [1,3]dioxan-2-yl-5-(4-fluoro-phenyl)-311-imidazol-4-yl]-pyri midin-2-ylamino}-ethanol, (Compound A132); N1-{4-[2-[1,3]dioxan-2-yl-5-(4-fluoro-phenyl)-3H-imidazol-4- yl]-pyrimidin-2-yl}-ethane-1,2- diamine, (Compound A133); <BR> <BR> <BR> {4-[2-[1,3]dioxan-2-yl-5-(4-fluoro-phenyl)-311-imidazol-4-yl ]-pyrimidin.2-yl)-[3-(511-imidazol-1- yl)-propyl]-amine, (Compound A134); <BR> <BR> <BR> <BR> {4-[2-[1,3]dioxan-2-yl-5-(4-fluoro-phenyl)-3H-imidazol-4-yl] -pyrimidin-2-yl}-(3-morpholin-4-yl- propyl)-amine, (Compound A135); 3-{4-[2-[1,3]dioxan-2-yl-5-(4-fluoro-phenyl)-3H-imidazol-4-y l]-pyrimidin-2-ylamino}-propan-1- ol, (Compound A136); benzyl-{4-[2-[1,3]dioxan-2-yl-5-(4-fluoro-phenyl)-311-imidaz ol-4-yl]-pyrimidin-2-yl}-amine, (Compound A137); 4-fluorobenzyl-{4-[2-[1,3]dioxan-2-yl-5-(4-fluoro-phenyl)-3H -imidazol-4-yl]-pyrimidin-2-yl}- amine, (Compound A138); 4-methoxybenzyl-{4-[2-[1,3]dioxan-2-yl-5-(4-fluoro-phenyl)-3 H-imidazol-4-yl]-pyrimidin-2-yl}- amine, (Compound A139); {4-[2-[1,3]dioxan-2-yl-5-(4-fluoro-phenyl)-3H-imidazol-4-yl] -pyrimidin-2-yl}-(1-phenyl-ethyl)- amine, R isomer, (Compound A140); {4-[2-[1,3]dioxan-2-yl-5-(4-fluoro-phenyl)-3H-imidazol-4-yl] -pyrimidin-2-yl}-(1-phenyl-ethyl)- amine, S isomer, (Compound A141); (4-[2-[1,3]dioxan-2-yl-5-(4-fluoro-phenyl)-3H-imidazol-4-yl] -pyrimidin-2-yl }-phenyl-amine, (Compound A142); {4-[2-[1,3]dioxan-2-yl-5-(4-fluoro-phenyl)-3H-imidazol-4-yl] -pyrimidin-2-yl}-(4-fluorophenyl)- amine, (Compound A143); {4-[2-[1,3]dioxan-2-yl-5-(4-fluoro-phenyl)-3H-imidazol-4-yl] -pyrimidin-2-yl}-(3,4- difluorophenyl)-amine, (Compound A144); {4-[2-[1,3]dioxan-2-yl-5-(4-fluoro-phenyl)-3H-imidazol-4-yl] -pyrimidin-2-yl}-(4-methoxyphenyl)- amine, (Compound A145); 4-[2-[1,3]dioxan-2-yl-5-(4-fluoro-phenyl) -3H-imidazol-4-yl]-2-piperidin- 1-yl-pyrimidine, (Compound A146); <BR> <BR> <BR> {4-[2-[1,3]dioxan-2-yl-5-(4-fluoro-phenyl)-3H-imidazol-4-yl] -pyrimidin-2-yl}-pyridin-4-ylmethyl- amine, (Compound A147); {4-[2-[1,3]dioxan-2-yl-5-(4-fluoro-phenyl)-3H-imidazol-4-yl] -pyrimidin-2-yl}-pyridin-3-ylmethyl- amine, (Compound A148); {4-[2-[1,3]dioxan-2-yl-5-(4-fluoro-phenyl)-3H-imidazol-4-yl] -pyrimidin-2-yl}-pyridin-2-ylmethyl- amine, (Compound A149);

(4- [2-[1,3]dioxan-2-yl-5-(4-fluoro-phenyl)-311-imidazol-4-yl]-p yrimidin-2-yl)-(furan-2-ylmethyi) amine {4-[2-[1,3]dioxan-2-yl-5-(4-fluoro-phenyl)-3H-imidazol-4-yl] -pyrimidin-2-yl}-(thiophen-2- ylmethyl)-amine, (Compound A150); {4-[2-[1,3]dioxan-2-yl-5-(4-fluoro-phenyl)-3H-imidazol-4-yl] -pyrimidin-2-yl}-(tetrahydro-furan- 2-ylmethyl)-amine, (Compound A151); 4-[2-[1,3]dioxan-2-yl-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]- 2-(4-methyl-piperazin-1-yl)- pyrimidine, (Compound A152); 4-{4-[2-[1,3]dioxan-2-yl-5-(4-fluoro-phenyl)-311-imidazol-4- yl]-pyrimidin-2-yl}-morpholine, (Compound A153); {4-[2-[1,3]dioxan-2-yl-5-(4-fluoro-phenyl)-3H-imidazol-4-yl] -pyrimidin-2-yl}-(3-methoxy- propyl)-amine, (Compound A154); {4-[2-[1,3]dioxan-2-yl-5-(4-fluoro-phenyl)-3H-imidazol-4-yl] -pyrimidin-2-yl}-(2-methoxy-ethyl)- amine, (Compound A155); N-{4-[2- [1,3]dioxan-2-yl-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-pyrim idin-2-yl}-N',N'-dimethyl- propane-1,3-diamine, (Compound A156); <BR> <BR> <BR> <BR> N-{4-[2-[1,3]dioxan-2-yl-5-(4.fluoro-phenyl)-3H-imidazol-4-y l]-pyrimidin-2-yl}-N',N'-dimethyl ethane-1,2-diamine, (Compound A157); {4-[2-[1,3]dioxan-2-yl-5-(4-fluoro-phenyl)-3H-imidazol-4-yl] -pyrimidin-2-ylamino}-acetic acid, (Compound A158); 3-{4-[2-[1,3]dioxan-2-yl-5-(4-fluoro-phenyl)-3H-imidazol-4-y l]-pyrimidin-2-ylamino}-propionic acid, (Compound A159); {4-[2-[1,3]dioxan-2-yl-5-(4-fluoro-phenyl)-3H-imidazol-4-yl] -pyrimidin-2-yl}-isopropyl-amine, (Compound A160); allyl-(4-[2-[1,3]dioxan-2-yl-5-(4-fluoro-phenyl)-3H-imidazol -4-yl]-pyrimidin-2-yl}-amine, (Compound A161); cyclopropylmethyl-{4-[2-[1,3]dioxan-2-yl-5-(4-fluoro-phenyl) -3H-imidazol-4-yl]-pyrimidin-2-yl}- amine, (Compound A162); {4-[2-[1,3]dioxan-2-yl-5-(4-fluoro-phenyl)-3H-imidazol-4-yl] -pyrimidin-2-ylamino}-acetonitrile, (Compound A163); 3-{4-[2-[1,3]dioxan-2-yl-5-(4-fluoro-phenyl)-3H-imidazol-4-y l]-pyrimidin-2-ylamino}- propionitrile, (Compound A164); {4-[2-[1,3]dioxan-2-yl-5-(4-fluoro-phenyl)-3H-imidazol-4-yl] -pyrimidin-2-yl}-pyridin-3-yl-amine, (Compound A165); {4-[2-[1,3]dioxan-2-yl-5-(4-fluoro-phenyl)-3H-imidazol-4-yl] -pyrimidin-2-yl}-pyridin-4-yl-amine, (Compound A166);

2-{4-[2- [1,3]dioxan-2-yl-5-(4-fiuoro-phenyl)-311-imidazol-4-yl]-pyri midin-2-ylamino }-acetamide, (Compound A167); 3-{4-[2-[1,3]dioxan-2-yl-5-(4-fluoro-phenyl)-3H-imidazol-4-y l]-pyrimidin-2-ylamino}- propionamide, (Compound A168); {4-[2-[1,3]dioxan-2-yl-5-(4-fluoro-phenyl)-3H-imidazol-4-yl] -pyrimidin-2-yl}-propyl-amine, (Compound A169); 4-[2-[1,3]dioxan-2-yl-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]- 2-pyrrolidin-1-yl-pyrimidine, (Compound A170); (k) By proceeding in a similar manner to Example 23 (b) but using {2-[4-(4-fluoro-phenyl)-5- (2-methylsulphonyl-pyrimidin-4-yl)-1H-imidazol-2-yl]-[1,3]di oxan-5-yl}-methanol,trans-isomer, (Compound KN) there are prepared Compounds A171 to A215:- (2-[5-(2-amino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-111-imida zol-2-yl]-[1,3]dioxan-5-yl)- methanol, trans-isomer, (Compound A171); {2-[4-(4-(fluoro-phenyl)-5-(2-methylamino-pyrimidin-4-yl)-1H -imidazol-2-yl]-[1,3]dioxan-5-yl}- methanol, trans-isomer, (Compound A172); <BR> <BR> <BR> <BR> (2-[5-(2-dimethylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1 11-imidazol-2-yl]-[1,3]dioxan-5-yll methanol, trans-isomer, (Compound A173); {2-[5-(2-cyclopropylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl )-1H-imidazol-2-yl]-[1,3]dioxan-5- yl)-methanol, trans-isomer, (Compound A174); (2-(4-(4-fluoro-phenyl)-5-[2-(piperidin-4-ylamino)-pyrimidin -4-yl]-1H-imidazol-2-yl)- [1,3]dioxan-5-yl)-methanol, trans-isomer, (Compound A175); <BR> <BR> <BR> (2-[5-(2-cyclohexylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl) lH-imidazol-2-yl]-[1,3]dioxan-5- yl)-methanol, trans-isomer, (Compound A176); 2-{4-[5-(4-fluoro-phenyl)-2-(5-hydroxymethyl-[1,3]dioxan-2-y l)-3H-imidazol-4-yl]-pyrimidin-2- ylamino}-ethanol, trans-isomer, (Compound A177); {2-[5-[2-(2-amino-ethylamino)-pyrimidin-4-yl]-4-(4-fluoro-ph enyl)-lH-imidazol-2-yl]- [1,3]dioxan-5-yl}-methanol, trans-isomer, (Compound A178); [2-(4-(4-fluoro-phenyl)-5-{2-[3-(5H-imidazol-1-yl)-propylami no]-pyrimidin-4-yl}-1H-imidazol-2- yl)-[1,3]dioxan-5-yl]-methanol, trans-isomer, (Compound A179); (2-{4-(4-fluoro-phenyl)-5-[2-(3-morpholin-4-yl-propylamino)- pyrimidin-4-yl]-1H-imidazol-2-yl}- [1,3]dioxan-5-yl)-methanol, trans-isomer, (Compound A180); 3-{4-[5- (4-fluoro-phenyl)-2-(5-hydroxymethyl- [1,3]dioxan-2-yl)-3H-imidazol-4-yl]-pyrimidin-2- ylamino}-propan-1-ol, trans-isomer, (Compound A181); {2-[5-(2-benzylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H- imidazol-2-yl]-[1,3]dioxan-5-yl}- methanol, trans-isomer, (Compound A182);

{2-[5-(2-(4-fluorobenzyl)amino-pyrimidin-4-yl)-4-(4-fluoro-p henyl)-1H-imidazol-2-yl]- [1,3]dioxan-5-yl)-methanol, trans-isomer, (Compound A183); {2-[5-(2-(4-methoxybenzyl)amino-pyrimidin-4-yl)-4-(4-fluoro- phenyl)-1H-imidazol-2-yl]- [1,3jdioxan-5-yl)-methanol, trans-isomer, (Compound A184); (2-{4-(4-fluoro-phenyl)-5-[2-(1-phenyl-ethylamino)-pyrimidin -4-yl]-lH-imidazol-2-yl}- [1,3]dioxan-5-yl)-methanol, R isomer, trans-isomer, (Compound A185); (2-{4-(4-fluoro-phenyl)-5-[2-(1-phenyl-ethylamino)-pyrimidin -4-yl]-1H-imidazol-2-yl}- [1,3]dioxan-5-yl)-methanol, S isomer, trans-isomer, (Compound A186); <BR> <BR> <BR> (2-[4-(4-fluoro-phenyl)-5-(2-phenylamino-pyrimidin-4-yl)-111 -imidazol-2-yl]-[1,3]dioxan-5-yl} methanol, trans-isomer, (Compound A187); {2-[4-(4-fluoro-phenyl)-5-(2-(4-fluorophenyl)amino-pyrimidin -4-yl)-1H-imidazol-2-yl]- [1,3]dioxan-5-yl )-methanol, trans-isomer, (Compound A188); {2-[4-(4-fluoro-phenyl)-5-(2-(3,4-difluorophenyl)amino-pyrim idin-4-yl)-1H-imidazol-2-yl]- [1,3]dioxan-5-yl}-methanol, trans-isomer, (Compound A189); {2-[4-(4-fluoro-phenyl)-5-(2-(4-methoxyphenyl)amino-pyrimidi n-4-yl)-1H-imidazol-2-yl]- [1,3]dioxan-5-yl}-methanol, trans-isomer, (Compound A190); <BR> <BR> <BR> {2-[4-(4-fluoro-phenyl)-5-(2-piperidin-1-yl-pyrimidin-4-yl)- lH-imidazol-2-yl]-[1,3]dioxan-5-yl}- methanol, trans-isomer, (Compound A191); [2-(4-(4-fluoro-phenyl)-5-{2-[(pyridin-4-ylmethyl)amino]-pyr imidin-4-yl}-1H-imidazol-2-yl)- [1,3]dioxan-5-yl]-methanol, trans-isomer, (Compound A192); [2-(4-(4-fluoro-phenyl)-5-(2-[(pyridin-3-ylmethyl)-amino]-py rimidin-4-yl )-111-imidazol-2-yl) [1,3]dioxan-5-yl]-methanol, trans-isomer, (Compound A193); [2-(4-(4-fluoro-phenyl)-5-{2-[(pyridin-2-ylmethyl)amino]-pyr imidin-4-yl}-1H-imidazol-2-yl)- [1,3]dioxan-5-yl]-methanol, trans-isomer, (Compound A194); [2-(4-(4-fluoro-phenyl)-5-{2- [(furan-2-ylmethyl)-amino]-pyrimidin-4-yl }- lH-imidazol-2-yl)- [1,3]dioxan-5-yl]-methanol, trans-isomer, (Compound A195); [2-(4-(4-fluoro-phenyl)-5-{2-[(thiophen-2-ylmethyl)amino]-py rimidin-4-yl}-1H-imidazol-2-yl)- [1,3]dioxan-5-yl]-methanol, trans-isomer, (Compound A196); [2-(4-(4-fluoro-phenyl)-5-{2-[(tetrahydro-furan-2-ylmethyl)- amino]-pyrimidin-4-yl}-1H- imidazol-2-yl)-[1,3]dioxan-5-yl]-methanol, trans-isomer, (Compound A197); (2-{4-(4-fluoro-phenyl)-5-[2-(4-methyl-piperazin-1-yl)-pyrim idin-4-yl]-1H-imidazol-2-yl}- [1,3]dioxan-5-yl)-methanol, trans-isomer, (Compound A198); {2-[4-(4-fluoro-phenyl)-5-(2-morpholin-4-yl-pyrimidin-4-yl)- 1H-imidazol-2-yl]-[1,3]dioxan-5-yl}- methanol, trans-isomer, (Compound A199); (2-{4-(4-fluoro-phenyl)-5-[2-(3-methoxy-propylamino)-pyrimid in-4-yl]-1H-imidazol-2-yl}- [1,3]dioxan-5-yl)-methanol, trans-isomer, (Compound A200);

(2-{4-(4-fluoro-phenyl)-5-[2-(2-methoxy-ethylamino)-pyrimidi n-4-yl]-1H-imidazol-2-yl}- [1,3]dioxan-5-yl)-methanol, trans-isomer, (Compound A201); <BR> <BR> <BR> {2-[5-[2-(3-dimethylamino-propylamino)-pyrimidin-4-yl]-4-(4- fluoro-phenyl)-lH-imidazol-2-yl]- [1,3]dioxan-5-yl}-methanol, trans-isomer, (Compound A202); {2-[5-[2-(2-dimethylamino-ethylamino)-pyrimidin-4-yl]-4-(4-f luoro-phenyl)-1H-imidazol-2-yl]- [1,3]dioxan-5-yl}-methanol, trans-isomer, (Compound A203); (4-[5- (4-fluoro-phenyl) -2-(5-hydroxymethyl -[1,3]dioxan-2-yl) -3H-imidazol-4-yl]-pyrimidin-2- ylamino}-acetic acid, trans-isomer, (Compound A204); <BR> <BR> <BR> 3-{4-[5-(4-fluoro-phenyl)-2-(5-hydroxymethyl-[1,3]dioxan-2-y l)-3H-imidazol-4-yl]-pyrimidin-2- ylamino}-propionic acid, trans-isomer, (Compound A205); {2-[4-(4-fluoro-phenyl)-5-(2-isopropylamino-pyrimidin-4-yl)- 1H-imidazol-2-yl]-[1,3]dioxan-5-yl}- methanol, trans-isomer, (Compound A206); {2-[5-(2-allylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-lH-i midazol-2-yl]-[1,3]dioxan-5-yl}- methanol, trans-isomer, (Compound A207); (2-[5-[2-(isopropylmethyl-amino)-pyrimidin-4-yl]-4-(4.fluoro -phenyl)-111-imidazol-2-yl]- [1,3]dioxan-5-yl}-methanol, trans-isomer, (Compound A208); {4-[5-(4-fluoro-phenyl)-2-(5-hydroxymethyl-[1,3]dioxan-2-yl) -3H-imidazol-4-yl]-pyrimidin-2- ylamino)-acetonitrile, trans-isomer, (Compound A209); <BR> <BR> <BR> 3-(4-[5-(4-fluoro-phenyl)-2-(5-hydroxymethyl-[1,3]dioxan-2-y l)-3H-imidazol-4-yl].pyrimidin-2- ylamino}-propionitrile, trans-isomer, (Compound A210); (2-{4-(4-fluoro-phenyl)-5-[2-(pyridin-3-ylamino)-pyrimidin-4 -yl]-1H-imidazol-2-yl}-[1,3]dioxan- 5-yl)-methanol, trans-isomer, (Compound A211); <BR> <BR> <BR> <BR> (2-{4-(4-fluoro-phenyl)-5-[2-(pyridin-4-ylamino)-pyrimidin-4 -yl]-1H-imidazol-2-yl)-[1,3]dioxan 5-yl)-methanol, trans-isomer, (Compound A212); 2-{4-[5-(4-fluoro-phenyl)-2-(5-hydroxymethyl-[1,3]dioxan-2-y l)-3H-imidazol-4-yl]-pyrimidin-2- ylamino}-acetamide, trans-isomer, (Compound A213); 3-{4-[5-(4-fluoro-phenyl)-2-(5-hydroxymethyl-[1,3]dioxan-2-y l)-3H-imidazol-4-yl]-pyrimidin-2- ylaminol-propionamide, trans-isomer, (Compound A214); <BR> <BR> <BR> {2-[4-(4-fluoro-phenyl)-5-(2-propylamino-pyrimidin-4-yl)-1H- imidazol-2-yl]-[1,3]dioxan-5-yl) methanol., trans-isomer, (Compound A215); (l) By proceeding in a similar manner to Example 23 (k) but using (2-[4-(4-fluoro-phenyl)-5- (2-methylsulphonyl-pyrimidin-4-yl)-1H-imidazol-2-yl]-[1,3]di oxan-5-yl}-methanol, cis-isomer, (Compound KO) there are prepared the corresponding cis-isomers of Compounds A171 to A215.

EXAMPLE 24 Compounds IP to IW (a) A stirred solution of (2-[4-(4-fluoro-phenyl)-5-(2-methanesulphonylpyrimidin-4-yl) -111- imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-morpholin-4-yl-met hanone, trans isomer, (1 equivalent, Compound KB) and an appropriately substituted alcohol or phenol [5 equivalents, see table 8] in dry dimethylformamide, at room temperature, was treated with sodium hydride [6 equivalents]. After stirring for 16 hours the reaction mixture was evaporated and the residue partitioned between water and ethyl acetate. The organic phase was evaporated to give Compounds IP to IW depicted in Table 8. The RF values indicated in Table 8 were determined using a mixture of ethyl acetate and methanol (9:1, v/v) as eluant [the eluant for Compound IT was a mixture of ethyl acetate and methanol (1:1, v/v)].

TABLE 8 STRUCTURE R170H RF MOLECULAR MH+ and FORMULA (Intensity) Compound number sO 0.37 C24H26FN505 484 NAN H (100%) 9 /8 WNC HO Compound IP ® 0.45 C30H30FN505 560 W N4N H (100%) N O A C HO X O Compound IQ 0.41 C29H28FN505 546 | ~ m to H N H HO ~ Corn oundIR 0.28 C26H30FN5O6 528 l (100%) H Ro/\/ r4 O Compound IS 0.19 C271133FN6O5 541 l 0.19 , Compound IT Compound IT 0 0.43 C29H34FN505 552 -o (loo) F ® Corn oundlU l 0.43 C26H30FN505 512 tO H (100%) H N H o- ""u >h Compound IW (b) By proceeding in the same manner to Example 24 (a) there are prepared Compounds A216 to A219. <BR> <BR> <BR> <BR> <BR> <BR> <BR> <BR> <BR> <BR> <BR> <P>(2-[4-(4-fluoro-phenyl)-5-(2-hydroxypyrimidin-4-yl) -1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5- yl)-morpholin-4-yl-methanone, trans-isomer, (Compound A216); <BR> <BR> <BR> (2-[4-(4-fluoro-phenyl)-5-(2-propoxy-pyrimidin-4-yl)-1H-imid azol-2-yl]-5-methyl-[1,3]dioxan-5- yl}-morpholin-4-yl-methanone, trans-isomer, (Compound A217); (2-{4-(4-fluoro-phenyl)-5-[2-(2-hydroxy-ethoxy)-pyrimidin-4- yl]-1H-imidazol-2-yl}-5-methyl- [1,3]dioxan-5-yl)-morpholin-4-yl-methanone, trans-isomer, (Compound A218); (2-{4-(4-fluoro-phenyl)-5-[2-(3-hydroxy-propoxy)-pyrimidin-4 -yl]-1H-imidazol-2-yl}-5-methyl- [1,3]dioxan-5-yl)-morpholin-4-yl-methanone, trans-isomer, (Compound A219);

(c) By proceeding in a similar manner to Example 24 (a) but using 2-[4-(4-fluoro-phenyl)-5- (2-methylsulphonylpyrimidin-4-yl)-lH-imidazol-2-yl]-5,5-dime thyl-[1,3]dioxane (Compound KI) there were prepared Compounds IV to JE in Table 8a.

TABLE 8a Xo HOz 11.44 C20H21FN403 386 HtN N o )< Compound IY HO 13.40 C26H25FN403 461 N H O W (100%) , f N o Compound IZ ®iO /+8 13.15 C25H23FN403 (10o%) NtN H ,NI O- F Compound JA oi \ 11.08 C22H25FN404 to e N O 9/ Compound JB .60 C231128FN5O3 442 one he \ 9.60 HO'N'N (100%) o H Corn oundjC

Oso he X 13.52 C25H29FN403 (14003%) t WNvOno r N OS Compound JD o ""-r 12.14 C22H25FN403 413 N4N H W N Ono Compound oundJE (d) By proceeding in the same manner to Example 24 (c) there are prepared Compounds A220 to A222.

4-[2-(5,5-dimethyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)-3H- imidazol-4-yl]-2-propoxy- pyrimidine, (Compound A220); 2-{4-[2-(5,5-dimethyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)- 3H-imidazol-4-yl]-pyrimidin-2- yloxy}-ethanol, (Compound A221); 3-{4-[2-(5,5-dimethyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)- 3H-imidazol-4-yl]-pyrimidin-2- yloxy)-propan-1-ol, (Compound A222); (e) By proceeding in a similar manner to Example 24 (a) but using {2-[5-(2-methanesulphonyl-pyrimidin-4-yl)-4-(4-fluoro-phenyl )-1H-imidazol-2-yl]-5-methyl- [1,3]dioxan-5-yl)-methanol, trans-isomer, (Compound KJ) there are prepared Compounds A223 to A232:- {2-[4-(4-fluoro-phenyl)-5-(2-methoxy-pyrimidin-4-yl)-1H-imid azol-2-yl]-5-methyl-[1,3]dioxan-5- yl)-methanol, trans-isomers, trans-isomer, (Compound A223); {2-[5-(2-benzyloxy-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-im idazol-2-yl]-5-methyl-[1,3]dioxan- 5-yl)-methanol, trans-isomer, (Compound A224); {2-[4-(4-fluoro-phenyl)-5-(2-phenoxy-pyrimidin-4-yl)-1H-imid azol-2-yl]-5-methyl-[1,3]dioxan-5- yl)-methanol, trans-isomer, (Compound A225); (2-{4-(4-fluoro-phenyl)-5-[2-(2-methoxy-ethoxy)-pyrimidin-4- yl]-1H-imidazol-2-yl}-5-methyl- [1,3]dioxan-5-yl)-methanol, trans-isomer, (Compound A226);

(2-[5-[2-(2-dimethyiamino-ethoxy)-pyrimidin-4-yl]-4-(4-fluor o-phenyl)- lH-imidazol-2-yl]-5- methyl-[1,3]dioxan-5-yl)-methanol, trans-isomer, (Compound A227); {2-[5-(2-cyclohexyloxy-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1 H-imidazol-2-yl]-5-methyl- [1,3]dioxan-5-yl}-methanol, trans-isomer, (Compound A228); (2-[5-(2-isopropoxy-pyrimidin-4-yl)-4-(4-fluoro-phenyl) 1H-imidazol-2-yl]-5-methyl-[1,3]dioxan- 5-yl}-methanol, trans-isomer, (Compound A229); {2-[4-(4-fluoro-phenyl-5-(2-propoxy-pyrimidin-4-yl)-1H-imida zol-2-yl]-5-methyl-[1,3]dioxan-5- yl}-methanol, trans-isomer, (Compound A230); 2-{4-[5-(4-fluoro-phenyl)-2-(5-hydroxymethyl-5-methyl-[1,3]d ioxan-2-yl)-3H-imidazol-4-yl]- pyrimidin-2-yloxy}-ethanol, trans-isomer, (Compound A231); 3-(4-[5-(4-fluoro- phenyl)-2-(5- hydroxymethyl-5-methyl- [1,3]dioxan-2-yl)- 3H-imidazol-4-yl]- pyrimidin-2-yloxy)-propan-1-ol., trans-isomer, (Compound A232); (f) By proceeding in a similar manner to Example 24 (e) but using {2-[5-(2-methanesulphonyl-pyrimidin-4-yl)-4-(4-fluoro-phenyl )-1H-imidazol-2-yl]-5-methyl- [1,3]dioxan-5-yl}-methanol, cis-isomer, (Compound KK) there are prepared the corresponding cis-isomers of Compounds A223 to A232.

(g) By proceeding in a similar manner to Example 24 (a) but using {2-[4-(4-fluoro-phenyl)-5- (2-methylsulphonyl-pyrimidin-4-yl)- lH-imidazol-2-yl]-[1,3]dioxan-5-yl}-methanol, trans-isomer, (Compound KN) there are prepared Compounds A233 to A242:- (2-[4-(4-fluoro-phenyl)-5-(2-methoxy-pyrimidin-4-yl)- 1H-imidazol-2-yl]-[ 1,3]dioxan-5-yl)- methanol, trans-isomer, (Compound A233); (2-[5-(2-benzyloxy-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-111-i midazol-2-yl]-[1,3]dioxan-5-yl)- methanol, trans-isomer, (Compound A234); {2-[4-(4-fluoro-phenyl)-5-(2-phenoxy-pyrimidin-4-yl)-1H-imid azol-2-yl]-[1,3]dioxan-5-yl}- methanol, trans-isomer, (Compound A235); (2-{4-(4-fluoro-phenyl)-5-[2-(2-methoxy-ethoxy)-pyrimidin-4- yl]-1H-imidazol-2-yl}-[1,3]dioxan- 5-yl)-methanol, trans-isomer, (Compound A236); {2-[5-[2-(2-dimethylamino-ethoxy)-pyrimidin-4-yl]-4-(4-fluor o-phenyl)-1H-imidazol-2-yl]- [1,3]dioxan-5-yl i-methanol, trans-isomer, (Compound A237); {2-[5-(2-cyclohexyloxy-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1 H-imidazol-2-yl]-[1,3]dioxan-5-yl}- methanol, trans-isomer, (Compound A238); {2-[5-(2-isopropoxy-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-i midazol-2-yl]-[1,3]dioxan-5-yl}- methanol, trans-isomer, (Compound A239);

(2-[4-(4-fluoro-phenyl)-5-(2-propoxy-pyrimidin-4-yl)- 111-imidazol-2-yl]-[1,3]dioxan-5-yl}- methanol, trans-isomer, (Compound A240); <BR> <BR> <BR> 2-{4-[5-(4-fluoro-phenyl)-2-(5-hydroxymethyl-[1,3]dioxan-2-y l)-3H-imidazol-4-yl]-pyrimidin-2- yloxy)-ethanol, trans-isomer, (Compound A241); <BR> <BR> <BR> 3-{4-[5-(4-fluoro-phenyl)-2-(5-hydroxymethyl-[1,3]dioxan-2-y l)-311-imidazol-4-yl]-pyrimidin-2- yloxy}-propan-1-ol, trans-isomer, (Compound A242); (h) By proceeding in a similar manner to Example 24 (g) but using (2-[4-(4-fluoro-phenyl) 5-(2-methylsulphonyl-pyrimidin-4-yl)-111-imidazol-2-yl]-[1,3 ]dioxan-5-yl)-methanol, cis-isomer, (Compound KO) there are prepared the corresponding cis-isomers of Compounds A233 to A242.

(i) By proceeding in a similar manner to Example 24 (a) but using 4-[5-(4-fluoro-phenyl)-2- (5-methylene-[1,3]dioxan-2-yl)-3H-imidazol-4-yl]-2-methylSul phonyl-pyrimidine (Compound KL) there are prepared Compounds A243 to A252:- 4-[5-(4-fluoro-phenyl)-2-(5-methylene-[1,3]dioxan-2-yl)-3H-i midazol-4-yl]-2-methoxy- pyrimidine, (Compound A243); 2-benzyloxy-4-[5-(4-fluoro-phenyl)-2-(5-methylene-[1,3]dioxa n-2-yl)-3H-imidazol-4-yl]- pyrimidine, (Compound A244); 4-[5-(4-fluoro-phenyl)-2-(5-methylene-[1,3]dioxan-2-yl)-3H-i midazol-4-yl]-2-phenoxy- pyrimidine, (Compound A245); 4-[5-(4-fluoro-phenyl)-2-(5-methylene- [1,3]dioxan-2-yl)-3H-imidazol-4-yl]-2-(2-methoxy-ethoxy)- pyrimidine, (Compound A246); (2-(4-[5-(4-fluoro-phenyl)-2-(5-methylene-[1,3]dioxan-2-yl)- 3H-imidazol-4-yl]-pyrimidin-2- yloxy)-ethyl)-dimethyl-amine, (Compound A247); 2-cyclohexyloxy-4-[5-(4-fluoro-phenyl)-2-(5-methylene-[1,3]d ioxan-2-yl)-3H-imidazol-4-yl]- pyrimidine, (Compound A248); 2-cyclopropoxy-4-[5-(4-fluoro-phenyl)-2-(5-methylene-[1,3]di oxan-2-yl)-3H-imidazol-4-yl]- pyrimidine, (Compound A249); 4-[5-(4-fluoro-phenyl)-2-(5-methylene-[1,3]dioxan-2-yl)-3H-i midazol-4-yl]-2-propoxy-pyrimidine, (Compound A250); 2-{4-[5-(4-fluoro-phenyl)-2-(5-methylene-[1,3]dioxan-2-yl)-3 H-imidazol-4-yl]-pyrimidin-2-yloxy}- ethanol, (Compound A251); 3-{4-[5-(4-fluoro-phenyl)-2-(5-methylene-[1,3]dioxan-2-yl)-3 H-imidazol-4-yl]-pyrimidin-2-yloxy}- propan-1-ol, (Compound A252);

(j) By proceeding in a similar manner to Example 24 (a) but using 4-[2-[1,3]dioxan-2-yl-5-(4- fluoro-phenyl)-3H-imidazol-4-yl]-2-methylsulphonyl-pyrimidin e (Compound KM) there are prepared Compounds A253 to A262:- 4-[2-[1,3]dioxan-2-yl-5-(4-fluoro-phenyl)-311-imidazol-4-yl] -2-methoxy-pyrimidine, (Compound A253); 2-benzyloxy-4-[2-[1,3]dioxan-2-yl-5-(4-fluoro-phenyl)-311-im idazol-4-yl]-pyrimidine, (Compound A254); 4-[2-[1,3]dioxan-2-yl-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]- 2-phenoxy-pyrimidine, (Compound A255); <BR> <BR> <BR> <BR> 4-[2-[1,3]dioxan-2-yl-5-(4-fluoro-phenyl)-311-imidazol-4-yl] -2-(2-methoxy-ethoxy)-pyrimidine, (Compound A256); (2-{4-[2-[1,3]dioxan-2-yl-5-(4-fluoro-phenyl)-3H-imidazol-4- yl]-pyrimidin-2-yloxy}-ethyl)- dimethyl-amine, (Compound A257); 2-cyclohexyioxy-4.[2-[1,3]dioxan-2-yl-5-(4-fluoro-phenyl)-3H -imidazol-4-yl]-pyrimidine, (Compound A258); 2-isopropyloxy-4-[2-[1,3]dioxan-2-yl-5-(4-fluoro-phenyl)-311 -imidazol-4-yl]-pyrimidine, (Compound A259); 4-[2-[1,3]dioxan-2-yl-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]- 2-propoxy-pyrimidine, (Compound A260); 2-{4-[2-[1,3]dioxan.2-yl-5-(4-fluoro-phenyl)-311-imidazol-4- yl]-pyrimidin-2-yloxy)-ethanol, (Compound A261); 3-{4-[2-[1,3]dioxan-2-yl-5-(4-fluoro-phenyl)-3H-imidazol-4-y l]-pyrimidin-2-yloxy}-propan-1-ol, (Compound A262); EXAMPLE 25 Compounds JF to KG (a) A solution of 2,2,2-trifluoro-N-[2-{4-(4-fluoro-phenyl)-5-(2-methanesulpho nylpyrimidin- 4-yl)- lH-imidazol-2-yl }-5-methyl-[1,3]dioxan-5-yl]acetamide, cis-isomer, (1 equivalent, Compound KP) and an appropriately substituted amine of formula HNY4Y5 [5 equivalents, see Table 9] in dry dimethylformamide was heated at 100"C for 8 hours (or in the case of JF reacted without a solvent in a pressure vessel). The reaction mixture was then treated with aqueous potassium carbonate solution (2 equivalents) and then heated at 1000C for 24 hours. The mixture was partitioned between water and dichloromethane. The organic phase was separated, evaporated and the residue subjected to high pressure liquid chromatography, on a C18 Dynamax 60A column using gradient elution with a mixture of acetonitrile and water as the mobile phase (0-3 minutes 20% acetonitrile; 2-15 minutes ramp up to 80% acetonitrile; 16 minutes to end of run 80% acetonitrile) and UV detection at 254nm, to give Compounds JF to KG depicted in Table 9. The RT values indicated in Table 9 refer to the high pressure liquid chromatography retention times determined as described above.

TABLE9 STRUCTURE RT MOLECULAR MH+ and HNY4Y5 (minutes) FORMULA (Intensity) EXAMPLE NUMBER NH NH3 11.41 C18H19FN602 371 N H (100%) 0-C NH, /N O -N o Compound JF HN' 11.65 C19H21FN602 385 N 4 N H H2N (100 % ) ,Ej ONH, XN O F Compound JG N N / / 11.85 C20H23FN602 399 HN (100 46) nun N o 7,NH, P NH H2NX 12.10 C21H23FN602 (1>401 CompoundJH V H,N-a 12.10 C21H23FN602 411 Compound N,, H2 2.70 C231128FN7O2 Corn ound JI N / \ 2.70 C23H28FN702 454 H2NNH (100%) NH N4N H 1Now2 F)NO Compound JJ

10.91 C24H29FN602 453 WJ H2Nt 10.91 H,N--(3 (100%) NH H XN N,H2 F Compound JK HO H N~OH 10.30 C20H23FN603 415 2 2 (100%) 9 H "" Compound JL ";'"2 H2N~NH2 1.96 C20H24FN702 (104014%) H,N N4N H I! ,Ei O NH, ~ N O FY2WNH2 Corn ound JM NoN H2NNn 1.98 C24H27FN802 479 (100%) NH .Ej ONH, Compound JN Corn ound JN O 1 H2N~N) 2.02 C25H32FN703 498 Ck CO (100%) NH NN H Compound JO Compound oundJO HO H2NOH 10.40 C21H25FN602 (100%) 7 N N H F/0/-N O- F Compound JP Ph=NH H2Nvph 10.18 C25H25FN602 1 461 (100%) NN H N O Compound JQ Ph Ph 10.91 C26H27FN602 475 NH H,N- (100%) H 0 NH, < NHO >* NH2 N O F Compound JR Ph H NatPh 10.91 C26H27FN602 475 5 (100%) N4N H NH, nf N O F Compound JS 0 11.01 C24H23FN602 447 S H2NX (100 % ) NH N H NH, N O F Compound JT Q HN3 13.15 C23H27FN602 439 (loo) H ,Fj 01 NH? 9 tN (100%) INH N4N H O1*NH' m N O Compound JV 9 2.14 C24H24FN702 462 Nt N J (100%) NH N4N H Lt F NH2 Compound JW H ,Njl 1.96 C24H24FN702 462 ""l (loo o) N4N H I! , o 7,Nr ef N O Fw Compound JX 0 H N(OM 11.93 C23H23FN603 451 II 11 (100%) 7 N4N H W NHO NH2 [f N O F)N Compound JY H2N H,N"ri" 12.10 C23H23FN602S ~11 (100%) AH N O- NH, ~N O Fw Compound JZ Co H,"l 12.44 C23H27FN603 455 (loo) WS Nv~ ) NH2 ef N O Fw ComPound KA 1 . 2.10 C231128FN7O2 454 /N\ HN N- (100%) tN) \ (100 % ) tN N4N H Ej 0 7t Nr yN O Compound KB 12.20 ' r\ 12.20 C22H25FN603 441 (100%) HN 0 (100%) N NwO H N 2 Ej O r NH, I N O FI Compound KC I H,N'""o' 11.10 C22H27FN603 443 O, (loo) 7 N O Compound KE oN H2NIN 2.02 C23H30FN702 456 (100%) tNH N N H ,[N O)NH Compound KF I l 2.04 C22H28FN702 442 H2NN (100%) N 4 N H ,Ei 0 -- NH, ®c,.N,H2 F Corn oundKG

(b) By proceeding in the same manner Example 25 (a) there are prepared Compounds A263 to A280. <BR> <BR> <BR> <BR> <BR> <BR> <P>{4-[2-(5-amino-5-methyl-[1,3]dioxan-2-yl)-5-(4-fluo ro-phenyl)-311-imidazol-4-yl]-pyrimidin-2- ylamino}-acetic acid, cis-isomer, (Compound A263); <BR> <BR> <BR> <BR> 3-{4-[2-(5-amino-5-methyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phen yl)-3H-imidazol-4-yl]-pyrimidin-2- ylamino}-propionic acid, cis-isomer, (Compound A264); <BR> <BR> <BR> <BR> {4-[2-(5-amino-5-methyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl )-311-imidazol-4-yl]-pyrimidin-2- yl}-isopropyl-amine, cis-isomer, (Compound A265); <BR> <BR> <BR> <BR> allyl-{4-[2-(5-amino-5-methyl-[1,3]dioxan-2-yl)-5-(4-fluoro- phenyl)-311-imidazol-4-yl]-pyrimidin- 2-yl}-amine, cis-isomer, (Compound A266); <BR> <BR> <BR> <BR> (4-[2-(5-amino-5-methyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl )-3H-imidazol-4-yl]-pyrimidin-2- yl}-cyclopropylmethyl-amine, cis-isomer, (Compound A267); (4-[2-(5-amino-5-methyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl )-311-imidazol-4-yl]-pyrimidin-2 ylamino}-acetonitrile, cis-isomer, (Compound A268); 3-{4-[2-(5-amino-5-methyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phen yl)-3H-imidazol-4-yl]-pyrimidin-2- ylamino}-propionitrile, cis-isomer, (Compound A269); {4-[2-(5-amino-5-methyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl )-3H-imidazol-4-yl]-pyrimidin-2- yl}-pyridin-3-yl-amine, cis-isomer, (Compound A270); {4-[2-(5-amino-5-methyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl )-3H-imidazol-4-yl]-pyrimidin-2- yl)-pyridin-4-yl-amine, cis-isomer, (Compound A271); 2-{4-[2-(5-amino-5-methyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phen yl)-3H-imidazol-4-yl]-pyrimidin-2- ylamino}-acetamide, cis-isomer, (Compound A272); 3-{4-[2-(5-amino-5-methyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phen yl)-3H-imidazol-4-yl]-pyrimidin-2- ylamino)-propionamide, cis-isomer, (Compound A273); {4-[2-(5-amino-5-methyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl )-3H-imidazol-4-yl]-pyrimidin-2- yl}-propyl-amine, cis-isomer, (Compound A274); 2-[4-(4-fluoro-phenyl)-5-(2-pyrrolidin- 1-yl-pyrimidin-4-yl)-lH-imidazol-2-yl]-5-methyl- [1,3]dioxan-5-ylamine, cis-isomer, (Compound A275); <BR> <BR> <BR> <BR> (4-[2-(5-amino-5-methyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl )-311-imidazol-4-yl]-pyrimidin-2- yl}-(4-fluorobenzyl)-amine, cis-isomer, (Compound A276); {4-[2-(5-amino-5-methyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl )-3H-imidazol-4-yl]-pyrimidin-2- yl}-(4-methoxybenzyl)-amine, cis-isomer, (Compound A277); <BR> <BR> <BR> <BR> (4-[2-(5-amino-5-methyI-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl )-3H-imidazol-4-yl]-pyrimidin2 yl}-(4-fluorophenyl)-amine, cis-isomer, (Compound A278);

{4- [2-(5- amino- 5- methyl- [1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-pyri midin-2- yl}-(3,4-difluorophenyl)-amine, cis-isomer, (Compound A279); <BR> <BR> <BR> <BR> {4-[2-(5-amino-5-methyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl )-3H-imidazol-4-yl]-pyrimidin-2- yl)-(4-methoxyphenyl)-amine, cis-isomer, (Compound A280); (c) By proceeding in a similar manner to Example 25 (a) but replacing the amine with a single equivalent of the sodium salt of an appropriately substituted alcohol or phenol there are prepared Compounds A281 to A290. <BR> <BR> <BR> <BR> <BR> <BR> <P>2-[4-(4-fluoro-phenyl)-5-(2-methoxy-pyrimidin-4-yl) -111-imidazol-2-yl]-5-methyl-[1,3]dioxan-5- ylamine, cis-isomer, (Compound A281); <BR> <BR> <BR> <BR> 2-[5-(2-benzyloxy-pyrimidin-4-yl)-4-(4-fluoro-phenyl)- 1H-imidazol-2-yl]-5-methyl- [1,3]dioxan-5- ylamine, cis-isomer, (Compound A282); <BR> <BR> <BR> 2.[4-(4-fluoro-phenyl)-5-(2-phenoxy-pyrirnidin-4.yl)-111-imi dazol-2-yl]-5-methyl-[1,3]dioxan-5- ylamine, cis-isomer, (Compound A283); 2-{4-(4-fluoro-phenyl)-5-[2-(2-methoxy-ethoxy)-pyrimidin-4-y l]-1H-imidazol-2-yl}-5-methyl- [1,3]dioxan-5-ylamine, cis-isomer, (Compound A284); 2-[5-[2-(2-dimethylamino-ethoxy)-pyrimidin-4-yl]-4-(4-fluoro -phenyl)-1H-imidazol-2-yl]-5- methyl-[1,3]dioxan-5-ylamine, cis-isomer, (Compound A285); 2-[5-(2-cyclohexyloxy-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H -imidazol-2-yl]-5-methyl- [1,3]dioxan-5-ylamine, cis-isomer, (Compound A286); 2-[5-(2-lsolopropoxy-pyrimidin-4-yl)-4-(4-fluoro-phenyl)- lH-imidazol-2-yl]-5-methyl- [1,3]dioxan-5-ylamine , cis-isomer, (Compound A287); 2-[4-(4-fluoro-phenyl)-5-(2-propoxy-pyrimidin-4-yl)-1H-imida zol-2-yl]-5-methyl-[1,3]dioxan-5- ylamine, cis-isomer, (Compound A288); 2-{4-[2-(5-amino-5-methyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phen yl)-3H-imidazol-4-yl]-pyrimidin-2- yloxy}-ethanol, cis-isomer, (Compound A289); <BR> <BR> <BR> <BR> 3-{4-[2-(5-amino-5-methyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phen yl)-311-imidazol-4-yl]-pyrimidin-2 yloxy)-propan-l-ol, cis-isomer, (Compound A290); (d) By proceeding in a similar manner to Example 25 (a) but using 2,2,2-trifluoro-N-{2-[5-(2- methylsulphonyl-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imida zol-2-yl]-5-methyl-[1,3]dioxan-5- ylmethyl)-acetamide, trans isomer (Compound LL) there are prepared Compounds A291 to A337.

4-[2-(5-aminomethyl-5-methyl-[1,3]dioxan-2-yl)-5-(4-fluoro-p henyl)-3H-imidazol-4-yl]- pyrimidin-2-ylamine, trans-isomer, (Compound A291); {4-[2-(5-aminomethyl-5-methyl-[1,3]dioxan-2-yl)-5-(4-fluoro- phenyl)-3H-imidazol-4-yl]- pyrimidin-2-yl )-methyl-amine, trans-isomer, (Compound A292); {4-[2-(5-aminomethyl-5-methyl-[1,3]dioxan-2-yl)-5-(4-fluoro- phenyl)-3H-imidazol-4-yl]- pyrimidin-2-yl)-dimethyl-amine, trans-isomer, (Compound A293); {4-[2-(5-aminomethyl-5-methyl-[1,3]dioxan-2-yl)-5-(4-fluoro- phenyl)-311-imidazol-4-yl]- pyrimidin-2-yl)-cyclopropyl-amine, trans-isomer, (Compound A294); {4-[2-(5-aminomethyl-5-methyl-[1,3]dioxan-2-yl)-5-(4-fluoro- phenyl)-3H-imidazol-4-yl]- pyrimidin-2-yl)-piperidin-4-yl-amine, trans-isomer, (Compound A295); {4-[2-(5-aminomethyl-5-methyl-[1,3]dioxan-2-yl)-5-(4-fluoro- phenyl)-311-imidazol-4-yl]- pyrimidin-2-yl)-cyclohexyl-amine, trans-isomer, (Compound A296); <BR> <BR> <BR> 2-{4-[2-(5-aminomethyl-5-methyl-[1,3]dioxan-2-yl)-5-(4-fluor o-phenyl)-311-imidazol-4-yl]- pyrimidin-2-ylamino}-ethanol, trans-isomer, (Compound A297); <BR> <BR> <BR> <BR> N1-{4-[2-(5-aminomethyl-5-methyl-[1,3]dioxan-2-yl).5-(4-fluo ro-phenyl)-311-imidazol-4-yl]- pyrimidin-2-yl)-ethane-1,2-diamine, trans-isomer, (Compound A298); {4-[2-(5-aminomethyl-5-methyl-[1,3]dioxan-2-yl)-5-[4-fluoro- phenyl)-3H-imidazol-4-yl]- pyrimidin-2yl)- [3-(SH-imidazol-l -yl)-propyl]-amine, trans-isomer, (Compound A299); {4-[2-(5-aminomethyl-5-methyl-[1,3]dioxan-2-yl)-5-(4-fluoro- phenyl)-3H-imidazol-4-yl]- pyrimidin-2-yl)-(3-morpholin-4-yl-propyl)-amine, trans-isomer, (Compound A300); <BR> <BR> <BR> <BR> 3-(4-[2-(5-aminomethyl-5-methyl-[1,3]dioxan-2-yl)-5-(4-fluor o-phenyl)-311-imidazol-4-yl]- pyrimidin-2-ylamino )-propan- 1-ol, trans-isomer, (Compound A301); {4-[2-(5-aminomethyl-5-methyl-[1,3]dioxan-2-yl)-5-(4-fluoro- phenyl)-3H-imidazol-4-yl]- pyrimidin-2-yl}-benzyl-amine, trans-isomer, (Compound A302); (4-[2-(5-aminomethyl-5-methyl-[1,3]dioxan-2-yl)-5-(4-fluoro- phenyl)-311-imidazol-4-yl]- pyrimidin-2-yl )-(4-fluorobenzyl)-amine , trans-isomer, (Compound A303); {4-[2-(5-arninomethyl-5-methyl-[1,3]dioxan-2-yl)-5-(4-fluoro -phenyl)-311-imidazol-4-yl] pyrimidin-2-yl)-(4-methoxybenzyl)-amine , trans-isomer, (Compound A304); {4-[2-(5-aminomethyl-5-methyl- [1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]- pyrimidin-2-yl}-(1-phenyl-ethyl)-amine, R isomer, trans-isomer, (Compound A305); {4-[2-(5-aminomethyl-5-methyl-[1,3]dioxan-2-yl)-5-(4-fluoro- phenyl)-3H-imidazol-4-yl]- pyrimidin-2-yl)-(1-phenyl-ethyl)-amine, S isomer, trans-isomer, (Compound A306); {4-[2-(5-aminomethyl-5-methyl-[1,3]dioxan-2-yl)-5-(4-fluoro- phenyl)-3H-imidazol-4-yl]- pyrimidin-2-yl)-phenyl-amine, trans-isomer, (Compound A307); {4-[2-(5-aminomethyl-5-methyl-[1,3]dioxan-2-yl)-5-(4-fluoro- phenyl)-3H-imidazol-4-yl]- pyrirnidin-2-yl)-(4-fluorophenyl)-amine , trans-isomer, (Compound A308);

{4-[2-(5-aminomethyl-5-methyl-{1,3]dioxan-2-yl)-5-(4-fluoro- phenyl)-3H-imidazol-4-yl]- pyrimidin-2-yl)-(3,4-difluorophenyl)-amine, trans-isomer, (Compound A309); {4-[2-(5-aminomethyl-5-methyl-[1,3]dioxan-2-yl)-5-(4-fluoro- phenyl)-3H-imidazol-4-yl]- pyrimidin-2-yl)-(3-methoxyphenyl)-amine , trans-isomer, (Compound A310); C-{2-[4-(4-fluoro-phenyl)-5-(2-piperidin- 1-yl-pyrimidin-4-yl)- 1H-imidazol-2-yl]-5-methyl- [1,3]dioxan-5-yl)-methylamine, trans-isomer, (Compound A311); {4-[2-(5-aminomethyl-5-methyl-[1,3]dioxan-2-yl)-5-(4-fluoro- phenyl)-311-imidazol-4-yl]- pyrimidin-2-yl)-pyridin-4-yimethyl-amine, trans-isomer, (Compound A312); {4-[2-(5-aminomethyl-5-methyl-[1,3]dioxan-2-yl)-5-(4-fluoro- phenyl)-3H-imidazol-4-yl]- pyrimidin-2-yl}-pyridin-3-ylmethyl-amine, trans-isomer, (Compound A313); {4-[2-(5-aminomethyl-5-methyl-[1,3]dioxan-2-yl)-5-(4-fluoro- phenyl)-3H-imidazol-4-yl]- pyrimidin-2-yl)-pyridin-2-ylmethyl-amine, trans-isomer, (Compound A314); {4-[2-(5-aminomethyl-5-methyl-[1,3]dioxan-2-yl)-5-(4-fluoro- phenyl)-3H-imidazol-4-yl]- pyrimidin-2-yli-(furan-2-ylmethyl)-amine, trans-isomer, (Compound A315); {4-[2-(5-aminomethyl-5-methyl-[1,3]dioxan-2-yl)-5-(4-fluoro- phenyl)-3H-imidazol-4-yl]- pyrimidin-2-yll-(thiophen-2-ylmethyl)-amine, trans-isomer, (Compound A316); {4-[2-(5-aminomethyl-5-methyl-[1,3]dioxan-2-yl)-5-(4-fluoro- phenyl)-311-imidazol-4-yl]- pyrimidin-2-yl)-(tetrahydro-furan-2-ylmethyl)-amine, trans-isomer, (Compound A317); C-(2-{4-(4-fluoro-phenyl)-5-[2-(4-methyl-piperazin-1-yl)-pyr imidin-4-yl]-1H-imidazol-2-yl}-5- methyl-[1,3]dioxan-5-yl)-methylamine, trans-isomer, (Compound A318); C-{2-[4-(4-fluoro-phenyl)-5-(2-morpholin-4-yl-pyrimidin-4-yl )-1H-imidazol-2-yl]-5-methyl- [1,3]dioxan-5-yl)-methylamine, trans-isomer, (Compound A319); {4-[2-(5-aminomethyl-5-methyl-[1,3]dioxan-2-yl)-5-(4-fluoro- phenyl)-3H-imidazol-4-yl]- pyrimidin-2-yl)-(3-methoxy-propyl)-amine, trans-isomer, (Compound A320); {4-[2-(5-aminomethyl-5-methyl-[1,3]dioxan-2-yl)-5-(4-fluoro- phenyl)-311-imidazol-4-yl]- pyrimidin-2-yl)-(2-methoxy-ethyl)-amine, trans-isomer, (Compound A321); N-{4-[2-(5-aminomethyl-5-methyl-[1,3]dioxan-2-yl)-5-(4-fluor o-phenyl)-3H-imidazol-4-yl] - pyrimidin-2-yl)-N',N'-dimethyl-propane-1,3-diamine, trans-isomer, (Compound A322); N-{4-[2-(5-aminomethyl-5-methyl-[1,3]dioxan-2-yl)-5-(4-fluor o-phenyl)-3H-imidazol-4-yl]- pyrimidin-2-yl}-N',N'-dimethyl-ethane-1,2-diamine, trans-isomer, (Compound A323); {4-[2-(5-aminomethyl-5-methyl-[1,3]dioxan-2-yl)-5-(4-fluoro- phenyl)-3H-imidazol-4-yl]- pyrimidin-2-ylamino)-acetic acid, trans-isomer, (Compound A324); 3-{4-[2-(5-aminomethyl-5-methyl-[1,3]dioxan-2-yl)-5-(4-fluor o-phenyl)-3H-imidazol-4-yl]- pyrimidin-2-ylamino)-propionic acid, trans-isomer, (Compound A325); C-{2-[4-(4-fluoro-phenyl)-5-(2-methylsulfanyl-pyrimidin-4-yl )-1H-imidazol-2-yl]-5-methyl- [1,3]dioxan-5-yl}-methylamine, trans-isomer, (Compound A326);

{4-l2-(5-aminomethyl-5-methyl- [1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]- pyrimidin-2-yl)-isopropyl-amine, trans-isomer, (Compound A327); allyl-{4-[2-(5-aminomethyl-5-methyl-[1,3]dioxan-2-yl)-5-(4-f luoro-phenyl)-311-imidazol-4yl] pyrimidin-2-yl}-amine, trans-isomer, (Compound A328); (4-[2-(5-aminomethyl-5-methyl-[1,3]dioxan-2-yl)-5-(4-fluoro- phenyl)-311-imidazol-4-yl]- pyrimidin-2-yl)-cyclopropylmethyl-amine, trans-isomer, (Compound A329); {4-[2-(5-aminomethyl-5-methyl-[1,3]dioxan-2-yl)-5-(4-fluoro- phenyl)-3H-imidazol-4-yl]- pyrimidin-2-ylaminol-acetonitrile, trans-isomer, (Compound A330); 3-{4-[2-(5-aminomethyl-5-methyl-[1,3]dioxan-2-yl)-5-(4-fluor o-phenyl)-311-imidazol-4-yl]- pyrimidin-2-ylamino)-propionitrile, trans-isomer, (Compound A331); {4-[2-(5-aminomethyl-5-methyl-[1,3]dioxan-2-yl)-5-(4-fluoro- phenyl)-3H-imidazol-4-yl]- pyrimidin-2-yll-pyridin-3-yl-amine, trans-isomer, (Compound A332); {4-[2-(5-aminomethyl-5-methyl-[1,3]dioxan-2-yl)-5-(4-fluoro- phenyl)-311-imidazol-4-yl]- pyrimidin-2-yl)-pyridin-4-yl-amine, trans-isomer, (Compound A333); 2-{4-[2-(5-aminomethyl-5-methyl-[1,3]dioxan-2-yl)-5-(4-fluor o-phenyl)-3H-imidazol-4-yl]- pyrimidin-2-ylamino}-acetamide, trans-isomer, (Compound A334); 3-{4-[2-(5-aminomethyl-5-methyl-[1,3]dioxan-2-yl)-5-(4-fluor o-phenyl)-3H-imidazol-4-yl]- pyrimidin-2-ylamino)-propionamide, trans-isomer, (Compound A335); {4-[2-(5-aminomethyl-5-methyl-[1,3]dioxan-2-yl)-5-(4-fluoro- phenyl)-3H-imidazol-4-yl]- pyrimidin-2-yl)-propyl-amine, trans-isomer, (Compound A336); C-{2-[4-(4-fluoro-phenyl)-5-(2-pyrrolidin-1-yl-pyrimidin-4-y l)-lH-imidazol-2-yl]-5-methyl- [1,3]dioxan-5-yl}-methylamine, trans-isomer, (Compound A337); (e) By proceeding in a similar manner to Example 25 (d) but using 2,2,2-trifluoro-N-(2-[5-(2- methylsulphonyl-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imida zol-2-yl]-5-methyl-[1,3]dioxan-5- ylmethyl)-acetamide, cis isomer (Compound LK) there are prepared the corresponding cis isomers of Compounds A291 to A337.

(f) By proceeding in a similar manner to Example 25 (c) but using 2,2,2-trifluoro-N-(2-[5-(2- methylsulphonyl-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imida zol-2-yl]-5-methyl-[1,3]dioxan-5- ylmethyl)-acetamide, trans isomer (Compound LL) there are prepared Compounds A338 to A347.

C-{2-[4-(4-fluoro-phenyl)-5-(2-methoxy-pyrimidin-4-yl)-1H -imidazol-2-yl]-5-methyl-[1,3]dioxan- 5-yl)-methylamine, trans-isomer, (Compound A338);

C-{2-[5-(2-benzyioxy-pyrimidin-4-yl)-4-(4-fluoro-phenyl)- lH-imidazol-2-yl]-5-methyl- [1,3]dioxan-5-yl)-methylamine, trans-isomer, (Compound A339); <BR> <BR> <BR> C-{2-[4-(4-fluoro-phenyl)-5-(2-phenoxy-pyrimidin-4-yl)-lH-im idazol-2-yl]-5-methyl-[1,3]dioxan- 5-yl}-methylamine, trans-isomer, (Compound A340); <BR> <BR> <BR> C-(2-{4-(4-fluoro-phenyl)-5-[2-(2-methoxy-ethoxy)-pyrimidin- 4-yl]-111-imidazol-2-yll-5-methyl- [1,3]dioxan-5-yl)-methylamine, trans-isomer, (Compound A341); (2-{4-[2-(5-aminomethyl-5-methyl-[1,3]dioxan-2-yl)-5-(4-fluo ro-phenyl)-3H-imidazol-4-yl]- pyrimidin-2-yloxy)-ethyl)-dimethyl-amine, trans-isomer, (Compound A342); C-{2-[5-(2-cyclohexyloxy-pyrimidin-4-yl)-4-(4-fluoro-phenyl) -lH-imidazol-2-yl]-5-methyl- [1,3]dioxan-5-yl)-methylamine, trans-isomer, (Compound A343); C-{2-[5-(2-isopropoxy-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H -imidazol-2-yl]-5-methyl- [1,3]dioxan-5-yl}-methylamine, trans-isomer, (Compound A344); C-{2-[4-(4-fluoro-phenyl)-5-(2-propoxy-pyrimidin-4-yl)-1H-im idazol-2-yl]-5-methyl-[1,3]dioxan- 5-yl)-methylamine, trans-isomer, (Compound A345); 2-{4-[2-(5-aminomethyl-5-methyl-[1,3]dioxan-2-yl)-5-(4-fluor o-phenyl)-3H-imidazol-4-yl]- pyrimidin-2-yloxyi-ethanol, trans-isomer, (Compound A346); 3-{4-[2-(5-aminomethyl-5-methyl-[1,3]dioxan-2-yl)-5-(4-fluor o-phenyl)-311-imidazol-4-yl]- pyrimidin-2-yloxyl-propan-1-ol, trans-isomer, (Compound A347); (g) By proceeding in a similar manner to Example 25 (f) but using 2,2,2-trifluoro-N-(2-[5-(2- methylsulphonyl-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imida zol-2-yl]-5-methyl-[1,3]dioxan-5- ylmethyl}-acetamide, cis isomer, (Compound LK) there are prepared the corresponding cis isomers of Compounds A338 to A347.

EXAMPLE 26 Compounds A348 to A575 (a) (i) Treatment of C-(2-[4-(4-fluoro-phenyl)-5-(2-methylsulphanyl-pyrimidin-4-y l)-111- imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-methylamine, cis-isomer (Compound KZ) with either acetyl chloride, benzoyl chloride, phenylacetyl chloride according to method described in Example 11 or methanesulphonyl chloride according to method described in Example 13; (ii) Treatment of compounds obtained from (i) with m-chloroperbenzoic acid according to method described for Example 27; (iii) Treatment of compounds from (ii) with amines of formula HNY4Y5 or sodium salts of appropriately substituted alcohols or phenols according to methods described in Example 23 or Example 24; gives compounds A348 to A575:-

N-{2-[5-(2-amino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)- lH-imidazol-2-yl]-5-methyl-[1,3]dioxan-5- ylmethyl)-acetamide, cis-isomer, (Compound A348); N-{2-[4-(4-fluoro-phenyl)-5-(2-methylamino-pyrimidin-4-yl)-l H-imidazol-2-yl]-5-methyl- [1,3]dioxan-5-ylmethyl )-acetamide, cis-isomer, (Compound A349); N-{2-[5-(2-dimethylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl) -111-imidazol-2-yl]-5-methyl- [1,3]dioxan-5-ylmethylj-acetamide, cis-isomer, (Compound A350); <BR> <BR> <BR> <BR> N-{2-[5-(2-cyclopropylamino-pyrimidin-4-yl)-4-(4-fluoro-phen yl)-111-imidazol-2-yl]-5-methyl- [1,3]dioxan-5-ylmethyl)-acetamide, cis-isomer, (Compound A351); N-(2-{4-(4-fluoro-phenyl)-5-[2-(piperidin-4-ylamino)-pyrimid in-4-yl]-imidazol-2-yl}-5- methyl-[1,3]dioxan-5-ylmethyl)-acetamide, cis-isomer, (Compound A352); N-{2-[5-(2-cyclohexylamino-pyrimidin-4-yl)-4-(4-fluoro-pheny l)-1H-imidazol-2-yl]-5-methyl- [1,3]dioxan-5-ylmethyl)-acetamide, cis-isomer, (Compound A353); N-(2-{4-(4-fluoro-phenyl)-5-[2-(2-hydroxy-ethylamino)-pyrimi din-4-yl]-1H-imidazol-2-yl}-5- methyl-[1,3]dioxan-5-ylmethyl)-acetamide, cis-isomer, (Compound A354); N-{2-[5-[2-(2-amino-ethylamino)-pyrimidin-4-yl]-4-(4-fluoro- phenyl)-1H-imidazol-2-yl]-5- methyl-[1,3]dioxan-5-ylmethyl)-acetamide, cis-isomer, (Compound A355); N-[2-(4-(4-fluoro-phenyl)-5-{2-[3-(5H-imidazol- 1-yl)-propylamino]-pyrimidin-4-yl )-1H-imidazol- 2-yl)-5-methyl-[1,3]dioxan-5-ylmethyl]-acetamide, cis-isomer, (Compound A356); N-(2-{4-(4-fluoro-phenyl)-5-[2-(3-morpholin-4-yl-propylamino )-pyrimidin-4-yl]-1H-imidazol-2- yl)-5-methyl-[1,3]dioxan-5-ylmethyl)-acetamide, cis-isomer, (Compound A357); N-(2-{4-(4-fluoro-phenyl)-5-[2-(3-hydroxy-propylamino)-pyrim idin-4-yl]-1H-imidazol-2-yl}-5- methyl-[1,3]dioxan-5-ylmethyl)-acetamide, cis-isomer, (Compound A358); N-{2-[5-(2-benzylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1 H-imidazol-2-yl]-5-methyl- [1,3]dioxan-5-ylmethyl}-acetamide, cis-isomer, (Compound A359); N-{2-[5-(2-(4-fluorobenzyl)amino-pyrimidin-4-yl)-4-(4-fluoro -phenyl)-1H-imidazol-2-yl]-5- methyl-[1,3]dioxan-5-ylmethyl)-acetamide, cis-isomer, (Compound A360); N-{2-[5-(2-(4-methoxybenzyl)amino-pyrimidin-4-yl)-4-(4-fluor o-phenyl)-1H-imidazol-2-yl]-5- methyl-[1,3]dioxan-5-ylmethyl)-acetamide cis-isomer, (Compound A361); N-(2-{4-(4-fluoro-phenyl)-5-[2-(1-phenyl-ethylamino)-pyrimid in-4-yl]- 1H-imidazol-2-yl)-5- methyl-[1,3]dioxan-5-ylmethyl)-acetamide, R isomer, cis-isomer, (Compound A362); N-(2-{4-(4-fluoro-phenyl)-5-[2-(1-phenyl-ethylamino)-pyrimid in-4-yl]-imidazol-2-yl}-5- methyl-[1,3]dioxan-5-ylmethyl)-acetamide, S isomer, cis-isomer, (Compound A363); N-{2-[4-(4-fluoro-phenyl)-5-(2-phenylamino-pyrimidin-4-yl)- 1H-imidazol-2-yl]-5-methyl- [1,3]dioxan-5-ylmethyl}-acetamide, cis-isomer, (Compound A364); N-{2-[4-(4-fluoro-phenyl)-5-(2-(4-fluorophenyl)amino-pyrimid in-4-yl)-1H-imidazol-2-yl]-5- methyl- [1,3]dioxan-5-ylmethyl)-acetamide , cis-isomer, (Compound A365);

N-{2-[4-(4-fluoro-phenyl)-5-(2-(3,4-difluorophenyl)amino-pyr imidin-4-yl)-lH-imidazol-2-yl]-5- methyl-[1,3] dioxan-5-ylmethyl)- acetamide , cis-isomer, (Compound A366); N-{2-[4-(4-fluoro-phenyl)-5-(2-(3-methoxyphenyl)amino-pyrimi din-4-yl)-1H-imidazol-2-yl]-5- methyl-[1,3]dioxan-5-ylmethyl)-acetamide, cis-isomer, (Compound A367); N-{2-[4-(4-fluoro-phenyl)-5-(2-piperidin-1-yl-pyrimidin-4-yl )-1H-imidazol-2-yl]-5-methyl- [1,3]dioxan-5-ylmethyl)-acetamide, cis-isomer, (Compound A368); N-[2-(4-(4-fluoro-phenyl)-5-{2-[(pyridin-4-ylmethyl)-amino]- pyrimidin-4-yl}-1H-imidazol-2-yl)- 5-methyl-[1,3]dioxan-5-ylmethyl]-acetamide, cis-isomer, (Compound A369); N-[2-(4-(4-fluoro-phenyl)-5-{2-[(pyridin-3-ylmethyl)-amino]- pyrimidin-4-yl}-1H-imidazol-2-yl)- 5-methyl-[1,3]dioxan-5-ylmethyl]-acetamide, cis-isomer, (Compound A370); N-[2-(4-(4-fluoro-phenyl)-5-{2-[(pyridin-2-ylmethyl)-amino]- pyrimidin-4-yl}-1H-imidazol-2-yl)- 5-methyl-[1,3]dioxan-5-ylmethyl]-acetamide, cis-isomer, (Compound A371); N-[2-(4-(4-fluoro-phenyl)-5-{2-[(furan-2-ylmethyl)-amino]-py rimidin-4-yl )-111-imidazol-2-yl)-5- methyl-[1,3]dioxan-5-ylmethyl]-acetamide, cis-isomer, (Compound A372); N-[2-(4-(4-fluoro-phenyl)-5-{2-[(thiophen-2-ylmethyl)-amino] -pyrimidin-4-yl}-1H-imidazol-2-yl)- 5-methyl-[1,3]dioxan-5-ylmethyl]-acetamide, cis-isomer, (Compound A373); N-[2-(4-(4-fluoro-phenyl)-5-{2-[(tetrahydro-furan-2-ylmethyl )-amino]-pyrimidin-4-yl}-1H- imidazol-2-yl)-5-methyl-[1,3]dioxan-5-ylmethyl]-acetamide, cis-isomer, (Compound A374); N-(2-{4-(4-fluoro-phenyl)-5-[2-(4-methyl-piperazin-1-yl)-pyr imidin-4-yl]-1H-imidazol-2-yl}-5- methyl-[1,3]dioxan-5-ylmethyl)-acetamide, cis-isomer, (Compound A375); N-{2-[4-(4-fluoro-phenyl)-5-(2-morpholin-4-yl-pyrimidin-4-yl )-1H-imidazol-2-yl]-5-methyl- [1,3]dioxan-5-ylmethyl}-acetamide, cis-isomer, (Compound A376); <BR> <BR> <BR> <BR> N-(2-(4-(4-fluoro-phenyi)-5- [2-(3-methoxy-propylamino)-pyrimidin-4-y 1H-imidazol-2-yl )-5- methyl-[1,3]dioxan-5-ylmethyl)-acetamide, cis-isomer, (Compound A377); N-(2-{4-(4-fluoro-phenyl)-5-[2- (2-methoxy-ethylamino)-pyrimidin-4-yl]- 1H-imidazol-2-yl)- 5- methyl-[1,3]dioxan-5-ylmethyl)-acetamide, cis-isomer, (Compound A378); N-{2-[5-[2-(3-dimethylamino-propylamino)-pyrimidin-4-yl]-4-( 4-fluoro-phenyl)-1H-imidazol-2- yl]-5-methyl-[1,3]dioxan-5-ylmethyl )-acetamide, cis-isomer, (Compound A379); N-{2-[5-[2-(2-dimethylamino-ethylamino)-pyrimidin-4-yl]-4-(4 -fluoro-phenyl)-1H-imidazol-2-yl]- 5-methyl-[1,3]dioxan-5-ylmethyl )-acetamide, cis-isomer, (Compound A380); {4-[2-[5-(acetylamino-methyl)-5-methyl-[1,3]dioxan-2-yl]-5-( 4-fluoro-phenyl)-3H-imidazol-4-yl]- pyrimidin-2-ylamino)-acetic acid, cis-isomer, (Compound A381); 3-{4-[2-[5-(acetylamino-methyl)-5-methyl-[1,3]dioxan-2-yl]-5 -(4-fluoro-phenyl)-3H-imidazol-4- yl]-pyrimidin-2-ylamino}-propionic acid, cis-isomer, (Compound A382); N-{2-[4-(4-fluoro-phenyl)-5-(2-methylsulfanyl-pyrimidin-4-yl )-1H-imidazol-2-yl]-5-methyl- [1,3]dioxan-5-ylmethyl}-acetamide, cis-isomer, (Compound A383);

N-{2-[4-(4-fluoro-phenyl)-5-(2-methoxy-pyrimidin-4-yl)- lH-imidazol-2-yl]-5-methyl-[1,3]dioxan- 5-ylmethyl)-acetamide, cis-isomer, (Compound A384); N-{2-[5-(2-benzyloxy-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-lH- imidazol-2-yl]-5-methyl- [1,3]dioxan-5-ylmethyll-acetamide, cis-isomer, (Compound A385); <BR> <BR> <BR> <BR> N-{2-[4-(4-fluoro-phenyl)-5-(2-phenoxy-pyrimidin-4-yl)-lH-im idazol-2-yl] -5-methyl-[1,3]dioxan- 5-ylmethyl)-acetamide, cis-isomer, (Compound A386); N-(2-{4-(4-fluoro-phenyl)-5-[2-(2-methoxy-ethoxy)-pyrimidin- 4-yl]-1H-imidazol-2-yl}-5-methyl- [1,3]dioxan-5-ylmethyl)-acetamide, cis-isomer, (Compound A387); N-{2-[5-[2-(2-dimethylamino-ethoxy)-pyrimidin-4-yl]-4-(4-flu oro-phenyl)-1H-imidazol-2-yl]-5- methyl-[1,3]dioxan-5-ylmethyl)-acetamide, cis-isomer, (Compound A388); N-{2-[5-(2-cyclohexyloxy-pyrimidin-4-yl)-4-(4-fluoro-phenyl) -1H-imidazol-2-yl]-5-methyl- [1,3]dioxan-5-ylmethyl)-acetamide, cis-isomer, (Compound A389); N-{2-[5-(2-Isopropoxy-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H -imidazol-2-yl]-5-methyl- [1,3]dioxan-5-ylmethyl)-acetamide, cis-isomer, (Compound A390); N-{-[4-(4-fluoro-phenyl)-5-(2-isopropylamino-pyrimidin-4-yl) -1H-imidazol-2-yl]-5-methyl- [1,3]dioxan-5-ylmethyl}-acetamide, cis-isomer, (Compound A391); N-{2-[5-(2-allylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H -imidazol-2-yl]-5-methyl- [1,3]dioxan-5-ylmethyl)-acetamide, cis-isomer, (Compound A392); N-{2-[5-[2-(cyclopropylmethyl-amino)-pyrimidin-4-yl]-4-(4-fl uoro-phenyl)-1H-imidazol-2-yl]-5- methyl-[1,3]dioxan-5-ylmethyl)-acetamide, cis-isomer, (Compound A393); N-{2-[5-[2-(cyanomethyl-amino)-pyrimidin-4-yl]-4-(4-fluoro-p henyl)-1H-imidazol-2-yl]-5- methyl-[1,3]dioxan-5-ylmethyl)-acetamide, cis-isomer, (Compound A394); N-{2-[5-[2-(2-cyano-ethylamino)-pyrimidin-4-yl]-4-(4-fluoro- phenyl)-1H-imidazol-2-yl]-5- methyl-[1,3]dioxan-5-ylmethyl}-acetamide, cis-isomer, (Compound A395); N-(2-{4-(4-fluoro-phenyl)-5-[2-(pyridin-3-ylamino)-pyrimidin -4-yl]-1H-imidazol-2-yl}-5-methyl- [1,3]dioxan-5-ylmethyl)-acetamide, cis-isomer, (Compound A396); N(2-{4-(4-fluoro-phenyl)-5-[2-(pyridin-4-ylamino)-pyrimidin- 4-yl]-1H-imidazol-2-yl}-5-methyl- [1,3]dioxan-5-ylmethyl)-acetamide, cis-isomer, (Compound A397); 2-{4-[2-[5-(acetylamino-methyl)-5-methyl-[1,3]dioxan-2-yl]-5 -(4-fluoro-phenyl)-3H-imidazol-4- yl]-pyrimidin-2-ylamino}.acetamide, cis-isomer, (Compound A398); 3-{4-[2-[5-(acetylamino-methyl)-5-methyl-[1,3]dioxan-2-yl]-5 -(4-fluoro-phenyl)-3H-imidazol-4- yl]-pyrimidin-2-ylamino)-propionamide, cis-isomer, (Compound A399); <BR> <BR> <BR> N-{2-[4-(4-fluoro-phenyl)-5-(2-propoxy-pyrimidin-4-yl)-1H-im idazol-2-yl]-5-methyl[1,3]dioxan 5-ylmethyl)-acetamide, cis-isomer, (Compound A400); N-(2-{4-(4-fluoro-phenyl)-5-[2-(2-hydroxy-ethoxy)-pyrimidin- 4-yl]-1H-imidazol-2-yl}-5-methyl- [1,3]dioxan-5-ylmethyl)-acetamide, cis-isomer, (Compound A401);

N-(2-{4-(4-fluoro-phenyl)-5-[2-(3-hydroxy-propoxy)-pyrimidin -4-yl]-1H-imidazol-2-yl}-5-methyl- [1,3]dioxan-5-ylmethyl)-acetamide, cis-isomer, (Compound A402); N-{2-[4-(4-fluoro-phenyl)-5-(2-propylamino-pyrimidin-4-yl)-1 H-imidazol-2-yl]-5-methyl- [1,3]dioxan-5-ylmethyl)-acetamide, cis-isomer, (Compound A403); N-{2-[4-(4-fluoro-phenyl)-5-(2-pyrrolidin-1-yl-pyrimidin-4-y l)-lH-imidazol-2-yl]-5-methyl- [1,3]dioxan-5-ylmethyl)-acetamide, cis-isomer, (Compound A404); N-{2-[5-(2-amino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imid azol-2-yl]-5-methyl-[1,3]dioxan-5- ylmethyl)-methanesulfonamide, cis-isomer, (Compound A405); N-{2-[4-(4-fluoro-phenyl)-5-(2-methylamino-pyrimidin-4-yl)-1 H-imidazol-2-yl]-5-methyl- [1,3]dioxan-5-ylmethyl)-methanesulfonamide, cis-isomer, (Compound A406); N-{2-[5-(2-dimethylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl) -1H-imidazol-2-yl]-5-methyl- [1,3]dioxan-5-ylmethyl i-methanesulfonamide, cis-isomer, (Compound A407); N-{2-[5-(2-cyclopropylamino-pyrimidin-4-yl)-4-(4-fluoro-phen yl)-1H-imidazol-2-yl]-5-methyl- [1,3]dioxan-5-ylmethyl )-methanesulfonamide, cis-isomer, (Compound A408); N-(2-{4-(4-fluoro-phenyl)-5-[2-(piperidin-4-ylamino)-pyrimid in-4-yl]- 1H-imidazol-2-yl)-5- methyl-[1,3]dioxan-5-ylmethyl)-methynesulfonamide, cis-isomer, (Compound A409); N-{2-[5-(2-cyclohexylamino-pyrimidin-4-yl)-4-(4-fluoro-pheny l)-1H-imidazol-2-yl]-5-methyl- [1,3]dioxan-5-ylmethyi )-methanesulfonamide, cis-isomer, (Compound A410); N-(2-{4-(4-fluorophenyl)-5-[2-(2-(2-hydroxy-ethylamino)-pyri midin-4-yl]-1H-imidazol-2-yl}-5- methyl-[1,3]dioxan-5-ylmethyl)-methanesulfonamide, cis-isomer, (Compound A41 1); N-(2-[5-[2-(2-amino-ethylamino)-pyrimidin-4-yl]-4-(4-fluoro- phenyl)-111-imidazol-2-yl]-5- methyl-[1,3]dioxan-5-ylmethyl}-methanesulfonamide, cis-isomer, (Compound A412); N-[2-(4-(4-fluoro-phenyl)-5-{2-[3-(5H-imidazol-1-yl)-propyla mino]-pyrimidin-4-yl}-1H-imidazol- 2-yl)-5-methyl-[1,3]dioxan-5-ylmethyl]-methanesulfonamide, cis-isomer, (Compound A413); N-(2-{4-(4-fluoro-phenyl)-5-[2-(3-morpholin-4-yl-propylamino )-pyrimidin-4-yl]-1H-imidazol-2- yl}-5-methyl-[1,3]dioxan-5-ylmethyl)-methanesulfonamide, cis-isomer, (Compound A414); <BR> <BR> <BR> <BR> N-(2-(4-(4-fluoro-phenyl)-5- [2- (3-hydroxy-propylamino)-pyrimidin-4-yl]- 1H-imidazol-2-yl)-5- methyl-[1,3]dioxan-5-ylmethyl)-methanesulfonamide, cis-isomer, (Compound A415); N-(2-[5-(2-benzylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)- lH-imidazol-2-yl]-5-methyl- [1,3]dioxan-5-ylmethyl )-methanesulfonamide, cis-isomer, (Compound A416); N-(2-[5-(2-(4-fluorobenzyl)amino-pyrimidin-4-yl)-4-(4-fluoro -phenyl)-111-imidazol-2-yl]-5 methyl-[1,3]dioxan-5-ylmethyl}-methanesulfonamide, cis-isomer, (Compound A417); N-{2-[5-(2-(4-methoxybenzyl)amino-pyrimidin-4-yl)-4-(4-fluor o-phenyl)- lH-imidazol-2-yl] -5- methyl-[1,3]dioxan-5-ylmethyl}-methanesulionamide , cis-isomer, (Compound A418); N-(2-{4-(4-fluoro-phenyl)-5-[2-(1-phenyl-ethylamino)-pyrimid in-4-yl]-1H-imidazol-2-yl}-5- methyl-[1,3]dioxan-5-ylmethyl)-methanesulfonamide, R isomer, cis-isomer, (Compound A419);

N-(2-{4-(4-fluoro-phenyl)-5-[2-(1-phenyl-ethylamino)-pyrimid in-4-yl]- 1H-imi dazol-2yl)- 5- methyl-[1,3]dioxan-5-ylmethyl)-methanesulfonamide, S isomer, cis-isomer, (Compound A420); N-{2-[4-(4-fluoro-phenyl)-5-(2-phenylamino-pyrimidin-4-yl)-l H-imidazol-2-yl]-5-methyl- [1,3]dioxan-5-ylmethyl )-methanesuifonamide, cis-isomer, (Compound A421); N-{2-[4-(4-fluoro-phenyl)-5-(2-(4-fluorophenyl)amino-pyrimid in-4-yl)-lH-imidazol-2-yl]-5- methyl-[1,3]dioxan-5-ylmethyl)-methanesulfonamide , cis-isomer, (Compound A422); N-{2-[4-4-fluoro-phenyl)-5-(2-(3,4-difluorophenyl)amino-pyri midin-4-yl)-1H-imidazol-2-yl]-5- methyl-[1,3]dioxan-5-ylmethyl]}-methanesulfonamide, cis-isomer, (Compound A423); N-{2-[4-(4-fluoro-phenyl)-5-(2-(3-methoxyphenyl)amino-pyrimi din-4-yl)-1H-imidazol-2-yl]-5- methyl-[1,3]dioxan-5-ylmethyl}-methanesulfonamide , cis-isomer, (Compound A424); N-{2-[4-(4-fluoro-phenyl)--5-(2-piperidin-1-yl-pyrimidin-4-y l)-1H-imidazol-2-yl]-5-methyl- [1,3]dioxan-5-ylmethyl }-methanesulfonamide, cis-isomer, (Compound A425); <BR> <BR> <BR> <BR> N-[2-(4-(4-fluoro-phenyl)-5-(2-[(pyridin-4-ylmethyl)-amino]- pyrimidin-4-yl }-lH-imidazol-2-yl)- 5-methyl-[1,3)dioxan-5-ylmethyl]-methanesulfonamide, cis-isomer, (Compound A426); N-[2-(4-(4-fluoro-phenyl)-5-{2-[(pyridin-3-ylmethyl)-amino]- pyrimidin-4-yl}-1H-imidazol-2-yl)- 5-methyl-[1,3]dioxan-5-ylmethyl]-methanesulfonamide, cis-isomer, (Compound A427); N-[2-(4-(4-fluoro-phenyl)-5-{2-[(pyridin-2-ylmethyl)-amino]- pyrimidin-4-yl-1H-imidazol-2-yl)- 5-methyl-[1,3]dioxan-5-ylmethyl]-methanesulfonamide, cis-isomer, (Compound A428); N-[2-(4-(4-fluoro-phenyl)-5-{2-[(furan-2-ylmethyl)-amino]-py rimidin-4-yl}-1H-imidazol-2-yl)-5- methyl-[1,3]dioxan-5-ylmethyl]-methanesulfonamide, cis-isomer, (Compound A429); N-[2-(4-(4-fluoro-phenyl)-5-{2-[(thiophen-2-ylmethyl)-amino} -pyrimidin-4-yl}-1H-imidazol-2-yl)- 5-methyl-[1,3]dioxan-5-ylmethyl]-methanesulfonamide, cis-isomer, (Compound A430); N-[2-(4-(4-fluoro-phenyl)-5-{2-[(tetrahydro-furan-2-ylmethyl )-amino]-pyrimidin-4-yl}-1H- imidazol-2-yl)-5-methyl-[1,3]dioxan-5-ylmethyl]-methanesulfo namide, cis-isomer, (Compound A431); N-(2-{4-(4-fluoro-phenyl)-5-[2-(4-methyl-piperazin-1-yl)-pyr imidin-4-yl]-1H-imidazol-2-yl}-5- methyl-[1,3]dioxan-5-ylmethyl)-methanesulfonamide, cis-isomer, (Compound A432); N-{2-[4-(4-fluoro-phenyl)-5-(2-morpholin-4-yl-pyrimidin-4-yl )-1H-imidazol-2-yl]-5-methyl- [1,3]dioxan-5-ylmethyl )-methanesulfonamide, cis-isomer, (Compound A433); N-(2-{4-(4-fluoro-phenyl)-5-[2-(3-methoxy-propylamino)-pyrim idin-4-yl]-1H-imidazol-2-yl}-5- methyl-[1,3]dioxan-5-ylmethyl)-methanesulfonamide, cis-isomer, (Compound A434); N-(2-(4-(4-fluoro-phenyl) -5-[2-(2-methoxy-ethylamino)-pyrimidin-4 1H-imidazol-2-yl )-5- methyl-[1,3]dioxan-5-ylmethyl)-methanesulfonamide, cis-isomer, (Compound A435); N-{2-[5-[2-(3-dimethylamino-propylamino)-pyrimidin-4-yl]-4-( 4-fluoro-phenyl)-1H-imidazol-2- yl]-5-methyl-[1,3]dioxan-5-ylmethyl}-methanesulfonamide, cis-isomer, (Compound A436);

N-{2-[5-[2-(2-dimethylamino-ethylamino)-pyrimidin-4-yl]-4-(4 -fluoro-phenyl)-1H-imidazol-2-yl]- 5-methyl-[1,3]dioxan-5-ylmethyl}-methanesulfonamide, cis-isomer, (Compound A437); (4-(5-(4-fluoro-phenyl)-2-[5-(methanesulfonylamino-methyl)-5 -methyl-[1,3]dioxan-2-yl]-311- imidazol-4-yl)-pyrimidin-2-ylamino)-acet acid, cis-isomer, (Compound A438); <BR> <BR> <BR> <BR> 3-(4-{5-(4-fluoro-phenyl)-2.[5-(methanesulfonylamino-methyl) -5-methyl-[1,3]dioxan-2-yl]-311- imidazol-4-yl}-pyrimidin-2-ylamino)-propionic acid, cis-isomer, (Compound A439); N-{2-[4-4-fluoro-phenyl)-5-(2-methylsulfanyl-pyrimidin-4-yl) -1H-imidazol-2-yl]-5-methyl- [1,3]dioxan-5-ylmethyl)-methanesulfonamide, cis-isomer, (Compound A440); N-{2-[4-(4-fluoro-phenyl)-5-(2-methoxy-pyrimidin-4-yl)-1H-im idazol-2-yl]-5-methyl-[1,3]dioxan- 5-ylmethyi)-methanesulfonamide, cis-isomer, (Compound A441); N-{2-[5-(2-benzyloxy-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H- imidazol-2-yl]-5-methyl- [1,3]dioxan-5-ylmethyl )-methanesulfonamide, cis-isomer, (Compound A442); <BR> <BR> <BR> <BR> N-{2-[4-(4-fluoro-phenyl)-5-(2-phenoxy-pyrimidin-4-yl)-lH-im idazol-2-yl]-5-methyl-[1,3]dioxan- 5-ylmethyl)-methanesulfonamide, cis-isomer, (Compound A443); N-(2-{4-(4-fluoro-phenyl)-5-[2-(2-methoxy-ethoxy)-pyrimidin- 4-yl]-1H-imidazol-2-yl}-5-methyl- [1,3]dioxan-5-ylmethyl)-methanesulfonamide, cis-isomer, (Compound A444); N-{2-[5-[2-(2-dimethylamino-ethoxy)-pyrimidin-4-yl]-4-(4-flu oro-phenyl)-1H-imidazol-2-yl]-5- methyl-[1,3]dioxan-5-ylmethyl}-methanesulfonamide, cis-isomer, (Compound A445); N-{2-[5-(2-cyclohexyloxy-pyrimidin-4-yl)-4-(4-fluoro-phenyl) -1H-imidazol-2-yl]-5-methyl- [1,3]dioxan-5-ylmethyl )-methanesulfonamide, cis-isomer, (Compound A446); N-{2-[5-(2-Isopropoxy-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H -imidazol-2-yl]-5-methyl- [1,3]dioxan-5-ylmethyl)-methanesulfonami cis-isomer, (Compound A447); N-{2-[4-(4-fluoro-phenyl)-5-(2-isopropylamino-pyrimidin-4-yl )-1H-imidazol-2-yl]-5-methyl- [1,3]dioxan-5-ylmethyl}-methanesulfonamide, cis-isomer, (Compound A448); N-{2- [5-(2-allylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)- 1H-imidazol-2-yl]-5-methyl- [1,3]dioxan-5-ylmethyl)-methanesulfonamide, cis-isomer, (Compound A449); N-{2-[5-[2-(cyclopropylmethyl-amino)-pyrimidin-4-yl]-4-(4-fl uoro-phenyl)-1H-imidazol-2-yl]-5- methyl-[1,3]dioxan-5-ylmethyl}-methanesulfonamide, cis-isomer, (Compound A450); N-{2-[5-[2-(cyanomethyl-amino)-pyrimidin-4-yl]-4-(4-fluoro-p henyl)-1H-imidazol-2-yl]-5- methyl-[1,3]dioxan-5-ylmethyl)-methanesulfonamide, cis-isomer, (Compound A451); N-(2-[5-[2-(2-cyano-ethylamino)-pyrimidin-4-yl]-4-(4-fiuoro- phenyl)-1H-imidazol-2-yl]-5- methyl-[1,3]dioxan-5-ylmethyl}-methanesulfonamide, cis-isomer, (Compound A452); <BR> <BR> <BR> <BR> N-(2-(4-(4-fluoro-phenyl)-5- [2-(pyridin-3-ylamino)-pyrimidin-4-yl]- 1H-imidazol-2-yl)-5-methyl- [1,3]dioxan-5-ylmethyl)-methanesulfonamide, cis-isomer, (Compound A453); <BR> <BR> <BR> <BR> N-(2-{4-(4-fluoro-phenyl)-5-[2-(pyridin-4-ylamino)-pyrimidin -4-yl]- lH-imidazol-2-yl )-5-methyl- [1,2]dioxan-5-ylmethyl)-methanesulfonamide, cis-isomer, (Compound A454);

2-(4-{5-(4-fluoro-phenyl)-2-[5-(methanesulfonylamino-methyl) -5-methyl-[1,3]dioxan-2-yl]-3H- imidazol-4-yl)-pyrimidin-2-ylamino)-acetamide, cis-isomer, (Compound A455); 3-(4-{4-fluoro-phenyl)-2-[5-(methanesulfonylamino-methyl)-5- methyl-[1,3]dioxan-2-yl]-3H- imidazol-4-yl)-pyrimidin-2-ylamino)-propionamide, cis-isomer, (Compound A456); <BR> <BR> <BR> <BR> N-{2-[4-(4-fluoro-phenyl)-5-(2-propoxy-pyrimidin-4-yl)-1H-im idazol-2-yl]-5-methyl-[1,3]dioxan- 5-ylmethyl}-methanesulfonamide, cis-isomer, (Compound A457); N-(2-{4-(4-fluoro-phenyl)-5-[2-(2-hydroxy-ethoxy)-pyrimidin- 4-yl]-1H-imidazol-2-yl}-5-methyl- [1,3]dioxan-5-ylmethyl)-methanesulfonamide, cis-isomer, (Compound A458); N-(2-{4-(4-fluoro-phenyl)-5-[2-(3-hydroxy-propoxy)-pyrimidin -4-yl]-1H-imidazol-2-yl}-5-methyl- [1,3]dioxan-5-ylmethyl)-methanesulfonamide, cis-isomer, (Compound A459); N-{2-[4-(4-fluoro-phenyl)-5-(2-propylamino-pyrimidin-4-yl)-1 H-imidazol-2-yl]-5-methyl- [1,3]dioxan-5-ylmethyl}-methanesulfonamide, cis-isomer, (Compound A460); N-{2-[4-(4-fluoro-phenyl)-5-(2-pyrrolidin-1-yl-pyrimidin-4-y l)-lH-imidazol-2-yl]-5-methyl- [1,3]dioxan-5-ylmethyl}-methanesulfonamide, cis-isomer, (Compound A461); <BR> <BR> <BR> <BR> N-{2-[5-(2-amino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)- lH-imidazol-2-yl]-5-methyl- [1,3]dioxan-5- ylmethyl)-benzamide, cis-isomer, (Compound A462); N-{2-[4-(4-fluoro-phenyl)-5-(2-methylamino-pyrimidin-4-yl)-1 H-imidazol-2-yl]-5-methyl- [1,3]dioxan-5-ylmethyl)-benzamide, cis-isomer, (Compound A463); N-{2-[5-(2-dimethylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl) -1H-imidazol-2-yl]-5-methyl- [1,3]dioxan-5-ylmethyl)-benzamide, cis-isomer, (Compound A464); N-{2-[5-(2-cyclopropylamino-pyrimidin-4-yl)-4-(4-fluoro-phen yl)-1H-imidazol-2-yl]-5-methyl- [1,3]dioxan-5-ylmethyl }-benzamide, cis-isomer, (Compound A465); N-(2-{4-(4-fluoro-phenyl)-5-[2-(piperidin-4-ylamino)-pyrimid in-4-yl]-111-imidazol-2-yl)-5 methyl-[1,3]dioxan-5-ylmethyl)-benzamide, cis-isomer, (Compound A466); N-{2-[5-(2-cyclohexylamino-pyrimidin-4-yl)-4-(4-fluoro-pheny l)-1H-imidazol-2-yl]-5-methyl- [1,3]dioxan-5-ylmethyl}-benzamide, cis-isomer, (Compound A467); N-(2-{4-(4-fluoro-phenyl)-5-[2-(2-hydroxy-ethylamino)-pyrimi din-4-yl]-1H-imidazol-2-yl}-5- methyl-[1,3]dioxan-5-ylmethyl)-benzamide, cis-isomer, (Compound A468); N-(2- [5-[2-(2-amino-ethylamino)-pyrimidin-4-yl]-4-(4-fluoro-pheny l)- lH-imidazol-2-yl]-5- methyl-[1,3]dioxan-5-ylmethyl}-benzamide, cis-isomer, (Compound A469); N-[2-(4-(4-fluoro-phenyl)-5-{2-[3-(5H-imidazol-1-yl)-propyla mino]-pyrimidin-4-yl}-1H-imidazol- 2-yl)-5-methyl-[1,3]dioxan-5-ylmethyl]-benzamide, cis-isomer, (Compound A470); N-(2-{4-(4-fluoro-phenyl)-5- [2-(3-morpholin-4-yl-propylamino)-pyrimidin-4-yl]-lH-imidazo l-2- yl)-5-methyl-[1,3]dioxan-5-ylmethyl)-benzamide, cis-isomer, (Compound A471); N-(2-{4-(4-fluoro-phenyl)-5-[2-(3-hydroxy-propylamino)-pyrim idin-4-yl]- 1H-imidazol-2-yl)-5- methyl- [1,3]dioxan-5-ylmethyl)- beuzamide, cis-isomer, (Compound A472);

N-{2-[5-(2-benzylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)- lH-imidazol-2-yl]-5-methyl- [1,3]dioxan-5-ylmethyl}-benzamide, cis-isomer, (Compound A473); N-{2-[5-(2-(4-fluorobenzyl)amino-pyrimidin-4-yl)-4-(4-fluoro -phenyl)-1H-imidazol-2-yl]-5- methyl-[1,3]dioxan-5-ylmethyl}-benzamide, cis-isomer, (Compound A474); N-{2-[5-(2-(4-methoxybenzyl)amino-pyrimidin-4-yl)-4-(4-fluor o-phenyl)-1H-imidazol-2-yl]-5- methyl-[1,3]dioxan-5-ylmethyl)-benzamide, cis-isomer, (Compound A475); N-(2-{4-(4-fluoro-phenyl)-5-[2-(1-phenyl-ethylamino)-pyrimid in-4-yl]-1H-imidazol-2-yl}-5- methyl-[1,3]dioxan-5-ylmethyl)-benzamide, R isomer, cis-isomer, (Compound A476); N-(2-{4-(4-fluoro-phenyl)-5-[2-(1-phenyl-ethylamino)-pyrimid in-4-yl]-1H-imidazol-2-yl}-5- methyl-[1,3]dioxan-5-ylmethyl)-benzamide, S isomer, cis-isomer, (Compound A477); N-{2-[4-(4-fluoro-phenyl)-5-(2-phenylamino-pyrimidin-4-yl)-1 H-imidazol-2-yl]-5-methyl- [1,3]dioxan-5-ylmethyl}-benzamide, cis-isomer, (Compound A478); N-{2-[4-(4-fluoro-phenyl)-5-(2-(4-fluorophenyl)amino-pyrimid in-4-yl)-1H-imidazol-2-yl]-5- methyl-[1,3]dioxan-5-ylmethyl)-benzamide , cis-isomer, (Compound A479); N-{2-[4-(4-fluoro-phenyl)-5-(2-(3,4-difluorophenyl)amino-pyr imidin-4-yl)-1H-imidazol-2-yl]-5- methyl-[1,3]dioxan-5-ylmethyl }-benzamide, cis-isomer, (Compound A480); N-{2-[4-(4-fluoro-phenyl)-5-(2-(3-methoxyphenyl)amino-pyrimi din-4-yl)-1H-imidazol-2-yl]-5- methyl-[1,3]dioxan-5-ylmethyl}-benzamide, cis-isomer, (Compound A481); N-{2-[4-(4-fluoro-phenyl)-5-(2-piperidin-1-yl-pyrimidin-4-yl )-1H-imidazol-2-yl]-5-methyl- [1,3]dioxan-5-ylmethyl}-benzamide, cis-isomer, (Compound A482); N-[2-(4-(4-fluoro-phenyl)-5-{2-[(pyridin-4-ylmethyl)-amino]- pyrimidin-4-yl}-1H-imidazol-2-yl)- 5-methyl- [1,3]dioxan-5-ylmethyl]-benzamide, cis-isomer, (Compound A483); <BR> <BR> <BR> <BR> N-[2-(4-(4-fluoro-phenyl)-5-(2-[(pyridin-3-ylmethyl)-amino]- pyrimidin-4-yl}-111-imidazol-2-yl) 5-methyl-[1,3]dioxan-5-ylmethyl]-benzamide, cis-isomer, (Compound A484); N-[2-(4-(4-fluoro-phenyl)-5-{2-[(pyridin-2-ylmethyl)-amino]- pyrimidin-4-yl}-1H-imidazol-2-yl)- 5-methyl-[1,3]dioxan-5-ylmethyl]-benzamide, cis-isomer, (Compound A485); N-[2-(4-(4-fluoro-phenyl)-5-{2-[(furan-2-ylmethyl)-amino]-py rimidin-4-yl}-1H-imidazol-2-yl)-5- methyl-[1,3]dioxan-5-ylmethyl]-benzamide, cis-isomer, (Compound A486); N-[2-(4-(4-fluoro-phenyl)-5- (2- [(thiophen-2-ylmethyl)-amino]-pyrimidin-4-yl}- lH-imidazol-2-yl)- 5-methyl-[1,3]dioxan-5-ylmethyl]-benzamide, cis-isomer, (Compound A487); N-[2-(4-(4-fluoro-phenyl)-5-{2-[(tetrahydro-furan-2-ylmethyl )-amino]-pyrimidin-4-yl}-1H- imidazol-2-yl)-5-methyl-[1,3]dioxan-5-ylmethyl]-benzamide, cis-isomer, (Compound A488); <BR> <BR> <BR> <BR> N-(2-{4-(4-fluoro-phenyl)-5-[2-(4-methyl-piperazin-1-yl)-pyr imidin-4-yl]-lH-imidazol-2-yl}-5- methyl-[1,3]dioxan-5-ylmethyl)-benzamide, cis-isomer, (Compound A489); N-(2-[4-(4-fluoro-phenyl)-5-(2-morpholin-4-yl-pyrimidin-4-yl ) 1H-imidazol-2-yl]-5-methyl- [1,3]dioxan-5-ylmethyl}-benzamide, cis-isomer, (Compound A490);

N- (2-{4-(4-fluoro-phenyl)-5- [2- (3-methoxy-propylamino)-pyrimidin-4-yl]-lH-imidazol-2-yl}-5- methyl-[1,3]dioxan-5-ylmethyl)-benzamide, cis-isomer, (Compound A491); N-(2-{4-(4-fluoro-phenyl)-5-[2-(2-methoxy-ethylamino)-pyrimi din-4-yl]-111-imidazol-2-ylj-5- methyl-[1,3]dioxan-5-ylmethyl)-benzamide, cis-isomer, (Compound A492); <BR> <BR> <BR> <BR> N-{2-[5-[2-(3-dimethylamino-propylamino)-pyrimidin-4-yl]-4-( 4-fluoro-phenyl)-lH-imidazol-2- yl]-5-methyl-[1,3]dioxan-5-ylmethyl)-benzamide, cis-isomer, (Compound A493); N-{2-[5-[2-(2-dimethylamino-ethylamino)-pyrimidin-4-yl]-4-(4 -fluoro-phenyl)-1H-imidazol-2-yl] 5-methyl-[1,3]dioxan-5-ylmethylj-benzamide, cis-isomer, (Compound A494); {4-[2-[5-(benzoylamino-methyl)-5-methyl-[1,3]dioxan-2-yl]-5- (4-fluoro-phenyl)-3H-imidazol-4- yl]-pyrimidin-2-ylamino)-acetic acid, cis-isomer, (Compound A495); <BR> <BR> <BR> <BR> 3-{4-[2-[5-(benzoylamino-methyl)-5-methyl-[1,3]dioxan-2-yl]- 5-(4-fluoro-phenyl)-3H-imidazol-4- yl]-pyrimidin-2-ylamino}-propionic acid, cis-isomer, (Compound A496); N-{2-[4-(4-fluoro-phenyl)-5-(2-methylsulfanyl-pyrimidin-4-yl )-1H-imidazol-2-yl]-5-methyl- [1,3]dioxan-5-ylmethyl)-benzamide, cis-isomer, (Compound A497); N-{2-[4-(4-fluoro-phenyl)-5-(2-methoxy-pyrimidin-4-yl)-1H-im idazol-2-yl]-5-methyl-[1,3]dioxan- 5-ylmethyl)-benzamide, cis-isomer, (Compound A498); N-{2-[5-(2-benzyloxy-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H- imidazol-2-yl]-5-methyl- [1,3]dioxan-5-ylmethyl}-benzamide, cis-isomer, (Compound A499); N-{2-[4-(4-fluoro-phenyl)-5-(2-phenoxy-pyrimidin-4-yl)-1H-im idazol-2-yl]-5-methyl-[1,3]dioxan- 5-ylmethyl)-benzamide, cis-isomer, (Compound A500); N-(2-{4-(4-fluoro-phenyl)-5-[2-(2-methoxy-ethoxy)-pyrimidin- 4-yl]-1H-imidazol-2-yl-5-methyl- [1,3]dioxan-5-ylmethyl)-benzamide, cis-isomer, (Compound A501); N-{2-[5-[2-(2-dimethylamino-ethoxy)-pyrimidin-4-yl]-4-(4-flu oro-phenyl)-1H-imidazol-2-yl]-5- methyl-[1,3]dioxan-5-ylmethylj-benzamide, cis-isomer, (Compound A502); N-{2-[5-(2-cyclohexyloxy-pyrimidin-4-yl)-4-(4-fluoro-phenyl) -1H-imidazol-2-yl]-5-methyl- [1,3]dioxan-5-ylmethyl)-benzamide, cis-isomer, (Compound A503); N-{2-[5-(2-Isopropoxy-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H -imidazol-2-yl]-5-methyl- [1,3]dioxan-5-ylmethyl)-benzamide, cis-isomer, (Compound A504); N-{2-[4-(4-fluoro-phenyl)-5-(2-isopropylamino-pyrimidin-4-yl )-lH-imidazol-2-yl]-5-methyl- [1,3]dioxan-5-ylmethyl}-benzamide, cis-isomer, (Compound A505); N-{2-[5-(2-allylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H -imidazol-2-yl]-5-methyl- [1,3]dioxan-5-ylmethyl )-benzamide, cis-isomer, (Compound A506); N-{2-[5-[2-(cyclopropylmethyl-amino)-pyrimidin-4-yl]-4-(4-fl uoro-phenyl)-1H-imidazol-2-yl]-5- methyl-[1 ,3]dioxan-5-ylmethyl l-benzamide, cis-isomer, (Compound A507); N-{2-[5-[2-(cyanomethyl-amino)-pyrimidin-4-yl]-4-(4-fluoro-p henyl)-1H-imidazol-2-yl]-5- methyl-[1,3]dioxan-5-ylmethyl }-benzamide, cis-isomer, (Compound A508);

N-{2-[5-[2-(2-cyano-ethylamino)-pyrimidin-4-yl]-4-(4-fluoro- phenyl)-1H-imidazol-2-yl]-5- methyl-[1,3]dioxan-5-ylmethyli-benzamide, cis-isomer, (Compound A509); N-(2-{4-(4-fluoro-phenyl)-5-[2-(pyridin-3-ylamino)-pyrimidin -4-yl]-1H-imidazol-2-yl}-5-methyl- [1,3]dioxan-5-ylmethyl)-benzamide, cis-isomer, (Compound A510); <BR> <BR> <BR> <BR> N-(2-{4-(4-fluoro-phenyl)-5-[2-(pyridin-4-ylamino)-pyrimidin -4-yl]-lH-imidazol-2-yl}-5-methyl- [1,3]dioxan-5-ylmethyl)-benzamide, cis-isomer, (Compound A51 1); N-{2-[5-[2-(Carbamoylmethyl-amino)-pyrimidin-4-yl]-4-(4-fluo ro-phenyl)-1H-imidazol-2-yl]-5- methyl-[1,3]dioxan-5-ylmethyl)-benzamide, cis-isomer, (Compound A512); N-{2-[5-[2-(2-Carbamoyl-ethylamino)-pyrimidin-4-yl]-4-(4-flu oro-phenyl)-1H-imidazol-2-yl]-5- methyl-[1,3]dioxan-5-ylmethyl)-benzamide, cis-isomer, (Compound AS 13); N-{2-[4-(4-fluoro-phenyl)-5-(2-propoxy-pyrimidin-4-yl)-1H-im idazol-2-yl]-5-methyl-[1,3]dioxan- 5-ylmethyl}-benzamide, cis-isomer, (Compound A514); <BR> <BR> <BR> N-(2-{4-(4-fluoro-phenyl)-5-[2-(2-hydroxy-ethoxy)-pyrimidin- 4-yl]- 1H-imidazol-2-yl)-5-methyl- [1,3]dioxan-5-ylmethyl)-benzamide, cis-isomer, (Compound A515); N-(2-{4-(4-fluoro-phenyl)-5-[2-(3-hydroxy-propoxy)-pyrimidin -4-yl]-1H-imidazol-2-yl}-5-methyl- [1,3]dioxan-5-ylmethyl)-benzamide, cis-isomer, (Compound A516); N-{2-[4-(4-fluoro-phenyl)-5-(2-propylamino-pyrimidin-4-yl)-1 H-imidazol-2-yl]-5-methyl- [1,3]dioxan-5-ylmethyl}-benzamide, cis-isomer, (Compound A517); N-(2-[4-(4-fluoro-phenyl)-5-(2-pyrrolidin-1-yl-pyrimidin-4-y l)-1H-imidazol-2-yl]-5-methyl- [1,3]dioxan-5-ylmethyl}-benzamide, cis-isomer, (Compound A518); N-{2-[5-(2-amino-pyridin-4-yl)-4-(4-fluoro-phenyl)-1H-imidaz ol-2-yl]-5-methyl-[1,3]dioxan-5- ylmethyl)-2-phenyl-acetamide, cis-isomer, (Compound A519); N-{2-[4-(4-fluoro-phenyl)-5-(2-methylamino-pyrimidin-4-yl)-1 H-imidazol-2-yl]-5-methyl [1,3]dioxan-5-ylmethyl )-2-phenyl-acetamide, cis-isomer, (Compound A520); N-{2-[5-(2-dimethylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl) -1H-imidazol-2-yl]-5-methyl- [1,3]dioxan-5-ylmethyl)-2-phenyl-acetamide, cis-isomer, (Compound A521); N-(2-[5-(2-cyciopropylamino-pyrimidin-4-yl)-4-(4-fluoro-phen yl)-111-imidazol-2-yl]-5-methyl [1,3]dioxan-5-ylmethyl }-2-phenyl-acetamide, cis-isomer, (Compound A522); N-(2-{4-(4-fluoro-phenyl)-5-[2-(piperidin-4-ylamino)-pyrimid in-4-yl]-1H-imidazol-2-yl}-5- methyl-[1,3]dioxan-5-ylmethyl)-2-phenyl-acetamide, cis-isomer, (Compound A523); N-(2-[5-(2-cyclohexylamino-pyrimidin-4-yl)-4-(4-fluoro-pheny l)- lH-imidazol-2-yl]-5-methyl- [1,3]dioxan-5-ylmethyl}-2-phenyl-acetamide, cis-isomer, (Compound A524); N-(2-{4-(4-fluoro-phenyl)-5-[2-(2-(hydroxy-ethylamino)-pyrim idin-4-yl]-1H-imidazol-2-yl}-5- methyl-[1,3]dioxan-5-ylmethyl)-2-phenyl-acetamide, cis-isomer, (Compound A525); N-{2-[5-[2-(2-amino-ethylamino)-pyrimidin-4-yl]-4-(4-fluoro- phenyl)-1H-imidazol-2-yl]-5- methyl-[1,3]dioxan-5-ylmethyl }-2-phenyl-acetamide, cis-isomer, (Compound A526);

N-[2-(4-(4-fluoro-phenyl)-5-{2-[3-(5H-imidazol-1-yl)-propyla mino]-pyrimidin-4-yli lH-imidazol- 2-yl)-5-methyl-[1,3]dioxan-5-ylmethyl]-2-phenyl-acetamide, cis-isomer, (Compound A527); <BR> <BR> <BR> <BR> N-(2-(4-(4-fluoro-phenyl)-5-[2-(3-morpholin-4-yl-propylamino )-pyrimidin-4-yl]-111-imidazol-2- yl}-5-methyl-[1,3]dioxan-5-ylmethyl)-2-phenyl-acetamide, cis-isomer, (Compound A528); <BR> <BR> <BR> <BR> N-(2-{4-(4-fluoro-phenyl)-5-[2-(3-hydroxy-propylamino)-pyrim idin-4-yl]-111-imidazol-2-yl)-5- methyl-[1,3]dioxan-5-ylmethyl)-2-phenyl-acetamide, cis-isomer, (Compound A529); N-{2-[5-(2-benzylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-l H-imidazol-2-yl]-5-methyl- [1,3]dioxan-5-ylmethyl}-2-phenyl-acetamide, cis-isomer, (Compound A530); N-{2-[5-(2-(4-fluorobenzyl)amino-pyrimidin-4-yl)-4-(4-fluoro -phenyl)-1H-imidazol-2-yl]-5- methyl-[1,3]dioxan-5-ylmethyl}-2-phenyl-acetamide, cis-isomer, (Compound A531); N-{2-[5-(2-(4-methoxybenzyl)amino-pyrimidin-4-yl)-4-(4-fluor o-phenyl)-1H-imidazol-2-yl]-5- methyl-[1,3]dioxan-5-ylmethyl}-2-phenyl-acetamide, cis-isomer, (Compound A532); N-(2-{4-(4-fluoro-phenyl)-5-[2-(1-phenyl-ethylamino)-pyrimid in-4-yl]-1H-imidazol-2-yl}-5- methyl-[1,3]dioxan-5-ylmethyl)-2-phenyl-acetamide, R isomer, cis-isomer, (Compound A533); N-(2-{4-(4-fluoro-phenyl)-5-[2-(1-phenyl-ethylamino)-pyrimid in-4-yl]-1H-imidazol-2-yl}-5- methyl-[1,3]dioxan-5-ylmethyl)-2-phenyl-acetamide, S isomer, cis-isomer, (Compound A534); N-{2-[4-(4-fluoro-phenyl)-5-(2-phenylamino-pyrimidin-4-yl)-1 H-imidazol-2-yl]-5-methyl- [1,3]dioxan-5-ylmethyll-2-phenyl-acetamide, cis-isomer, (Compound A535); N-{2-[4-(4-fluoro-phenyl)-5-(2-(4-fluorophenyl)amino-pyrimid in-4-yl)-1H-imidazol-2-yl]-5- methyl-[1,3]dioxan-5-ylmethyl )-2-phenyl-acetamide , cis-isomer, (Compound A536); <BR> <BR> <BR> <BR> N-(2-[4-(4-fluoro-phenyl)-5-(2- (3,4-difluorophenyl)amino-pyrimidin-4-yl) 1H-imidazol-2-yl]-5- methyl-[1,3]dioxan-5-ylmethyl )-2-phenyl-acetamide , cis-isomer, (Compound A537); N-{2-[4-(4-fluoro-phenyl)-5-(2-(2-(3-methoxyphenyl)amino-pyr imidin-4-yl)-1H-imidazol-2-yl]-5- methyl-[1,3]dioxan-5-ylmethyl}-2-phenyl-acetamide, cis-isomer, (Compound A538); N-{2-[4-(4-fluoro-phenyl)-5-(2-piperidin-1-yl-pyrimidin-4-yl )-1H-imidazol-2-yl]-5-methyl- [1,3]dioxan-5-ylmethyl)-2-phenyl-acetamide, cis-isomer, (Compound A539); N-[2-(4-(4-fluoro-phenyl)-5-{2-[(pyridin-4-ylmethyl)-amino]- pyrimidin-4-yl}-1H-imidazol-2-yl)- 5-methyl-[1,3]dioxan-5-ylmethyl]-2-phenyl-acetamide, cis-isomer, (Compound A540); N-[-(4-(4-fluoro-phenyl)-5-{2-[(pyridin-3-ylmethyl)-amino]-p yrimidin-4-yl}-1H-imidazol-2-yl)- 5-methyl-[1,3]dioxan-5-ylmethyl]-2-phenyl-acetamide, cis-isomer, (Compound A541); N-[2-(4-(4-fluoro-phenyl)-5-{2-[(pyridin-2-ylmethyl)-amino]- pyrimidin-4-yl}-1H-imidazol-2-yl)- 5-methyl-[1,3]dioxan-5-ylmethyl]-2-phenyl-acetamide, cis-isomer, (Compound A542); <BR> <BR> <BR> <BR> N-[2-(4-(4-fluoro-phenyl)-5-{2-[(furan-2-ylmethyl)-amino]-py rimidin-4-yl )-111-imidazol-2-yl)-5 methyl-[1,3]dioxan-5-ylmethyl]-2-phenyl-acetamide, cis-isomer, (Compound A543); N-[2-(4-(4-fluoro-phenyl)-5-(2- [(thiophen-2-ylmethyl)-amino]-pyrimidin-4-yl)-111-imidazol-2 -yl)- 5-methyl-[1,3]dioxan-5-ylmethyl]-2-phenyl-acetamide, cis-isomer, (Compound A544);

N- [2- (4-(4- fluoro-phenyl)- 5-(2- [(tetrahydro-furan- 2-ylm ethyl)-amino ]-py rimi din-4yl)- 1H- imidazol-2-yl)-5-methyl-[1,3]dioxan-5-ylmethyl]-2-phenyl-ace tamide, cis-isomer, (Compound A545); <BR> <BR> <BR> <BR> N-(2-{4-(4-fluoro-phenyl)-5-[2-(4-methyl-piperazin- 1-yl)-pyrimidin-4-yl]- lH-imidazol-2-yl}-5- methyl-[1,3]dioxan-5-ylmethyl)-2-phenyl-acetamide, cis-isomer, (Compound A546); N-{2-[4-(4-fluoro-phenyl)-5-(2-morpholin-4-yl-pyrimidin-4-yl )-1H-imidazol-2-yl]-5-methyl- [1,3]dioxan-5-ylmethyl}-2-phenyl-acetamide, cis-isomer, (Compound A547); N-(2-{4-(4-fluoro-phenyl)-5-[2-(3-methoxy-propylamino)-pyrim idin-4-yl]-1H-imidazol-2-yl}-5- methyl-[1,3]dioxan-5-ylmethyl)-2-phenyl-acetamide, cis-isomer, (Compound A548); N-(2-{4-(4-fluoro-phenyl)-5-[2-(2-methoxy-ethylamino)-pyrimi din-4-yl]-1H-imidazol-2-yl}-5- methyl-[1,3]dioxan-5-ylmethyl)-2-phenyl-acetamide, cis-isomer, (Compound A549); N-{2-[5-[2-(3-dimethylamino-propylamino)-pyrimidin-4-yl]-4-( 4-fluoro-phenyl)-1H-imidazol-2- yl]-5-methyl-[1,3]dioxan-5-ylmethyl}-2-phenyl-acetamide, cis-isomer, (Compound A550); N-{2-[5-[2-(2-dimethylamino-ethylamino)-pyrimidin-4-yl]-4-(4 -fluoro-phenyl)-1H-imidazol-2-yl]- 5-methyl-[1,3]dioxan-5-ylmethyl}-2-phenyl-acetamide, cis-isomer, (Compound A551); (4-(5-(4-fluoro-phenyl)-2-[5-methyl-5-(phenylacetylamino-met hyl)-[1,3]dioxan-2-yl]-311 imidazol-4-yl}-pyrimidin-2-ylamino)-acetic acid, cis-isomer, (Compound A552); 3-(4-(5-(4-fluoro-phenyl)-2-[5-methyl-5-(phenylacetylamino-m ethyl)-[1,3]dioxan-2-yl]-311- imidazol-4-yl)-pyrimidin-2-ylamino)-propionic acid, cis-isomer, (Compound A553); N-{2-[4-(4-fluoro-phenyl)-5-(2-methylsulfanyl-pyrimidin-4-yl )-1H-imidazol-2-yl]-5-methyl- [1,3]dioxan-5-ylmethyl}-2-phenyl-acetamide, cis-isomer, (Compound A554); N---{2-[4-(4-fluoro-phenyl)-5-(2-methoxy-pyrimidin-4-yl)-1H- imidazol-2-yl]-5-methyl-[1,3]dioxan- 5-ylmethyl)-2-phenyl-acetamide, cis-isomer, (Compound A555); N-{2-[5-(2-benzyloxy-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H- imidazol-2-yl]-5-methyl- [1,3]dioxan-5-ylmethyl)-2-phenyl-acetamide, cis-isomer, (Compound A556); N-{2-[4-(4-fluoro-phenyl)-5-(2-phenoxy-pyrimidin-4-yl)-1H-im idazol-2-yl]-5-methyl-[1,3]dioxan- 5-ylmethyl)-2-phenyl-acetamide, cis-isomer, (Compound A557); N-(2-{4-(4-fluoro-phenyl)-5-[2-(2-methoxy-ethoxy)-pyrimidin- 4-yl]-1H-imidazol-2-yl}-5-methyl- [1,3]dioxan-5-ylmethyl)-2-phenyl-acetamide, cis-isomer, (Compound A558); <BR> <BR> <BR> <BR> N-{2-[5-[2-(2-dimethylamino-ethoxy)-pyrimidin-4-yl]-4-(4-flu oro-phenyl)- lH-imidazol-2-yl]-5- methyl-[1,3]dioxan-5-ylmethyl}-2-phenyl-acetamide, cis-isomer, (Compound A559); N-{2-[5-(2-cyclohexyloxy-pyrimidin-4-yl)-4-(4-fluoro-phenyl) -1H-imidazol-2-yl]-5-methyl- [1,3]dioxan-5-ylmethyl}-2-phenyl-acetamide, cis-isomer, (Compound A560); N-{2-[5-(2-Isopropoxy-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H -imidazol-2-yl]-5-methyl- [1,3]dioxan-5-ylmethyl}-2-phenyl-acetamide, cis-isomer, (Compound A561);

N-{2-[4-(4-fluoro-phenyl)-5-(2-isopropylamino-pyrimidin-4-yl )- 1H-imidazol-2-yl]-5-methyl- [1,3]dioxan-5-ylmethyl}-2-phenyl-acetamide, cis-isomer, (Compound A562); N-{2-[5-(2-allylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)- 1H-imidazol-2-yl]-5-methyl- [1,3]dioxan-5-ylmethyl}-2-phenyl-acetamide, cis-isomer, (Compound A563); <BR> <BR> <BR> <BR> N-{2-[5-[2-(cyclopropylmethyl-amino)-pyrimidin-4-yl]-4-(4-fl uoro-phenyl)- lH-imidazol-2-yl]-5- methyl-[1,3]dioxan-5-ylmethyl}-2-phenyl-acetamide, cis-isomer, (Compound A564); N-{2-[5-[2-(cyanomethylamino)-pyrimidin-4-yl]-4-(4-fluoro-ph enyl)-1H-imidazol-2-yl]-5- methyl-[1,3]dioxan-5-ylmethyl}-2-phenyl-acetamide, cis-isomer, (Compound A565); N-{2-[5-[2-(2-cyano-ethylamino)-pyrimidin-4-yl]-4-(4-fluoro- phenyl)-1H-imidazol-2-yl]-5- methyl-[1,3]dioxan-5-ylmethyl}-2-phenyl-acetamide, cis-isomer, (Compound A566); N-(2-{4-(4-fluoro-phenyl)-5-[2-(pyridin-3-ylamino)-pyrimidin -4-yl]-1H-imidazol-2-yl}-5-methyl- [1,3]dioxan-5-ylmethyl)-2-phenyl-acetamide, cis-isomer, (Compound A567); N-(2-{4-(4-fluoro-phenyl)-5-[2-(pyridin-4-ylamino)-pyrimidin -4-yl]- 111-imidazol-2-yl)-5-methyl- [1,3]dioxan-5-ylmethyl)-2-phenyl-acetamide, cis-isomer, (Compound A568); 2-(4-{5-(4-fluoro-phenyl)-2-[5-methyl-5-(phenylacetylamino-m ethyl)-[1,3]dioxan-2-yl]-311- imidazol-4-yl)-pyrimidin-2-ylamino)-acetamide, cis-isomer, (Compound A569); 3-(4-{5-(4-fluoro-phenyl)-2-[5-methyl-5-(phenylacetylamino-m ethyl)-[1,3]dioxan-2-yl]-3H- imidazol-4-yl)-pyrimidin-2-ylamino)-propionamide, cis-isomer, (Compound A570); <BR> <BR> <BR> N-(2-[4-(4-fluoro-phenyl)-5-(2-propoxy-pyrimidin-4-yl)-111-i midazol-2-yl]-5-methyl-[1,3]dioxan 5-ylmethyl)-2-phenyl-acetamide, cis-isomer, (Compound A571); N-(2-{4-(4-fluoro-phenyl)-5-[2-(2-hydroxy-ethoxy)-pyrimidin- 4-yl]-1H-imidazol-2-yl}-5-methyl- [1,3]dioxan-5-ylmethyl)-2-phenyl-acetamide, cis-isomer, (Compound A572); <BR> <BR> <BR> N-(2-{4-(4-fluoro-phenyl)-5-[2-(3-hydroxy-propoxy)-pyrimidin -4-yl]-lH-imidazol-2-yl}-5-methyl- [1,3]dioxan-5-ylmethyl)-2-phenyl-acetamide, cis-isomer, (Compound A573); N-{2-[4-(4-fluoro-phenyl)-5-(2-propylamino-pyrimidin-4-yl)-1 H-imidazol-2-yl]-5-methyl- [1,3]dioxan-5-ylmethyl}-2-phenyl-acetamide, cis-isomer, (Compound A574); N-{2-[4-(4-fluoro-phenyl)-5-(2-pyrrolidin-1-yl-pyrimidin-4-y l)-1H-imidazol-2-yl]-5-methyl- [1,3]dioxan-5-ylmethyl)-2-phenyl-acetamide, cis-isomer, (Compound A575).

(b) By proceeding in a similar manner to Example 26 (a) but using C-(2-[4-(4-fluoro-phenyl)- 5-(2-methylsulphanyl-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-met hyl-[1,3]dioxan-5-yl}- methylamine, cis-isomer, there are prepared the corresponding trans-isomers of Compounds A348 to A575.

EXAMPLE 27 ComPounds KH to KP A suspension of {2-[4-(4-fluoro-phenyl)-5-(2-methylsulphanylpyrimidin-4-yl)- 1H-imidazol-2-yl]- 5-methyl-[1,3]dioxan-5-yl}-morpholin-r-yl-methanone, trans isomer, (5.00g, Compound KQ) in dichloromethane at OOC was treated with meta-chloroperbenzoic acid (2 equivalents) and the mixture stirred at 0-50C for 2 hours and then at room temperature for a further 16 hours. The reaction mixture was treated with aqueous saturated sodium bicarbonate solution. The organic layer was separated then evaporated. The residue was triturated with ether to give {2-F4-(4- fluoro-phenyl)-5-(2-methylsulphonylpyrimidin-4-yl)-1H-imidaz ol-2-yl]-5-methyl-[1,3]dioxan-5- vll-morPholin-4-vl-methanone trans isomer, (4.9g, Compound KH) as a yellow solid, m.p. 264- 266~C. MH+ 532.

By proceeding in a similar manner but using 2-[4-(4-fluoro-phenyl)-5-(2-methylsulphanyl- pyrimidin-4-yl)-1H-imidazol-2-yl]-5,5-dimethyl-[1,3]dioxane (Compound KR) there was prepared 2-[4-(4-fluoro-phenyl)-5-(2-methylsulphonylpyrimidin-4-yl)-1 H-imidazol-2-yl]-5,5- dirnethvi-F1.3ldioxane (Compound KI) as a cream solid, m.p. 204-206~C. MH+433.

By proceeding in a similar manner but using {2-[4-(4-fluoro-phenyl)-5-(2-methylsulphanyl- pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl} -methanol, trans-isomer (Compound KU) there is prepared {2-14-(4-fluoro-phenvl)-5-(2-methvlsulphonvl-pvrimidin-4- yll-1H-imidazol-2-vll-5-methvl-11.3ldioxan-5-vll-methanol. trans-isomer (Compound KJ).

By proceeding in a similar manner but using (2-[4-(4-fluoro-phenyl)-5-(2-methylsulphanyl- pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl} -methanol, cis-isomer (Compound KT) there is prepared -{2-[4-(4-fluoro-phenyl)-5-(2-methylsulphonyl-pyrimidin-4-yl )-1H- imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-methanol, cis-isomer (Compound KK).

By proceeding in a similar manner but using 2-[4-(4-fluoro-phenyl)-5-(2- methylsulphanylpyrimidin-4-yl)- 1H-imidazol-2-yl]-5-methylene-[1,3]dioxane (Compound KV) there is prepared 2-[4-(4-fluoro-phenyl)-5-(2-methylsulphonylpyrimidin-4-yl)-1 H-imidazol-2-yl]- 5-methvlene-F1,3ldioxane (Compound KL).

By proceeding in a similar manner but using 4-[2-[1,3]dioxan-2-yl-5-(4-fluoro-phenyl)-3H- imidazol-4-yl]-2-methylsulphanyl-pyrimidine (Compound KW) there is prepared 4-[2-[1,3]dioxan-2-yl-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]- 2-methylsulphonyl-pyrimidine (Compound KM).

By proceeding in a similar manner but using (2-[4-(4-fluoro-phenyl)-5-(2-methylsulphanyl- pyrimidin-4-yl)-qH-imidazol-2-yl]-[1,3]dioxan-5-yl}-methanol , trans-isomer (Compound KX) there is prepared {2-[4-(4-fluoro-phenyl)-5-(2-methylsulphonyl-pyrimidin-4-yl) -1H-imidazol-2- vll-rldldioxan--vl -methanol. trans-isomer (Compound KN).

By proceeding in a similar manner but using (2-[4-(4-fluoro-phenyl)-5-(2-methylsulphanyl- pyrimidin-4-yl)-1H-imidazol-2-yl]-[1,3]dioanyl}-methanol, cis-isomer (Compound KY) there is prepared {2-[4-(4-fluoro-phenyl)-5-(2-methylsulphonyl-pyrimidin-4-yl) -1H-imidazol-2-yl]- [1,3]dioxan-5-yl}-methanol, cis-isomer (Compound KO).

By proceeding in a similar manner but using 2,2,2-trifluoro-N-[2-{4-(4-fluoro-phenyl)-5-(2- methylsuphanylpyrimidin-4-yl)-1H-imidazol-2-yl}-5-methyl--81 ,3]dioxan-5-yl-]acetamide, cis- isomer (Compound KQ) there was prepared 2,2,2-trifluoro-N-[2-{4-(4-fluoro-phenyl)-5-(2- methanesulphonylpyrimidin-4-yl)-1H-yl)-1H-imidazol-2-yl}-5-m ethyl-[1,3]dioxan-5-yl]acetamide, cis- isomer (Compound KP) as a yellow solid, m.p. 236-238~C. MH+ 530.

EXAMPLE 28 COMPOUNDS KO and KY A solution of 4-[2-dimethoxymethyl-5(4)-(4-fluoro-phenyl)-1H-imidazol-4(5) -yl]-2- methanesulphanyl-pyrimidine (16.0g, Reference Example 7), p-toluenesulphonic acid (21.13g), and 3-hydroxy-2-hydroxymethyl-2-methyl-1-morpholino-1-propanone (10.82g, Reference Example 6) in a mixture of dry tetrahydrofuran and dry dimethylformamide was heated at reflux under a soxhlet apparatus charged with molecular seives (3~) for 26 hours. The reaction mixture was evaporated and the residue treated with ethyl acetate and aqueous saturated sodium bicarbonate solution. The organic phase was evaporated and the residue was subjected to flash chromatography on silica eluting with a mixture of ethyl acetate and methanol (9:1, v/v) to give {2-r4-(4-fluoro-phenvl)-5-(2-methvlsulPhanvlPvrimidin-4-vl)- lH-imidazol-2-vll-5-methvl- [1,3]dioxan-5-yl}-morpholin-4-yl-methanone, trans isomer, (13.8g, Compound KQ) as a colourless solid, m.p. 1600C (with decomposition). MH+ 500.

By proceeding in a similar manner but using 2,2-dimethylpropan-1,3-diol there was prepared 2-r4-(4-fluoro-phenvl)-5-(2-methvlsulPhanvlPvrimidin-4-vl)-1 H-imidazol-2-vll-5.5-dimethvl- -[1,3]dioxane (Compound KR) as a colourless solid, m.p. 163-165~C (with decomposition). MH+ 401.

By proceeding in a similar manner but using 2-methyl-2-trifluoroacetamido-1,3-propanediol (Reference Example 4) there was prepared 2 2,2,2-trifluoro-N-[2-{4-(4-fluoro-phenyl)-5-(2- methylsulphanyl-pyrimidin-4-yl)-1H-imidazol-2-yl}-5-methyl-[ 1,3]dioxan-5-yl]acetamide, cis- isomer, (Compound KS) as a colourless solid. MH+ 498. RF: 0.55 determined on silica gel plates using a mixture of ethyl acetate and methanol (19:1, v/v).

By proceeding in a similar manner but using 1,1,1-tris(hydroxymethyl)ethane there was prepared {2-[4-(4-fluoro-phenyl)-5-(2-methylsulfanyl-pyrimidin-4-yl)- 1H-imidazol-2-yl]-5- methyl-[1,3]dioxan-5-yl}-methanol, cis isomer (Compound KT) as white solid [MH+ 417. RF = 0.32 determined on silica gel plates eluting with a mixture of ethyl acetate and methanol (19:1, v/v] and {2-[4-(4-fluoro-phenyl)-5-(2-methylsulfanyl-pyrimidin-4-yl)- 1H-imidazol-2-yl]-5- methvl-rl,3ldioxan-5-yl )-methanol, trans isomer (Compound KU) as a white solid (MH+ 417, RF = 0.24, determined on silica gel plates eluting with a mixture of ethyl acetate and methanol (19:1, v/v)].

By proceeding in a similar manner but using 2-methylene-1,3-propanediol there is prepared 4-r5-(4-fluoro-phenvl) -2-(5-methvlene-T1 ,3ldioxan-2-vl) 3H-imidazol4-vll -2-methvisulfanvl- Pvrimidine (Compound KV).

By proceeding in a similar manner but using 1,3-propanediol there is prepared 4-[2-[1,3]dioxan- 2-yl-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-2-methylsulphanyl -pyrimidine (Compound KW).

By proceeding in a similar manner but using 2-(hydroxymethyl)-1,3-propanediol there is prepared {2-[4-(4-fluoro-phenyl)-5-(2-methylsuophanyl-pyrimidin-4-yl) -1H-imidazol-2-yl]- f1.3ldioxan-5-vl}-methanol. trans-isomer (Compound KX) and f2-F4-(4-fluoro-phenvl)-5-(2- methylsulphanyl-pyrimidin-4-yl)-1H-imidazol-2-yl]-[1,3]dioxa n-5-yl}-methanol, cis-isomer (Compound KY).

EXAMPLE 29 COMPOUND KZ A solution of 2-[4-(4-fluoro-phenyl)-5-(2-methylsulfanyl-pyrimidin-4-yl)-1 H-imidazol-2-yl]-5 methyl-[1,3]dioxane-5-carboxylic acid amide, cis isomer (0.5g, Compound LA) in tetrahydrofuran was treated with lithium aluminium hydride (0.18g) and the mixture heated at reflux for 0.5 hour. To the cooled solution was added water (0.2ml), then aqueous sodium

hydroxide (15%, 0.2ml) and then water (0.6ml). The mixture was then filtered and the filtrate was evaporated. The residue was subjected to flash chromatography on silica, eluting with a mixture of methanol and ethyl acetate (3:7, v/v) to give C-{2-[4-(4-fluoro-phenyl)-5-(2- methvlsulfanvl-pvrimidin-4-vl )- 1H-imidazol-2-vll-5-methvl -T13ldioxan5-vl -methviamine. cis isomer (69mg, Compound KZ) as a gum. MH+ 416. RF = 0.3 determined on silica gel plates using methanol.

EXAMPLE 30 COMPOUND LA To a solution of 2-[4-(4-fluoro-phenyl)-5-(2-methylsulfinyl-pyrimidin-4-yl)-1 H-imidazol-2-yl]-5- methyl-[1,3]dioxane-5-carboxylic acid, cis isomer (1.3g, Compound LB), diethyl isopropyl amine (0.85g) and O-(7-azabenzotriazol-1-yl) 1,1,3,3-tetramethyluronium hexafluorophosphate (1.14g) in dimethylformamide (anhydrous) was added ammonia (1.2mL, 0.5M solution in 1,4-dioxane).

The solution was stirred at room temperature for 3 hours and then evaporated. The residue was stirred with water and the solid filtered to give 2-[4-(4-fluoro-phenyl)-5-(2-methylsulfinyl- pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-ca rboxylic acid amide cis isomer (1.2g, Compound LA) as white solid. MH+ 430. RF = 0.27 [determined on silica gel plates using a mixture of ethyl acetate and methanol (8:2 v/v)].

EXAMPLE 31 COMPOUND LB A solution of 2-[4-(4-fluorophenyl)-5-(2-methylenesulphanylpyrimidin-4-yl) -1H-imidazol-2-yl]- 5-methyl-[1,3]dioxan-5-carboxylic acid methyl ester, cis isomer, (5.1g, Compound LD) and aqueous sodium hydroxide (34.4ml, 1N) in methanol was heated at reflux for 6 hours. To the cold solution was added aqueous hydrochloric acid (34.4.ml, 1N) and the methanol evaporated. The aqueous was decanted and the residue triturated with acetonitrile to give 2-F4-(4-fluoro-phenvl)- <BR> <BR> <BR> 5-(2-rnethvisulfanyl-pvrimidin-4-yl)- 111-imidazol-2-vll-5-methyl- 3ldioxane-5-carboxvlic acid, cis isomer (4.43g, Compound LB) as a white solid. MH+ 431. TLC RF = 0.22 (eluting with ethyl Acetate and methanol (8:2, v/v) on silica gel).

EXAMPLE 32 COMPOUND LC and LD A solution of 2-dimethoxymethyl-4-(4-fluorophenyl)-5-(2-methylsulphanylpyr imidin-4-yl)-1H- imidazole (4.5g, Reference Example 7), methyl 2,2-bis(hydroxymethyl)propionate (lOg) and methylorthoformate (11.9ml) in dimethylformamide was treated with 4-toluenesulphonic acid (20.6g) and then heated at 800C for 4 hours. The reaction mixture was evaporated then

partitioned between ethyl acetate and aqueous sodium bicarbonate solution. The organic phase was evaporated and the residue purified using flash chromatography on silica gel eluting with a ethyl acetate to give 2-[4-(4-fluorophenyl)-5-(2-methylsulphanylpyrimidin-4-yl)-1H -imidazol-2- yl]-5-methyl-[1,3]dioxan-5-carboxylic acid methyl ester. trans isomer, (4.95g, Compound LC), [MH+ 445, m.p. 1992000 C] and 2-F4-(4-fluorophenvl)-5-(2-rnethvlsulphanvlvvrimidin-4-vl)-1 H- imidazol-2-yl]-5-methyl-[1,3]dioxan-5-carboxylic acid methvl ester. cis isomer, (7.11g, Compound LD), MH+ 445, m.p. 161-163~C).

EXAMPLE 33 COMPOUND LE To a solution of {2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-n itro-[1,3]dioxan-5- yl)-methanol, cis isomer (0.1g, Compound LG) in ethanol was added palladium on carbon (5%, 0.2g) and the mixture was hydrogenated at latmosphere of hydrogen, at 50~C, for 6 hours. The solution was filtered through Celite, the solvent evaporated and the residue subjected to flash chromatography on silica gel, eluting with a mixture of methanol and ethyl acetate (1:1, v/v) to give {5-Amino-2-r4-(4-fluoro-Phenvl)-5-Pvridin-4-vl-1H-imidazol-2 -vll-r193ldioxan-5-vll- methanol. cis isomer, (77mg, Compound LE) as a gum. MH+ 371. TLC RF = 0.27 (eluting with methanol on silica gel).

EXAMPLE 34 COMPOUND LF To a solution of {2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-n itro-[1,3]dioxan-5- yl}-methanol, trans isomer (0.1g, Compound LH) in ethanol was added palladium on carbon (5%, 0.2g) and the mixture was hydrogenated, at latmosphere of hydrogen, at 50"C for 8 hours.

The solution was filtered through celite and the solvent was evaporated and the residue subjected to flash chromatography on silica gel, eluting with a mixture of methanol and ethyl acetate (1:1, v/v) to give {5-Amino-2-r4-(4-fluoro-Phenvl)-5-Pvridin-4-vl-1H-imidazol-2 -vll-r1*3ldioxan-5-vll- methanol. trans isomer, (75mg, Compound LF) as a gum. MH+ 371. TLC RF = 0.19 (eluting with a mixture of ethyl acetate:methanol 1:1 on silica gel).

EXAMPLE 35 COMPOUND LG and LH A solution of of 4-[2-dimethoxymethyl-5(4)-(4-fluoro-phenyl)-1H-imidazol-4(5) -yl]-pyridine (2.2g, Reference Example 3), p-toluenesulphonic acid (1.74g) and tris(hydroxymethyl)- nitromethane (4.24g) in tetrahydrofuran (anhydrous) and dimethylformamide (anhydrous) was heated at reflux under a soxhlet apparatus charged with molecular sieve (3~) for 48 hours. The

solvent was evaporated and the residue partitioned between ethyl acetate and aqueous saturated sodium carbonate solution. The organic layer was evaporated and the residue subjected to flash chromatography on silica, eluting with a mixture of methanol and ethyl acetate (1:9, v/v) to give {2-[4-(4-Fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-n itro-[1,3]dioxan-5-yl}-methanol, cis isomer, (0.61g, Compound LG) as white solid (MH+ 401, TLC RF = 0.3, eluting with a mixture of Ethyl acetate: Methanol 8:2 on silica gel) and {2-[4-(4-Fluoro-phenyl)-5-pyridin-4-yl-1H imidazol-2-yl]-5-nitro-[1,3]dioxan-5-yl}-methanol, trans isomer,(0.39g, Compound LH) as a yellow gum (MH+ 401, TLC RF = 0.55, eluting with a mixture of ethyl acetate:methanol 8:2 on silica gel).

EXAMPLE 36 COMPOUND LI To a solution of 4-[2-(5,5-Dimethyl-4-nitromethyl-[1,3]dioxan-2-yl)-5-(4-fluo ro-phenyl)-3H- imidazol-4-yl]-pyridine (115mg, Compound LJ) in methanol was added to a suspension of nickel boride which had been previously prepared by sonication of nickel chloride and sodium borohydride. The mixture was stirred and sodium borohydride (250mg) added in portions over 1 hour. The reaction mixture was filtered through a thin pad of silica gel and purified using preparative TLC eluting twice with a mixture of dichloromethane, pentane, methanol and ammonia (55:25:18:2, v/v) to give C-{2-F4-(4-fluoro-phenvl)-5-nvridin-4-vl-1H-irnidazol-2-vll- 55- dimethvl-rl,3ldioxan-4-vl -methvlamine (57mg, Compound LI). MH+ 383. RF = 0.54, eluting twice with dichloromethane, pentane, methanol and ammonia (55:25:18:2, v/v).

EXAMPLE 37 COMPOUND LJ To a solution of 4-[2-dimethoxymethyl-5(4)-(4-fluoro-phenyl)-1H-imidazol-4(5) -yl]-pyridine (115mg, Reference Example 3) in dry tetrahydrofuran was added 2,2-dimethyl-4-nitrobutane- 1,3-diol (150mg) and p-toluenesulphonic acid. The mixture was heated under reflux for 7 hours before partitioning between water and ethyl acetate and purifying using flash chromatography on silica gel eluting with ethyl acetate:methanol (9:1, v/v) to give 4-12-(5 5-dimethvl-4- nitromethyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)-3H-imidazo l-4-yl]-pyridine (130mg, Compound LJ). MH+ 413. TLC RF = 0.36 (eluting twice with ethyl acetate: on silica gel).

EXAMPLE 38 COMPOUND LK and LL (i)~Treatment of C-{2-[4-(4-fluoro-phenyl)-5-(2-methylsulphanyl-pyrimidin-4-y l)-1H-imidazol-2- yl]-5-methyl-[1,3]dioxan-5-yl}-methylamine, cis-isomer (Compound KZ) with trifluoroacetic anhydride (according to method described in Example 12); followed by (ii) treatment of compounds obtained from (i) with meta-chloroperbenzoic acid (according to method described for Example 27) gives 22-trifluoro-N-{2- [5-(2-methylsulphonyl-pyrimidin-4-yl)-4-(4-fluoro- phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-ylmethyl}-a cetamide, cis isomer (Compound LK).

By proceeding in a similar manner but using the trans-isomer of Compound KZ there is prepared 2,2,2-trifluoro-N-{2-[5-(2-methylsulphonyl-pyrimidin-4-yl)-4 -(4-fluoro-phenyl)-1H- imidazol-2-vll-5-methvl-T1 ,3ldioxan-5-vlmethvl -acetamide. trans isomer (Compound LL).

EXAMPLE 39 COMPOUND LM and LN A solution of 2-[4-(4-fluorophenyl)-5-(2-methylsulphanylpyrimidin-4-yl)-1H -imidazol-2-yl]-5- methyl-[1,3]dioxan-5-carboxylic acid methyl ester, trans isomer, (3.15g, Compound LC) in a mixture of dichloromethane and methanol (9:1, v/v) was treated with 3-chloroperoxybenzoic acid (2.2 equivalents) and stirred at room temperature for 16 hours. The solution was diluted with ether and shaken with aqueous saturated sodium bicarbonate solution. The organic solution was evaporated and the residue triturated with a mixture of ethyl acetate and ether to give 2-F4-(4- <BR> <BR> <BR> <BR> fluorohenvl)-5-(2-methvlsul phonvlpvrim idin -4-vl)-1H-im idazol-Zvll-5-m ethvl-r 1 3ldioxanJ- carboxylic acid methvl ester trans isomer (2.95g, Compound LM) as a colourless crystalline solid, m.p. 186-187~C. MH+ 477.

By proceeding in a similar manner but using 2-[4-(4-fluorophenyl)-5-(2- methylsulphanylpyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1 ,3]dioxan-5-carboxylic acid methyl ester, cis isomer (Compound LD) there is prepared 2-14-(4-fluorophenvl)-5-(2- methylenesulphonylpyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl -[1,3]dioxan-5-carboxylic acid methyl ester. cis isomer (Compound LN).

EXAMPLE 40 COMPOUND GT and A557 to A2062 (a) Step 1: A suspension of Merrifield resin (20g, chloromethylpolystyrene resin, Novabiochem) in dimethylformamide (150ml) was treated with potassium thioacetate (21g). After stirring at room temperature for 24 hours the mixture was filtered and the modified resin was washed with dimethylformamide, then with tetrahydrofuran, then with water, then with tetrahydrofuran, then with dichloromethane and then dried under high vacuum at 600C to give Resin A (20.5g). IR: 3024s, 2920s, 1691s, 1599m, 1493s, 1453s, 1130m, 758s, 700s.

Step 2: A suspension of Resin A from Step 1 (20.5g) in tetrahydrofuran (150ml) was treated with lithium borohydride (5g). After stirring at room temperature for 24 hours the mixture was filtered and the modified resin was washed with tetrahydrofuran, then with a mixture of hydrochloric acid (1N) and tetrahydrofuran (3:7, v/v), then with water, then with tetrahydrofuran, then with methanol, then with dichloromethane and then dried under high vacuum at 600C to give Resin B (20g). IR: 3026 s, 2924 s, 1599w, 1493 s, 1452 s, 757 s, 700s.

Step 3: A suspension of Resin B from Step 2 (0.log) in dimethylformamide (0.5ml) was treated with sodium hydride (5mg, 60% dispersion in mineral oil), then stirred at room temperature for 15 minutes, then treated with 2-[4-(4-fluorophenyl)-5-(2- methylylsulphonylpyrimidin-4-yl)-lH-imidazol-2-yl]-5-methyl- [1,3]dioxan-5-carboxylic acid methyl ester, trans isomer, (60mg, Compound LM) and then heated at 800 for 20 hours. The reaction mixture was filtered and the modified resin was washed with dimethylformamide, then with tetrahydrofuran, then with methanol, then with dichloromethane and then dried under high vacuum at 600C to give Resin C (O.llg).

IR:3021m, 2920 m, 1732 m, 1569 m, 1487 s, 1452s, 1091 m, 835 m, 757 s, 699 s.

Step 4: A suspension of Resin C (0.09g) in tetrahydrofuran was treated with aqueous sodium hydroxide solution (1N, 0.3ml) and then stirred at 700C for 8 hours. The reaction mixture was filtered and the modified resin was washed with tetrahydrofuran, then with a mixture of tetrahydrofuran and hydrochloric acid(lN), then with tetrahydrofuran, then with dimethylformamide, then with tetrahydrofuran, then with methanol then with dichloromethane and then dried under high vacuum at 60"C to give Resin D (0.09g). IR: 3060w, 3025 m, 2923m, 2852 w, 1720 w, 1601 m, 1571 s, 1493 s, 1452 s, 1335 s, 1235 m, 1199 m, 1183 m, 1097 s, 838 m, 760 s, 704s.

Step 5: A suspension of Resin D (0.07g) in dichloromethane was treated with oxalyl chloride solution in dichloromethane (16%), then stirred at room temperature for 10 minutes and then filtered. This procedure was repeated three times. The modified resin was washed with dichloromethane, then treated with a solution of morpholine (0.log) in dichloromethane (0.8ml). After stirring at room temperature for 10 minutes this reaction mixture was filtered and the further modifed resin was washed with dichloromethane, then with tetrahydrofuran, then with methanol, then with dichioromethane and then dried under high vacuum at 600C to give Resin E (0.07g). IR: 3025s, 2922s, 1636w, 1600w, 1570w, 1493s, 1452s, 1329w, 1181w,1115w, 759m, 704s.

Step 6: A suspension of Resin E (0.06g) in a mixture of dichloromethane (0.8ml) and methanol (0.1m1) was treated with m-chloroperoxybenzoic acid (0.24g). After stirring at room temperature for 96 hours the reaction mixture was filtered and the modified resin was washed with dichloromethane, then with tetrahydrofuran, then with methanol, then with dichloromethane and then dried under high vacuum at 600C to give Resin F (0.06g).

IR: 3082 m, 3026 s, 2927 s, 2851 w, 1635 w, 1602 m, 1582 m, 1493 m, 1452 s, 1350 w,1240 m, 1180 m, 1117 m, 1032 m, 761s, 705 s.

Step 7: A suspension of Resin F (0.04g) in dimethoxyethane (0.4ml) was treated with benzylamine (0.01ml) and then heated at 70"C for 6 hours. The reaction mixture was filtered to remove resin and the filtrate was evaporated. The residue was subjected to high pressure liquid chromatography (gradient elution using water and acetonitrile mixtures as follows: 0-2 minutes 20% acetonitrile, 2-16 minutes ramp up to 80% acetonitrile) to give the {2-r4-(4-fluoroPhenvl)-5-(2-benzvlaminonvrimidin-4-vl)-1H- imidazol-2-vi-5-methvl-F13ldioxan-5-vl -rnorpholin-4-vl-methanone trans isomer (Compound GT). MH+ 559. High pressure liquid chromatography retention time = 11 minutes.

(b) By proceeding in a similar manner but using amines of formula HNY4Y5 in Step 5; and amines of formula HNY4Y5 or sodium salts of appropriately substituted alcohols or phenols in Step 7 there is prepared Compounds A557 to A2062:- [5-(2-amino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)- 1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5- carboxylic acid amide, trans-isomer, (Compound A577); 2-[4-(4-fluoro-phenyl)-5-(2-methylamino-pyrimidin-4-yl)-1H-i midazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid amide, trans-isomer, (Compound A578);

2- [5-(2-dimethylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)- lH*imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid amide, trans-isomer, (Compound A579); 2-[5-(2-cyclopropylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl) -1H-imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid amide, trans-isomer, (Compound A580); 2-{4-(4-fluoro-phenyl)-5-[2-(piperidin-4-ylamino)-pyrimidin- 4-yl]-1H-imidazol-2-yl}-5-methyl- [1,3]dioxane-5-carboxylic acid amide, trans-isomer, (Compound A581); 2-[5-(2-cyclohexylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)- 1H-imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid amide, trans-isomer, (Compound A582); 2-{4-(4-fluoro-phenyl)-5-[2-(2-hydroxy-ethylamino)-pyrimidin -4-yl]-1H-imidazol-2-yl}-5-methyl- [1,3]dioxane-5-carboxylic acid amide, trans-isomer, (Compound A583); 2-[5-[2-(2-amino-ethylamino)-pyrimidin-4-yl]-4-(4-fluoro-phe nyl)-1H-imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid amide, trans-isomer, (Compound A584); <BR> <BR> <BR> 2-(4-(4-fluoro-phenyl)-5-(2-[3-(511-imidazol-1-yl)-propylami no]-pyrimidin-4-yl)-1H-imidazol-2 yl)-5-methyl-[1,3]dioxane-5-carboxylic acid amide, trans-isomer, (Compound A585); 2-{4-(4-fluoro-phenyl)-5-[2-(3-morpholin-4-yl-propylamino)-p yrimidin-4-yl]-1H-imidazol-2-yl}- 5-methyl-[1,3]dioxane-5-carboxylic acid amide, trans-isomer, (Compound A586); 2-{4-(4-fluoro-phenyl)-5- [2-(3-hydroxy-propylamino)-pyrimidin-4-yl]- la-imidazol-2yl)- 5- methyl-[1,3]dioxane-5-carboxylic acid amide, trans-isomer, (Compound A587); 2-[5-(2-benzylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-i midazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid amide, trans-isomer, (Compound A588); 2-{4-(4-fluoro-phenyl)-5-[2-(1-phenyl-ethylamino)-pyrimidin- 4-yl]-1H-imidazol-2-yl}-5-methyl- [1,3]dioxane-5-carboxylic acid amide, R-isomer, trans-isomer, (Compound A589); 2-{4-(4-fluoro-phenyl)-5-[2-(1-phenyl-ethylamino)-pyrimidin- 4-yl]-1H-imidazol-2-yl}-5-methyl- [1,3]dioxane-5-carboxylic acid amide, S-isomer, trans-isomer, (Compound A590); 2-[4-(4-fluoro-phenyl)-5-(2-phenylamino-pyrimidin-4-yl)-1H-i midazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid amid, trans-isomer, (Compound A591); 2-[4-(4-fluoro-phenyl)-5-(2-piperidin-1-yl-pyrimidin-4-yl)-1 H-imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid amide, trans-isomer, (Compound A592); <BR> <BR> <BR> 2-(4-(4-fluoro-phenyl)-5-{2-[(pyridin-4-ylmethyl)-amino]-pyr imidin-4-yl}-lH-imidazol-2-yl)-5- methyl-[1,3]dioxane-5-carboxylic acid amide, trans-isomer, (Compound A593); 2-(4-(4-fluoro-phenyl)-5-{2-[(pyridin-3-ylmethyl)-amino]-pyr imidin-4-yl}-1H-imidazol-2-yl)-5- methyl-[1,3]dioxane-5-carboxylic acid amide, trans-isomer, (Compound A594); 2-(4-(4-fluoro-phenyl)-5- (2- [(pyridin-2-ylmethyl)-amino]-pyrimidin-4 lH-imidazol-2-yl)-5- methyl-[1,3]dioxane-5-carboxylic acid amide, trans-isomer, (Compound A595); 2-(4-(4-fluoro-phenyl)-5-{2-[(furan-2-ylmethyl)-amino]-pyrim idin-4-yl}-1H-imidazol-2-yl)-5- methyl-[1,3]dioxane-5-carboxylic acid amide, trans-isomer, (Compound A596);

2-(4-(4-fluoro-phenyl)-5- (2-[(thiophen-2-ylmethyl)-amino]-pyrimidin-4-yl)- lH-imidazol-2-yl)-5- methyl-[1,3]dioxane-5-carboxylic acid amide, trans-isomer, (Compound A597); <BR> <BR> <BR> <BR> 2-(4-(4-fluoro-phenyl)-5-(2-[(tetrahydro-furan-2-ylmethyl)-a mino]-pyrimidin-4-yl)-111-imidazol 2-yl)-5-methyl-[1,3]dioxane-5-carboxylic acid amide, trans-isomer, (Compound A598); 2-{4-(4-fluoro-phenyl)-5-[2-(4-methyl-piperazin-1-yl)-pyrimi din-4-yl]-1H-imidazol-2-yl}-5- methyl-[1,3]dioxane-5-carboxylic acid amide, trans-isomer, (Compound A599); 2-[4-(4-fluoro-phenyl)-5-(2-morpholin-4-yl-pyrimidin-4-yl)-l H-imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid amide, trans-isomer, (Compound A600); 2-{4-(4-fluoro-phenyl)-5-[2-(3-methoxy-propylamino)-pyrimidi n-4-yl]-lH-imidazol-2-yl}-5- methyl-[1,3]dioxane-5-carboxylic acid amide, trans-isomer, (Compound A601); <BR> <BR> <BR> <BR> 2-{4-(4-fluoro-phenyl)-5-[2-(2-methoxy-ethylamino)-pyrimidin -4-yl]- H-imidazol-2-yl)- 5-methyl- [1,3]dioxane-5-carboxylic acid amide, trans-isomer, (Compound A602); 2- [5-[2-(3-dimethylamino-propylamino)-pyrimidin-4-yl]-4-(4-flu oro-phenyl)-lH-imidazol-2-yl]- 5-methyl-[1,3]dioxane-5-carboxylic acid amide, trans-isomer, (Compound A603); <BR> <BR> <BR> <BR> 2-[5-[2-(2-dimethylamino-ethylamino)-pyrimidin-4-yl]-4-(4-fl uoro-phenyl)-lH-imidazol-2-yl]-5- methyl-[1,3]dioxane-5-carboxylic acid amide, trans-isomer, (Compound A604); <BR> <BR> <BR> <BR> {4-[2-(5-Carbamoyl-5-methyl-[1,3]dioxan-2-yl)-5-(4-fluoro-ph enyl)-311-imidazol-4-yl]-pyrimidin- 2-ylamino}-acetic acid, trans-isomer, (Compound A605); 3-{4-[2-(5-Carbamoyl-5-methyl-[1,3]dioxan-2-yl)-5-(4-fluoro- phenyl)-3H-imidazol-4-yl]- pyrimidin-2-ylaminol-propionic acid, trans-isomer, (Compound A606); 2-[4-(4-fluoro-phenyl)-5-(2-isopropylamino-pyrimidin-4-yl)-1 H-imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid amide, trans-isomer, (Compound A607); 2-[5-(2-allylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-im idazol-2-yl]-5-methyl-[1,3]dioxane- 5-carboxylic acid amide, trans-isomer, (Compound A608); 2-[5-[2-(cyclopropylmethyl-amino)-pyrimidin-4-yl]-4-(4-fluor o-phenyl)-1H-imidazol-2-yl]-5- methyl-[1,3]dioxane-5-carboxylic acid amide, trans-isomer, (Compound A609); 2-[5-[2-(cyanomethyl-amino)-pyrimidin-4-yl]-4-(4-fluoro-phen yl)-1H-imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid amide, trans-isomer, (Compound A610); 2-[5-[2-(2-cyano-ethylamino)-pyrimidin-4-yl]-4-(4-fluoro-phe nyl)-1H-imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid amide, trans-isomer, (Compound A611); 2-{4-(4-fluoro-phenyl)-5-[2-(pyridin-3-ylamino)-pyrimidin-4- yl]-1H-imidazol-2-yl}-5-methyl- [1,3]dioxane-5-carboxylic acid amide, trans-isomer, (Compound A612); 2-{4-(4-fluoro-phenyl)-5-[2-(pyridin-4-ylamino)-pyrimidin-4- yl]-1H-imidazol-2-yl}-5-methyl- [1,3]dioxane-5-carboxylic acid amide, trans-isomer, (Compound A613); 2-[4-(4-fluoro-phenyl)-5-(2-propylamino-pyrimidin-4-yl)-1H-i midazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid amide, trans-isomer, (Compound A614);

2-[4-(4-fluoro-phenyl)-5-(2-pyrrolidin 1-yl-pyrimidin-4-yl)-111-imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid amide, trans-isomer, (Compound A615); <BR> <BR> <BR> 2-{4-(4-fluoro-phenyl)-5-[2-(4-fluoro-phenylamino)-pyrimidin -4-yl]-1H-imidazol-2-yl)-5-methyl- [1,3]dioxane-5-carboxylic acid amide, trans-isomer, (Compound A616); 2-[5-[2-(3,4-difluoro-phenylamino)-pyrimidin-4.yl]-4-(4-fluo ro-phenyl)-111-imidazol-2-yl]-5- methyl-[1,3]dioxane-5-carboxylic acid amide, trans-isomer, (Compound A617); 2-{4-(4-fluoro-phenyl)-5-[2-(3-methoxy-phenylamino)-pyrimidi n-4-yl]-lH-imidazol-2-yl}-5- methyl-[1,3]dioxane-5-carboxylic acid amide, trans-isomer, (Compound A618); <BR> <BR> <BR> 2-[5-[2-(4-fluoro-benzylamino)-pyrimidin-4-yl]-4-(4.fluoro-p henyl)-111-imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid amide, trans-isomer, (Compound A619); 2-{4-(4-fluoro-phenyl)-5-[2-(4-methoxy-benzylamino)-pyrimidi n-4-yl]-111-imidazol-2-yl}-5- methyl-[1,3]dioxane-5-carboxylic acid amide, trans-isomer, (Compound A620); 2-[4-(4-fluoro-phenyl)-5-(2-methoxy-pyrimidin-4-yl)-1H-imida zol-2-yl]-5-methyl-[1,3]dioxane-5- carboxylic acid amide, trans-isomer, (Compound A621); 2-[5-(2-benzyloxy-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imi dazol-2-yl]-5-methyl-[1,3]dioxane- 5-carboxylic acid amide, trans-isomer, (Compound A622); 2-[4-(4-fluoro-phenyl)-5-(2-phenoxy-pyrimidin-4-yl)-1H-imida zol-2-yl]-5-methyl-[1,3]dioxane-5- carboxylic acid amide, trans-isomer, (Compound A623); 2-{4-(4-fluoro-phenyl)-5-[2-(2-methoxy-ethoxy)-pyrimidin-4-y l]-1H-imidazol-2-yl}-5-methyl- [1,3]dioxane-5-carboxylic acid amide, trans-isomer, (Compound A624); 2-[5-[2-(2.dimethylamino-ethoxy)-pyrimidin-4-yl]-4-(4-fluoro -phenyl)-111-imidazol-2-yl]-5- methyl-[1,3]dioxane-5-carboxylic acid amide, trans-isomer, (Compound A625); 2-[5-(2-cyclohexyloxy-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H -imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid amide, trans-isomer, (Compound A626); 2-[5-(2-Isopropoxy-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-im idazol-2-yl]-5-methyl-[1,3]dioxane- 5-carboxylic acid amide, trans-isomer, (Compound A627); <BR> <BR> <BR> 2-[4-(4-fluoro-phenyl)-5-(2-propoxy-pyrimidin-4-yl)-1H-imida zol-2-yl]-5-methyl-[1,3]dioxane-5- carboxylic acid amide, trans-isomer, (Compound A628); 2-(4-(4-fluoro-phenyl)-5- [2-(2-hydroxy-ethoxy)-pyrimidin-4-yl]- lH-imidazol-2-yl}-5-methyl- [1,3]dioxane-5-carboxylic acid amide, trans-isomer, (Compound A629); 2-{4-(4-fluoro-phenyl)-5-[2-(3-hydroxy-propoxy)-pyrimidin-4- yl]-1H-imidazol-2-yl}-5-methyl- [1,3]dioxane-5-carboxylic acid amide, trans-isomer, (Compound A630); 2-[4-(4-fluoro-phenyl)-5-(2-methylsulfanyl-pyrimidin-4-yl)-1 H-imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid amide, trans-isomer, (Compound A631); 2-[5-(2-amino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-111-imidaz ol-2-yl]-5-methyl-[1,3]dioxane5 carboxylic acid methylamide, trans-isomer, (Compound A632);

2-[4-(4-fluoro-phenyl)-5-(2-methylamino-pyrimidin-4-yl)-1H-i midazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid methylamide, trans-isomer, (Compound A633); 2-[5-(2-dimethylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H -imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid methylamide, trans-isomer, (Compound A634); 2-[5-(2-cyclopropylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl) -lH-imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid methylamide, trans-isomer, (Compound A635); 2-{4-(4-fluoro-phenyl)-5-[2-(piperidin-4-ylamino)-pyrimidin- 4-yl]-1H-imidazol-2-yl}-5-methyl- [1,3]dioxane-5-carboxylic acid methylamide, trans-isomer, (Compound A636); 2-[5-(2-cyclohexylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)- 1H-imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid methylamide, trans-isomer, (Compound A637); 2-{4-(4-fluoro-phenyl)-5-[2-(2-hydroxy-ethylamino)-pyrimidin -4-yl]-1H-imidazol-2-yl}-5-methyl- [1,3]dioxane-5-carboxylic acid methylamide, trans-isomer, (Compound A638); 2-[5-[2-(2-amino-ethylamino)-pyrimidin-4-yl]-4-(4-fluoro-phe nyl)-1H-imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid methylamide, trans-isomer, (Compound A639); 2-(4-(4-fluoro-phenyl)-5-{2-[3-(5H-imidazol-1-yl)-propylamin o]-pyrimidin-4-yl}-1H-imidazol-2- yl)-5-methyl-[1,3]dioxane-5-carboxylic acid methylamide, trans-isomer, (Compound A640); 2-{4-(4-fluoro-phenyl)-5-[2-(3-morpholin-4-yl-propylamino)-p yrimidin-4-yl]-1H-imidazol-2-yl}- 5-methyl-[1,3]dioxane-5-carboxylic acid methylamide, trans-isomer, (Compound A641); 2-{4-(4-fluoro-phenyl)-5-[2-(3-hydroxy-propylamino)-pyrimidi n-4-yl]-lH-imidazol-2-yl}-5- methyl-[1,3]dioxane-5-carboxylic acid methylamide, trans-isomer, (Compound A642); 2-[5-(2-benzylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-i midazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid methylamide, trans-isomer, (Compound A643); 2-{4-(4-fluoro-phenyl)-5-[2-(1-phenyl-ethylamino)-pyrimidin- 4-yl]-1H-imidazol-2-yl}-5-methyl- [1,3]dioxane-5-carboxylic acid methylamide, R-isomer, trans-isomer, (Compound A644); 2-{4-(4-fluoro-phenyl)-5-[2-(1-phenyl-ethylamino)-pyrimidin- 4-yl]-1H-imidazol-2-yl}-5-methyl [1,3]dioxane-5-carboxylic acid methylamide, S-isomer, trans-isomer, (Compound A645); 2-[4-(4-fluoro-phenyl)-5-(2-phenylamino-pyrimidin-4-yl)-1H-i midazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid methylamide, trans-isomer, (Compound A646); 2-[4-(4-fluoro-phenyl)-5-(2-piperidin-1-yl-pyrimidin-4-yl)-1 H-imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid methylamide, trans-isomer, (Compound A647); <BR> <BR> <BR> 2-(4-(4-fluoro-phenyl)-5-(2- [(pyridin-4-ylmethyl)-amino] -pyrimidin-Cyl)-l H-imidazol-2-yl)-5- methyl-[1,3]dioxane-5-carboxylic acid methylamide, trans-isomer, (Compound A648); <BR> <BR> <BR> 2-(4-(4-fluoro-phenyl)-5-{2-[(pyridin-3-ylmethyl)-amino]-pyr imidin-4-yl}-lH-imidazol-2-yl)-5- methyl-[1,3]dioxane-5-carboxylic acid methylamide, trans-isomer, (Compound A649); 2-(4-(4-fluoro-phenyl)-5-{2-[(pyridin-2-ylmethyl)-amino]-pyr imidin-4-yl}-1H-imidazol-2-yl)-5- methyl-[1,3]dioxane-5-carboxylic acid methylamide, trans-isomer, (Compound A650);

2-(4-(4-fluoro-phenyl)-5-{2-[(furan-2-ylmethyl)-amino]-pyrim idin-4-yl}- lH-imidazol-2-yl)-5- methyl-[1,3]dioxane-5-carboxylic acid methylamide, trans-isomer, (Compound A651); <BR> <BR> <BR> 2-(4-(4-fluoro-phenyl)-5-{2-[(thiophen-2-ylmethyl)-amino]-py rimidin-4-yl}-lH-imidazol-2-yl)-5- methyl-[1,3]dioxane-5-carboxylic acid methylamide, trans-isomer, (Compound A652); <BR> <BR> <BR> 2-(4-(4-fluoro-phenyl)-5-(2-[(tetrahydro-furan-2-ylmethyl)-a mino]-pyrimidin-4-yl}-111-imidazol- 2-yl)-5-methyl-[1,3]dioxane-5-carboxylic acid methylamide, trans-isomer, (Compound A653); 2-{4-(4-fluoro-phenyl)-5-[2-(4-methyl-piperazin-1-yl)-pyrimi din-4-yl]-111-imidazol-2-yl}-5- methyl-[1,3]dioxane-5-carboxylic acid methylamide, trans-isomer, (Compound A654); 2-[4-(4-fluoro-phenyl)-5-(2-morpholin-4-yl-pyrimidin-4-yl)-1 11-imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid methylamide, trans-isomer, (Compound A655); 2-{4-(4-fluoro-phenyl)-5-[2-(3-methoxy-propylarnino)-pyrimid in-4-yl]-111-imidazol-2-yl}-5- methyl-[1,3]dioxane-5-carboxylic acid methylamide, trans-isomer, (Compound A656); <BR> <BR> <BR> 2-{4-(4-fluoro-phenyl)-5-[2-(2-methoxy-ethylamino)-pyrimidin -4-yl]- 1H-imidazol-2-yl)-5-methyl- [1,3]dioxane-5-carboxylic acid methylamide, trans-isomer, (Compound A657); 2-[5-[2-(3-dimethylamino-propylamino)-pyrimidin-4-yl]-4-(4-f luoro-phenyl)-1H-imidazol-2-yl]- 5-methyl-[1,3]dioxane-5-carboxylic acid methylamide, trans-isomer, (Compound A658); 2-[5-[2-(2-dimethylamino-propylamino)-pyrimidin-4-yl]-4-(4-f luoro-phenyl)-1H-imidazol-2-yl]-5- methyl-[1,3]dioxane-5-carboxylic acid methylamide, trans-isomer, (Compound A659); {4-[5-(4-fluoro-phenyl)-2-(5-methyl-5-methylcarbamoyl-[1,3]d ioxan-2-yl)-311-imidazol-4-yl] pyrimidin-2-ylamino)-acetic acid, trans-isomer, (Compound A660); 3-{4-[5-(4-fluoro-phenyl)-2-(5-methyl-5-methylcarbamoyl-[1,3 ]dioxan-2-yl)-3H-imidazol-4-yl]- pyrimidin-2-ylamino}-propionic acid, trans-isomer, (Compound A661); 2-[4-(4-fluoro-phenyl)-5-(2-isopropylamino-pyrimidin-4-yl)-1 H-imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid methylamide, trans-isomer, (Compound A662); 2-[5-(2-allylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-im idazol-2-yl]-5-methyl-[1,3]dioxane- 5-carboxylic acid methylamide, trans-isomer, (Compound A663); 2-[5-[2-(cyclopropylmethyl-amino)-pyrimidin-4.yl]-4-(4-fluor o-phenyl)-111-imidazol-2-ylj5 methyl-[1,3]dioxane-5-carboxylic acid methylamide, trans-isomer, (Compound A664); 2-[5-[2-(cyanomethyl-amino)-pyrimidin-4-yl]-4-(4-fluoro-phen yl)-1H-imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid methylamide, trans-isomer, (Compound A665); 2-[5-[2-(2-cyano-ethylamino)-pyrimidin-4-yl]-4-(4-fluoro-phe nyl)-1H-imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid methylamide, trans-isomer, (Compound A666); 2-{4-(4-fluoro-phenyl)-5-[2-(pyridin-3-ylamino)-pyrimidin-4- yl]-1H-imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid methylamide, trans-isomer, (Compound A667); 2-{4-(4-fluoro-phenyl)-5-[2-(pyridin-4-ylamino)-pyrimidin-4- yl]-1H-imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid methylamide, trans-isomer, (Compound A668);

2-[4-(4-fluoro-phenyl)-5-(2-propylamino-pyrimidin-4-yl)- lH-imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid methylamide, trans-isomer, (Compound A669); 2-[4-(4-fluoro-phenyl)-5-(2-pyrrolidin-1-yl-pyrimidin-4-yl)- lH-imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid methylamide, trans-isomer, (Compound A670); <BR> <BR> <BR> <BR> 2-{4-(4-fluoro-phenyl)-5-[2-(4-fluoro-phenylamino)-pyrimidin -4-yl]-111-imidazol-2-yl}-5-methyl- [1,3]dioxane-5-carboxylic acid methylamide, trans-isomer, (Compound A671); 2-[5-[2-(3,4-difluoro-phenylamino)-pyrimidin-4-yl]-1H-imidaz ol-2-yl]-5- methyl-[1,3]dioxane-5-carboxylic acid methylamide, trans-isomer, (Compound A672); 2-{4-(4-fluoro-phenyl)-5-[2-(3-methoxy-phenylamino)-pyrimidi n-4-yl]-1H-imidazol-2-yl}-5- methyl-[1,3]dioxane-5-carboxylic acid methylamide, trans-isomer, (Compound A673); <BR> <BR> <BR> <BR> 2-[5-{ 2-(4-fluoro-benzylamino)-pyrimidin-4-yl]-4(4-fluoro-phenyl)- lH-imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid methylamide, trans-isomer, (Compound A674); 2-{4-(4-fluoro-phenyl)-5-[2-(4-methoxy-benzylamino)-pyrimidi n-4-yl]-1H-imidazol-2-yl]-5- methyl-[1,3]dioxane-5-carboxylic acid methylamide, trans-isomer, (Compound A675); 2-[4-(4-fluoro-phenyl)-5-(2-methoxy-pyrimidin-4-yl)-1H-imida zol-2-yl]-5-methyl-[1,3]dioxane-5- carboxylic acid methylamide, trans-isomer, (Compound A676); <BR> <BR> <BR> <BR> 2-[5 -(2-benzyloxy-pyrimidin-4-yl) -4-(4-fluoro-phenyl) -1H-imidazol-2-yl] -5-methyl-[1,3] dioxane- 5-carboxylic acid methylamide, trans-isomer, (Compound A677); 2-[4-(4-fluoro-phenyl)-5-(2-phenoxy-pyrimidin-4-yl)-1H-imida zol-2-yl]-5-methyl-[1,3]dioxane-5- carboxylic acid methylamide, trans-isomer, (Compound A678); 2-{4-(4-fluoro-phenyl)-5-[2-(2-methoxy-ethoxy)-pyrimidin-4-y l]- lH-imidazol-2-yl 1-5-methyl- [1,3]dioxane-5-carboxylic acid methylamide, trans-isomer, (Compound A679); 2-[5-[2-(2-dimethylamino-ethoxy)-pyrimidin-4-yl]-4-(4-fluoro -phenyl)-1H-imidazol-2-yl]-5- methyl-[1,3]dioxane-5-carboxylic acid methylamide, trans-isomer, (Compound A680); 2-[5-(2-cyclohexyloxy-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H -imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid methylamide, trans-isomer, (Compound A681); 2-[5-(2-Isopropoxy-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-im idazol-2-yl]-5-methyl-[1,3]dioxane- 5-carboxylic acid methylamide, trans-isomer, (Compound A682); 2-[4-(4-fluoro-phenyl)-5-(2-propoxy-pyrimidin-4-yl)-1H-imida zol-2-yl]-5-methyl-[1,3]dioxane-5- carboxylic acid methylamide, trans-isomer, (Compound A683); 2-{4-(4-fluoro-phenyl)-5-[2-(2-hydroxy-ethoxy)-pyrimidin-4-y l]- 1H-imidazol- 2-yl)- 5-m ethyl- [1,3]dioxane-5-carboxylic acid methylamide, trans-isomer, (Compound A684); 2-{4-(4-fluoro-phenyl)-5-[2-(3-hydroxy-propoxy)-pyrimidin-4- yl]-1H-imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid methylamide, trans-isomer, (Compound A685); 2-[4-(4-fluoro-phenyl)-5-(2-methylsulfanyl-pyrimidin-4-yl)-1 H-imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid methylamide, trans-isomer, (Compound A686);

2-t5-(2-amino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)- 1H-imidazol-2-yli-5-methyl-[1,3]dioxane-5- carboxylic acid dimethylamide, trans-isomer, (Compound A687); 2-[4-(4-fluoro-phenyl)-5-(2-methylamino-pyrimidin-4-yl)-1H-i midazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid dimethylamide, trans-isomer, (Compound A688); 2-[5-(2-dimethylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H -imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid dimethylamide, trans-isomer, (Compound A689); 2-[5-(2-cyclopropylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl) -1H-imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid dimethylamide, trans-isomer, (Compound A690); 2-{4-(4-fluoro-phenyl)-5-[2-(piperidin-4-ylamino)-pyrimidin- 4-yl]-1H-imidazol-2-yl}-5-methyl- [1,3]dioxane-5-carboxylic acid dimethylamide, trans-isomer, (Compound A691); 2-[5-(2-cyclohexylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)- lH-imidazol-2-yl]-5-methyl- [1,3jdioxane-5-carboxylic acid dimethylamide, trans-isomer, (Compound A692); 2-{4-(4-fluoro-phenyl)-5-[2-(2-hydroxy-ethylamino)-pyrimidin -4-yl]-1H-imidazol-2-yl}-5-methyl- [1,3]dioxane-5-carboxylic acid dimethylamide, trans-isomer, (Compound A693); 2-[5-[2-(2-amino-ethylamino)-pyrimidin-4-yl]-4-(4-fluoro-phe nyl)-1H-imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid dimethylamide, trans-isomer, (Compound A694); 2-(4-(4-fluoro-phenyl)-5-{2-[3-(5H-imidazol-1-yl)-propylamin o]-pyrimidin-4-yl}-1H-imidazol-2- yl)-5-methyl-[1,3]dioxane-5-carboxylic acid dimethylamide, trans-isomer, (Compound A695); <BR> <BR> <BR> <BR> 2-{4-(4-fluoro-phenyl)-5-[2-(3-morpholin-4-yl-propylamino)-p yrimidin-4-yl]-lH-imidazol-2-yl}- 5-methyl-[1,3]dioxane-5-carboxylic acid dimethylamide, trans-isomer, (Compound A696); 2-{4-(4-fluoro-phenyl)-5-[2-(3-hydroxy-propylamino)-pyrimidi n-4-yl]- 111-imidazol-2-yl)-5- methyl-[1,3]dioxane-5-carboxylic acid dimethylamide, trans-isomer, (Compound A697); 2-[5-(2-benzylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-i midazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid dimethylamide, trans-isomer, (Compound A698); 2-{4-(4-fluoro-phenyl)-5-[2-(1-phenyl-ethylamino)-pyrimidin- 4-yl]-1H-imidazol-2-yl}-5-methyl- [1,3]dioxane-5-carboxylic acid dimethylamide, R-isomer, trans-isomer, (Compound A699); 2-{4-(4-fluoro-phenyl)-5-[2-(1-phenyl-ethylamino)-pyrimidin- 4-yl]-1H-imidazol-2-yl}-5-methyl- [1,3]dioxane-5-carboxylic acid dimethylamide, S-isomer, trans-isomer, (Compound A700); 2-[4-(4-fluoro-phenyl)-5-(2-phenylamino-pyrimidin-4-yl)-1H-i midazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid dimethylamide, trans-isomer, (Compound A701); 2-[4-(4-fluoro-phenyl)-5-(2-piperidin- 1-yl-pyrimidin-4-yl)-lH-imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid dimethylamide, trans-isomer, (Compound A702); <BR> <BR> <BR> <BR> 2-(4-(4-fluoro-phenyl)-5-{2-[(pyridin-4-ylmethyl)-amino]-pyr imidin-4-yl}-lH-imidazol-2-yl)-5- methyl-[1,3]dioxane-5-carboxylic acid dimethylamide, trans-isomer, (Compound A703); 2-(4-(4-fluoro-phenyl)-5-{2-[(pyridin-3-ylmethyl)-amino]-pyr imidin-4-yl}-1H-imidazol-2-yl)-5- methyl-[1,3]dioxane-5-carboxylic acid dimethylamide, trans-isomer, (Compound A704);

2-(4-(4-fluoro-phenyl)-5-{2-[(pyridin-2-ylmethyl)-amino]-pyr imidin-4-yl}-1H-imidazol-2-yl)-5- methyl- [1,3]dioxane-5-carboxylic acid dimethylamide, trans-isomer, (Compound A705); 2-(4-(4-fluoro-phenyl)-5-{2-[(furan-2-ylmethyl)-amino]-pyrim idin-4-yl}-lH-imidazol-2-yl)-5- methyl-[1,3]dioxane-5-carboxylic acid dimethylamide, trans-isomer, (Compound A706); <BR> <BR> <BR> <BR> 2-(4-(4-fluoro-phenyl)-5-{2-[(thiophen-2-ylmethyl)-amino]-py rimidin-4-yl)-111-imidazol-2-yl)-5- methyl-[1,3]dioxane-5-carboxylic acid dimethylamide, trans-isomer, (Compound A707); <BR> <BR> <BR> <BR> 2-(4-(4-fluoro-phenyl)-5-{2-[(tetrahydro-furan-2-ylmethyl)-a mino]-pyrimidin-4-yl}-lH-imidazol- 2-yl)-5-methyl-[1,3]dioxane-5-carboxylic acid dimethylamide, trans-isomer, (Compound A708); 2-{4-(4-fluoro-phenyl)-5-[2-(4-methyl-piperazin-1-yl)-pyrimi din-4-yl]-lH-imidazol-2-yl}-5- methyl-[1,3]dioxane-5-carboxylic acid dimethylamide, trans-isomer, (Compound A709); 2-[4-(4-fluoro-phenyl)-5-(2-morpholin-4-yl-pyrimidin-4-yl)-l H-imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid dimethylamide, trans-isomer, (Compound A710); 2-{4-(4-fluoro-phenyl)-5-[2-(3-methoxy-propylamino)-pyrimidi n-4-yl]-1H-imidazol-2-yl}-5- methyl-[1,3]dioxane-5-carboxylic acid dimethylamide, trans-isomer, (Compound A711); 2-{4-(4-fluoro-phenyl)-5-[2-(2-methoxy-ethylamino)-pyrimidin -4-yl]-1H-imidazol-2-yl}-5-methyl- [1,3]dioxane-5-carboxylic acid dimethylamide, trans-isomer, (Compound A712); 2-[5-[2-(3-dimethylamino-propylamino)-pyrimidin-4-yl]-4-(4-f luoro-phenyl)-1H-imidazol-2-yl]- 5-methyl-[1,3]dioxane-5-carboxylic acid dimethylamide, trans-isomer, (Compound A713); 2-[5-[2-(2-dimethylamino-ethylamino)-pyrimidin-4-yl]-4-(4-fl uoro-phenyl)-1H-imidazol-2-yl]-5- methyl-[1,3]dioxane-5-carboxylic acid dimethylamide, trans-isomer, (Compound A714); (4-[2- (5-dimethylcarbamoyl-5-methyl- [1,3]dioxan-2-yl)-5- (4-fluoro-phenyl)-3H-imidazol-4-yl]- pyrimidin-2-ylamino)-acetic acid, trans-isomer, (Compound A715); 3-{4-[2-(5-dimethylcarbamoyl-5-methyl-[1,3]dioxan-2-yl)-5-(4 -fluoro-phenyl)-3H-imidazol-4-yl]- pyrimidin-2-ylamino)-propionic acid, trans-isomer, (Compound A716); 2-[4-(4-fluoro-phenyl)-5-(2-isopropylamino-pyrimidin-4-yl)-1 H-imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid dimethylamide, trans-isomer, (Compound A717); 2-[5-(2-allylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-im idazol-2-yl]-5-methyl-[1,3]dioxane- 5-carboxylic acid dimethylamide, trans-isomer, (Compound A718); 2-[5-[2-(cyclopropylmethyl-amino)-pyrimidin-4-yl]-4-(4-fluor o-phenyl)-1H-imidazol-2-yl]-5- methyl-[1,3]dioxane-5-carboxylic acid dimethylamide, trans-isomer, (Compound A719); 2-[5-[2-(cyanomethyl-amino)-pyrimidin-4-yl]-4-(4-fluoro-phen yl)-1H-imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid dimethylamide, trans-isomer, (Compound A720); 2-[5-[2-(2-cyano-ethylamino)-pyrimidin-4-yl]-4-(4-fluoro-phe nyl)-1H-imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid dimethylamide, trans-isomer, (Compound A721); 2-{4-(4-fluoro-phenyl)-5-[2-(pyridin-3-ylamino)-pyrimidin-4- yl]- 111-imidazol-2-yl)-5-methyl- [1,3]dioxane-5-carboxylic acid dimethylamide, trans-isomer, (Compound A722);

2-{4-(4-fluoro-phenyl)-5-[2-(pyridin-4-ylamino)-pyrimidin-4- yl]-1H-imidazol-2-yl}-5-methyl- [1,3]dioxane-5-carboxylic acid dimethylamide, trans-isomer, (Compound A723); 2-[4-(4-fluoro-phenyl)-5-(2-propylamino-pyrimidin-4-yl)-1H-i midazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid dimethylamide, trans-isomer, (Compound A724); 2-[4-(4-fluoro-phenyl)-5-(2-pyrrolidin 1-yl-pyrimidin-4-yl)-lH-imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid dimethylamide, trans-isomer, (Compound A725); <BR> <BR> <BR> 2-{4-(4-fluoro-phenyl)-5-[2-(4-fluoro-phenylamino)-pyrimidin -4-yl]- 1H-imidazol- 2-yl)-5-methyl- [1,3]dioxane-5-carboxylic acid dimethylamide, trans-isomer, (Compound A726); 2-[5-[2-(3,4-difluoro-phenylamino)-pyrimidin-4-yl]-4-(4-fluo ro-phenyl)-1H-imidazol2ylj-5- methyl-[1,3]dioxane-5-carboxylic acid dimethylamide, trans-isomer, (Compound A727); 2-{4-(4-fluoro-phenyl)-5-[2-(3-methoxy-phenylamino)-pyrimidi n-4-yl]-1H-imidazol-2-yl}-5- methyl-[1,3]dioxane-5-carboxylic acid dimethylamide, trans-isomer, (Compound A728); 2-[5-[2-(4-fluoro-benzylamino)-pyrimidin-4-yl]-4-(4-fluoro-p henyl)-1H-imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid dimethylamide, trans-isomer, (Compound A729); 2-{4-(4-fluoro-phenyl)-5-[2-(4-methoxy-benzylamino)-pyrimidi n-4-yl]-1H-imidazol-2-yl}-5- methyl-[1,3]dioxane-5-carboxylic acid dimethylamide, trans-isomer, (Compound A730); 2-[4-(4-fluoro-phenyl)-5-(2-methoxy-pyrimidin-4-yl)-1H-imida zol-2-yl]-5-methyl-[1,3]dioxane-5- carboxylic acid dimethylamide, trans-isomer, (Compound A731); 2-[5-(2-benzyloxy-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imi dazol-2-yl]-5-methyl-[1,3]dioxane- 5-carboxylic acid dimethylamide, trans-isomer, (Compound A732); 2-[4-(4-fluoro-phenyl)-5-(2-methoxy-pyrimidin-4-yl)-1H-imida zol-2-yl]-5-methyl-[1,3]dioxane-5- carboxylic acid dimethylamide, trans-isomer, (Compound A733); 2-{4-(4-fluoro-phenyl)-5-[2-(2-methoxy-ethoxy)-pyrimidin-4-y l]-1H-imidazol-2-yl}-5-methyl- [1,3]dioxane-5-carboxylic acid dimethylamide, trans-isomer, (Compound A734); 2-[5-[2-(2-dimethylamino-ethoxy)-pyrimidin-4-yl]-4-(4-fluoro -phenyl)-1H-imidazol-2-yl]-5- methyl-[1,3]dioxane-5-carboxylic acid dimethylamide, trans-isomer, (Compound A735); 2-[5-(2-cyclohexyloxy-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H -imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid dimethylamide, trans-isomer, (Compound A736); 2-[5-(2-Isopropoxy-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-im idazol-2-yl]-5-methyl-[1,3]dioxane- 5-carboxylic acid dimethylamide, trans-isomer, (Compound A737); 2-[4-(4-fluoro-phenyl)-5-(2-propoxy-pyrimidin-4-yl)-1H-imida zol-2-yl]-5-methyl-[1,3]dioxane-5- carboxylic acid dimethylamide, trans-isomer, (Compound A738); 2-{4-(4-fluoro-phenyl)-5-[2-(2-hydroxy-ethoxy)-pyrimidin-4-y l]- 1H- imidazol- 2-yl)- 5- methyl- [1,3]dioxane-5-carboxylic acid dimethylamide, trans-isomer, (Compound A739); 2-{4-(4-fluoro-phenyl)-5-[2-(3-hydroxy-propoxy)-pyrimidin-4- yl]-1H-imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid dimethylamide, trans-isomer, (Compound A740);

2-[4-(4-fluoro-phenyl)-5-(2-methylsulfanyl-pyrimidin-4-yl)- lH-imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid dimethylamide, trans-isomer, (Compound A741); 2-[5-(2-amino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-111-imidaz ol-2-yl]-5-methyl-[1,3]dioxane-5 carboxylic acid cyclopropylamide, trans-isomer, (Compound A742); 2-[4-(4-fluoro-phenyl)-5-(2-methylamino-pyrimidin-4-yl)-1H-i midazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid cyclopropylamide, trans-isomer, (Compound A743); 2-[5-(2-dimethylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H -imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid cyclopropylamide, trans-isomer, (Compound A744); 2-[5-(2-cyclopropylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl) -lH-imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid cyclopropylamide, trans-isomer, (Compound A745); <BR> <BR> <BR> <BR> 2-{4-(4-fluoro-phenyl)-5-[2-(piperidin-4-ylamino)-pyrimidin- 4-yl]-lH-imidazol-2-yl}-5-methyl- [1,3]dioxane-5-carboxylic acid cyclopropylamide, trans-isomer, (Compound A746); 2-[5-(2-cyclohexylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)- 1H-imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid cyclopropylamide, trans-isomer, (Compound A747); 2-{4-(4-fluoro-phenyl)-5-[2-(2-hydroxy-ethylamino)-pyrimidin -4-yl]-1H-imidazol-2-yl}-5-methyl- [1,3]dioxane-5-carboxylic acid cyclopropylamide, trans-isomer, (Compound A748); 2-[5-[2-(2-amino-ethylamino)-pyrimidin-4-yl]-4-(4-fluoro-phe nyl)-1H-imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid cyclopropylamide, trans-isomer, (Compound A749); <BR> <BR> <BR> <BR> 2-(4-(4-fluoro-phenyl)-5-{2-[3-(5H-imidazol-1-yl)-propylamin o]-pyrimidin-4-yl}-lH-imidazol-2- yl)-5-methyl-[1,3]dioxane-5-carboxylic acid cyclopropylamide, trans-isomer, (Compound A750); 2-{4-(4-fluoro-phenyl)-5-[2-(3-morpholin-4-yl-propylamino)-p yrimidin-4-yl]-1H-imidazol-2-yl}- 5-methyl-[1,3]dioxane-5-carboxylic acid cyclopropylamide, trans-isomer, (Compound A751); 2-{4-(4-fluoro-phenyl)-5-[2-(3-hydroxy-propylamino)-pyrimidi n-4-yl]-1H-imidazol-2-yl}-5- methyl-[1,3]dioxane-5-carboxylic acid cyclopropylamide, trans-isomer, (Compound A752); 2-[5-(2-benzylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-i midazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid cyclopropylamide, trans-isomer, (Compound A753); 2-{4-(4-fluoro-phenyl)-5-[2-(1-phenyl-ethylamino)-pyrimidin- 4-yl]-1H-imidazol-2-yl}-5-methyl- [1,3]dioxane-5-carboxylic acid cyclopropylamide, R-isomer, trans-isomer, (Compound A754); 2-{4-(4-fluoro-phenyl)-5-[2-(1-phenyl-ethylamino)-pyrimidin- 4-yl]-1H-imidazol-2-yl}-5-methyl- [1,3]dioxane-5-carboxylic acid cyclopropylamide, S-isomer, trans-isomer, (Compound A755); 2-[4-(4-fluoro-phenyl)-5-(2-phenylamino-pyrimidin-4-yl)-1H-i midazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid cyclopropylamide, trans-isomer, (Compound A756); 2-[4-(4-fluoro-phenyl)-5-(2-piperidin- 1-yl-pyrimidin-4-yl)-111-imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid cyclopropylamide, trans-isomer, (Compound A757); <BR> <BR> <BR> <BR> 2-(4-(4-fluoro-phenyl)-5-{2-[(pyridin-4-ylmethyl)-amino]-pyr imidin-4-yl}-lH-imidazol-2-yl)-5- methyl-[1,3]dioxane-5-carboxylic acid cyclopropylamide, trans-isomer, (Compound A758);

2-(4-(4-fluoro-phenyl)-5-{2-[(pyridin-3-ylmethyl)-amino3-pyr imidin-4-yl}-lH-imidazol-2-yl)-5- methyl-[1,3]dioxane-5-carboxylic acid cyclopropylamide, trans-isomer, (Compound A759); <BR> <BR> <BR> 2-(4-(4-fluoro-phenyl)-5-{2-[(pyridin-2-ylmethyl)-amino]-pyr imidin-4-yl )-111-imidazol-2-yl)-5- methyl-[1,3]dioxane-5-carboxylic acid cyclopropylamide, trans-isomer, (Compound A760); 2-(4-(4-fluoro-phenyl)-5-{2-[(furan-2-ylmethyl)-aminoi-pyrim idin-4-yl l-111-imidazol-2-yl)-5 methyl- [1,3]dioxane-5-carboxylic acid cyclopropylamide, trans-isomer, (Compound A761); <BR> <BR> <BR> 2-(4-(4-fluoro-phenyl)-5-{2-[(thiophen-2-ylmethyl)-amino]-py rimidin-4-yl)- 111-imidazol-2-yl)-5- methyl-[1,3]dioxane-5-carboxylic acid cyclopropylamide, trans-isomer, (Compound A762); <BR> <BR> <BR> <BR> 2-(4-(4-fluoro-phenyl)-5-{2-[(tetrahydro-furan-2-ylmethyl)-a mino]-pyrimidin-4-ylj- 111-imidazol- 2-yl)-5-methyl-[1,3]dioxane-5-carboxylic acid cyclopropylamide, trans-isomer, (Compound A763); 2-{4-(4-fluoro-phenyl)-5-[2-(4-methyl-piperazin-1-yl)-pyrimi din-4-yl]-1H-imidazol-2-yl}-5- methyl-[1,3]dioxane-5-carboxylic acid cyclopropylamide, trans-isomer, (Compound A764); 2-[4-(4-fluoro-phenyl)-5-(2-morpholin-4-yl-pyrimidin-4-yl)-1 H-imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid cyclopropylamide, trans-isomer, (Compound A765); 2-{4-(4-fluoro-phenyl)-5-[2-(3-methoxy-propylamino)-pyrimidi n-4-yl]-1H-imidazol-2-yl}-5- methyl-[1,3]dioxane-5-carboxylic acid cyclopropylamide, trans-isomer, (Compound A766); 2-{4-(4-fluoro-phenyl)-5-[2-(2-methoxy-ethylamino)-pyrimidin -4-yl]-1H-imidazol-2-yl}-5-methyl- [1,3]dioxane-5-carboxylic acid cyclopropylamide, trans-isomer, (Compound A767); 2-[5-[2-(3-dimethylamino-propylamino)-pyrimidin-4-yl]-4-(4-f luoro-phenyl)-1H-imidazol-2-yl]- 5-methyl-[1,3]dioxane-5-carboxylic acid cyclopropylamide, trans-isomer, (Compound A768); 2-[5-[2-(2-dimethylamino-ethylamino)-pyrimidin-4-yl]-4-(4-fl uoro-phenyl)-1H-imidazol-2-yl]-5- methyl-[1,3]dioxane-5-carboxylic acid cyclopropylamide, trans-isomer, (Compound A769); {4-[2-(5-cyclopropylcarbamoyl-5-methyl-[1,3]dioxan-2-yl)-5-( 4-fluoro-phenyl)-3H-imidazol-4-yl]- pyrimidin-2-ylamino)-acetic acid, trans-isomer, (Compound A770); <BR> <BR> <BR> 3-(4- [2-(5-cyclopropylcarbamoyl- 5-methyl- [1,3]dioxan-2-yl)- 5- (6fluoro-phenyl)- 3H-imidazol-4- yl]-pyrimidin-2-ylamino)-propionic acid, trans-isomer, (Compound A771); 2-[4-(4-fluoro-phenyl)-5-(2-isopropylamino-pyrimidin-4-yl)-1 H-imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid cyclopropylamide, trans-isomer, (Compound A772); 2-[5-(2-allylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-im idazol-2-yl]-5-methyl-[1,3]dioxane- 5-carboxylic acid cyclopropylamide, trans-isomer, (Compound A773); 2-[5-[2-(cyclopropylmethyl-amino)-pyrimidin-4-yl]-4-(4-fluor o-phenyl)-1H-imidazol-2-yl]-5- methyl-[1,3]dioxane-5-carboxylic acid cyclopropylamide, trans-isomer, (Compound A774); 2-[5-[2-(cyanomethyl-amino)-pyrimidin-4-yl]-4-(4-fluoro-phen yl)-1H-imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid cyclopropylamide, trans-isomer, (Compound A775);

2-[5-[2-(2-cyano-ethylamino)-pyrimidin-4-yl]-4-(4-fluoro-phe nyl)- H-imidazol-2-yl] -5-methyl- [1,3]dioxane-5-carboxylic acid cyclopropylamide, trans-isomer, (Compound A776); <BR> <BR> <BR> 2-[5-[2-(2-cyano-ethylamino)-pyrimidin-4-yl]-4-(4-fluoro-phe nyl)-lH-imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid cyclopropylamide, trans-isomer, (Compound A777); 2-{4-(4-fluoro-phenyl)-5-[2-(pyridin-3-ylamino)-pyrimidin-4- yl]-lH-imidazol-2-yl}-5-methyl- [1,3]dioxane-5-carboxylic acid cyclopropylamide, trans-isomer, (Compound A778); 2-{4-(4-fluoro-phenyl)-5-[2-(pyridin-4-ylamino)-pyrimidin-4- yl]-1H-imidazol-2-yl}-5-methyl- [1,3]dioxane-5-carboxylic acid cyclopropylamide, trans-isomer, (Compound A779); 2-[4-(4-fluoro-phenyl)-5-(2-propylamino-pyrimidin-4-yl)-1H-i midazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid cyclopropylamide, trans-isomer, (Compound A780); 2-[4-(4-fluoro-phenyl)-5-(2-pyrrolidin-1-yl-pyrimidin-4-yl)- lH-imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid cyclopropylamide, trans-isomer, (Compound A781); <BR> <BR> <BR> 2-(4-(4-fluoro-phenyl) -5- [2-(4-fluoro-phenylamino)-pyrimidin-4-yl] 1H-imidazol-2-yl)-5-methyl- [1,3]dioxane-5-carboxylic acid cyclopropylamide, trans-isomer, (Compound A782); 2-[5-[2-(3,4-difluoro-phenylamino)-pyrimidin-4-yl]-4-(4-fluo ro-phenyl)-1H-imidazol-2-yl]-5- methyl-[1,3]dioxane-5-carboxylic acid cyclopropylamide, trans-isomer, (Compound A783); 2-{4-(4-fluoro-phenyl)-5-[2-(3-methoxy-phenylamino)-pyrimidi n-4-yl]-1H-imidazol-2-yl}-5- methyl-[1,3]dioxane-5-carboxylic acid cyclopropylamide, trans-isomer, (Compound A784); 2-[5-[2-(4-fluoro-benzylamino)-pyrimidin-4-yl]-4-(4-fluoro-p henyl)-1H-imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid cyclopropylamide, trans-isomer, (Compound A785); 2-{4-(4-fluoro-phenyl)-5-[2-(4-methoxy-benzylamino)-pyrimidi n-4-yl]-1H-imidazol-2-yl}-5- methyl-[1,3]dioxane-5-carboxylic acid cyclopropylamide, trans-isomer, (Compound A786); 2-[4-(4-fluoro-phenyl)-5-(2-methoxy-phenylamino-4-yl)-1H-imi dazol-2-yl]-5-methyl-[1,3]dioxane-5- carboxylic acid cyclopropylamide, trans-isomer, (Compound A787); 2-[5-(2-benzyloxy-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imi dazol-2-yl]-5-methyl-[1,3]dioxane- 5-carboxylic acid cyclopropylamide, trans-isomer, (Compound A788); 2-[4-(4-fluoro-phenyl)-5-(2-phenoxy-pyrimidin-4-yl)-1H-imida zol-2-yl]-5-methyl-[1,3]dioxane-5- carboxylic acid cyclopropylamide, trans-isomer, (Compound A789); 2-{4-(4-fluoro-phenyl)-5-[2-(2-methoxy-ethoxy)-pyrimidin-4-y l]-1H-imidazol-2-yl}-5-methyl- [1,3]dioxane-5-carboxylic acid cyclopropylamide, trans-isomer, (Compound A790); 2-[5-[2-(2-dimethylamino-ethoxy)-pyrimidin-4-yl]-4-(4-fluoro -phenyl)-1H-imidazol-2-yl]-5- methyl-[1,3]dioxane-5-carboxylic acid cyclopropylamide, trans-isomer, (Compound A791); 2-[5-(2-cyclohexyloxy-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H -imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid cyclopropylamide, trans-isomer, (Compound A792); 2-[5-(2-Isopropoxy-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-im idazol-2-yl]-5-methyl-[1,3]dioxane- 5-carboxylic acid cyclopropylamide, trans-isomer, (Compound A793);

2- [4-(4-fluoro-phenyl)-5-(2-propoxy-pyrimidin-4yl)- lH-imidazol-2-yl]-5-methyl-[1,3]dioxane-5- carboxylic acid cyclopropylamide, trans-isomer, (Compound A794); 2-{4-(4-fluoro-phenyl)-5-[2-(2-hydroxy-ethoxy)-pyrimidin-4-y l]-111-imidazol-2-yl}-5-methyl- [1,3]dioxane-5-carboxylic acid cyclopropylamide, trans-isomer, (Compound A795); <BR> <BR> <BR> 2-{4-(4-fluoro-phenyl)-5-[2-(3-hydroxy-propoxy)-pyrimidin-4- yl]-111-imidazol-2-yl)-5-methyl- [1,3]dioxane-5-carboxylic acid cyclopropylamide, trans-isomer, (Compound A796); 2-[4-(4-fluoro-phenyl)-5-(2-methylsulfanyl-pyrimidin-4-yl)- 1H-imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid cyclopropylamide, trans-isomer, (Compound A797); 2-[5-(2-amino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-111-imidaz ol-2-yl]-5-methyl-[1,3]dioxane-5 carboxylic acid propylamide, trans-isomer, (Compound A798); 2-[4-(4-fluoro-phenyl)-5-(2-methylamino-pyrimidin-4-yl)-lH-i midazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid propylamide, trans-isomer, (Compound A799); 2-[5-(2-dimethylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-11 1-imidazol-2-yli-5-methyl- [1,3]dioxane-5-carboxylic acid propylamide, trans-isomer, (Compound A800); 2- [5-(2-cyclopropylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)- 1H-imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid propylamide, trans-isomer, (Compound A801); 2-{4-(4-fluoro-phenyl)-5-[2-(piperidin-4-ylamino)-pyrimidin- 4-yl]-1H-imidazol-2-yl}-5-methyl- [1,3]dioxane-5-carboxylic acid propylamide, trans-isomer, (Compound A802); 2-[5-(2-cyclohexylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)- 1H-imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid propylamide, trans-isomer, (Compound A803); <BR> <BR> <BR> 2-(4-(4-fluoro-phenyl)-5- [2-(2-hydroxy-ethylamino)-pyrimidin-4-yl 1H-imidazol-2-yl )-5-methyl- [1,3]dioxane-5-carboxylic acid propylamide, trans-isomer, (Compound A804); 2-[5-[2-(2-amino-ethylamino)-pyrimidin-4-yl]-4-(4-fluoro-phe nyl)-1H-imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid propylamide, trans-isomer, (Compound A805); <BR> <BR> <BR> <BR> 2-(4-(4-fluoro-phenyl)-5-{2-[3-(5H-imidazol-1-yl)-propylamin o]-pyrimidin-4-yl}-lH-imidazol-2- yl)-5-methyl-[1,3]dioxane-5-carboxylic acid propylamide, trans-isomer, (Compound A806); 2-{4-(4-fluoro-phenyl)-5-[2-(3-morpholin-4-yl-propylamino)-p yrimidin-4-yl]-1H-imidazol-2-yl}- 5-methyl-[1,3]dioxane-5-carboxylic acid propylamide, trans-isomer, (Compound A807); 2-{4-(4-fluoro-phenyl)-5-[2-(3-hydroxy-propylamino)-pyrimidi n-4-yl]-1H-imidazol-2-yl}-5- methyl-[1,3]dioxane-5-carboxylic acid propylamide, trans-isomer, (Compound A808); 2-[5-(2-benzylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-i midazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid propylamide, trans-isomer, (Compound A809); 2-{4-(4-fluoro-phenyl)-5-[2-(1-phenyl-ethylamino)-pyrimidin- 4-yl]-1H-imidazol-2-yl}-5-methyl- [1,3]dioxane-5-carboxylic acid propylamide, R-isomer, trans-isomer, (Compound A810); 2-[4-(4-fluoro-phenyl)-5-[2-(1-phenyl-ethylamino)-pyrimidin- 4-yl]-1H-imidazol-2-yl}-5-methyl- [1,3]dioxane-5-carboxylic acid propylamide, S-isomer, trans-isomer, (Compound A811);

2-[4-(4-fluoro-phenyl)-5-{2-phenylamino-pyrimidin-4-yl)-lH-i midazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid propylamide, trans-isomer, (Compound A812); 2-[4-(4-fluoro-phenyl)-5-(2-piperidin- 1-yl-pyrimidin-4-yl)- lH-imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid propylamide, trans-isomer, (Compound A813); <BR> <BR> <BR> <BR> 2-(4-(4-fluoro-phenyl)-5-(2-[(pyridin-4-ylmethyl)-amino]-pyr imidin-4-yl)-111-imidazol-2-yl)-5- methyl-[1,3]dioxane-5-carboxylic acid propylamide, trans-isomer, (Compound A814); 2-(4-fluoro-phenyl)-5-[2-[(pyridin-3-ylmethyl)-amino]-pyrimi din-4-yl}-1H-imidazol-2-yl)-5- methyl-[1,3]dioxane-5-carboxylic acid propylamide, trans-isomer, (Compound A815); 2-(4-fluoro-phenyl)-5-[2-[(pyridin-3-ylmethyl)-amino]-pyrimi din-4-yl}-1H-imidazol-2-yl)-5- methyl-[1,3]dioxane-5-carboxylic acid propylamide, trans-isomer, (Compound A816); 2-(4-fluoro-phenyl)-5-[2-[(furan-2-ylmethyl)-amino]-pyrimidi n-4-yl}-1H-imidazol-2-yl)-5- methyl-[1,3]dioxane-5-carboxylic acid propylamide, trans-isomer, (Compound A817); 2-(4-fluoro-phenyl)-5-[2-[(thiophen-2-ylmethyl)-amino]-pyrim idin-4-yl}-1H-imidazol-2-yl)-5- methyl-[1,3]dioxane-5-carboxylic acid propylamide, trans-isomer, (Compound A818); 2-(4-(4-fluoro-phenyl)-5-{2-[(tetrahydro-furan-2-ylmethyl)-a mino]-pyrimidin-4-yl}-1H-imidazol- 2-yl)-5-methyl-[1,3]dioxane-5-carboxylic acid propylamide, trans-isomer, (Compound A819); 2-{4-(4-fluoro-phenyl)-5-[2-(4-methyl-piperazin-1-yl)-pyrimi din-4-yl]-1H-imidazol-2-yl}-5- methyl-[1,3]dioxane-5-carboxylic acid propylamide, trans-isomer, (Compound A820); 2-[4-(4-fluoro-phenyl)-5-(2-morpholin-4-yl)-1H-uimidazol-2-y l]-5-methyl- [1,3]dioxane-5-carboxylic acid propylamide, trans-isomer, (Compound A821); 2-(4-(4-fluoro-phenyl)-5-[2-(3-methoxy-propylamino)-pyrimidi n-4-yl]-1H-imidazol-2-yl)-5- methyl-[1,3]dioxane-5-carboxylic acid propylamide, trans-isomer, (Compound A822); 2-{4-(4-fluoro-phenyl)-5-[2-(2-methoxy-ethylamino)-pyrimidin -4-yl]-1H-imidazol-2-yl}-5-methyl- [1,3]dioxane-5-carboxylic acid propylamide, trans-isomer, (Compound A823); 2-[5-[2-(3-dimethylamino-propylamino)-pyrimidin-4-yl]-4-(4-f luoro-phenyl)-1H-imidazol-2-yl]- 5-methyl-[1,3]dioxane-5-carboxylic acid propylamide, trans-isomer, (Compound A824); 2-[5-[2-(2-dimethylamino-ethylamino)-pyrimidin-4-yl]-4-(4-fl uoro-phenyl)-1H-imidazol-2-yl]-5- methyl-[1,3]dioxane-5-carboxylic acid propylamide, trans-isomer, (Compound A825); {4-[5-(4-fluoro-phenyl)-2-(5-methyl-5-propylcarbamoyl-[1,3]d ioxan-2-yl)-3H-imidazol-4-yl]- pyrimidin-2-ylamino}-acetic acid, trans-isomer, (Compound A826); {3-[5-(4-fluoro-phenyl)-2-(5-methyl-5-propylcarbamoyl-[1,3]d ioxan-2-yl)-3H-imidazol-4-yl]- pyrimidin-2-ylamino}-propionic acid, trans-isomer, (Compound A827); 2-[4-(4-fluoro-phenyl)-5-(2-isopropylamino-pyrimidin-4-yl)-1 H-imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid propylamide, trans-isomer, (Compound A828); 2-[5-(2-allylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-im idazol-2-yl]-5-methyl-[1,3]dioxane- 5-carboxylic acid propylamide, trans-isomer, (Compound A829);

2- [5- [2- (cyclopropylmethyl-amino)-pyrimidin-4-yl]-4 (4-fluoro-phenyl)- 111-imidazol-2-yl]-5- methyl-[1,3]dioxane-5-carboxylic acid propylamide, trans-isomer, (Compound A830); <BR> <BR> <BR> 2-[5-[2-(cyanomethyl-amino)-pyrimidin-4-yl]-4-(4-fluoro-phen yl)-lH-imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid propylamide, trans-isomer, (Compound A831); <BR> <BR> <BR> 2-[5-[2-(2-cyano-ethylamino)-pyrimidin-4-yl]-4-(4-fluoro-phe nyl)-111-imidazol-2-yl]-5-methyl.

[1,3]dioxane-5-carboxylic acid propylamide, trans-isomer, (Compound A832); 2-{4-(4-fluoro-phenyl)-5-[2-(pyridin-3-ylamino)-pyrimidin-4- yl]-111-imidazol-2-yl}-5-methyl [1,3]dioxane-5-carboxylic acid propylamide, trans-isomer, (Compound A833); 2-(4-(4-fluoro-phenyl)-5- [2-(pyridin-4-ylamino)-pyrimidin-4-yl]- 1H-imidazol-2-yl)-5-methyl- [1,3]dioxane-5-carboxylic acid propylamide, trans-isomer, (Compound A834); 2-[4-(4-fluoro-phenyl)-5-(2-propylamino-pyrimidin-4-yl)-lH-i midazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid propylamide, trans-isomer, (Compound A835); 2-[4-(4-fluoro-phenyl)-5-(2-pyrrolidin-1-yl-pyrimidin-4-yl)- lH-imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid propylamide, trans-isomer, (Compound A836); <BR> <BR> <BR> 2-{4-(4-fluoro-phenyl)-5-[2-(4-fluoro-phenylamino)-pyrimidin -4-yl]-111-imidazol-2-yl}-5methyl- [1,3]dioxane-5-carboxylic acid propylamide, trans-isomer, (Compound A837); 2-[5-[2-(3,4-difluoro-phenyiamino)-pyrimidin-4-yl]-4-(4-fluo ro-phenyl)-111-imidazol-2-yl]-5- methyl-[1,3]dioxane-5-carboxylic acid propylamide, trans-isomer, (Compound A838); 2-{4-(4-fluoro-phenyl)-5-[2-(3-methoxy-phenylamino)-pyrimidi n-4-yl]-1H-imidazol-2-yl}-5- methyl-[1,3]dioxane-5-carboxylic acid propylamide, trans-isomer, (Compound A839); 2-[5-[2-(4-fluoro-benzylamino)-pyrimidin-4-yl]-4-(4-fluoro-p henyl)-1H-imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid propylamide, trans-isomer, (Compound A840); 2-{4-(4-fluoro-phenyl)-5-[2-(4-methoxy-benzylamino)-pyrimidi n-4-yl]-1H-imidazol-2-yl}-5- methyl-[1,3]dioxane-5-carboxylic acid propylamide, trans-isomer, (Compound A841); 2-[4-(4-fluoro-phenyl)-5-(2-methoxy-pyrimidin-4-yl)-1H-imida zol-2-yl]-5-methyl-[1,3]dioxane-5- carboxylic acid propylamide, trans-isomer, (Compound A842); 2-[5-(2-benzyloxy-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imi dazol-2-yl]-5-methyl-[1,3]dioxane- 5-carboxylic acid propylamide, trans-isomer, (Compound A843); 2-[4-(4-fluoro-phenyl)-5-(2-phenoxy-pyrimidin-4-yl)-1H-imida zol-2-yl]-5-methyl-[1,3]dioxane-5- carboxylic acid propylamide, trans-isomer, (Compound A844); 2-{4-(4-fluoro-phenyl)-5-[2-(2-methoxy-ethoxy)-pyrimidin-4-y l]-1H-imidazol-2-yl}-5-methyl- [1,3]dioxane-5-carboxylic acid propylamide, trans-isomer, (Compound A845); 2--[2- (2-dimethylamino-ethoxy)-pyrimidin-4-yl]-4-(4-fluoro-phenyl) - lH-imidazol-2-yl]-5- methyl-[1,3]dioxane-5-carboxylic acid propylamide, trans-isomer, (Compound A846); 2-[5-(2-cyclohexyloxy-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H -imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid propylamide, trans-isomer, (Compound A847);

2-[5-(2-Isopropoxy-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-111-i midazol-2-yl]-5-methyl-[1,3]dioxane- 5-carboxylic acid propylamide, trans-isomer, (Compound A848); <BR> <BR> <BR> <BR> 2-[4-(4-fluoro-phenyl)-5-(2-propoxy-pyrimidin-4-yl)-111-imid azol-2-yl]-5-methyl-[1,3]dioxane-5- carboxylic acid propylamide, trans-isomer, (Compound A849); 2-{4-(4-fluoro-phenyl)-5-[2-(2-hydroxy-ethoxy)-pyrirnidin-4- yl]-111-imidazol-2-yl)-5-methyl- [1,3]dioxane-5-carboxylic acid propylamide, trans-isomer, (Compound A850); 2-{4-(4-fluoro-phenyl) -5-[2-(3-hydroxy-propoxy)-pyrimidin-4-yl]-111-imidazol-2-yl }-5-methyl [1,3]dioxane-5-carboxylic acid propylamide, trans-isomer, (Compound A851); 2-[4-(4-fluoro-phenyl)-5-(2-methylSulfanyl-pyrimidin-4-yl)-l H-imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid propylamide, trans-isomer, (Compound A852); <BR> <BR> <BR> <BR> 2-[5-(2-amino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)- 111-imidazol-2-yl]-5-methyl-[1,3]dioxane-5- carboxylic acid cyclohexylamide, trans-isomer, (Compound A853); 2-[4-(4-fluoro-phenyl)-5-(2-methylamino-pyrimidin-4-yl)-111- imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid cyclohexylamide, trans-isomer, (Compound A854); 2-[5-(2-dimethylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-lH -imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid cyclohexylamide, trans-isomer, (Compound A855); 2-(5-(2-cyclopropylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl) - lH-imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid cyclohexylamide, trans-isomer, (Compound A856); 2-{4-(4-fluoro-phenyl)-5-[2-(piperidin-4-ylamino)-pyrimidin- 4-yl]-1H-imidazol-2-yl}-5-methyl- [1,3]dioxane-5-carboxylic acid cyclohexylamide, trans-isomer, (Compound A857); 2-[5-(2-cyclohexylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)- 1H-imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid cyclohexylamide, trans-isomer, (Compound A858); 2-{4-(4-fluoro-phenyl)-5-[2-(2-hydroxy-ethylamino)-pyrimidin -4-yl]-1H-imidazol-2-yl}-5-methyl- [1,3]dioxane-5-carboxylic acid cyclohexylamide, trans-isomer, (Compound A859); 2-[5-[2-amino-ethylamino)-pyrimidin-4-yl]-4-(4-fluoro-phenyl )-1H-imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid cyclohexylamide, trans-isomer, (Compound A860); 2-(4-(4-fluoro-phenyl)-5-{2-[3-(5H-imidazol-1-yl)-propylamin o]-pyrimidin-4-yl}-1H-imidazol-2- yl)-5-methyl-[1,3]dioxane-5-carboxylic acid cyclohexylamide, trans-isomer, (Compound A861); 2-{4-(4-fluoro-phenyl)-5-[2-(3-morpholin-4-yl-propylamino)-p yrimidin-4-yl]-1H-imidazol-2-yl}- 5-methyl-[1,3]dioxane-5-carboxylic acid cyclohexylamide, trans-isomer, (Compound A862); 2-{4-(4-fluoro-phenyl)-5-[2-(3-hydroxy-propylamino)-pyrimidi n-4-yl]-1H-imidazol-2-yl}-5- methyl-[1,3]dioxane-5-carboxylic acid cyclohexylamide, trans-isomer, (Compound A863); 2-[5-(2-benzylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-i midazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid cyclohexylamide, trans-isomer, (Compound A864); 2-{4-(4-fluoro-phenyl)-5-[2-(1-phenyl-ethylamino)-pyrimidin- 4-yl]-1H-imidazol-2-yl}-5-methyl- [1,3]dioxane-5-carboxylic acid cyclohexylamide, R-isomer, trans-isomer, (Compound A865);

2-{4-(4-fluoro-phenyl)-5- [2-(1-phenyl-ethylamino)-pyrimidin-4-yl]- 1 H-imidazol-2yl)- 5-methyl- [1,3]dioxane-5-carboxylic acid cyclohexylamide, S-isomer, trans-isomer, (Compound A866); 2-[4-(4-fluoro-phenyl)-5-(2-phenylamino-pyrimidin-4-yl)- lH-imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid cyclohexylamide, trans-isomer, (Compound A867); 2-[4-(4-fluoro-phenyl)-5-(2-piperidin-1-yl-pyrimidin-4-yl)-l H-imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid cyclohexylamide, trans-isomer, (Compound A868); <BR> <BR> <BR> <BR> 2-(4-(4-fluoro-phenyl)-5-(2-[(pyridin-4-ylmethyl)-amino]-pyr imidin-4-yl}-111-imidazol-2-yl)-5- methyl-[1,3]dioxane-5-carboxyiic acid cyclohexylamide, trans-isomer, (Compound A869); 2-(4-(4-fluoro-phenyl)-5-{2-[(pyridin-3-ylmethyl)-amino]-pyr imidin-4-yl}-1H-imidazol-2-yl)-5- methyl-[1,3]dioxane-5-carboxylic acid cyclohexylamide, trans-isomer, (Compound A870); 2-(4-(4-fluoro-phenyl)-5-{2-[(pyridin-2-ylmethyl)-amino]-pyr imidin-4-yl}-1H-imidazol-2-yl)-5- methyl-[1,3]dioxane-5-carboxylic acid cyclohexylamide, trans-isomer, (Compound A871); 2-(4-(4-fluoro-phenyl)-5-{2-[(furan-2-ylmethyl)-amino]-pyrim idin-4-yl}- lH-imidazol-2-yl)-5- methyl-[1,3]dioxane-5-carboxylic acid cyclohexylamide, trans-isomer, (Compound A872); <BR> <BR> <BR> <BR> 2-(4-(4-fluoro-phenyl)-5-(2- [(thiophen-2-ylmethyl)-amino]-pyrimidin-4-yl)- lH-imidazol-2-yl)-5- methyl-[1,3]dioxane-5-carboxylic acid cyclohexylamide, trans-isomer, (Compound A873); 2-(4-(4-fluoro-phenyl)-5-{2-[(tetrahydro-furan-2-ylmethyl)-a mino]-pyrimidin-4-yl}-1H-imidazol- 2-yl)-5-methyl-[1,3]dioxane-5-carboxylic acid cyclohexylamide, trans-isomer, (Compound A874); 2-(4-(4-fluoro-phenyl)-5-{2-(4-methyl-piperazin-1-yl)-pyrimi din-4-yl]-1H-imidazol-2-yl}-5- methyl-[1,3]dioxane-5-carboxylic acid cyclohexylamide, trans-isomer, (Compound A875); 2-[4-(4-fluoro-phenyl)-5-(2-morpholin-4-yl-pyrimidin-4-yl)-l H-imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid cyclohexylamide, trans-isomer, (Compound A876); 2-(4-(4-fluoro-phenyl)-5-{2-(3-methoxy-propylamino)-pyrimidi n-4-yl]-1H-imidazol-2-yl}-5- methyl-[1,3]dioxane-5-carboxylic acid cyclohexylamide, trans-isomer, (Compound A877); <BR> <BR> <BR> <BR> 2-{4-(4-fluoro-phenyl)-5-[2-(2-methoxy-ethylamino)-pyrimidin -4-yl]-lH-imidazol-2-yl}-5-methyl- [1,3]dioxane-5-carboxylic acid cyclohexylamide, trans-isomer, (Compound A878); 2-[5-[2-(3-dimethylamino-propylamino)-pyrimidin-4-yl]-4-(4-f luoro-phenyl)-1H-imidazol-2-yl]- 5-methyl-[1,3]dioxane-5-carboxylic acid cyclohexylamide, trans-isomer, (Compound A879); 2-[5-[2-(2-dimethylamino-ethylamino)-pyrimidin-4-yl]-4-(4-fl uoro-phenyl)-1H-imidazol-2-yl]-5- methyl-[1,3]dioxane-5-carboxylic acid cyclohexylamide, trans-isomer, (Compound A880); {4-[2-(5-cyclohexylcarbamoyl-5-methyl-[1,3]dioxan-2-yl)-5-(4 -fluoro-phenyl)-3H-imidazol-4-yl]- pyrimidin-2-ylamino)-acetic acid, trans-isomer, (Compound A881); 3-{4-[2-(5-cyclohexylcarbamoyl-5-methyl-[1,3]dioxan-2-yl)-5- (4-fluoro-phenyl)-3H-imidazol-4- yl]-pyrimidin-2-ylamino}-propionic acid, trans-isomer, (Compound A882); 2-[4-(4-fluoro-phenyl)-5-(2-isopropylamino-pyrimidin-4-yl)-1 H-imidazol-2-yl]-5-methyl.

[1,3]dioxane-5-carboxylic acid cyclohexylamide, trans-isomer, (Compound A883);

2-[5-(2-allylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)- 111-imidazol-2-yl]-5-methyl- [1,3]dioxane- 5-carboxylic acid cyclohexylamide, trans-isomer, (Compound A884); 2-[5-[2-(cyclopropylmethyl-amino)-pyrimidin-4-yl]-4-(4-fluor o-phenyl)-lH-imidazol-2-yl]-5- methyl-[1,3]dioxane-5-carboxylic acid cyclohexylamide, trans-isomer, (Compound A885); <BR> <BR> <BR> 2-[5-[2-(cyanomethyl-amino)-pyrimidin-4-yl]-4-(4-fluoro-phen yl)-lH-imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid cyclohexylamide, trans-isomer, (Compound A886); <BR> <BR> <BR> 2-[5-[2-(2-cyano-ethylamino)-pyrimidin-4-yl]-4-(4-fluoro-phe nyl)-lH-imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid cyclohexylamide, trans-isomer, (Compound A887); 2-{4-(4-fluoro-phenyl)-5-[2-(pyridin-3-ylamino)-pyrimidin-4- yl]-111-imidazol-2-yl)-5-methyl [1,3]dioxane-5-carboxylic acid cyclohexylamide, trans-isomer, (Compound A888); 2-{4-(4-fluoro-phenyl)-5-[2-(pyridin-4-ylamino)-pyrimidin-4- yl]-lH-imidazol-2-yl}-5-methyl- [1,3]dioxane-5-carboxylic acid cyclohexylamide, trans-isomer, (Compound A889); 2-[4-(4-fluoro-phenyl)-5-(2-propylamino-pyrimidin-4-yl)-1H-i midazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid cyclohexylamide, trans-isomer, (Compound A890); 2-[4-(4-fluoro-phenyl)-5-(2-pyrrolidin- 1-yl-pyrimidin-4-yl)-lH-imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid cyclohexylamide, trans-isomer, (Compound A891); <BR> <BR> <BR> 2-{4-(4-fluoro-phenyl)-5-[2-(4-fluoro-phenylamino)-pyrimidin -4-yl]- 1H-imidazol-2-yl)-5-methyl- [1,3]dioxane-5-carboxylic acid cyclohexylamide, trans-isomer, (Compound A892); 2-[5-[2-(3,4-difluoro-phenylamino)-pyrimidin-4-yl]-4-(4-fluo ro-phenyl)-1H-imidazol-2-yl]-5- methyl-[1,3]dioxane-5-carboxylic acid cyclohexylamide, trans-isomer, (Compound A893); 2-{4-(4-fluoro-phenyl)-5-[2-(3-methoxy-phenylamino)-pyrimidi n-4-yl]-1H-imidazol-2-yl}-5- methyl-[1,3]dioxane-5-carboxylic acid cyclohexylamide, trans-isomer, (Compound A894); <BR> <BR> <BR> 2-[5-[2-(4-fluoro-benzylamino)-pyrimidin-4-yl]-4-(4-fluoro-p henyl)- lH-imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid cyclohexylamide, trans-isomer, (Compound A895); 2-{4-(4-fluoro-phenyl)-5-[2-(4-methoxy-benzylamino)-pyrimidi n-4-yl]-1H-imidazol-2-yl}-5- methyl-[1,3]dioxane-5-carboxylic acid cyclohexylamide, trans-isomer, (Compound A896); 2-[4-(4-fluoro-phenyl)-5-(2-methoxy-pyrimidin-4-yl)-1H-imida zol-2-yl]-5-methyl-[1,3]dioxane-5- carboxylic acid cyclohexylamide, trans-isomer, (Compound A897); 2-[5-(2-benzyloxy-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imi dazol-2-yl]-5-methyl-[1,3]dioxane- 5-carboxylic acid cyclohexylamide, trans-isomer, (Compound A898); 2-[4-(4-fluoro-phenyl)-5-(2-methoxy-pyrimidin-4-yl)-1H-imida zol-2-yl]-5-methyl-[1,3]dioxane-5- carboxylic acid cyclohexylamide, trans-isomer, (Compound A899); 2-{4-(4-fluoro-phenyl)-5-[2-(2-methoxy-ethoxy)-pyrimidin-4-y l]-1H-imidazol-2-yl}-5-methyl- [1,3]dioxane-5-carboxylic acid cyclohexylamide, trans-isomer, (Compound A900); 2-[5-[2-(2-dimethylamino-ethoxy)-pyrimidin-4-yl]-4-(4-fluoro -phenyl)-1H-imidazol-2-yl]-5- methyl-[1,3]dioxane-5-carboxylic acid cyclohexylamide, trans-isomer, (Compound A901);

2-[5-(2-cyclohexyloxy-pyrimidin-4-yl)-4-(4-fluoro-phenyl)- lH-imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid cyclohexylamide, trans-isomer, (Compound A902); <BR> <BR> <BR> <BR> 2-[5-(2-Isopropoxy-pyrimidin-4-yl)-4-(4-fluoro-phenyl)- lH-imidazol-2-yl]-5-methyl-[1,3]dioxane- 5-carboxylic acid cyclohexylamide, trans-isomer, (Compound A903); 2-[4-(4-fluoro-phenyl)-5-(2-propoxy-pyrimidin-4-yl)-1H-imida zol-2-yl]-5-methyl-[1,3]dioxane-5- carboxylic acid cyclohexylamide, trans-isomer, (Compound A904); 2-{4-(4-fluoro-phenyl)-5-[2-(2-hydroxy-ethoxy)-pyrimidin-4-y l]-1H-imidazol-2-yl}-5-methyl- [1,3]dioxane-5-carboxylic acid cyclohexylamide, trans-isomer, (Compound A905); 2-{4-(4-fluoro-phenyl)-5-[2-(3-hydroxy-propoxy)-pyrimidin-4- yl]-1H-imidazol-2-yl}-5-methyl- [1,3]dioxane-5-carboxylic acid cyclohexylamide, trans-isomer, (Compound A906); 2-[4-(4-fluoro-phenyl)-5-(2-methylsulfanyl-pyrimidin-4-yl)-1 H-imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid cyclohexylamide, trans-isomer, (Compound A907); <BR> <BR> <BR> 2-[5-(2-amino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)- 1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5- carboxylic acid (2-hydroxy-ethyl)-amide, trans-isomer, (Compound A908); 2-[4-(4-fluoro-phenyl)-5-(2-methylamino-pyrimidin-4-yl)-1H-i midazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid (2-hydroxy-ethyl)-amide, trans-isomer, (Compound A909); 2-[5-(2-dimethylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H -imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid (2-hydroxy-ethyl)-amide, trans-isomer, (Compound A910); 2-[5-(2-cyclopropylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl) -1H-imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid (2-hydroxy-ethyl)-amide, trans-isomer, (Compound A911); 2-{4-(4-fluoro-phenyl)-5-[2-(piperidin-4-ylamino)-pyrimidin- 4-yl]-1H-imidazol-2-yl}-5-methyl- [1,3]dioxane-5-carboxylic acid (2-hydroxy-ethyl)-amide, trans-isomer, (Compound A912); 2-[5-(2-cyclohexylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)- 1H-imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid (2-hydroxy-ethyl)-amide, trans-isomer, (Compound A913); 2-{4-(4-fluoro-phenyl)-5-[2-(2-hydroxy-ethylamino)-pyrimidin -4-yl]-1H-imidazol-2-yl}-5-methyl- [1,3]dioxane-5-carboxylic acid (2-hydroxy-ethyl)-amide, trans-isomer, (Compound A914); 2-[5-[2-(2-amino-ethylamino)-pyrimidin-4-yl]-4-(4-fluoro-phe nyl)-1H-imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid (2-hydroxy-ethyl)-amide, trans-isomer, (Compound A915); 2-(4-(4-fluoro-phenyl)-5-(2-[3-(5H-imidaz 1-yl)-propylamino]-pyrimidin-4-yl }- lH-imidazol-2- yl)-5-methyl-[1,3]dioxane-5-carboxylic acid (2-hydroxy-ethyl)-amide, trans-isomer, (Compound A916); <BR> <BR> <BR> <BR> 2-{4-(4-fluoro-phenyl)-5-[2-(3-morpholin-4-yl-propylamino)-p yrimidin-4-yl]-lH-imidazol-2-yl}- 5-methyl-[1,3]dioxane-5-carboxylic acid (2-hydroxy-ethyl)-amide, trans-isomer, (Compound A917);

2-{4-(4-fluoro-phenyl)-5- [2-(3-hydroxy-propylamino)-pyrimidin-4-yl]- 1H-imidazol- 2-yl)- 5- methyl-[1,3]dioxane-5-carboxylic acid (2-hydroxy-ethyl)-amide, trans-isomer, (Compound A918); 2-[5-(2-benzylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-i midazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid (2-hydroxy-ethyl)-amide, trans-isomer, (Compound A919); 2-{4-(4-fluoro-phenyl)-5-[2-(1-phenyl-ethylamino)-pyrimidin- 4-yl]-1H-imidazol-2-yl}-5-methyl- [1,3]dioxane-5-carboxylic acid (2-hydroxy-ethyl)-amide, R-isomer, trans-isomer, (Compound A920); 2-{4-(4-fluoro-phenyl)-5-[2-(1-phenyl-ethylamino)-pyrimidin- 4-yl]-1H-imidazol-2-yl}-5-methyl- [1,3]dioxane-5-carboxylic acid (2-hydroxy-ethyl)-amide, S-isomer, trans-isomer, (Compound A921); 2-[4-(4-fluoro-phenyl)-5-(2-phenylamino-pyrimidin-4-yl)-1H-i midazol-2-yl]-5-methyl [1,3]dioxane-5-carboxylic acid (2-hydroxy-ethyl)-amide, trans-isomer, (Compound A922); 2-[4-(4-fluoro-phenyl)-5-(2-piperidin-1-yl-pyrimidin-4-yl)-1 H-imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid (2-hydroxy-ethyl)-amide, trans-isomer, (Compound A923); <BR> <BR> <BR> 2-(4-(4-fluoro-phenyl)-5-{2-[(pyridin-4-ylmethyl)-amino]-pyr imidin-4-yl}-lH-imidazol-2-yl)-5- methyl-[1,3]dioxane-5-carboxylic acid (2-hydroxy-ethyl)-amide, trans-isomer, (Compound A924); 2-(4-(4-fluoro-phenyl)-5-{2-[(pyridin-3-ylmethyl)-amino]-pyr imidin-4-yl}-1H-imidazol-2-yl)-5- methyl-[1,3]dioxane-5-carboxylic acid (2-hydroxy-ethyl)-amide, trans-isomer, (Compound A925); 2-(4-(4-fluoro-phenyl)-5-{2-[(pyridin-2-ylmethyl)-amino]-pyr imidin-4-yl}-1H-imidazol-2-yl)-5- methyl-[1,3]dioxane-5-carboxylic acid (2-hydroxy-ethyl)-amide, trans-isomer, (Compound A926); 2-(4-(4-fluoro-phenyl)-5-{2-[(furan-2-ylmethyl)-amino]-pyrim idin-4-yl}-1H-imidazol-2-yl)-5- methyl-[1,3]dioxane-5-carboxylic acid (2-hydroxy-ethyl)-amide, trans-isomer, (Compound A927); 2-(4-(4-fluoro-phenyl)-5-{2-[(thiophen-2-ylmethyl)-amino]-py rimidin-4-yl}-1H-imidazol-2-yl)-5- methyl-[1,3]dioxane-5-carboxylic acid (2-hydroxy-ethyl)-amide, trans-isomer, (Compound A928); 2-(4-(4-fluoro-phenyl)-5-{2-[(tetrahydro-furan-2-ylmethyl)-a mino]-pyrimidin-4-yl}-1H-imidazol- 2-yl)-5-methyl-[1,3]dioxane-5-carboxylic acid (2-hydroxy-ethyl)-amide, trans-isomer, (Compound A929); 2-{4-(4-fluoro-phenyl)-5-[2-(4-methyl-piperazin-1-yl)-pyrimi din-4-yl]-1H-imidazol-2-yl}-5- methyl-[1,3]dioxane-5-carboxylic acid (2-hydroxy-ethyl)-amide, trans-isomer, (Compound A930);

2-[4-(4-fluoro-phenyl)-5-(2-morpholin-4-yl-pyrimidin-4-yl)- lH-imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid (2-hydroxy-ethyl)-amide, trans-isomer, (Compound A931); 2-(4-(4-fluoro-phenyl)-5-[2-(3-methoxy-propylamino)-pyrimidi n-4-yl]-1H-imidazol-2-yl)-5 methyl-[1,3]dioxane-5-carboxylic acid (2-hydroxy-ethyl)-amide, trans-isomer, (Compound A932); <BR> <BR> <BR> 2-{4-(4-fluoro-phenyl)-5-[2-(2-methoxy-ethylamino)-pyrimidin -4-yl]-lH-imidazol-2-yl}-5-methyl- [1,3]dioxane-5-carboxylic acid (2-hydroxy-ethyl)-amide, trans-isomer, (Compound A933); <BR> <BR> <BR> <BR> 2-[5-[2-(3-dimethylamino-propylamino)-pyrimidin-4-yl]-4-(4-f luoro-phenyl)-lH-imidazol-2-yl]- 5-methyl-[1,3]dioxane-5-carboxylic acid (2-hydroxy-ethyl)-amide, trans-isomer, (Compound A934); 2-[5-[2-(2-dimethylamino-ethylamino)-pyrimidin-4-yl]-4-(4-fl uoro-phenyl)-1H-imidazol-2-yl]-5- methyl-[1,3]dioxane-5-carboxylic acid (2-hydroxy-ethyl)-amide, trans-isomer, (Compound A935); (4-{5-(4-fluoro-phenyl)-2-[5- (2-hydroxy-ethylcarbamoyl)-5-methyl- [1,3]dioxan-2-yl]-311- imidazol-4-yl}-pyrimidin-2-ylamino)-acetic acid, trans-isomer, (Compound A936); 3-(4-{5-(4-fluoro-phenyl)-2-[5-(2-hydroxy-ethylcarbamoyl)-5- methyl-[1,3idioxan-2-yl]-311- imidazol-4-yl)-pyrimidin-2-ylamino)-propionic acid, trans-isomer, (Compound A937); 2-[4-(4-fluoro-phenyl)-5-(2-isopropylamino-pyrimidin-4-yl)-1 H-imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid (2-hydroxy-ethyl)-amide, trans-isomer, (Compound A938); 2-[5-(2-allylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)- 1H-imidazol-2-ylj-5-methyl-[1,3]dioxane- 5-carboxylic acid (2-hydroxy-ethyl)-amide, trans-isomer, (Compound A939); 2-[5-[2-(cyclopropylmethyl-amino)-pyrimidin-4-yl]-4-(4-fluor o-phenyl)-1H-imidazol-2-yl]-5- methyl-[1,3]dioxane-5-carboxylic acid (2-hydroxy-ethyl)-amide, trans-isomer, (Compound A940); 2-[5-[2-(cyanomethyl-amino)-pyrimidin-4-yl]-4-(4-fluoro-phen yl)-1H-imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid (2-hydroxy-ethyl)-amide, trans-isomer, (Compound A941); 2-[5-[2-(2-cyano-ethylamino)-pyrimidin-4-yl]-4-(4-fluoro-phe nyl)-1H-imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid (2-hydroxy-ethyl)-amide, trans-isomer, (Compound A942); 2-{4-(4-fluoro-phenyl)-5-[2-(pyridin-3-ylamino)-pyrimidin-4- yl]-1H-imidazol-2-yl}-5-methyl- [1,3]dioxane-5-carboxylic acid (2-hydroxy-ethyl)-amide, trans-isomer, (Compound A943); 2-{4-(4-fluoro-phenyl)-5-[2-(pyridin-4-ylamino)-pyrimidin-4- yl]-lH-imidazol-2-yl}-5-methyl- [1,3]dioxane-5-carboxylic acid (2-hydroxy-ethyl)-amide, trans-isomer, (Compound A944); 2-[4-(4-fluoro-phenyl)-5-(2-propylamino-pyrimidin-4-yl)-1H-i midazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid (2-hydroxy-ethyl)-amide, trans-isomer, (Compound A945); 2-[4-(4-fluoro-phenyl)-5-(2-pyrrolidin-1-yl-pyrimidin-4-yl)- 1H-imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid (2-hydroxy-ethyl)-amide, trans-isomer, (Compound A946);

2-(4-(4-fluoro- phenyl)-5-[2- (4-fluoro- phenylamino)- pyrimidin-4-yl]- la-imidazol-2-yl)- 5-methyl- [1,3]dioxane-5-carboxylic acid (2-hydroxy-ethyl)-amide, trans-isomer, (Compound A947); 2-[5-[2-(3,4-difluoro-phenylamino) -pyrimidin-4-yl]-4-(4-fluoro-phenyl)-lH-imidazol-2-yl]-5- methyl-[1,3]dioxane-5-carboxylic acid (2-hydroxy-ethyl)-amide, trans-isomer, (Compound A948); 2-{4-(4-fluoro-phenyl)-5-[2-(3-methoxy-phenylamino)-pyrimidi n-4-yl]-111-imidazol-2-yl}-5- methyl-[1,3]dioxane-5-carboxylic acid (2-hydroxy-ethyl)-amide, trans-isomer, (Compound A949); <BR> <BR> <BR> <BR> 2-[5-[2-(4-fluoro-benzylamino)-pyrimidin-4-yl]-4-(4-fluoro-p henyl)-lH-imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid (2-hydroxy-ethyl)-amide, trans-isomer, (Compound A950); 2-{4-(4-fluoro-phenyl)-5-[2-(4-methoxy-benzylamino)-pyrimidi n-4-yl]-lH-imidazol-2-yl}-5- methyl-[1,3]dioxane-5-carboxylic acid (2-hydroxy-ethyl)-amide, trans-isomer, (Compound A951); 2-[4-(4-fluoro-phenyl)-5-(2-methoxy-pyrimidin-4-yl)-1H-imida zol-2-yl]-5-methyl-[1,3]dioxane-5- carboxylic acid (2-hydroxy-ethyl)-amide, trans-isomer, (Compound A952); 2-[5-(2-benzyloxy-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imi dazol-2-yl]-5-methyl-[1,3]dioxane- 5-carboxylic acid (2-hydroxy-ethyl)-amide, trans-isomer, (Compound A953); 2-[4-(4-fluoro-phenyl)-5-(2-phenoxy-pyrimidin-4-yl)-1H-imida zol-2-yl]-5-methyl-[1,3]dioxane-5- carboxylic acid (2-hydroxy-ethyl)-amide, trans-isomer, (Compound A954); 2-{4-(4-fluoro-phenyl)-5-[2-(2-methoxy-ethoxy)-pyrimidin-4-y l]-1H-imidazol-2-yl}-5-methyl- [1,3]dioxane-5-carboxylic acid (2-hydroxy-ethyl)-amide, trans-isomer, (Compound A955); 2--[2- (2-dimethylamino-ethoxy)-pyrimidin-4-yl]-4-(4-fluoro-phenyl) - lH-imidazol-2-yl]-5- methyl-[1,3]dioxane-5-carboxylic acid (2-hydroxy-ethyl)-amide, trans-isomer, (Compound A956); 2-[5-(2-cyclohexyloxy-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-lH -imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid (2-hydroxy-ethyl)-amide, trans-isomer, (Compound A957); 2-[5-(2-Isopropoxy-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-im idazol-2-yl]-5-methyl-[1,3]dioxane- 5-carboxylic acid (2-hydroxy-ethyl)-amide, trans-isomer, (Compound A958); <BR> <BR> <BR> <BR> 2-[4-(4-fluoro-phenyl)-5-(2-propoxy-pyrimidin-4yl)- lH-imidazol-2-yl]-5-methyl-[1,3]dioxane-5- carboxylic acid (2-hydroxy-ethyl)-amide, trans-isomer, (Compound A959); 2-{4-(4-fluoro-phenyl)-5-[2-(2-hydroxy-ethoxy)-pyrimidin-4-y l]-1H-imidazol-2-yl}-5-methyl- [1,3]dioxane-5-carboxylic acid (2-hydroxy-ethyl)-amide, trans-isomer, (Compound A960); 2-{4-(4-fluoro-phenyl)-5-[2-(3-hydroxy-propoxy)-pyrimidin-4- yl]-1H-imidazol-2-yl}-5-methyl- [1,3]dioxane-5-carboxylic acid (2-hydroxy-ethyl)-amide, trans-isomer, (Compound A961); 2-[4-(4-fluoro-phenyl)-5-(2-methylsulfanyl-pyrimidin-4-yl)- 1H-imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid (2-hydroxy-ethyl)-amide, trans-isomer, (Compound A962);

2-[5-(2-amino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)- lH-imidazol-2-yl]-5-methyl-[1,3]dioxane-5- carboxylic acid (2-amino-ethyl)-amide, trans-isomer, (Compound A963); 2-[4-(4-fluoro-phenyl)-5-(2-methylamino-pyrimidin-4-yl)-1H-i midazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid (2-amino-ethyl)-amide, trans-isomer, (Compound A964); 2-[5-(2-dimethylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H -imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid (2-amino-ethyl)-amide, trans-isomer, (Compound A965); 2-[5-(2-cyclopropylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl) -1H-imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid (2-amino-ethyl)-amide, trans-isomer, (Compound A966); <BR> <BR> <BR> <BR> 2-(4-(4-fluoro-phenyl)-5- [2-(piperidin-4-ylamino)-pyrimidin-4-yl] 1H-imidazol-2-yl )-5-methyl- [1,3]dioxane-5-carboxylic acid (2-amino-ethyl)-amide, trans-isomer, (Compound A967); 2-[5-(2-cyclohexylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)- 1H-imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid (2-amino-ethyl)-amide, trans-isomer, (Compound A968); 2-{4-(4-fluoro-phenyl)-5-[2-(2-hydroxy-ethylamino)-pyrimidin -4-yl]-1H-imidazol-2-yl}-5-methyl- [1,3]dioxane-5-carboxylic acid (2-amino-ethyl)-amide, trans-isomer, (Compound A969); 2- [5-[2-(2-amino-ethylamino)-pyrimidin-4-yl]-4-(4-fluoro-pheny l)- 1H-imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid (2-amino-ethyl)-amide, trans-isomer, (Compound A970); 2-(4-(4-fluoro-phenyl)-5-{2-[3-(5H-imidazol-1-yl)-propylamin o]-pyrimidin-4-yl}-1H-imidazol-2- yl)-5-methyl-[1,3]dioxane-5-carboxylic acid (2-amino-ethyl)-amide, trans-isomer, (Compound A971); <BR> <BR> <BR> <BR> 2-{4-(4-fluoro-phenyl)-5-[2-(3-morpholin-4-yl-propylamino)-p yrimidin-4-yl]-lH-imidazol-2-yl}- 5-methyl-[1,3]dioxane-5-carboxylic acid (2-amino-ethyl)-amide, trans-isomer, (Compound A972); 2-{4-(4-fluoro-phenyl)-5-[2-(3-hydroxy-propylamino)-pyrimidi n-4-yl]-lH-imidazol-2-yl}-5- methyl-[1,3]dioxane-5-carboxylic acid (2-amino-ethyl)-amide, trans-isomer, (Compound A973); 2-[5-(2-benzylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl) lH-imidazol-2-yl] -5-methyl- [1,3]dioxane-5-carboxylic acid (2-amino-ethyl)-amide, trans-isomer, (Compound A974); <BR> <BR> <BR> <BR> 2-{4-(4-fluoro-phenyl)-5-[2-(1-phenyl-ethylamino)-pyrimidin- 4-yl]-lH-imidazol-2-yl}-5-methyl- [1,3]dioxane-5-carboxylic acid (2-amino-ethyl)-amide, R-isomer, trans-isomer, (Compound A975); <BR> <BR> <BR> <BR> 2-{4-(4-fluoro-phenyl)-5-[2-(1-phenyl-ethylamino)-pyrimidin- 4-yl]-lH-imidazol-2-yl}-5-methyl- [1,3]dioxane-5-carboxylic acid (2-amino-ethyl)-amide, S-isomer, trans-isomer, (Compound A976); 2-[4-(4-fluoro-phenyl)-5-(2-phenylamino-pyrimidin-4-yl) 1H-imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid (2-amino-ethyl)-amide, trans-isomer, (Compound A977); 2-[4-(4-fluoro-phenyl)-5-(2-piperidin-1-yl-pyrimidin-4-yl)-l H-imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid (2-amino-ethyl)-amide, trans-isomer, (Compound A978);

2-(4-(4-fluoro-phenyl)-5-{2-[(pyridin-4-ylmethyl)-amino]-pyr imidin-4-yl}-lH-imidazol-2-yl)-5- methyl-[1,3]dioxane-5-carboxylic acid (2-amino-ethyl)-amide, trans-isomer, (Compound A979); 2-(4-(4-fluoro-phenyl)-5-{2-[(pyridin-3-ylmethyl)-amino] -pyrimidin-4-yl}-lH-imidazol-2-yl)-5- methyl-[1,3]dioxane-5-carboxylic acid (2-amino-ethyl)-amide, trans-isomer, (Compound A980); <BR> <BR> <BR> 2-(4-(4-fluoro-phenyl)-5-(2-[(pyridin-2-ylmethyl)-amino]-pyr imidin-4-yl )-111-imidazol-2-yl)-5- methyl-[1,3]dioxane-5-carboxylic acid (2-amino-ethyl)-amide, trans-isomer, (Compound A981); -(4-(4-fluoro-phenyl)-5-{2-[(furan-2-ylmethyl)-amino]-pyrimi din-4-yl}-lH-imidazol-2-yl)-5- methyl-[1,3]dioxane-5-carboxylic acid (2-amino-ethyl)-amide, trans-isomer, (Compound A982); <BR> <BR> <BR> 2-(4-(4-fluoro-phenyl)-5-{2-[(thiophen-2-ylmethyl)-amino]-py rimidin-4-yl}-lH-imidazol-2-yl)-5- methyl-[1,3]dioxane-5-carboxylic acid (2-amino-ethyl)-amide, trans-isomer, (Compound A983); 2-(4-(4-fluoro-phenyl)-5-{2-[(tetrahydro-furan-2-ylmethyl)-a mino]-pyrimidin-4-yl}-1H-imidazol- 2-yl)-5-methyl-[1,3]dioxane-5-carboxylic acid (2-amino-ethyl)-amide, trans-isomer, (Compound A984); 2-{4-(4-fluoro-phenyl)-5-[2-(4-methyl-piperazin-1-yl)-pyrimi din-4-yl]-1H-imidazol-2-yl}-5- methyl-[1,3]dioxane-5-carboxylic acid (2-amino-ethyl)-amide, trans-isomer, (Compound A985); 2-[4-(4-fluoro-phenyl)-5-(2-morpholin-4-yl-pyrimidin-4-yl)-1 H-imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid (2-amino-ethyl)-amide, trans-isomer, (Compound A986); 2-{4-(4-fluoro-phenyl)-5-[2-(3-methoxy-propylamino)-pyrimidi n-4-yl]-1H-imidazol-2-yl}-5- methyl-[1,3]dioxane-5-carboxylic acid (2-amino-ethyl)-amide, trans-isomer, (Compound A987); 2-{4-(4-fluoro-phenyl)-5-[2-(2-methoxy-ethylamino)-pyrimidin -4-yl]-1H-imidazol-2-yl}-5-methyl- [1,3]dioxane-5-carboxylic acid (2-amino-ethyl)-amide, trans-isomer, (Compound A988); 2-[5-[2-(3-dimethylamino-propylamino)-pyrimidin-4-yl]-4-(4-f luoro-phenyl)-1H-imidazol-2-yl]- 5-methyl-[1 ,3]dioxane-5-carboxylic acid (2-amino-ethyl)-amide, trans-isomer, (Compound A989); 2-[5-[2-(2-dimethylamino-ethylamino)-pyrimidin-4-yl]-4-(4-fl uoro-phenyl)-1H-imidazol-2-yl]-5- methyl-[1,3]dioxane-5-carboxylic acid (2-amino-ethyl)-amide, trans-isomer, (Compound A990); {4-[2-[5-(2-amino-ethylcarbamoyl)-5-methyl-[1,3]dioxan-2-yl] -5-(4-fluoro-phenyl)-3H-imidazol- 4-yl]-pyrimidin-2-ylamino)-acetic acid, trans-isomer, (Compound A991); 3-(4-[2-[5-(2-amino-ethyicarbamoyl) -5-methyl- [1,3]dioxan-2-yl] -5-(4-fluoro-phenyl)-3H- imidazol-4-yl]-pyrimidin-2-ylamino)-propionic acid, trans-isomer, (Compound A992); 2-[4-(4-fluoro- phenyl)-5- (2-isopropylamino-pyrimi din-4-yl)-1H-imi dazol-2-yl] -5-methyl- [1,3]dioxane-5-carboxylic acid (2-amino-ethyl)-amide, trans-isomer, (Compound A993); 2-[5-(2-allylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-im idazol-2-yl]-5-methyl-[1,3]dioxane- 5-carboxylic acid (2-amino-ethyl)-amide, trans-isomer, (Compound A994); 2-[5-[2-(cyclopropylmethyl-amino)-pyrimidin-4-yl]-4-(4-fluor o-phenyl)-1H-imidazol-2-yl]-5- methyl-[1,3]dioxane-5-carboxylic acid (2-amino-ethyl)-amide, trans-isomer, (Compound A995);

2-[5- [2-(cyanomethyl-amino)-pyrimidin-4-yl]-4-(4-fluoro-phenyl)- lH-imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid (2-amino-ethyl)-amide, trans-isomer, (Compound A996); 2-[5-[2-(2-cyano-ethylamino)-pyrimidin-4-yl]-4-(4-fluoro-phe nyl)-lH-imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid (2-amino-ethyl)-amide, trans-isomer, (Compound A997); 2-{4-(4-fluoro-phenyl)-5-[2-(pyridin-3-ylamino)-pyrimidin-4- yl]-1H-imidazol-2-yl}-5-methyl- [1,3]dioxane-5-carboxylic acid (2-amino-ethyl)-amide, trans-isomer, (Compound A998); 2-{4-(4-fluoro-phenyl)-5-[2-(pyridin-4-ylamino)-pyrimidin-4- yl]-1H-imidazol-2-yl}-5-methyl- [1,3]dioxane-5-carboxylic acid (2-amino-ethyl)-amide, trans-isomer, (Compound A999); 2-{4-(4-fluoro-phenyl)-5-(2-propylamino-pyrimidin-4-yl)-1H-i midazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid (2-amino-ethyl)-amide, trans-isomer, (Compound A1000); 2-[4-(4-fluoro-phenyl)-5-(2-pyrrolidin- 1-yl-pyrimidin-4-yl)-lH-imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid (2-amino-ethyl)-amide, trans-isomer, (Compound A1001); 2-{4-(4-fluoro-phenyl)-5-[2-(4-fluoro-phenylamino)-pyrimidin -4-yl]-1H-imidazol-2-yl}-5-methyl- [1,3]dioxane-5-carboxylic acid (2-amino-ethyl)-amide, trans-isomer, (Compound A1002); 2-[5-[2-(3,4-difluoro-phenylamino)-pyrimidin-4-yl]-4-(4-fluo ro-phenyl)-1H-imidazol-2-yl]-5- methyl-[1,3]dioxane-5-carboxylic acid (2-amino-ethyl)-amide, trans-isomer, (Compound A1003); 2-{4-(4-fluoro-phenyl)-5-[2-(3-methoxy-phenylamino)-pyrimidi n-4-yl]-1H-imidazol-2-yl}-5- methyl-[1,3]dioxane-5-carboxylic acid (2-amino-ethyl)-amide, trans-isomer, (Compound A1004); 2-[5-[2-(4-fluoro-benzylamino)-pyrimidin-4-yl]-4-(4-fluoro-p henyl)-1H-imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid (2-amino-ethyl)-amide, trans-isomer, (Compound A1005); 2-{4-(4-fluoro-phenyl)-5-[2-(4-methoxy-benzylamino)-pyrimidi n-4-yl]-lH-imidazol-2-yl}-5- methyl-[1,3]dioxane-5-carboxylic acid (2-amino-ethyl)-amide, trans-isomer, (Compound A1006); <BR> <BR> <BR> 2-[4-(4-fluoro-phenyl)-5-(2-methoxy-pyrimidin-4-yl)- lH-imidazol-2-yl]-5-methyl-[1,3]dioxane-5- carboxylic acid (2-amino-ethyl)-amide, trans-isomer, (Compound A1007); <BR> <BR> <BR> 2-[5 -(2-benzyloxy-pyrimidin -4-yl)-4-(4-fl uoro-phenyl)-1H-imi dazol-2-yl] -5-methyl-[1,3] dioxane- 5-carboxylic acid (2-amino-ethyl)-amide, trans-isomer, (Compound A1008); 2-[4-(4-fluoro-phenyl)-5-(2-phenoxy-pyrimidin-4-yl)-1H-imida zol-2-yl]-5-methyl-[1,3]dioxane-5- carboxylic acid (2-amino-ethyl)-amide, trans-isomer, (Compound A1009); 2-{4-(4-fluoro-phenyl)-5-[2-(2-methoxy-ethoxy)-pyrimidin-4-y l]- 1H-imidazol-2-yl)-5-methyl- [1,3]dioxane-5-carboxylic acid (2-amino-ethyl)-amide, trans-isomer, (Compound A1010); 2-[5-[2-(2-dimethylamino-ethoxy)-pyrimidin-4-yl]-4-(4-fluoro -phenyl)- lH-imidazol-2-yl]-5- methyl-[1,3]dioxane-5-carboxylic acid (2-amino-ethyl)-amide, trans-isomer, (Compound A1011); 2-[5-(2-cyclohexyloxy-pyrimidin-4-yl)-4-(4-fluoro-phenyl)- 1H-imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid (2-amino-ethyl)-amide, trans-isomer, (Compound A1012); 2-[5-(2-Isopropoxy-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-im idazol-2-yl]-5-methyl-[1,3]dioxane- 5-carboxylic acid (2-amino-ethyl)-amide, trans-isomer, (Compound A1013);

2-[4-(4-fluoro-phenyl)-5- (2-propoxy-pyrimidin-4-yl)- lH-imidazol-2-yl]-5-methyl-[1,3]dioxane-5- carboxylic acid (2-amino-ethyl)-amide, trans-isomer, (Compound A1014); 2-{4-(4-fluoro-phenyl)-5-[2-(2-hydroxy-ethoxy)-pyrimidin-4-y l]-lH-imidazol-2-yl}-5-methyl- [1,3]dioxane-5-carboxylic acid (2-amino-ethyl)-amide, trans-isomer, (Compound A1015); <BR> <BR> <BR> 2-{4-(4-fluoro-phenyl)-5-[2-(3-hydroxy-propoxy)-pyrimidin-4- yl]-111-imidazol-2yl)5methyl [1,3]dioxane-5-carboxylic acid (2-amino-ethyl)-amide, trans-isomer, (Compound A1016); 2-[4-(4-fluoro-phenyl)-5-(2-methylsulfanyl-pyrimidin-4-yl)- lH-imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid (2-amino-ethyl)-amide, trans-isomer, (Compound A1017); <BR> <BR> <BR> 2-[5-(2-amino-pyrimidin-4-yl) -4-(4-fluoro-phenyl)- 1H-imidazol-2-yl]-5-methyl- [1,3]dioxane-5- carboxylic acid (3-hydroxy-propyl)-amide, trans-isomer, (Compound A1018); 2-[4-(4-fluoro-phenyl)-5-(2-methylamino-pyrimidin-4-yl)-lH-i midazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid (3-hydroxy-propyl)-amide, trans-isomer, (Compound A1019); 2-[5-(2-dimethylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-lH -imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid (3-hydroxy-propyl)-amide, trans-isomer, (Compound A1020); 2-[5-(2-cyclopropylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl) -lH-imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid (3-hydroxy-propyl)-amide, trans-isomer, (Compound A1021); <BR> <BR> <BR> 2-{4-(4-fluoro-phenyl)-5-[2-(piperidin-4-ylamino)-pyrimidin- 4-yl]-111-imidazol-2-yl}-5-methyl- [1,3]dioxane-5-carboxylic acid (3-hydroxy-propyl)-amide, trans-isomer, (Compound A1022); 2-[5-(2-cyclohexylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)- 1H-imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid (3-hydroxy-propyl)-amide, trans-isomer, (Compound A1023); 2-{4-(4-fluoro-phenyl)-5-[2-(2-hydroxy-ethylamino)-pyrimidin -4-yl]-1H-imidazol-2-yl}-5-methyl- [1,3]dioxane-5-carboxylic acid (3-hydroxy-propyl)-amide, trans-isomer, (Compound A1024); 2-[5-[2-(2-amino-ethylamino)-pyrimidin-4-yl]-4-(4-fluoro-phe nyl)-1H-imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid (3-hydroxy-propyl)-amide, trans-isomer, (Compound A1025); 2-(4-(4-fluoro-phenyl)-5-{2-[3-(5H-imidazol-1-yl)-propylamin o]-pyrimidin-4-yl}-1H-imidazol-2- yl)-5-methyl-[1,3]dioxane-5-carboxylic acid (3-hydroxy-propyl)-amide, trans-isomer, (Compound A1026); 2-{4-(4-fluoro-phenyl)-5-[2-(3-morpholin-4-yl-propylamino)-p yrimidin-4-yl]-1H-imidazol-2-yl}- 5-methyl-[1,3]dioxane-5-carboxylic acid (3-hydroxy-propyl)-amide, trans-isomer, (Compound A1027); 2-{4-(4-fluoro-phenyl)-5-[2-(3-hydroxy-propylamino)-pyrimidi n-4-yl]-1H-imidazol-2-yl]-5- methyl-[1,3]dioxane-5-carboxylic acid (3-hydroxy-propyl)-amide, trans-isomer, (Compound A1028); 2-[5-(2-benzylamino-pyrimidin-4-yl]-4-(4-fluoro-phenyl)-1H-i midazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid (3-hydroxy-propyl)-amide, trans-isomer, (Compound A1029);

2-{4-(4-fluoro-phenyl)-5-[2- ( 1-phenyl-ethylamino)-pyrimidin-4-yl]- H-imidazol-2-yl)- 5-methyl- [1,3]dioxane-5-carboxylic acid (3-hydroxy-propyl)-amide, R-isomer, trans-isomer, (Compound A1030); 2-{4-(4-fluoro-phenyl)-5- [2-(1-phenyl-ethylamino)-pyrimidin-4-yl]- 1H-imidazol-2-yl)-5-methyl- [1,3]dioxane-5-carboxylic acid (3-hydroxy-propyl)-amide, S-isomer, trans-isomer, (Compound A1031); 2-[4-(4-fluoro-phenyl)-5-(2-phenylamino-pyrimidin-4-yl)-lH-i midazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid (3-hydroxy-propyl)-amide, trans-isomer, (Compound A1032); 2-[4-(4-fluoro-phenyl)-5-(2-piperidin-1-yl-pyrimidin-4-yl)-l H-imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid (3-hydroxy-propyl)-amide, trans-isomer, (Compound A1033); <BR> <BR> <BR> <BR> 2-(4-(4-fluoro-phenyl)-5-(2-[(pyridin-4-ylmethyl)-amino]-pyr imidin-4-yl )-111-imidazol-2-yl)-5- methyl-[1,3]dioxane-5-carboxylic acid (3-hydroxy-propyl)-amide, trans-isomer, (Compound A1034); 2-(4-(4-fluoro-phenyl)-5-{2-[(pyridin-3-ylmethyl)-amino]-pyr imidin-4-yl}-1H-imidazol-2-yl)-5- methyl-[1,3]dioxane-5-carboxylic acid (3-hydroxy-propyl)-amide, trans-isomer, (Compound A1035); 2-(4-(4-fluoro-phenyl)-5-{2-[(pyridin-2-ylmethyl)-amino]-pyr imidin-4-yl}-1H-imidazol-2-yl)-5- methyl-[1,3]dioxane-5-carboxylic acid (3-hydroxy-propyl)-amide, trans-isomer, (Compound A1036); 2-(4-(4-fluoro-phenyl)-5-{2-[(furan-2-ylmethyl)-amino]-pyrim idin-4-yl}-1H-imidazol-2-yl)-5- methyl-[1,3]dioxane-5-carboxylic acid (3-hydroxy-propyl)-amide, trans-isomer, (Compound A1037); 2-(4-(4-fluoro-phenyl)-5-{2-[(thiohen-2-ylmethyl)-amino]-pyr imidin-4-yl}-1H-imidazol-2-yl)-5- methyl-[1,3]dioxane-5-carboxylic acid (3-hydroxy-propyl)-amide, trans-isomer, (Compound A1038); <BR> <BR> <BR> <BR> 2-(4-(4-fluoro-phenyl)-5-{2-[(tetrahydro-furan-2-ylmethyl)-a mino]-pyrimidin-4-yl}-lH-imidazol- 2-yl)-5-methyl-[1,3]dioxane-5-carboxylic acid (3-hydroxy-propyl)-amide, trans-isomer, (Compound A1039); 2-{4-(4-fluoro-phenyl)-5-[2-(4-methyl-piperazin-1-yl)-pyrimi din-4-yl]-1H-imidazol-2-yl}-5- methyl-[1,3]dioxane-5-carboxylic acid (3-hydroxy-propyl)-amide, trans-isomer, (Compound A1040); 2-[4-(4-fluoro-phenyl)-5-(2-morpholin-4-yl-pyrimidin-4-yl)-1 H-imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid (3-hydroxy-propyl)-amide, trans-isomer, (Compound A1041); 2-{4-(4-fluoro-phenyl)-5-[2-(3-methoxy-propylamino)-pyrimidi n-4-yl]-1H-imidazol-2-yl}-5- methyl-[1,3]dioxane-5-carboxylic acid (3-hydroxy-propyl)-amide, trans-isomer, (Compound A1042);

2-(4- (4fluoro-phenyl)- 5- [2- (2-m ethoxy- ethylamino)- pyrimidin- 4-yl]- lH-imidazol-2-yl}-5-methyl- [1,3]dioxane-5-carboxylic acid (3-hydroxy-propyl)-amide, trans-isomer, (Compound A1043); <BR> <BR> <BR> <BR> 2-[5-[2-(3-dimethylamino-propylamino)-pyrimidin-4-yl]-4-(4-f luoro-phenyl)-lH-imidazol-2-yl]- 5-methyl-[1,3]dioxane-5-carboxylic acid (3-hydroxy-propyl)-amide, trans-isomer, (Compound A1044); 2-[5-[2-(2-dimethylamino-ethylamino)-pyrimidin-4-yl]-4-(4-fl uoro-phenyl)-1H-imidazol-2-yl]-5- methyl-[1,3]dioxane-5-carboxylic acid (3-hydroxy-propyl)-amide, trans-isomer, (Compound A1045); (4-{5-(4-fluoro-phenyl)-2-[5-(3-hydroxy-propylcarbamoyl)-5-m ethyl-[1,3]dioxan-2-yl]-3H- imidazol-4-yl}-pyrimidin-2-ylamino)-acetic acid, trans-isomer, (Compound A1046); 3-(4-{5-(4-fluoro-phenyl)-2-[5-(3-hydroxy-propylcarbamoyl)-5 -methyl-[1,3]dioxan-2-yl]-3H- imidazol-4-yl}-pyrimidin-2-ylamino)-propionic acid, trans-isomer, (Compound A1047); 2-[4-(4-fluoro-phenyl)-5-(2-isopropylamino-pyrimidin-4-yl)- lH-imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid (3-hydroxy-propyl)-amide, trans-isomer, (Compound A1048); 2-[5-(2-allylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-im idazol-2-yl]-5-methyl-[1,3]dioxane- 5-carboxylic acid (3-hydroxy-propyl)-amide, trans-isomer, (Compound A1049); 2-[5-[2-(cyclopropylmethyl-amino)-pyrimidin-4-yl]-4-(4-fluor o-phenyl)-1H-imidazol-2-y]-5- methyl-[1,3]dioxane-5-carboxylic acid (3-hydroxy-propyl)-amide, trans-isomer, (Compound A1050); 2-[5-[2-(cyanomethyl-amino)-pyrimidin-4-yl]-4-(4-fluoro-phen yl)-1H-imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid (3-hydroxy-propyl)-amide, trans-isomer, (Compound A1051); <BR> <BR> <BR> <BR> 2-[5-[2-(2-cyano-ethylamino)-pyrimidin-4-yl]-4-(4-fluoro-phe nyl)- lH-imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid (3-hydroxy-propyl)-amide, trans-isomer, (Compound A1052); 2-{4-(4-fluoro-phenyl)-5-[2-(pyridin-3-ylamino)-pyrimidin-4- yl]-1H-imidazol-2-yl}-5-methyl- [1,3]dioxane-5-carboxylic acid (3-hydroxy-propyl)-amide, trans-isomer, (Compound A1053); 2-{4-(4-fluoro-phenyl)-5-[2-(pyridin-4-ylamino)-pyrimidin-4- yl]-1H-imidazol-2-yl}-5-methyl- [1,3]dioxane-5-carboxylic acid (3-hydroxy-propyl)-amide, trans-isomer, (Compound A1054); 2-[4-(4-fluoro-phenyl)-5-(2-propylamino-pyrimidin-4-yl)-1H-i midazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid (3-hydroxy-propyl)-amide, trans-isomer, (Compound A1055); 2-[4-(4-fluoro-phenyl)-5-(2-pyrrolidin-1-yl-pyrimidin-4-yl)- lH-imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid (3-hydroxy-propyl)-amide, trans-isomer, (Compound A1056); <BR> <BR> <BR> <BR> 2-{4-(4-fluoro-phenyl)-5-[2-(4-fluoro-phenylamino)-pyrimidin -4-yl]-lH-imidazol-2-yl}-5-methyl- [1,3]dioxane-5-carboxylic acid (3-hydroxy-propyl)-amide, trans-isomer, (Compound A1057); 2-[5-[2-(3,4-difluoro-phenylamino)-pyrimidin-4-yl]-4-(4-fluo ro-phenyl)-1H-imidazol-2-yl]-5- methyl-[1,3]dioxane-5-carboxylic acid (3-hydroxy-propyl)-amide, trans-isomer, (Compound A1058);

2-{4-(4-fluoro-phenyl)-5-[2-(3-methoxy-phenylamino)-pyrimidi n-4-yl]-lH-imidazol-2-yl}-5- methyl-[1,3]dioxane-5-carboxylic acid (3-hydroxy-propyl)-amide, trans-isomer, (Compound A1059); <BR> <BR> <BR> <BR> <BR> 2-[5-[2-(4-fluoro-benzylamino)-pyrimidin-4-yl]-4-(4-fluoro-p henyl)- 111-imidazol-2-ylj-5-methyl- [1,3]dioxane-5-carboxylic acid (3-hydroxy-propyl)-amide, trans-isomer, (Compound A1060); 2-{4-(4-fluoro-phenyl)-5-[2-(4-methoxy-benzylamino)-pyrimidi n-4-yl]-lH-imidazol-2-yl}-5- methyl-[1,3]dioxane-5-carboxylic acid (3-hydroxy-propyl)-amide, trans-isomer, (Compound A1061); <BR> <BR> <BR> <BR> <BR> 2-[4-(4-fluoro-phenyl)-5-(2-methoxy-pyrimidin-4-yl)-lH-imida zol-2-yl]-5-methyl-[1,3]dioxane-5- carboxylic acid (3-hydroxy-propyl)-amide, trans-isomer, (Compound A1062); 2-[5-(2-benzyloxy-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imi dazol-2-yl]-5-methyl-[1,3]dioxane- 5-carboxylic acid (3-hydroxy-propyl)-amide, trans-isomer, (Compound A1063); 2-[4-(4-fluoro-phenyl)-5-(2-phenoxy-pyrimidin-4-yl)-1H-imida zol-2-yl]-5-methyl-[1,3]dioxane-5- carboxylic acid (3-hydroxy-propyl)-amide, trans-isomer, (Compound A1064); 2-{4-(4-fluoro-phenyl)-5-[2-(2-methoxy-ethoxy)-pyrimidin-4-y l]-1H-imidazol-2-yl}-5-methyl- [1,3]dioxane-5-carboxylic acid (3-hydroxy-propyl)-amide, trans-isomer, (Compound A1065); 2-[5-[2-(2-dimethylamino-ethoxy)-pyrimidin-4-yl]-4-(4-fluoro -phenyl)-1H-imidazol-2-yl]-5- methyl-[1,3]dioxane-5-carboxylic acid (3-hydroxy-propyl)-amide, trans-isomer, (Compound A1066); 2-[5-(2-cyclohexyloxy-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H -imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid (3-hydroxy-propyl)-amide, trans-isomer, (Compound A1067); 2-[5-(2-Isopropoxy-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-im idazol-2-yl]-5-methyl-[1,3]dioxane- 5-carboxylic acid (3-hydroxy-propyl)-amide, trans-isomer, (Compound A1068); 2-[4-(4-fluoro-phenyl)-5-(2-propoxy-pyrimidin-4-yl)-1H-imida zol-2-yl]-5-methyl-[1,3]dioxane-5- carboxylic acid (3-hydroxy-propyl)-amide, trans-isomer, (Compound A1069); 2-{4-(4-fluoro-phenyl)-5-[2-(2-hydroxy-ethoxy)-pyrimidin-4-y l]-1H-imidazol-2-yl}-5-methyl- [1,3]dioxane-5-carboxylic acid (3-hydroxy-propyl)-amide, trans-isomer, (Compound A1070); 2-{4-(4-fluoro-phenyl)-5-[2-(3-hydroxy-propoxy)-pyrimidin-4- yl]-1H-imidazol-2-yl}-5-methyl- [1,3]dioxane-5-carboxylic acid (3-hydroxy-propyl)-amide, trans-isomer, (Compound A1071); 2-[4-(4-fluoro-phenyl)-5-(2-methylsulfanyl-pyrimidin-4-yl)-1 H-imidazol-2-yl]-5-methyl- [1,3idioxane-5-carboxylic acid (3-hydroxy-propyl)-amide, trans-isomer, (Compound A1072); 2-[5-(2-amino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazo l-2-yl]-5-methyl-[1,3]dioxane-5- carboxylic acid benzylamide, trans-isomer, (Compound A1073); 2-[4-(4-fluoro-phenyl)-5-(2-methylamino-pyrimidin-4-yl)-1H-i midazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid benzylamide, trans-isomer, (Compound A1074);

2-[5-(2-dimethylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)- lH-imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid benzylamide, trans-isomer, (Compound A1075); 2-[5-(2-cyclopropylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl) -1H-imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid benzylamide, trans-isomer, (Compound A1076); 2-{4-(4-fluoro-phenyl)-5-[2-(piperidin-4-ylamino)-pyrimidin- 4-yl]-1H-imidazol-2-yl}-5-methyl- [1,3]dioxane-5-carboxylic acid benzylamide, trans-isomer, (Compound A1077); 2-[5-(2-cyclohexylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)- 1H-imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid benzylamide, trans-isomer, (Compound A1078); 2-{4-(4-fluoro-phenyl)-5-[2-(2-hydroxy-ethylamino)-pyrimidin -4-yl]-1H-imidazol-2-yl}-5-methyl- [1,3]dioxane-5-carboxylic acid benzylamide, trans-isomer, (Compound A1079); 2-[5-[2-(2-amino-ethylamino)-pyrimidin-4-yl]-4-(4-fluoro-phe nyl)-1H-imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid benzylamide, trans-isomer, (Compound A1080); 2-(4-(4-fluoro-phenyl)-5-{2-[3-(5H-imidazol-1-yl)-propylamin o]-pyrimidin-4-yl}-1H-imidazol-2- yl)-5-methyl-[1,3]dioxane-5-carboxylic acid benzylamide, trans-isomer, (Compound A1081); <BR> <BR> <BR> <BR> 2-{4-(4-fluoro-phenyl)-5-[2-(3-morpholin-4-yl-propylamino)-p yrimidin-4-yl]-lH-imidazol-2-yl}- 5-methyl-[1,3]dioxane-5-carboxylic acid benzylamide, trans-isomer, (Compound A1082); 2-{4-(4-fluoro-phenyl)-5-[2-(3-hydroxy-propylamino)-pyrimidi n-4-yl]-1H-imidazol-2-yl}-5- methyl-[1,3]dioxane-5-carboxylic acid benzylamide, trans-isomer, (Compound A1083); 2-[5-(2-benzylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-lH-i midazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid benzylamide, trans-isomer, (Compound A1084); <BR> <BR> <BR> <BR> <BR> 2-{4-(4-fluoro-phenyl)-5-[2-(1-phenyl-ethylamino)-pyrimidin- 4-yl]-lH-imidazol-2-yl}-5-methyl- [1,3]dioxane-5-carboxylic acid benzylamide, R-isomer, trans-isomer, (Compound A1085); 2-{4-(4-fluoro-phenyl)-5-[2-(1-phenyl-ethylamino)-pyrimidin- 4-yl]-1H-imidazol-2-yl}-5-methyl- [1,3]dioxane-5-carboxylic acid benzylamide, S-isomer, trans-isomer, (Compound A1086); 2-[4-(4-fluoro-phenyl)-5-(2-phenylamino-pyrimidin-4-yl)- lH-imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid benzylamide, trans-isomer, (Compound A1087); 2-[4-(4-fluoro-phenyl)-5-(2-piperidin-1-yl-pyrimidin-4-yl)-l H-imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid benzylamide, trans-isomer, (Compound A1088); <BR> <BR> <BR> <BR> 2-(4-(4-fluoro-phenyl)-5-{2-[(pyridin-4-ylmethyl)-amino]-pyr imidin-4-yl )-111-imidazol-2-yl)-5- methyl-[1,3]dioxane-5-carboxylic acid benzylamide, trans-isomer, (Compound A1089); 2-(4-(4-fluoro-phenyl)-5-{2-[(pyridin-3-ylmethyl)-amino]-pyr imidin-4-yl}-1H-imidazol-2-yl)-5- methyl-[1,3]dioxane-5-carboxylic acid benzylamide, trans-isomer, (Compound A1090); 2-(4-(4-fluoro-phenyl)-5-{2-[(pyridin-2-ylmethyl)-amino]-pyr imidin-4-yl }-lH-imidazol-2-yl)-5- methyl-[1,3]dioxane-5-carboxylic acid benzylamide, trans-isomer, (Compound A1091); 2-(4-(4-fluoro-phenyl)-5-{2-[(furan-2-ylmethyl)-amino]-pyrim idin-4-yl}-1H-imidazol-2-yl)-5- methyl-[1,3]dioxane-5-carboxylic acid benzylamide, trans-isomer, (Compound A1092);

2-(4-(4-fluoro-phenyl)-5-{2-[(thiophen-2-ylmethyl)-aminoj-py rimidin-4-yl}- lH-imidazol-2-yl)-5- methyl-[1,3]dioxane-5-carboxylic acid benzylamide, trans-isomer, (Compound A1093); <BR> <BR> <BR> 2-(4-(4-fluoro-phenyl)-5-{2-[(tetrahydro-furan-2-ylmethyl)-a mino]-pyrimidin-4-yl}-lH-imidazol- 2-yl)-5-methyl-[1,3]dioxane-5-carboxylic acid benzylamide, trans-isomer, (Compound A1094); 2-{4-(4-fluoro-phenyl)-5-[2-(4-methyl-piperazin-1-yl)-pyrimi din-4-yl]-lH-imidazol-2-yl}-5- methyl-[1,3]dioxane-5-carboxylic acid benzylamide, trans-isomer, (Compound A1095); 2-[4-(4-fluoro-phenyl)-5-(2-morpholin-4-yl-pyrimidin-4-yl)-l H-imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid benzylamide, trans-isomer, (Compound A1096); 2-{4-(4-fluoro-phenyl)-5-[2-(3-methoxy-propylamino)-pyrimidi n-4-yl)-1H-imidazol-2-yl}-5 methyl-[1,3]dioxane-5-carboxylic acid benzylamide, trans-isomer, (Compound A1097); 2-{4-(4-fluoro-phenyl)-5-[2-(2-methoxy-ethylamino)-pyrimidin -4-yl)-1H-imidazol-2-yl}-5-methyl- [1,3]dioxane-5-carboxylic acid benzylamide, trans-isomer, (Compound A1098); 2-[5-[2-(3-dimethylamino-propylamino)-pyrimidin-4-yl]-4-(4-f luoro-phenyl)-lH-imidazol-2-yl]- 5-methyl-[1,3]dioxane-5-carboxylic acid benzylamide, trans-isomer, (Compound A1099); 2-[5-[2-(2-dimethylamino-ethylamino)-pyrimidin-4-yl]-4-(4-fl uoro-phenyl)-1H-imidazol-2-yl]-5- methyl-[1,3]dioxane-5-carboxylic acid benzylamide, trans-isomer, (Compound A1100); {4-[2-(5-benzylcarbamoyl-5-methyl-[1,3]dioxan-2-yl)-5-(4-flu oro-phenyl)-3H-imidazol-4-yl]- pyrimidin-2-ylamino}-acetic acid, trans-isomer, (Compound A1101); 3-{4-[2-(5-benzylcarbamoyl-5-methyl-[1,3]dioxan-2-yl)-5-(4-f luoro-phenyl)-3H-imidazol-4-yl]- pyrimidin-2.ylamino)-propionic acid, trans-isomer, (Compound A1102); 2-[4-(4-fluoro-phenyl)-5-(2-isopropylamino-pyrimidin-4-yl)-1 H-imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid benzylamide, trans-isomer, (Compound A1103); 2-[5-(2-allylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)- lH-imidazol-2-yl]-5-methyl-[1,3]dioxane- 5-carboxylic acid benzylamide, trans-isomer, (Compound A1104); 2- [5-[2-(cyclopropylmethyl-amino)-pyrimidin-4yl]-4-(4-fluoro-p henyl)- lH-imidazol-2-yl]-5- methyl-[1,3]dioxane-5-carboxylic acid benzylamide, trans-isomer, (Compound A1105); 2-[5-[2-(cyanomethyl-amino)-pyrimidin-4-yl]-4-(4-fluoro-phen yl)-1H-imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid benzylamide, trans-isomer, (Compound A1106); 2-[5-[2-(2-(cyano-ethylamino)-pyrimidin-4-yl]-4-(4-fluoro-ph enyl)-1H-imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid benzylamide, trans-isomer, (Compound A1107); 2-(4-(4-fluoro-phenyl)-5-[2-(pyridin-3-ylamino)-pyrimidin-4- yl]- 1H-imidazol-2-yl )-5-methyl- [1,3]dioxane-5-carboxylic acid benzylamide, trans-isomer, (Compound A1108); 2-{4-(4-fluoro-phenyl)-5-[2-(pyridin-4-ylamino)-pyrimidin-4- yl]-1H-imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid benzylamide, trans-isomer, (Compound A1109); 2-[4-(4-fluoro-phenyl)-5-(2-propylamino-pyridimin-4-yl)-1H-i midazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid benzylamide, trans-isomer, (Compound A1110);

2-[4-(4-fluoro-phenyl)-5-(2-pyrrolidin- 1-yl-pyrimidin-4-yl)- lH-imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid benzylamide, trans-isomer, (Compound A1111); <BR> <BR> <BR> 2-{4-(4-fluoro-phenyl)-5-[2-(4-fluoro-phenylamino)-pyrimidin -4-yl]-111-imidazol-2-ylj-5-methyl- [1,3]dioxane-5-carboxylic acid benzylamide, trans-isomer, (Compound A1112); 2-[5-[2-(3,4-difluoro-phenylamino)-pyrimidin-4-yl]-4-(4-fluo ro-phenyl)-l11-imidazol2yl]-5- methyl-[1,3]dioxane-5-carboxylic acid benzylamide, trans-isomer, (Compound A1113); 2-{4-(4-fluoro-phenyl)-5-[2-(3-methoxy-phenylamino)-pyrimidi n-4-yl]-1H-imidazol-2-yl}-5- methyl-[1,3]dioxane-5-carboxylic acid benzylamide, trans-isomer, (Compound A1114); 2-[5-[2-(4-fluoro-benzylamino)-pyrimidin-4-yl]-4-(4-fluoro-p henyl)-1H-imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid benzylamide, trans-isomer, (Compound A1115); 2-(4-(4-fluoro-phenyl)-5-[2-(4-methoxy-benzylamino)-pyrimidi n-4-yl]-lH-imidazol-2-ylj-5- methyl-[1,3]dioxane-5-carboxylic acid benzylamide, trans-isomer, (Compound A1116); <BR> <BR> <BR> 2-[4-(4-fluoro-phenyl)-5-(2-methoxy-pyrimidin-4-yl)- lH-imidazol-2-yl]-5-methyl-[1,3]dioxane-5- carboxylic acid benzylamide, trans-isomer, (Compound A1117); <BR> <BR> <BR> 2-[5-(2-benzyloxy-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-lH-imi dazol-2-yl]-5-methyl-[1,3]dioxane- 5-carboxylic acid benzylamide, trans-isomer, (Compound A1118); 2-[4-(4-fluoro-phenyl)-5-(2-phenoxy-pyrimidin-4-yl)-1H-imida zol-2-yl]-5-methyl-[1,3]dioxane-5- carboxylic acid benzylamide, trans-isomer, (Compound A1119); 2-{4-(4-fluoro-phenyl)-5-[2-(2-methoxy-ethoxy)-pyrimidin-4-y l]-1H-imidazol-2-yl}-5-methyl- [1,3]dioxane-5-carboxylic acid benzylamide, trans-isomer, (Compound A1120); 2-[5-[2-(2-dimethylamino-ethoxy)-pyrimidin-4-yl]-4-(4-fluoro -phenyl)-1H-imidazol-2-yl]-5- methyl-[1,3]dioxane-5-carboxylic acid benzylamide, trans-isomer, (Compound A1121); 2-[5-(2-cyclohexyloxy-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-lH -imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid benzylamide, trans-isomer, (Compound A1122); 2-[5-(2-Isopropoxy-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-im idazol-2-yl]-5-methyl-[1,3]dioxane- 5-carboxylic acid benzylamide, trans-isomer, (Compound A1123); 2-[4-(4-fluoro-phenyl)-5-(2-propoxy-pyrimidin-4-yl)-1H-imida zol-2-yl]-5-methyl-[1,3]dioxane-5- carboxylic acid benzylamide, trans-isomer, (Compound A1124); 2-{4-(4-fluoro-phenyl)-5-[2-(2-hydroxy-ethoxy)-pyrimidin-4-y l)-1H-imidazol-2-yl}-5-methyl- [1,3]dioxane-5-carboxylic acid benzylamide, trans-isomer, (Compound A1125); 2-{4-(4-fluoro-phenyl)-5-[2-(3-hydroxy-propoxy)-pyrimidin-4- yl)-1H-imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid benzylamide, trans-isomer, (Compound A1126); 2-[4-(4-fluoro-phenyl)-5-(2-methylsulfanyl-pyrimidin-4-yl)-1 H-imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid benzylamide, trans-isomer, (Compound A1127); <BR> <BR> <BR> 2-[5-(2-amino-pyrimidin-4-yl)-4-(4-fluoro-phenyl) 1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5- carboxylic acid phenylamide, trans-isomer, (Compound A1128);

2-[4-(4-fluoro-phenyl)-5-(2-methylamino-pyrimidin-4-yl)-1H-i midazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid phenylamide, trans-isomer, (Compound A1129); 2-[5-(2-dimethylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H -imidzol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid phenylamide, trans-isomer, (Compound A1130); 2-[5-(2-cyclopropylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl) -1H-imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid phenylamide, trans-isomer, (Compound A1131); 2-{4-(4-fluoro-phenyl)5-[2-(piperidin-4-ylamino)-pyrimidin-4 -yl]-1H-imidazol-2-yl}-5-methyl- [1,3]dioxane-5-carboxylic acid phenylamide, trans-isomer, (Compound A1132); 2-[5-(2-cyclohexylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)- lH-imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid phenylamide, trans-isomer, (Compound A1133); 2-{4-(4-fluoro-phenyl)-5-[2-(2-hydroxy-ethylamino)-pyrimidin -4-yl]-1H-imidazol-2-yl}-5-methyl- [1,3]dioxane-5-carboxylic acid phenylamide, trans-isomer, (Compound A1134); 2-[5-[2-(2-amino-ethylamino)-pyrimidin-4-yl]-4-(4-fluoro-phe nyl)-1H-imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid phenylamide, trans-isomer, (Compound A1135); <BR> <BR> <BR> 2-(4-(4-fluoro-phenyl)-5-{2-[3-(5H-imidazol-1-yl)-propylamin o]-pyrimidin-4-yl}-lH-imidazol-2- yl)-5-methyl-[1,3]dioxane-5-carboxylic acid phenylamide, trans-isomer, (Compound A1136); 2-{4-(4-fluoro-phenyl)-5-[2-(3-morpholin-4-yl-propylamino)-p yrimidin-4-yl]-1H-imidazol-2-yl}- 5-methyl-[1,3]dioxane-5-carboxylic acid phenylamide, trans-isomer, (Compound A1137); 2-{4-(4-fluoro-phenyl)-5-[2-(3-hydroxy-propylamino)-pyrimidi n-4-yl]-1H-imidazol-2-yl}-5- methyl-[1,3]dioxane-5-carboxylic acid phenylamide, trans-isomer, (Compound A1138); 2-[5-(2-benzylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-i midazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid phenylamide, trans-isomer, (Compound A1139); <BR> <BR> <BR> 2-{4-(4-fluoro-phenyl)-5-[2-(1-phenyl-ethylamino)-pyrimidin- 4-yl]-lH-imidazol-2-yl}-5-methyl- [1,3]dioxane-5-carboxylic acid phenylamide, R-isomer, trans-isomer, (Compound A1140); 2-{4-(4-fluoro-phenyl)-5-[2-(1-phenyl-ethylamino)-pyrimidin- 4-yl]-1H-imidazol-2-yl}-5-methyl- [1,3]dioxane-5-carboxylic acid phenylamide, S-isomer, trans-isomer, (Compound A1141); 2-[4-(4-fluoro-phenyl)-5-(2-phenylamino-pyrimidin-4-yl)-1H-i midazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid phenylamide, trans-isomer, (Compound A1142); 2-[4-(4-fluoro-phenyl)-5-(2-piperidin-1-yl-pyrimidin-4-yl)-1 H-imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid phenylamide, trans-isomer, (Compound A1143); 2-(4-(4-fluoro-phenyl)-5-{2-[(pyridin-4-ylmethyl)-amino]-pyr imidin-4-yl)-1H-imidazol-2-yl-)-5- methyl-[1,3]dioxane-5-carboxylic acid phenylamide, trans-isomer, (Compound A1144); 2-(4-(4-fluoro-phenyl)-5-{2-[(pyridin-3-ylmethyl)-amino]-pyr imidin-4-yl}-1H-imidazol-2-yl)-5- methyl-[1,3]dioxane-5-carboxylic acid phenylamide, trans-isomer, (Compound A1145); 2-(4-(4-fluoro-phenyl)-5-{2-[(pyridin-2-ylmethyl)-amino]-pyr imidin-4-yl}-1H-imidazol-2-yl)-5- methyl-E1,3]dioxane-5-carboxylic acid phenylamide, trans-isomer, (Compound A1146);

2-(4-(4-fluoro-phenyl)-5-{2-[(furan-2-ylmethyl)-amino]-pyrim idin-4-yl}-lH-imidazol-2-yl)-5- methyl-[1,3]dioxane-5-carboxylic acid phenylamide, trans-isomer, (Compound A1147); <BR> <BR> <BR> 2-(4-(4-fluoro-phenyl)-5-(2-[(thiophen-2-ylmethyl)-aminoj-py rimidin-4-yl)- lH-imidazol-2-yl)-5- methyl-[1,3]dioxane-5-carboxylic acid phenylamide, trans-isomer, (Compound A1148); 2-(4-(4-fluoro-phenyl)-5-{2-[(tetrahydro-furan-2-ylmnethyl)- amino]-pyrimidin-4-yl}-1H-imidazol- 2-yl)-5-methyl-[1,3]dioxane-5-carboxylic acid phenylamide, trans-isomer, (Compound A1149); 2-{4-(4-fluoro-phenyl)-5-[2-(4-methyl-piperazin-1-yl)-pyrimi din-4-yl]-1H-imidazol-2-yl}-5- methyl-[1,3]dioxane-5-carboxylic acid phenylamide, trans-isomer, (Compound A1150); 2-[4-(4-fluoro-phenyl)-5-(2-morpholin-4-yl-pyrimidin-4-yl)- lH-imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid phenylamide, trans-isomer, (Compound A1151); 2-{4-(4-fluoro-phenyl)-5-[2-(3-methoxy-propylamino)-pyrimidi n-4-yl]-1H-imidazol-2-yl}-5- methyl-[1,3]dioxane-5-carboxylic acid phenylamide, trans-isomer, (Compound Al 152); 2-{4-(4-fluoro-phenyl)-5-[2-(2-methoxy-ethylamino)-pyrimidin -4-yl]-1H-imidazol-2-yl}-5-methyl- [1,3]dioxane-5-carboxylic acid phenylamide, trans-isomer, (Compound A1153); 2-[5-[2-(3-dimethylamino-propylamino)-pyrimidin-4-yl]-4-(4-f luoro-phenyl)-1H-imidazol-2-yl]- 5-methyl-[1,3]dioxane-5-carboxylic acid phenylamide, trans-isomer, (Compound A1154); 2-[5-[2-(2-dimethylamino-ethylamino)-pyrimidin-4-yl]-4-(4-fl uoro-phenyl)-1H-imidazol-2-yl]-5- methyl-[1,3]dioxane-5-carboxylic acid phenylamide, trans-isomer, (Compound A1155); {4-[5-(4-fluoro-phenyl)-2-(5-methyl-5-phenylcarbamoyl-[1,3]d ioxan-2-yl)-3H-imidazol-4-yl]- pyrimidin-2-ylamino)-acetic acid, trans-isomer, (Compound A1156); 3-(4-[5-(4-fluoro-phenyl)-2-(5-methyl-5-phenylcarbamoyl- [1,3]dioxan-2-yl)-3H-imidazol-4-yl]- pyrimidin-2-ylamino}-propionic acid, trans-isomer, (Compound A1157); 2-[4-(4-fluoro-phenyl)-5-(2-isopropylamino-pyrimidin-4-yl)-1 H-imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid phenylamide, trans-isomer, (Compound A1158); 2-[5-(2-allylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-im idazol-2-yl]-5-methyl-[1,3]dioxane- 5-carboxylic acid phenylamide, trans-isomer, (Compound A1159); 2-[5-[2-(cyclopropylmethyl-amino)-pyrimidin-4-yl]-4-(4-fluor o-phenyl)-1H-imidazol-2-yl]-5- methyl-[1,3]dioxane-5-carboxylic acid phenylamide, trans-isomer, (Compound A1160); 2-[5-[2-(cyanomethyl-amino)-pyrimidin-4-yl]-4-(4-fluoro-phen yl)-1H-imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid phenylamide, trans-isomer, (Compound A1161); 2-[5-[2-(2-cyano-ethylamino)-pyrimidin-4-yl]-4-(4-fluoro-phe nyl)- lH-imidazol-2-yl] -5-methyl- [1,3]dioxane-5-carboxylic acid phenylamide, trans-isomer, (Compound A1162); 2-{4-(4-fluoro-phenyl)-5-[2-(pyridin-3-ylamino)-pyrimidin-4- yl]-1H-imidazol-2-yl}-5-methyl- [1,3]dioxane-5-carboxylic acid phenylamide, trans-isomer, (Compound A1163); 2-{4-(4-fluoro-phenyl)-5-[2-(pyridin-4-ylamino)-pyrimidin-4- yl]-1H-imidazol-2-yl}-5-methyl- [1,3]dioxane-5-carboxylic acid phenylamide, trans-isomer, (Compound A1164);

2-[4-(4-fluoro-phenyl)-5-(2-propylamino-pyrimidin-4-yl)- 1H-imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid phenylamide, trans-isomer, (Compound A1165); 2-[4-(4-fluoro-phenyl)-5-(2-pyrrolidin- 1-yl-pyrimidin-4-yl)-lH-imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid phenylamide, trans-isomer, (Compound A1166); <BR> <BR> <BR> 2- (4-(4-fluoro-phenyl) -5-[2-(4 -fluoro-phenylamino) -pyrimidin-4-yl]- la-imidazol3-yl) -5-methyl- [1,3]dioxane-5-carboxylic acid phenylamide, trans-isomer, (Compound A1167); 2-[5-[2-(3,4-difluoro-phenylamino)-pyrimidin-4-yl]-4-(4-fluo ro-phenyl)-1H-imidazol-2-yl]-5- methyl-[1,3]dioxane-5-carboxylic acid phenylamide, trans-isomer, (Compound A1168); 2-{4-(4-fluoro-phenyl)-5-[2-(3-methoxy-phenylamino)-pyrimidi n-4-yl]-1H-imidazol-2-yl}-5- methyl-[1,3]dioxane-5-carboxylic acid phenylamide, trans-isomer, (Compound A1169); 2-[5-[2-(4-fluoro-benzylamino)-pyrimidin-4-yl]-4-(4-fluoro-p henyl)-1H-imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid phenylamide, trans-isomer, (Compound A1170); 2-{4-(4-fluoro-phenyl)-5-[2-(4-methoxy-benzylamino)-pyrimidi n-4-yl]-1H-imidazol-2-yl}-5- methyl-[1,3]dioxane-5-carboxylic acid phenylamide, trans-isomer, (Compound A1171); 2-[4-(4-fluoro-phenyl)-5-(2-methoxy-pyrimidin-4-yl)-1H-imida zol-2-yl]-5-methyl-[1,3]dioxane-5- carboxylic acid phenylamide, trans-isomer, (Compound A1172); 2-[5-(2-benzyloxy-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imi dazol-2-yl]-5-methyl-[1,3]dioxane- 5-carboxylic acid phenylamide, trans-isomer, (Compound A1173); 2-[4-(4-fluoro-phenyl)-5-(2-phenoxy-pyrimidin-4-yl)-1H-imida zol-2-yl]-5-methyl-[1,3]dioxane-5- carboxylic acid phenylamide, trans-isomer, (Compound A1174); 2-{4-(4-fluoro-phenyl)-5-[2-(2-methoxy-ethoxy)-pyrimidin-4-y l]-1H-imidazol-2-yl}-5-methyl- [1,3]dioxane-5-carboxylic acid phenylamide, trans-isomer, (Compound A1175); 2-[5-[2-(2-dimethylamino-ethoxy)-pyrimidin-4-yl]-4-(4-fluoro -phenyl)-1H-imidazol-2-yl]-5- methyl-[1,3]dioxane-5-carboxylic acid phenylamide, trans-isomer, (Compound A1176); 2-[5-(2-cyclohexyloxy-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H -imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid phenylamide, trans-isomer, (Compound A1177); 2-[5-(2-Isopropoxy-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-im idazol-2-yl]-5-methyl-[1,3]dioxane- 5-carboxylic acid phenylamide, trans-isomer, (Compound A1178); <BR> <BR> <BR> 2-[4-(4-fluoro-phenyl)-5-(2-propoxy-pyrimidin-4-yl)- lH-imidazol-2-yl]-5-methyl-[1,3]dioxane-5- carboxylic acid phenylamide, trans-isomer, (Compound A1179); 2-(4-(4-fluoro-phenyl)-5-[2-(2-hydroxy-ethoxy)-pyrimidin-4-y l]- lH-imidazol-2-yl}-5-methyl- [1,3]dioxane-5-carboxylic acid phenylamide, trans-isomer, (Compound A1180); 2-{4-(4-fluoro-phenyl)-5-[2-(3-hydroxy-propoxy)-pyrimidin-4- yl]-1H-imidazol-2-yl}-5-methyl- [1,3]dioxane-5-carboxylic acid phenylamide, trans-isomer, (Compound A1181); 2-[4-(4-fluoro-phenyl)-5-(2-methylsulfanyl-pyrimidin-4-yl)-1 H-imidazol-2-yl]-5-methyl- [l,3]dioxane-5-carboxylic acid phenylamide, trans-isomer, (Compound A1182);

{2-[5-(2-amino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)- lH-imidazol-2-yl]-5-methyl-[1,3]dioxan-5- yl}-piperidin-1-yl-methanone, trans-isomer, (Compound A1183); {2-[4-(4-fluoro.phenyl)-5-(2-methylamino-pyrimidin-4-yl)- lH-imidazol-2-yl]-5-methyl- [1,3]dioxan-5-yl)-piperidin-1-yl-methanone, trans-isomer, (Compound A1184); {2-[5-(2-dimethylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-l H-imidazol-2-yl]-5-methyl- [1,3]dioxan-5-yl)-piperidin-1-yl-methanone, trans-isomer, (Compound A1185); {2-[5-(2-cyclopropylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl )-1H-imidazol-2-yl]-5-methyl- [1,3]dioxan-5-yl}-piperidin-1-yl-methanone, trans-isomer, (Compound A1186); (2-{4-(4-fluoro-phenyl)-5-[2-(piperidin-4-ylamino)-pyrimidin -4-yl]-1H-imidazol-2-yl}-5-methyl- [1,3]dioxan-5-yl)-piperidin-l-yl-methanone, trans-isomer, (Compound A1187); {2-[5-(2-cyclohexylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl) -1H-imidazol-2-yl]-5-methyl- [1,3]dioxan-5-yl)-piperidin- l-yl-methanone, trans-isomer, (Compound A1188); (2-{4-(4-fluoro-phenyl)-5-[2-(2-hydroxy-ethylamino)-pyrimidi n-4-yl]-1H-imidazol-2-yl}-5- methyl-[1,3]dioxan-5-yl)-piperidin-1-yl-methanone, trans-isomer, (Compound A1189); {2-[5-[2-(2-amino-ethylamino)-pyrimidin-4-yl]-4-(4-fluoro-ph enyl)-1H-imidazol-2-yl]-5-methyl- [1,3]dioxan-5-yl )-piperidin-l-yl-methanone, trans-isomer, (Compound A1190); [2-(4-(4-fluoro-phenyl)-5-{2-[3-(5H-imidazol-1-yl)-propylami no]-pyrimidin-4-yl}-1H-imidazol-2- yl)-5-methyl-[1,3]dioxan-5-yl]-piperidin 1-yl-methanone, trans-isomer, (Compound A1191); <BR> <BR> <BR> (2-{4-(4-fluoro-phenyl)-5-[2-(3-morpholin-4-yl-propylamino)- pyrimidin-4-yl]-lH-imidazol-2-yl}- 5-methyl-[1,3]dioxane-5-yl)-piperidin-1-yl-methanone, trans-isomer, (Compound A1192); (2-{4-(4-fluoro-phenyl)-5-[2-(3-hydroxy-propylamino)-pyrimid in-4-yl]-1H-imidazol-2-yl}-5- methyl-[1,3]dioxan-5-yl)-piperidin-1-yl-methanone, trans-isomer, (Compound A1193); {2-[5-(2-benzylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-lH- imidazol-2-yl]-5-methyl- [1,3]dioxan-5-yl }-piperidin-l-yl-methanone, trans-isomer, (Compound A1194); <BR> <BR> <BR> <BR> (2-{4-(4-fluoro-phenyl)-5-[2-(1-phenyl-ethylamino)-pyrimidin -4-yl]-lH-imidazol-2-yl}-5-methyl- [1,3]dioxan-5-yl)-piperidin-1-yl-methanone, R-isomer, trans-isomer, (Compound A1195); <BR> <BR> <BR> (2-{4-(4-fluoro-phenyl)-5-[2-(1-phenyl-ethylamino)-pyrimidin -4-yl]-lH-imidazol-2-yl}-5-methyl- [1,3]dioxan-5-yl)-piperidin-1-yl-methanone, S-isomer, trans-isomer, (Compound A1196); {2-[4-(4-fluoro-phenyl)-5-(2-phenylamino-pyrimidin-4-yl)-lH- imidazol-2-yl]-5-methyl- [1,3]dioxan-5-yl )-piperidin- 1-yl-methanone, trans-isomer, (Compound A1197); {2-[4-(4-fluoro-phenyl)-5-(2-piperidin- 1-yl-pyrimidin-4-yl)-lH-imidazol-2-yl]-5-methyl- [l,3]dioxan-5-yl )-piperidin-l-yl-methanone, trans-isomer, (Compound A1198); [2-(4-(4-fluoro-phenyl)-5-{2-[(pyridin-4-ylmethyl)-amino]-py rimidin-4-yl}-1H-imidazol-2-yl)-5- methyl-[1,3]dioxan-5-yl]-piperidin-1-yl-methanone, trans-isomer, (Compound A1199); [2-(4-(4-fluoro-phenyl)-5-{2-[(pyridin-3-ylmethyl)-amino]-py rimidin-4-yl l-l11-imidazol-2-yl)-5- methyl-[1,3]dioxan-5-yl]-piperidin-1-yl-methanone, trans-isomer, (Compound A1200);

[2-(4-(4-fluoro-phenyl)-5-{2-[(pyridin-2-ylmethyl)-amino]-py rimidin-4-yl}-1H-imidazol-2-yl)-5- methyl-[1,3]dioxan-5-yl]-piperidin-1-yl-methanone, trans-isomer, (Compound A1201); [2-(4-(4-fluoro-phenyl)-5-(2-[(furan-2-ylmethyl)-amino]-pyri midin-4-yl)-111-imidazol-2-yl)-5 methyl-[1,3]dioxan-5-yl]-piperidin-1-yl-methanone, trans-isomer, (Compound A1202); [2-(4-(4-fluoro-phenyl)-5-{5-[(thiophen-2-ylmethyl)-amino]-p yrimidin-4-yl}-1H-imidazol-2-yl)-5- methyl-[1,3]dioxan-5-yl]-piperidin-1-yl-methanone, trans-isomer, (Compound A1203); [2-(4-(4-fluoro-phenyl)-5-{2-[(tetrahydro-furan-2-ylmethyl)- amino]-pyrimidin-4-yl}-1H- imidazol-2-yl)-5-methyl-[1,3]dioxan-5-yl]-piperidin-1-yl-met hanone, trans-isomer, (Compound A1204); (2-{4-(4-fluoro-phenyl)-5-[2-(4-methyl-piperazin-1-yl)-pyrim idin-4-yl]-lH-imidazol-2-yl}-5- methyl-[1,3]dioxan-5-yl)-piperidin-1-yl-methanone, trans-isomer, (Compound A1205); (2-[4-(4-fluoro-phenyl)-5-(2-morpholin-4-yl-pyrimidin-4-yl)- lH-imidazol-2-yl]-5-methyl- [1,3]dioxan-5-yl}-piperidin-1-yl-methanone, trans-isomer, (Compound A1206); (2-{4-(4-fluoro-phenyl)-5-[2-(3-methoxy-propylamino)-pyrimid in-4-yl]- 1H-imidazol-2-yli-5- methyl-[1,3]dioxan-5-yl)-piperidin-1-yl-methanone, trans-isomer, (Compound A1207); (2-{4-(4-fluoro-phenyl)-5-[2-(2-methoxy-ethylamino)-pyrimidi n-4-yl]-1H-imidazol-2-yl}-5- methyl-[1,3]dioxan-5-yl)-piperidin-1-yl-methanone, trans-isomer, (Compound A1208); {2-[5-[2-(3-dimethylamino-propylamino)-pyrimidin-4-yl]-4-(4- fluoro-phenyl)-1H-imidazol-2-yl]- 5-methyl-[1,3]dioxan-5-yl)-piperidin-1-yl-methanone, trans-isomer, (Compound A1209); {2-[5-[2-(2-dimethylamino-ethylamino)-pyrimidin-4-yl]-4-(4-f luoro-phenyl)-1H-imidazol-2-yl]-5- methyl-[1,3]dioxan-5-yl}-piperidin-1-yl-methanone, trans-isomer, (Compound A1210); <BR> <BR> <BR> (4-{5-(4-fluoro-phenyl)-2-[5-methyl-5-(piperidine- 1-carbonyl)-[1,3]dioxan-2-yl]-3H-imidazol-4- yl}-pyrimidin-2-ylamino)-acetic acid, trans-isomer, (Compound A1211); <BR> <BR> <BR> 3-(4-{5-(4-fluoro-phenyl)-2-[5-methyl-5-(piperidine- 1-carbonyl)-[1,3]dioxan-2-yl]-3H-imidazol-4- yl}-pyrimidin-2-ylamino)-propionic acid, trans-isomer, (Compound A1212); {2-[4-(4-fluoro-phenyl)-5-(2-isopropylamino-pyrimidin-4-yl)- 1H-imidazol-2-yl]-5-methyl- [1,3]dioxan-5-yl)-piperidin-1-yl-methanone, trans-isomer, (Compound A1213); (2-[5-(2-allylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)- lH-imidazol-2-yl]-5-methyl-[1,3]dioxan- 5-yl}-piperidin-1-yl-methanone, trans-isomer, (Compound A1214); {2-[5-[2-(cyclopropylmethyl-amino)-pyrimidin-4-yl]-4-(4-fluo ro-phenyl)-1H-imidazol-2-yl]-5- methyl-[1,3]dioxan-5-yll-piperidin-1-yl-methanone, trans-isomer, (Compound A1215); <BR> <BR> <BR> (4-(5-(4-fluoro-phenyl)-2-[5-methyl-5-(piperidine- 1-carbonyl)-[1,3]dioxan-2-yl]-3H-imidazol-4- yl}-pyrimidin-2-ylamino)-acetonitrile, trans-isomer, (Compound A1216); 3-(4-{5-(4-fluoro-phenyl)-2-[5-methyl-5-(piperidine-1-carbon yl)-[1,3]dioxan-2-yl]-3H-imidazol-4 yl}-pyrimidin-2-ylamino)-propionitrile, trans-isomer, (Compound A1217);

(2-{4-(4-fluoro-phenyl)-5-[2-(pyridin-3-ylamino)-pyrimidin-4 -yl]-1H-imidazol-2-yl}-5-methyl- [1,3]dioxan-5-yl)-piperidin-1-yl-methanone, trans-isomer, (Compound A1218); (2-{4-(4-fluoro-phenyl)-5-[2-(pyridin-4-ylamino)-pyrimidin-4 -yl]-1H-imidazol-2-yl}-5-methyl- [1,3]dioxan-5-yl)-piperidin-1-yl-methanone, trans-isomer, (Compound A1219); {2-[4-(4-fluoro-phenyl-)-5-(2-propylamino-pyrimidin-4-yl)-1H -imidazol-2-yl]-5-methyl- [1,3]dioxan-5-yl}-piperidin-1-yl-methanone, trans-isomer, (Compound A1220); (2-[4-(4-fluoro-phenyl)-5-(2-pyrrolidin- 1-yl-pyrimidin-4-yl)-lH-imidazol-2-yl]-5-methyl- [1,3]dioxan-5-yl)-piperidin- 1-yl-methanone, trans-isomer, (Compound A1221); (2-{4-(4-fluoro-phenyl)-5-[2-(4-fluoro-phenylamino)-pyrimidi n-4-yl]-1H-imidazol-2-yl}-5-methyl- [1,3]dioxan-5-yl)-piperidin-1-yl-methanone, trans-isomer, (Compound A1222); {2-[5-[2-(3,4-difluoro-phenylamino)-pyrimidin-4-yl]-4-(4-flu oro-phenyl)-1H-imidazol-2-yl]-5- methyl-[1,3]dioxan-5-yll-piperidin- 1-yl-methanone, trans-isomer, (Compound A1223); (2-{4-(4-fluoro-phenyl)-5-[2-(3-methoxy-phenylamino)-pyrimid in-4-yl]-1H-imidazol-2-yl}-5- methyl-[1,3]dioxan-5-yl)-piperidin-1-yl-methanone, trans-isomer, (Compound A1224); {2-[5-[2-(4-fluoro-benzylamino)-pyrimidin-4-yl]-4-(4-fluoro- phenyl)-1H-imidazol-2-yl]-5-methyl- [1,3]dioxan-5-yl )-piperidin-1-yl-methanone, trans-isomer, (Compound A1225); (2-{4-(4-fluoro-phenyl)-5-[2-(4-methoxy-benzylamino)-pyrimid in-4-yl]-1H-imidazol-2-yl}-5- methyl-[1,3]dioxan-5-yl)-piperidin-1-yl-methanone, trans-isomer, (Compound A1226); {2-[4-(4-fluoro-phenyl)-5-(2-methoxy-pyrimidin-4-yl)-1H-imid azol-2-yl]-5-methyl-[1,3]dioxan-5- yl}-piperidin-1-yl-methanone, trans-isomer, (Compound A1227); {2-[5-(2-benzyloxy-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-im idazol-2-yl]-5-methyl-[1,3]dioxan- 5-yl)-piperidin-1-yl-methanone, trans-isomer, (Compound A1228); {2-[4-(4-fluoro-phenyl)-5-(2-phenoxy-pyrimidin-4-yl)-1H-imid azol-2-yl]-5-methyl-[1,3]dioxan-5- yl)-piperidin-l-yl-methanone, trans-isomer, (Compound A1229); (2-{4-(4-fluoro-phenyl)-5-[2-(2-methoxy-ethoxy)-pyrimidin-4- yl]-1H-imidazol-2-yl}-5-methyl- [1,3]dioxan-5-yl)-piperidin- 1-yl-methanone, trans-isomer, (Compound A1230); {2-[5-[2-(2-dimethylamino-ethoxy)-pyrimidin-4-yl]-4-(4-fluor o-phenyl)-1H-imidazol-2-yl]-5- methyl-[1,3]dioxan-5-yl}-piperidin-1-yl-methanone, trans-isomer, (Compound A1231); (2-[5 -(2-cyclohexyloxy- pyrimidin-4-yl) -4-(4-fluoro- phenyl)-l H-imidazol-2-yl]-5 -methyl- [1,3]dioxan-5-yl )-piperidin-1-yl-methanone, trans-isomer, (Compound A1232); {2-[5-(2-Isopropoxy-pyrimidin-4-yl)-4-(4-fluoro-phenyl)- lH-imidazol-2-yl]-5-methyl-[1,3]dioxan- 5-yl)-piperidin-1-yl-methanone, trans-isomer, (Compound A1233); {2-[4-(4-fluoro-phenyl)-5-(2-propoxy-pyrimidin-4-yl)-1H-imid azol-2-yl]-5-methyl-[1,3]dioxan-5- yl}-piperidin-1-yl-methanone, trans-isomer, (Compound A1234); (2-{4-(4-fluoro-phenyl)-5-[2-(2-hydroxy-ethoxy)-pyrimidin-4- yl]-1H-imidazol-2-yl}-5-methyl- [1,3]dioxan-5-yl)-piperidin-1-yl-methanone, trans-isomer, (Compound A1235);

(2-{4-(4-fluoro-phenyl)-5-[2-(3-hydroxy-propoxy)-pyrimidin-4 -yl]-1H-imidazol-2-yl}-5-methyl- [1,3]dioxan-5-yl)-piperidin-1-yl-methanone, trans-isomer, (Compound A1236); {2-[4-(4-fluoro-phenyl-5-(2-methylsulfanyl-pyrimidin-4-yl)-1 H-imidazol-2-yl]-5-methyl- [1,3]dioxan-5-ylj-piperidin-1-yl-methanone, trans-isomer, (Compound A1237); 2-[5-(2-amino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazo l-2-yl]-5-methyl-[1,3]dioxane-5- carboxylic acid (tetrahydro-furan-2-ylmethyl)-amide, trans-isomer, (Compound A1238); 2-[4-(4-fluoro-phenyl)-5-(2-methylamino-pyrimidin-4-yl)-1H-i midazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid (tetrahydro-furan-2-ylmethyl)-amide, trans-isomer, (Compound A1239); 2-[5-(2-dimethylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H -imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid (tetrahydro-furan-2-ylmethyl)-amide, trans-isomer, (Compound A1240); 2-[5-(2-cyclopropylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl) -1H-imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid (tetrahydro-furan-2-ylmethyl)-amide, trans-isomer, (Compound A1241); 2-{4-(4-fluoro-phenyl)-5-[2-(piperidin-4-ylamino)-pyrimidin- 4-yl]-1H-imidazol-2-yl}-5-methyl- [1,3]dioxane-5-carboxylic acid (tetrahydro-furan-2-ylmethyl)-amide, trans-isomer, (Compound A1242); 2-[5-(2-cyclohexylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)- 1H-imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid (tetrahydro-furan-2-ylmethyl)-amide, trans-isomer, (Compound A1243); <BR> <BR> <BR> <BR> <BR> 2-(4-(4-fluoro-phenyl)-5- [2- (2-hydroxy-ethylamino)-pyrimidin-4-yl]- 1H-imidazol-2-yl )-5-methyl- [1,3]dioxane-5-carboxylic acid (tetrahydro-furan-2-ylmethyl)-amide, trans-isomer, (Compound A1244); 2-[5-[2-(2-amino-ethylamino)-pyrimidin-4-yl]-4-(4-fluoro-phe nyl)-1H-imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid (tetrahydro-furan-2-ylmethyl)-amide, trans-isomer, (Compound A1245); <BR> <BR> <BR> <BR> <BR> 2-(4-(4-fluoro-phenyl)-5-{2-[3-(5H-imidazol-1-yl)-propylamin o]-pyrimidin-4-yl}-lH-imidazol-2- yl)-5-methyl-[1,3]dioxane-5-carboxylic acid (tetrahydro-furan-2-ylmethyl)-amide, trans-isomer, (Compound A1246); 2-{4-(4-fluoro-phenyl)-5-[2-(3-morpholin-4-yl-propylamino)-p yrimidin-4-yl]-1H-imidazol-2-yl}- 5-methyl-[1,3]dioxane-5-carboxylic acid (tetrahydro-furan-2-ylmethyl)-amide, trans-isomer, (Compound A1247); 2-{4-(4-fluoro-phenyl)-5-[2-(3-hydroxy-propylamino)-pyrimidi n-4-yl]-1H-imidazol-2-yl}-5- methyl-[1,3]dioxane-5-carboxylic acid (tetrahydro-furan-2-ylmethyl)-amide, trans-isomer, (Compound A1248);

2[5-(2-benzylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-111-i midazol-2-yl]-5-methyi- [1,3]dioxane-5-carboxylic acid (tetrahydro-furan-2-ylmethyl)-amide, trans-isomer, (Compound A1249); <BR> <BR> <BR> <BR> <BR> 2-{4-(4-fluoro-phenyl)-5-[2-(1-phenyl-ethylamino)-pyrimidin- 4-yl]-111-imidazol-2-yl}-5-methyl [1,3]dioxane-5-carboxylic acid (tetrahydro-furan-2-ylmethyl)-amide, R-isomer, trans-isomer, (Compound A1250); <BR> <BR> <BR> <BR> <BR> 2-{4-(4-fluoro-phenyl)-5-[2-(1-phenyl-ethylamino)-pyrimidin- 4-yl]-111-imidazol-2-yl}-5-rnethyl- [1,3]dioxane-5-carboxylic acid (tetrahydro-furan-2-ylmethyl)-amide, S-isomer, trans-isomer, (Compound A1251); 2-[4-(4-fluoro-phenyl)-5-(2-phenylamino-pyrimidin-4-yl)-lH-i midazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid (tetrahydro-furan-2-ylmethyl)-amide, trans-isomer, (Compound A1252); 2-[4-(4-fluoro-phenyl)-5-(2-piperidin-1-yl-pyrimidin-4-yl)-1 11-imidazol-2-yli-5-methyl- [1,3]dioxane-5-carboxylic acid (tetrahydro-furan-2-ylmethyl)-amide, trans-isomer, (Compound A1253); 2-(4-(4-fluoro-phenyl)-5-{2-[(pyridin-4-ylmethyl)-amino]-pyr imidin-4-yl}-1H-imidazol-2-yl)-5- methyl-[1,3]dioxane-5-carboxylic acid (tetrahydro-furan-2-ylmethyl)-amide, trans-isomer, (Compound A1254); 2-(4-(4-fluoro-phenyl)-5-{2-[(pyridin-3-ylmethyl)-amino]-pyr imidin-4-yl}-1H-imidazol-2-yl)-5- methyl-[1,3]dioxane-5-carboxylic acid (tetrahydro-furan-2-ylmethyl)-amide, trans-isomer, (Compound A1255); 2-(4-(4-fluoro-phenyl)-5-{2-[(pyridin-2-ylmethyl)-amino]-pyr imidin-4-yl}-1H-imidazol-2-yl)-5- methyl-[1,3]dioxane-5-carboxylic acid (tetrahydro-furan-2-ylmethyl)-amide, trans-isomer, (Compound A1256); 2-(4-(4-fluoro-phenyl)-5-{2-[(furan-2-ylmethyl)-amino]-pyrim idin-4-yl}-1H-imidazol-2-yl)-5- methyl-[1,3]dioxane-5-carboxylic acid (tetrahydro-furan-2-ylmethyl)-amide, trans-isomer, (Compound A1257); 2-(4-(4-fluoro-phenyl)-5-{2-[(thiopen-2-ylmethyl)-amino]-pyr imidin-4-yl}-1H-imidazol-2-yl)-5- methyl-[1,3]dioxane-5-carboxylic acid (tetrahydro-furan-2-ylmethyl)-amide, trans-isomer, (Compound A1258); 2-(4-(4-fluoro-phenyl)-5-{2-[(tetrahydro-furan-2-ylmethyl)-a mino]-pyrimidin-4-yl}-1H-imidazol- 2-yl)-5-methyl-[1,3]dioxane-5-carboxylic acid (tetrahydro-furan-2-ylmethyl)-amide, trans- isomer, (Compound A1259); 2-{4-(4-fluoro-phenyl)-5-[2-(4-methyl-piperazin-1-yl)-pyrimi din-4-yl]-1H-imidazol-2-yl}-5- methyl-[1,3]dioxane-5-carboxylic acid (tetrahydro-furan-2-ylmethyl)-amide, trans-isomer, (Compound A1260);

2-[4-(4-fluoro-phenyl)-5-(2-morpholin-4-yl-pyrimidin-4-yl)-1 H-imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid (tetrahydro-furan-2-ylmethyl)-amide, trans-isomer, (Compound A1261); 2-{4-(4-fluoro-phenyl)-5-[2-(3-methoxy-propylamino)-pyrimidi n-4-yl]-111-imidazol-2-yl}-5- methyl-[1,3]dioxane-5-carboxylic acid (tetrahydro-furan-2-ylmethyl)-amide, trans-isomer, (Compound A1262); <BR> <BR> <BR> <BR> 2-{4-(4-fluoro-phenyl)-5-[2-(2-methoxy-ethylamino)-pyrimidin -4-yl]-111-imidazol-2-yl}-5-methyl- [1,3]dioxane-5-carboxylic acid (tetrahydro-furan-2-ylmethyl)-amide, trans-isomer, (Compound A1263); <BR> <BR> <BR> 2-[5-[2-(3-dimethylamino-propylamino)-pyrimidin-4-yl]-4-(4-f luoro-phenyl)-111-imidazol-2-ylj- 5-methyl-[1,3]dioxane-5-carboxylic acid (tetrahydro-furan-2-ylmethyl)-amide, trans-isomer, (Compound A1264); 2-[5-[2-(2-dimethylamino-ethylamino)-pyrimidin-4-yl]-4-(4-fl uoro-phenyl)-1H-imidazol-2-yl]-5- methyl-[1,3]dioxane-5-carboxylic acid (tetrahydro-furan-2-ylmethyl)-amide, trans-isomer, (Compound A1265); <BR> <BR> <BR> [4-(5-(4-fluoro-phenyl)-2-(5-methyl-5-[(tetrahydro-furan-2-y lmethyl)-carbamoyl]-[1,3]dioxan-2- yl)3H-imidazol -4-yl)- pyrimidin-2-ylamino] -acetic acid, trans-isomer, (Compound A1266); <BR> <BR> <BR> <BR> 3-[4-(5-(4-fluoro-phenyl)-2-(5-methyl-5-[(tetrahydro-furan-2 -ylmethyl)-carbamoyl]-[1,3]dioxan- 2-yl}-3H-imidazol-4-yl)-pyrimidin-2-ylamino]-propionic acid, trans-isomer, (Compound A1267); 2-[4-(4-fluoro-phenyl)-5-(2-isopropylamino-pyrimidin-4-yl)- lH-imidazol-2-yl] -5-methyl- [1,3]dioxane-5-carboxylic acid (tetrahydro-furan-2-ylmethyl)-amide, trans-isomer, (Compound A1268); 2-[5-(2-allylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-im idazol-2-yl]-5-methyl-[1,3]dioxane- 5-carboxylic acid (tetrahydro-furan-2-ylmethyl)-amide, trans-isomer, (Compound A1269); 2-[5-[2-(cyclopropylmethyl-amino)-pyrimidin-4-yl]-4-(4-fluor o-phenyl)-1H-imidazol-2-yl]-5- methyl-[1,3]dioxane-5-carboxylic acid (tetrahydro-furan-2-ylmethyl)-amide, trans-isomer, (Compound A1270); 2-[5-[2-(cyanomethyl-amino)-pyrimidin-4-yl]-4-(4-fluoro-phen yl)-1H-imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid (tetrahydro-furan-2-ylmethyl)-amide, trans-isomer, (Compound A1271); <BR> <BR> <BR> 2-[5-[2-(2-cyano-ethylamino)-pyrimidin-4-yl]-4-(4-fluoro-phe nyl)- 1H-imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid (tetrahydro-furan-2-ylmethyl)-amide, trans-isomer, (Compound A1272); 2-(4-(4-fluoro-phenyl)-5- [2-(pyridin-3-ylamino)-pyrimidin-4-yl]- 1H-imidazol-2-yl )-5-methyl- [1,3]dioxane-5-carboxylic acid (tetrahydro-furan-2-ylmethyl)-amide, trans-isomer, (Compound A1273);

2-{4-(4-fluoro-phenyl)-5-[2-(pyridin-4-ylamino)-pyrimidin-4- yl]- lH-imidazol-2-yl}-5-methyl- [1,3]dioxane-5-carboxylic acid (tetrahydro-furan-2-ylmethyl)-amide, trans-isomer, (Compound A1274); 2-[4-(4-fluoro-phenyl)-5-(2-propylamino-pyrimidin-4-yl)-1H-i midazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid (tetrahydro-furan-2-ylmethyl)-amide, trans-isomer, (Compound A1275); 2-[4-(4-fluoro-phenyl)-5-(2-pyrrolidin-1-yl-pyrimidin-4-yl)- 111-imidazol-2-ylj-5-methyl- [1,3]dioxane-5-carboxylic acid (tetrahydro-furan-2-ylmethyl)-amide, trans-isomer, (Compound A1276); <BR> <BR> <BR> <BR> 2-{4-(4-fluoro-phenyl)-5-[2-(4-fluoro-phenylamino)-pyrimidin -4-yl]-111-imidazol-2-yl)-5-methyl- [1,3]dioxane-5-carboxylic acid (tetrahydro-furan-2-ylmethyl)-amide, trans-isomer, (Compound A1277); 2-[5-[2-(3,4-difluoro-phenylamino)-pyrimidin-4-yl]-4-(4-fluo ro-phenyl)-111-imidazol-2-yl]-5- methyl-[1,3]dioxane-5-carboxylic acid (tetrahydro-furan-2-ylmethyl)-amide, trans-isomer, (Compound A1278); 2-{4-(4-fluoro-phenyl)-5-[2-(3-methoxy-phenylamino)-pyrimidi n-4-yl]-111-imidazol2-yl}-5- methyl-[1,3]dioxane-5-carboxylic acid (tetrahydro-furan-2-ylmethyl)-amide, trans-isomer, (Compound A1279); 2-[5-[2-(4-fluoro-benzylamino)-pyrimidin-4-yl]-4-(4-fluoro-p henyl)-1H-imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid (tetrahydro-furan-2-ylmethyl)-amide, trans-isomer, (Compound A1280); 2-{4-(4-fluoro-phenyl)-5-[2-(4-methoxy-benzylamino)-pyrimidi n-4-yl]-1H-imidazol-2-yl}-5- rnethyl-[1,3]dioxane-5-carboxylic acid (tetrahydro-furan-2-ylmethyl)-amide, trans-isomer, (Compound A1281); 2-[4-(4-fluoro-phenyl)-5-(2-methoxy-pyrimidin-4-yl)-1H-imida zol-2-yl]-5-methyl-[1,3]dioxane-5- carboxylic acid (tetrahydro-furan-2-ylmethyl)-amide, trans-isomer, (Compound A1282); 2-[5-(2-benzyloxy-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imi dazol-2-yl]-5-methyl-[1,3]dioxane- 5-carboxylic acid (tetrahydro-furan-2-ylmethyl)-amide, trans-isomer, (Compound A1283); 2-[4-(4-fluoro-phenyl)-5-(2-phenoxy-pyrimidin-4-yl)-1H-imida zol-2-yl]-5-methyl-[1,3]dioxane-5- carboxylic acid (tetrahydro-furan-2-ylmethyl)-amide, trans-isomer, (Compound A1284); 2-{4-(4-fluoro-phenyl)-5-[2-(2-methoxy-ethoxy)-pyrimidin-4-y l]-1H-imidazol-2-yl}-5-methyl- [1,3]dioxane-5-carboxylic acid (tetrahydro-furan-2-ylmethyl)-amide, trans-isomer, (Compound A1285); 2-[5-[2-(2-dimethylamino-ethoxy)-pyrimidin-4-yl]-4-(4-fluoro -phenyl)-1H-imidazol-2-yl]-5- methyl-[1,3]dioxane-5-carboxylic acid (tetrahydro-furan-2-ylmethyl)-amide, trans-isomer, (Compound A1286);

2-[5-(2-cyclohexyloxy-pyrimidin-4-yl)-4-(4-fluoro-phenyl)- lH-imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid (tetrahydro-furan-2-ylmethyl)-amide, trans-isomer, (Compound A1287); <BR> <BR> <BR> 2-[5-(2-Isopropoxy-pyrimidin-4-yl)-4-(4-fluoro-phenyl)- lH-imidazol-2-yl]-5-methyl-[1,3]dioxane- 5-carboxylic acid (tetrahydro-furan-2-ylmethyl)-amide, trans-isomer, (Compound A1288); <BR> <BR> <BR> 2-[4-(4-fluoro-phenyl)-5-(2-propoxy-pyrimidin-4-yl)-lH-imida zol-2-yl]-5-methyl-[1,3]dioxane-5- carboxylic acid (tetrahydro-furan-2-ylmethyl)-amide, trans-isomer, (Compound A1289); 2-{4-(4-fluoro-phenyl)-5-[2-(2-hydroxy-ethoxy)-pyrimidin-4-y l]-lH-imidazol-2-yl}-5-methyl- [1,3]dioxane-5-carboxylic acid (tetrahydro-furan-2-ylmethyl)-amide, trans-isomer, (Compound A1290); 2-{4-(4-fluoro-phenyl)-5-[2-(3-hydroxy-propoxy)-pyrimidin-4- yl]-1H-imidazol-2-yl}-5-methyl- [1,3]dioxane-5-carboxylic acid (tetrahydro-furan-2-ylmethyl)-amide, trans-isomer, (Compound A1291); 2-[4-(4-fluoro-phenyl)-5-(2-methylsulfanyl-pyrimidin-4-yl)-1 H-imidazol-2-yl]-5-methyl [1,3]dioxane-5-carboxylic acid (tetrahydro-furan-2-ylmethyl)-amide, trans-isomer, (Compound A1292); {2-[5-(2-amino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidaz ol-2-yl]-5-methyl-[1,3]dioxan-5- yl}-(4-methyl-piperazin-1-yl)-methanone, trans-isomer, (Compound A1293); {2-[4-(4-fluoro-phenyl)-5-(2-methylamino-pyrimidin-4-yl)-1H- imidazol-2-yl]-5-methyl- [1,3]dioxan-5-yl)-(4-methyl-piperazin-1-yl)-methanone, trans-isomer, (Compound A1294); {2-[5-(2-dimethylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1 H-imidazol-2-yl]-5-methyl- [1,3]dioxan-5-yl}-(4-methyl-piperazin-1-yl)-methanone, trans-isomer, (Compound A1295); {2-[5-(2-cyclopropylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl )-1H-imidazol-2-yl]-5-methyl- [1,3]dioxan-5-yl }-(4-methyl-piperazin-1-yl)-methanone, trans-isomer, (Compound A1296); (2-{4-(4-fluoro-phenyl)-5-[2-(piperidin-4-ylamino)-pyrimidin -4-yl]-1H-imidazol-2-yl}-5-methyl- [1,3]dioxan-5-yl)-(4-methyl-piperazin-1-yl)-methanone, trans-isomer, (Compound A1297); {2-[5-(2-cyclohexylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl) -1H-imidazol-2-yl]-5-methyl- [1,3]dioxan-5-yl}-(4-methyl-piperazin-1-yl)-methanone, trans-isomer, (Compound A1298); (2-{4-(4-fluoro-phenyl)-5-[2-(2-hydroxy-ethylamino)-pyrimidi n-4-yl]-1H-imidazol-2-yl}-5- methyl-[1,3]dioxan-5-yl)-(4-methyl-piperazin-1-yl)-methanone , trans-isomer, (Compound A1299); {2-[5-[2-(2-amino-ethylamino)-pyrimidin-4-yl]-4-(4-fluoro-ph enyl)-1H-imidazol-2-yl]-5-methyl- [1,3]dioxan-5-yl}-84-methyl-piperazin- 1-yl)-methanone, trans-isomer, (Compound A1300); <BR> <BR> <BR> [2-(4-(4-fluoro-phenyl)-5-(2-[3-(511-imidazol- 1-yl)-propylamino]-pyrimidin-4-yl)-1Himidazol-2- yl)-5-methyl-[1,3]dioxan-5-yl]-(4-methyl-piperazin-1-yl)-met hanone, trans-isomer, (Compound A1301);

(2-{4-(4-fluoro-phenyl)-5-[2-(3-morpholin-4-yl-propylamino)- pyrimidin-4-yl]-1H-imidazol-2-yl}- 5-methyl-[1,3]dioxan-5-yl)-(4-methyl-piperazin-1-yl)-methano ne, trans-isomer, (Compound A1302); (2-{4-(4-fluoro-phenyl)-5-[2-(3-hydroxy-propylamino)-pyrimid in-4-yl]-1H-imidazol-2-yl}-5- methyl-[1,3]dioxan-5-yl)-(4-methyl-piperazin-1-yl)-methanone , trans-isomer, (Compound A1303); {2-[5-(2-benzylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H- imidazol-2-yl]-5-methyl- [1,3]dioxan-5-yl}-(4-methyl-piperazin- 1-yl)-methanone, trans-isomer, (Compound A1304); (2-{4-(4-fluoro-phenyl)-5-[2-(1-phenyl-ethylamino)-pyrimidin -4-yl]-1H-imidazol-2-yl}-5-methyl- [1,3jdioxan-5-yl)-(4-methyl-piperazin-1-yl)-methanone, R-isomer, trans-isomer, (Compound A1305); (2-{4-(4-fluoro-phenyl)-5-[2-(1-phenyl-ethylamino)-pyrimidin -4-yl]-1H-imidazol-2-yl}-5-methyl- [1,3]dioxan-5-yl)-(4-methyl-piperazin-1-yl)-methanone, S-isomer, trans-isomer, (Compound A1306); (2-[4-(4-fluoro-phenyl)-5-(2-phenylamino-pyrimidin-4yl)- lH-imidazol-2-yl]-5-methyl- [1,3]dioxan-5-yl)-(4-methyl-piperazin-1yl)-methanone, trans-isomer, (Compound A1307); {2-[4-(4-fluoro-pheny)-5-(2-piperidin-1-yl-pyrimidin-4-yl)-1 H-imidazol-2-yl]-5-methyl- [l,3jdioxan-5-yl)-(4-methyl-piperazin-1-yl)methanone, trans-isomer, (Compound A1308); [2-(4-(4-fluoro-phenyl)-5-{2-[(pyridin-4-ylmethyl)-amino]-py rimidin-4-yl}-1H-imidazol-2-yl)-5- methyl-[1,3]dioxan-5-yl]-(4-methyl-piperazin-1-yl)-methanone , trans-isomer, (Compound A1309); [2-(4-(4-fluoro-phenyl)-5-{2-[(pyridin-3-ylmethyl)-amino]-py rimidin-4-yl}-1H-imidazol-2-yl)-5- methyl-[1,3]dioxan-5-yl]-(4-methyl-piperazin-1-yl)-methanone , trans-isomer, (Compound A1310); [2-(4-(4-fluoro-phenyl)-5-{2-[(pyridin-2-ylmethyl)-amino]-py rimidin-4-yl}-1H-imidazol-2-yl)-5- methyl-[1,3]dioxan-5-yl]-(4-methyl-piperazin-1-yl)-methanone , trans-isomer, (Compound A1311); [2-(4-(4-fluoro-phenyl)-5-{2-[(furan-2-ylmethyl)-amino]-pyri midin-4-yl}-1H-imidazol-2-yl)-5- methyl-[1,3]dioxan-5-yl]-(4-methyl-piperazin-1-yl)-methanone , trans-isomer, (Compound A1312); [2-(4-(4-fluoro-phenyl)-5-{2-[(thiophen-2-ylmethyl)-amino]-p yrimidin-4-yl}-1H-imidazol-2-yl)-5- methyl-[1,3]dioxan-5-yl]-(4-methyl-piperazin-1-yl)-methanone , trans-isomer, (Compound A1313); [2-(4-(4-fluoro-phenyl)-5-{2-[(tetrahydro-furan-2-ylmethyl)- amino]-pyrimidin-4-yl}-1H- imidazol-2-yl)-5-methyl-[1,3]dioxan-5-yl]-(4-methyl-piperazi n-1-yl)-methanone, trans-isomer, (Compound A1314);

(2-{4-(4-fluoro-phenyl)-5- [2-(4-methyi-piperazin- 1-yl)-pyrimidin-4-yl]- lH-imidazol-2-yl}-5- methyl-[1,3]dioxan-5-yl)-(4-methyl-piperazin-1-yl)-methanone , trans-isomer, (Compound A1315); {2-[4-(4-fluoro-phenyl)-5-(2-morpholin-4-yl-pyrimidin-4-yl)- lH-imidazol-2-yl]-5-methyl- [1,3]dioxan-5-yl)-(4-methyl-piperazin-1-yl)-methanone, trans-isomer, (Compound A1316); (2-{4-(4-fluoro-phenyl)-5-[2-(3-methoxy-propylamino)-pyrimid in-4-yl]-lH-imidazol-2-yl}-5- methyl-[1,3]dioxan-5-yl)-(4-methyl-piperazin-1-yl)-methanone , trans-isomer, (Compound A1317); (2-{4-(4-fluoro-phenyl)-5-[2-(2-methoxy-ethylamino)-pyrimidi n-4-yl]-111-imidazol-2-yl}-5- methyl-[1,3]dioxan-5-yl)-(4-methyl-piperazin-1-yl)-methanone , trans-isomer, (Compound A1318); {2-[5-[2-(3-dimethylamino-propylamino)-pyrimidin-4-yl]-4-(4- fluoro-phenyl)-1H-imidazol-2-yl]- 5-methyl-[1,3]dioxan-5-yl}-(4-methyl-piperazin-1-yl)-methano ne, trans-isomer, (Compound A1319); {2-[5-[2-(2-dimethylamino-ethylamino)-pyrimidin-4-yl]-4-(4-f luoro-phenyl)-1H-imidazol-2-yl]-5- methyl-[1,3]dioxan-5-yl}-(4-methyl-piperazin-1-yl)-methanone , trans-isomer, (Compound A1320); (4-{5-(4-fluoro-phenyl)-2-[5-methyl-5-(4-methyl-piperazine-1 -carbonyl)-[1,3]dioxan-2-yl]-3H- imidazol-4-yl)-pyrimidin-2-ylamino)-acet acid, trans-isomer, (Compound A1321); 3-(4-{5-(4-fluoro-phenyl)-2-[5-methyl-5-(4-methyl-piperazine -1-carbonyl)-[1,3]dioxan-2-yl]-3H- imidazol-4-yl}-pyrimidin-2-ylamino)-propionic acid, trans-isomer, (Compound A1322); {2-[4-(4-fluoro-phenyl)-5-(2-isopropylamino-pyrimidin-4-yl)- 1H-imidazol-2-yl]-5-methyl- [1,3]dioxan-5-yl)-(4-methyl-piperazin-1-yl)-methanone, trans-isomer, (Compound A1323); {2-[5-(2-allylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-i midazol-2-yl]-5-methyl-[1,3]dioxan- 5-yl}-(4-methyl-piperazin-1-yl)-methanone, trans-isomer, (Compound A1324); {2-[5-[2-(cyclopropylmethyl-amino)-pyrimidin-4-yl]-4-(4-fluo ro-phenyl)-1H-imidazol-2-yl]-5- methyl-[1,3]dioxan-5-yl}-(4-methyl-piperazin-1-yl)-methanone , trans-isomer, (Compound A1325); (4-{5-(4-fluoro-phenyl)-2-[5-methyl-5-(4-methyl-piperazine-1 -carbonyl)-[1,3]dioxan-2-yl]-3H- imidazol-4-yl)-pyrimidin-2-ylamino)-acetonitrile, trans-isomer, (Compound A1326); 3-(4-{5-(4-fluoro-phenyl)-2-[5-methyl-5-(4-methyl-piperazine -1-carbonyl)-[1,3]dioxan-2-yl]-3H- imidazol-4-yl )-pyrimidin-2-ylamino)-propionitrile, trans-isomer, (Compound A1327); <BR> <BR> <BR> (2-{4-(4-fluoro-phenyl)-5-[2-(pyridin-3-ylamino)-pyrimidin-4 -yl]- 111-imidazol-2-yli-5-methyl- [1,3]dioxan-5-yl)-(4-methyl-piperazin-1-yl)-methanone, trans-isomer, (Compound A1328); (2-{4-(4-fluoro-phenyl)-5-[2-(pyridin-4-ylamino)-pyrimidin-4 -yl]-1H-imidazol-2-yl}-5-methyl- [1,3]dioxan-5-yl)-(4-methyl-piperazin- 1-yl)-methanone, trans-isomer, (Compound A1329);

(2-[4-(4-fluoro-phenyl)-5-(2-propyiamino-pyrimidin-4-yl)-111 -imidazol-2-yl]-5-methyl- [1,3]dioxan-5-yl )-(4-methyl-piperazin-1-yl)-methanone, trans-isomer, (Compound A1330); {2-[4-(4-fluoro-phenyl)-5-(2-pyrrolidin-1-yl-pyrimidin-4-yl) -lH-imidazol-2-yl]-5-methyl- [1,3]dioxan-5-yl)-(4-methyl-piperazin-1-yl)-methanone, trans-isomer, (Compound A1331); <BR> <BR> <BR> (2-{4-(4-fluoro-phenyl)-5-[2-(4-fluoro-phenylamino)-pyrimidi n-4-yl]-lH-imidazol-2-yl}-5-methyl- [1,3]dioxan-5-yl)-(4-methyl-piperazin-1-yl)-methanone, trans-isomer, (Compound A1332); {2-[5-[2-(3,4-difluoro-phenylamino)-pyrimidin-4-yl]-4-(4-flu oro-phenyl)-1H-imidazol-2-yl]-5- methyl-[1,3]dioxan-5-yl )-(4-methyl-piperazin-1-yl)-methanone, trans-isomer, (Compound A1333); (2-{4-(4-fluoro-phenyl)-5-[2-(3-methoxy-phenylamino)-pyrimid in-4-yl]-1H-imidazol-2-yl}-5- methyl-[1,3]dioxan-5-yl)-(4-methyl-piperazin-1-yl)-methanone , trans-isomer, (Compound A1334); {2-[5-[2-(4-fluoro-benzylamino)-pyrimidin-4-yl]-4-(4-fluoro- phenyl)-1H-imidazol-2-yl]-5-methyl- [1,3]dioxan-5-yl)-(4-methyl-piperazin-1-yl)-methanone, trans-isomer, (Compound A1335); (2-{4-(4-fluoro-phenyl)-5-[2-(4-methoxy-benzylamino)-pyrimid in-4-yl]-1H-imidazol-2-yl}-5- methyl-[1,3]dioxan-5-yl)-(4-methyl-piperazin-1-yl)-methanone , trans-isomer, (Compound A1336); {2-[4-(4-fluoro-phenyl)-5-(2-methoxy-pyrimidin-4-yl)-1H-imid azol-2-yl]-5-methyl-[1,3]dioxan-5- yl}-(4-methyl-piperazin- 1-yl)-methanone, trans-isomer, (Compound A1337); {2-[5-(2-benzyloxy-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-im idazol-2-yl]-5-methyl-[1,3]dioxan- 5-yl}-(4-methyl-piperazin- 1-yl)-methanone, trans-isomer, (Compound A1338); {2-[4-(4-fluoro-phenyl)-5-(2-phenoxy-pyrimidin-4-yl)-1H-imid azol-2-yl]-5-methyl-[1,3]dioxan-5- yl}-(4-methyl-piperazin-1-yl)-methanone, trans-isomer, (Compound A1339); (2-{4-(4-fluoro-phenyl)-5-[2-(2-methoxy-ethoxy)-pyrimidin-4- yl]-1H-imidazol-2-yl}-5-methyl- [1,3]dioxan-5-yl)-(4-methyl-piperazine-1-yl)-methanone, trans-isomer, (Compound A1340); {2-[5-[2-(2-dimethylamino-ethoxy)-pyrimidin-4-yl]-4-(4-fluor o-phenyl)-1H-imidazol-2-yl]-5- methyl-[1,3]dioxan-5-yl )-(4-methyl-piperazin-1-yl)-methanone, trans-isomer, (Compound A1341); {2-[5-(2-cyclohexyloxy-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1 H-imidazol-2-yl]-5-methyl- [1,3]dioxan-5-yl)-(4-methyl-piperazin- 1-yl)-methanone, trans-isomer, (Compound A1342); {2-[5-(2-Isopropoxy-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-i midazol-2-yl]-5-methyl-[1,3]dioxan- 5-yl}-(4-methyl-piperazin- 1-yl)-methanone, trans-isomer, (Compound A1343); (2- [4-(4-fluoro-phenyl)-5-(2-propoxy-pyrimidin-4-yl) 1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5 yl}-(4-methyl-piperazin-1-yl)-methanone, trans-isomer, (Compound A1344); (2-[4-(4-fluoro-phenyl)-5-[2-(2-hydroxy-ethoxy)-pyrimidin-4- yl]-1H-imidazol-2-yl}-5-methyl- [1,3]dioxan-5-yl)-(4-methyl-piperazin-1-yl)-methanone, trans-isomer, (Compound A1345);

(2-{4-(4-fluoro-phenyl)-5- [2-(3-hydroxy-propoxy)-pyrimidin-4-yl]- 1H-imidazoi-2-yl)- 5-methyl- [1,3]dioxan-5-yl)-(4-methyl-piperazin-1-yl)-methanone, trans-isomer, (Compound A1346); {2-[4-(4-fluoro-phenyl)-5-(2-methylsulfanyl-pyrimidin-4-yl)- 111-imidazol-2-yl]-5-methyl- [1,3]dioxan-5-yl}-(4-methyl-piperazin-1-yl)-methanone, trans-isomer, (Compound A1347); (2-[5-(2-amino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-111-imida zol-2-yl]-5-methyl-[1,3]dioxan-5 yl}-morpholin-4-yl-methanone, trans-isomer, (Compound A1348); {2-[4-(4-fluoro-phenyl)-5-(2-methylamino-pyrimidin-4-yl)-1H- imidazol-2-yl]-5-methyl- [1,3]dioxan-5-yl)-morpholin-4-yl-methanone, trans-isomer, (Compound A1349); {-[5-(2-dimethylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H -imidazol-2-yl]-5-methyl- [1,3]dioxan-5-yl)-morpholin-4-yl-methanone, trans-isomer, (Compound A1350); {2-[5-(2-cyclopropylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl )-1H-imidazol-2-yl]-5-methyl- [1,3]dioxan-5-yl}-morpholin-4-yl-methanone, trans-isomer, (Compound A1351); <BR> <BR> <BR> <BR> (2-(4-(4-fluoro-pheny1) -5- [2-(piperidin-4-ylamino)-pyrimidin-4-yl] 1H-imidazol-2-yl )-5-methyl- [1,3]dioxan-5-yl)-morpholin-4-yl-methanone, trans-isomer, (Compound A1352); (2-[5-(2-cyclohexylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl) - 111-imidazol-2-yl]-5-methyi- [1,3]dioxan-5-yl )-morphoiin-4-yi-methanone, trans-isomer, (Compound A1353); (2-[4-fluoro-phenyl)-5-[2-(2-hydroxy-ethylamino)-pyrimidin-4 -yl]-1H-imidazol-2-yl}-5- methyl-[1,3]dioxan-5-yl)-morpholin-4-yl-methanone, trans-isomer, (Compound A1354); {2-[5-[2-amino-ethylamino)-pyrimidin-4-yl]-4-(4-fluoro-pheny l)-1H-imidazol-2-yl]-5-methyl- [1,3]dioxan-5-yl)-morpholin-4-yl-methanone, trans-isomer, (Compound A1355); [2-(4-(4-fluoro-phenyl)-5-{2-[3-(5H-imidazol-1-yl)-propylami no]-pyrimidin-4-yl}-1H-imidazol-2- yl)-5-methyxl-[1,3]dioxan-5-yl]-morpholin-4-yl-methanone, trans-isomer, (Compound A1356); (2-{4-(4-fluoro-phenyl)-5-[2-(3-morpholin-4-yl-propylamino)- pyrimidin-4-yl]-1H-imidazol-2-yl}- 5-methyl-[1,3]dioxan-5-yl)-morpholin-4-yl-methanone, trans-isomer, (Compound A1357); (2-{4-(4-fluoro-phenyl)-5-[2-(3-hydroxy-propylamino)-pyrimid in-4-yl]-1H-imidazol-2-yl}-5- methyl-[1,3]dioxan-5-yl)-morpholin-4-yl-methanone, trans-isomer, (Compound A1358); {2-[5-(2-benzylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H- imidazol-2-yl]-5-methyl- [1,3]dioxan-5-yl }-morpholin-4-yl-methanone, trans-isomer, (Compound A1359); (2-{4-(4-fluoro-phenyl)-5-[2-(1-phenyl-ethylamino)-pyrimidin -4-yl]- 1H-imidazol-2-yl)-5-methyl- [1,3]dioxan-5-yl)-morpholin-4-yl-methanone, R-isomer, trans-isomer, (Compound A1360); <BR> <BR> <BR> <BR> <BR> (2-(4-(4-fluoro-phenyl)-5-[2-(1-phenyl-ethylamino)-pyrimidin -4-yl]-1H-imidazol-2-yl)-5-methyl- [1,3]dioxan-5-yl)-morpholin-4-yl-methanone, S-isomer, trans-isomer, (Compound A1361); {2-[4-fluoro-phenyl)-5-(2-phenylamino-pyrimidin-4-yl)-1H-imi dazol-2-yl]-5-methyl- [1,3]dioxan-5-yl)-rnorpholin-4-yl-methanone, trans-isomer, (Compound A1362); {2-[4-fluoro-phenyl)-5-(2-piperidin-1-yl-pyrimidin-4-yl)-1H- imidazol-2-yl]-5-methyl- [1,3]dioxan-5-yl }-morpholin-4-yl-methanone, trans-isomer, (Compound A1363);

[2-(4-(4-fluoro-phenyl)-5-(2-[(pyridin-4-ylmethyl)-amino]-py rimidin-4-yl)-111-imidazol-2-yi)-5- methyl-[1,3]dioxan-5-yl]-morpholin-4-yl-methanone, trans-isomer, (Compound A1364); <BR> <BR> <BR> [2-(4-(4-fluoro-phenyl)-5-{2-[(pyridin-3-ylmethyl)-amino]-py rimidin-4-yl)-111-irnidazol-2-yl)-5- methyl-[1,3]dioxan-5-yl]-morpholin-4-yl-methanone, trans-isomer, (Compound A1365); <BR> <BR> <BR> [2-(4-(4-fluoro-phenyl)-5-{2-[(pyridin-2-ylmethyl)-amino]-py rimidin-4-yl )-111-imidazol-2-yl)-5- methyl-[1,3]dioxan-5-yl]-morpholin-4-yl-methanone, trans-isomer, (Compound A1366); [2-(4-(4-fluoro-phenyl)-5-{2-[(furan-2-ylmethyl)-amino]-pyri midin-4-yl}-1H-imidazol-2-yl)-5- methyl-[1,3]dioxan-5-yl]-morpholin-4-yl-methanone, trans-isomer, (Compound A1367); [2-(4-(4-fluoro-phenyl)-5-{2-[(thiophen-2-ylmethyl)-amino]-p yrimidin-4-yl}-1H-imidazol-2-yl)-5- methyl-[1,3]dioxan-5-yl]-morpholin-4-yl-methanone, trans-isomer, (Compound A1368); [2-(4-(4-fluoro-phenyl)-5-{2-[(tetrahydro-furan-2-ylmethyl)- amino]-pyrimidin-4-yl}-1H- imidazol-2-yl)-5-methyl-[1,3]dioxan-5-yl]-morpholin-4-yl-met hanone, trans-isomer, (Compound A1369); (2-{4-(4-fluoro-phenyl)-5-[2-(4-methyl-piperazin-1-yl)-pyrim idin-4-yl]-1H-imidazol-2-yl]}-5- methyl-[1,3]dioxan-5-yl)-morpholin-4-yl-methanone, trans-isomer, (Compound A1370); {2-[4-(4-fluoro-phenyl)-5-(2-morpholin-4-yl-pyrimidin-4-yl)- 1H-imidazol-2-yl]-5-methyl- [1,3]dioxan-5-yl )-morpholin-4-yl-methanone, trans-isomer, (Compound A1371); {2-[4-(4-fluoro-phenyl)-5-(3-methoxy-propylamino)-pyrimidin- 4-yl]-1H-imidazol-2-yl}-5- methyl-[1,3]dioxan-5-yl)-morpholin-4-yl-methanone, trans-isomer, (Compound A1372); {2-[4-(4-fluoro-phenyl)-5-(2-methoxy-ethylamino)-pyrimidin-4 -yl]-1H-imidazol-2-yl}-5- methyl-[1,3]dioxan-5-yl)-morpholin-4-yl-methanone, trans-isomer, (Compound A1373); {2-[5-[2-(3-dimethylamino-propylamino)-pyrimidin-4-yl]-4-(4- fluoro-phenyl)-1H-imidazol-2-yl]- 5-methyl-[1,3]dioxan-5-yl )-morpholin-4-yl-methanone, trans-isomer, (Compound A1374); <BR> <BR> <BR> <BR> (2-[5-[2-(2-dimethylamino-ethylamino)-pyrimidin-4-yl]-4-(4-f luoro-phenyl)-111-imidazol-2-yl]-5 methyl-[1,3]dioxan-5-yl}-morpholin-4-yl-methanone, trans-isomer, (Compound A1375); (4-[5-(4-fluoro-phenyl)-2-[5-methyl-5-(morpholine-4-carbonyl )-[1,3]dioxan-2-yl]-3H-imidazol-4- yl}-pyrimidin-2-ylamino)-acetic acid, trans-isomer, (Compound A1376); (3-[5-(4-fluoro-phenyl)-2-[5-methyl-5-(morpholine-4-carbonyl )-[1,3]dioxan-2-yl]-3H-imidazol- 4-yl}-pyrimidin-2-ylamino)-propionic acid, trans-isomer, (Compound A1377); {2-[4-(4-fluoro-phenyl)-5-(2-isopropylamino-pyrimidin-4-yl)- 111-imidazol-2-ylj-5-methyl- [1,3]dioxan-5-yl)-morpholin-4-yl-methanone, trans-isomer, (Compound A1378); {2-[5-(2-allylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-i midazol-2-yl]-5-methyl-[1,3]dioxan- 5-yl)-morpholin-4-yl-methanone, trans-isomer, (Compound A1379); {2-[5-[2-(cyclopropylmethyl-amino)-pyrimidin-4-yl]-4-(4-fluo ro-phenyl)-1H-imidazol-2-yl]-5- methyl-[1,3]dioxan-5-yl}-morpholin-4-yl-methanone, trans-isomer, (Compound A1380);

(4-(5-(4-fluoro-pheny1)-2- [5-methyl-5-(morpholine-4-carbonyl)-[1,3]dioxan-2-yl]-311-im idazol-4 yl}-pyrimidin-2-ylamino)-acetonitrile, trans-isomer, (Compound A1381); <BR> <BR> <BR> 3-(4-{5-(4-fluoro-phenyl)-2-[5-methyl-5-(morpholine-4-carbon yl)-[1,3]dioxan-2-ylj-311-imidazol- 4-yl}-pyrimidin-2-ylamino)-propionitrile, trans-isomer, (Compound A1382); (2-{4-(4-fluoro-phenyl)-5-[2-pyridin-3-ylamino)-pyrimidin-4- yl]-1H-imidazol-2-yl}-5-methyl- [1,3]dioxan-5-yl)-morpholin-4-yl-methanone, trans-isomer, (Compound A1383); (2-{4-(4-fluoro-phenyl)-5-[2-(pyridin-4-ylamino)-pyrimidin-4 -yl]- 1H-imidazol-2-yl )-5-methyl- [1,3]dioxan-5-yl)-morpholin-4-yl-methanone, trans-isomer, (Compound A1384); (2-{4-(4-fluoro-phenyl)-5-(2-propylamino-pyrimidin-4-yl)-1H- imidazol-2-yl]-5-methyl- [1,3]dioxan-5-yl}-morpholin-4-yl-methanone, trans-isomer, (Compound A1385); {2-[4-(4-fluoro-phenyl)-5-(2-pyrrolidin-1-yl-pyrimidin-4-yl) -1H-imidazol-2-yl]-5-methyl- [1,3]dioxan-5-yl }-morpholin-4-yl-methanone, trans-isomer, (Compound A1386); (2-{4-(4-fluoro-phenyl)-5-[2-(4-fluoro-phenylamino)-pyrimidi n-4-yl]-1H-imidazol-2-yl}-5-methyl- [1,3]dioxan-5-yl)-morpholin-4-yl-methanone, trans-isomer, (Compound A1387); {2-[5-[2-(3,4-difluoro-phenylamino)-pyrimidin-4-yl]-4-(4-flu oro-phenyl)-1H-imidazol-2-yl]-5- methyl-[1,3]dioxan-5-yl]-morpholin-4-yl-methanone, trans-isomer, (Compound A1388); (2-{4-(4-fluoro-phenyl)-5-[2-(3-methoxy-phenylamino)-pyrimid in-4-yl]~1H-imidazol-2-yl}-5- methyl-[1,3]dioxan-5-yl)-morpholin-4-yl-methanone, trans-isomer, (Compound A1389); {2-[5-[2-(4-fluoro-benzylamino)-pyrimidin-4-yl]-4-(4-fluoro- phenyl)-1H-imidazol-2-yl]-5-methyl- [1,3]dioxan-5-yl)-morpholin-4-yl-methanone, trans-isomer, (Compound A1390); (2-{4-(4-fluoro-phenyl)-5-[2-(4-methoxy-benzylamino)-pyrimid in-4-yl]-1H-imidazol-2-yl}-5- methyl-[1,3]dioxan-5-yl)-morpholin-4-yl-methanone, trans-isomer, (Compound A1391); (2-[4-(4-fluoro-phenyl)-5-(2-methoxy-pyrimidin-4-yl)- lH-imidazol-2-yl]-5-methyl-[1,3]dioxan-5- yl}-morpholin-4-yl-methanone, trans-isomer, (Compound A1392); {2-[5-(2-benzyloxy-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-im idazol-2-yl]-5-methyl-[1,3]dioxan- 5-yl)-morpholin-4-yl-methanone, trans-isomer, (Compound A1393); {2-[4-(4-fluoro-phenyl)-5-(2-phenoxy-pyrimidin-4-yl)-1H-imid azol-2-yl]-5-methyl-[1,3]dioxan-5- yl}-morpholin-4-yl-methanone, trans-isomer, (Compound A1394); (2-{4-(4-fluoro-pheny)-5-[2-(2-methoxy-ethoxy)-pyrimidin-4-y l]-1H-imidazol-2-yl)-5-methyl- [1,3]dioxan-5-yl)-morpholin-4-yl-methanone, trans-isomer, (Compound A1395); {2-[5-[2-(2-dimethylamino-ethoxy)-pyrimidin-4-yl]-4-(4-fluor o-phenyl)-1H-imidazol-2-yl]-5- methyl-[1,3]dioxan-5-yl}-morpholin-4-yl-methanone, trans-isomer, (Compound A1396); {2-[5-(2-cyclohexyloxy-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1 H-imidazol-2-yl]-5-methyl- [1,3jdioxan-5-yl }-morpholin-4-yl-methanone, trans-isomer, (Compound A1397); {2-[5-(2-Iosporpoxy-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-i midazol-2-yl]-5-methyl-[1,3]dioxan- 5-yl)-morpholin-4-yl-methanone, trans-isomer, (Compound A1398);

(2-14-(4-fluoro-pheny1)-5- (2-propoxy-pyrimidin-4-yl)- lH-imidazol-2-yl]-5-methyl-[1,3]dioxan-5- yl}-morpholin-4-yl-methanone, trans-isomer, (Compound A1399); (2-{4-(4-fluoro-phenyl)-5-[2-(2-hydroxy-ethoxy)-pyrimidin-4- yl]-111-imidazol-2-yl 5-methyl- [1,3]dioxan-5-yl)-morpholin-4-yl-methanone, trans-isomer, (Compound A1400); (2-{4-(4-fluoro-phenyl)-5-[2-(3-hydroxy-propoxy)-pyrimidin-4 -yl]-1H-imidazol-2-yl)-5-methyl- [1,3]dioxan-5-yl)-morpholin-4-yl-methanone, trans-isomer, (Compound A1401); (2-{4-(4-fluoro-phenyl)-5-[2-methylsulfanyl-pyrimidin-4-yl]- 1H-imidazol-2-yl)-5-methyl- [1,3]dioxan-5-yl }-morpholin-4-yl-methanone, trans-isomer, (Compound A1402); <BR> <BR> <BR> 2-[5-(2-amino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)- lH-imidazol-2-yl]-5-methyl-[1,3]dioxane-5- carboxylic acid (3-methoxy-propyl)-amide, trans-isomer, (Compound A1403); (2-{4-(4-fluoro-phenyl)-5-[2-methylamino-pyrimidin-4-yl]-1H- imidazol-2-yl)-5-methyl- [1,3]dioxane-5-carboxylic acid (3-methoxy-propyl)-amide, trans-isomer, (Compound A1404); 2-[5-(2-dimethylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H -imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid (3-methoxy-propyl)-amide, trans-isomer, (Compound A1405); 2[5-(2-cyclopropylamino-pyrimidin-4-yl)-4-(4-fLuoro-phenyl)- 1H-imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid (3-methoxy-propyl)-amide, trans-isomer, (Compound A1406); 2-{4-(4-fluoro-phenyl)-5-[2-(piperidin-4-ylamino)-pyrimidin- 4-yl]-1H-imidazol-2-yl}-5-methyl- [1,3]dioxane-5-carboxylic acid (3-methoxy-propyl)-amide, trans-isomer, (Compound A1407); 2-[5-(2-cyclohexylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)- 1H-imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid (3-methoxy-propyl)-amide, trans-isomer, (Compound A1408); 2-{4-(4-fluoro-phenyl)-5-[2-(2-hydroxy-ethylamino)-pyrimidin -4-yl]-1H-imidazol-2-yl}-5-methyl- [1,3]dioxane-5-carboxylic acid (3-methoxy-propyl)-amide, trans-isomer, (Compound A1409); 2-[5-[2-(2-amino-ethylamino)-pyrimidin-4-yl]-4-(4-fluoro-phe nyl)-1H-imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid (3-methoxy-propyl)-amide, trans-isomer, (Compound A1410); <BR> <BR> <BR> 2-(4-(4-fluoro-phenyl)-5-{2-[3-(5H-imidazol-1-yl)-propylamin o]-pyrimidin-4-yl}-lH-imidazol-2- yl)-5-methyl-[1,3]dioxane-5-carboxylic acid (3-methoxy-propyl)-amide, trans-isomer, (Compound A1411); 2-{4-(4-fluoro-phenyl)-5-[2-(3-morpholin-4-yl-propylamino)-p yrimidin-4-yl]-1H-imidazol-2-yl}- 5-methyl-[1,3]dioxane-5-carboxylic acid (3-methoxy-propyl)-amide, trans-isomer, (Compound A1412); 2-{4-(4-fluoro-phenyl)-5-[2-(3-hydroxy-propylamino)-pyrimidi n-4-yl]- lH-imidazol-2-yl}-5- methyl-[1,3]dioxane-5-carboxylic acid (3-methoxy-propyl)-amide, trans-isomer, (Compound A1413); 2-[5-(2-benzylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-i midazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid (3-methoxy-propyl)-amide, trans-isomer, (Compound A1414);

2-{4-(4-fluoro-phenyl)-5-[2-(1-phenyl-ethylamino)-pyrimidin- 4-yl]-lH-imidazol-2-yl}-5-methyl- [1,3]dioxane-5-carboxylic acid (3-methoxy-propyl)-amide, R-isomer, trans-isomer, (Compound <BR> <BR> <BR> <BR> A1415); <BR> <BR> <BR> <BR> <BR> 2-{4-(4-fluoro-phenyl)-5-[2-(1-phenyl-ethylamino)-pyrimidin- 4-yl]-lH-imidazol-2-yl}-5-methyl- [1,3]dioxane-5-carboxylic acid (3-methoxy-propyl)-amide, S-isomer, trans-isomer, (Compound A1416); 2-[4-(4-fluoro-phenyl)-5-(2-phenylamino-pyrimidin-4-yl)-1H-i midazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid (3-methoxy-propyl)-amide, trans-isomer, (Compound A1417); 2-[4-(4-floro-phenyl)-5-(2-piperidin-1-yl-pyrimidin-4-yl)-1H -imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid (3-methoxy-propyl)-amide, trans-isomer, (Compound A1418); 2-(4-(4-fluoro-phenyl)-5-{2-[(pyridin-4-ylmethyl)-amino]-pyr imidin-4-yl}-1H-imidazol-2-yl)-5- methyl-[1,3]dioxane-5-carboxylic acid (3-methoxy-propyl)-amide, trans-isomer, (Compound A1419); <BR> <BR> <BR> <BR> 2-(4-(4-fluoro-phenyl)-5-{2-[(pyridin-3-ylmethyl)-amino]-pyr imidin-4-yl )-111-imidazol-2-yl)-5- methyl-[1,3]dioxane-5-carboxylic acid (3-methoxy-propyl)-amide, trans-isomer, (Compound A1420); 2-(4-(4-fluoro-phenyl)-5-{2-[(pyridin-2-ylmethyl)-amino]-pyr imdin-4-yl}-1H-imidazol-2-yl)-5- methyl-[1,3]dioxane-5-carboxylic acid (3-methoxy-propyl)-amide, trans-isomer, (Compound A1421); 2-(4-(4-fluoro-phenyl)-5-(2-[(furan-2-ylmethyl)-amino]-pyrim idin-4-yl 1- lH-imidazol-2-yl)-5- methyl-[1,3]dioxane-5-carboxylic acid (3-methoxy-propyl)-amide, trans-isomer, (Compound A1422); <BR> <BR> <BR> <BR> 2-(4-(4-fluoro-phenyl)-5-(2-[(thiophen-2-ylmethyl)-amino]-py rimidin-4-yl 1- lH-imidazol-2-yl)-5- methyl-[1,3]dioxane-5-carboxylic acid (3-methoxy-propyl)-amide, trans-isomer, (Compound A1423); 2-(4-(4-fluoro-phenyl)-5-{2-[(tetrahydro-furan-2-ylmethyl)-a mino]-pyrimidin-4-yl}-1H-imidazol- 2-yl)-5-methyl-[1,3]dioxane-5-carboxylic acid (3-methoxy-propyl)-amide, trans-isomer, (Compound A1424); 2-{4-(4-fluoro-phenyl)-5-[2-(4-methyl-piperazin-1-yl)pyrimid in-4-yl]-1H-imidazol-2-yl}-5- methyl-[1,3]dioxane-5-carboxylic acid (3-methoxy-propyl)-amide, trans-isomer, (Compound A1425); 2-[4-(4-fluoro-phenyl)-5-(2-morpholin-4-yl-pyrimidin-4-yl)- 1H-imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid (3-methoxy-propyl)-amide, trans-isomer, (Compound A1426); 2-{4-(4-fluoro-phenyl)-5-[2-(3-methoxy-propylamino)-pyrimidi n-4-yl]-1H-imidazol-2-yl}-5- methyl-[1,3]dioxane-5-carboxylic acid (3-methoxy-propyl)-amide, trans-isomer, (Compound A1427);

2-(4- (4-fluoro-phenyl)- 5-[2-(2- methoxy-ethylamino )-pyrimidin-4yl]-l lH-imidazol-2-yl}-5-methyl- [1,3]dioxane-5-carboxylic acid (3-methoxy-propyl)-amide, trans-isomer, (Compound A1428); <BR> <BR> <BR> <BR> 2-[5-[2-(3-dimethylamino-propylamino)-pyrimidin-4-yl]-4-(4-f luoro-phenyl)-111-imidazol-2-yl]- 5-methyl-[1,3]dioxane-5-carboxylic acid (3-methoxy-propyl)-amide, trans-isomer, (Compound A1429); <BR> <BR> <BR> <BR> 2-[5-[2-(2-dimethylamino-ethylamino)-pyrimidin-4-yl]-4-(4-fl uoro-phenyl)-111-imidazol-2-ylj-5- methyl-[1,3]dioxane-5-carboxylic acid (3-methoxy-propyl)-amide, trans-isomer, (Compound A1430); (4-{5-(4-fluoro-phenyl)-2-[5-(3-methoxy-propylcarbamoyl)-5-m ethyl-[1,3]dioxan-2-yl]-311- imidazol-4-yl)-pyrimidin-2-ylamino)-acetic acid, trans-isomer, (Compound A1431); 3-(4-{5-(4-fluoro-phenyl)-2-[5-(3-methoxy-propylcarbamoyl)-5 -methyl-[1,3]dioxan-2-yl]-3H- imidazol-4-yl)-pyrimidin-2-ylamino)-propionic acid, trans-isomer, (Compound A1432); 2-[4-(4-fluoro-phenyl)-5-(2-isopropylamino-pyrimidin-4-yl)- lH-imidazol-2-yl] -5-methyl- [1,3]dioxane-5-carboxylic acid (3-methoxy-propyl)-amide, trans-isomer, (Compound A1433); 2-[5-(2-allylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-im idazol-2-yl]-5-methyl-[1,3]dioxane- 5-carboxylic acid (3-methoxy-propyl)-amide, trans-isomer, (Compound A1434); 2-[5-[2-(cyclopropylmethyl-amino)-pyrimidin-4-yl]-4-(4-fluor o-phenyl)-1H-imidazol-2-yl]-5- methyl-[1,3]dioxane-5-carboxylic acid (3-methoxy-propyl)-amide, trans-isomer, (Compound A1435); 2-[5-[2-cyanomethyl-amino)-pyrimidin-4-yl]-4-(4-fluoro-pheny l)-1H-imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid (3-methoxy-propyl)-amide, trans-isomer, (Compound A1436); 2-[5-[2-cyano-ethylamino)-pyrimidin-4-yl]-4-(4-fluoro-phenyl )-1H-imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid (3-methoxy-propyl)-amide, trans-isomer, (Compound A1437); 2-(4-(4-fluoro-phenyl)-5-[2-(pyridin-3-ylamino)-pyrimidin-4- yl]-1H-imidazol-2-yl)-5-methyl- [1,3]dioxane-5-carboxylic acid (3-methoxy-propyl)-amide, trans-isomer, (Compound A1438); 2-{4-(4-fluoro-phenyl)-5-[2-(pyridin-4-ylamino)-pyrimidin-4- yl]-1H-imidazol-2-yl}-5-methyl- [1,3]dioxane-5-carboxylic acid (3-methoxy-propyl)-amide, trans-isomer, (Compound A1439); 2-[4-(4-fluoro-phenyl)-5-(2-propylamino-pyrimidin-4-yl)-1H-i midazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid (3-methoxy-propyl)-amide, trans-isomer, (Compound A1440); 2-[4-(4-fluoro-phenyl)-5- (2-pyrrolidin- 1-yl-pyrimidin-4-yl)- 111-imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid (3-methoxy-propyl)-amide, trans-isomer, (Compound A1441); 2-{4-(4-fluoro-phenyl)-5-[2-(4-fluoro-phenylamino)-pyrimidin -4-yl]-1H-imidazol-2-yl}-5-methyl- [1,3]dioxane-5-carboxylic acid (3-methoxy-propyl)-amide, trans-isomer, (Compound A1442); 2-[5-[2-(3,4-difluoro-phenylamino)-pyrimidin-4-yl]-4-(4-fluo ro-phenyl)-lH-imidazol-2-yl]-5- methyl-[1,3]dioxane-5-carboxylic acid (3-methoxy-propyl)-amide, trans-isomer, (Compound A1443);

2-{4-(4-fluoro-phenyl)-5- [2-(3-methoxy-phenylamino)-pyrimidin-4-yl]- 1H-imidazol- 2-yl)- 5- methyl-[1,3]dioxane-5-carboxylic acid (3-methoxy-propyl)-amide, trans-isomer, (Compound A1444); <BR> <BR> <BR> <BR> 2-[5-[2-(4-fluoro-benzylamino)-pyrimidin-4-yl]-4-(4-fluoro-p henyl)-111-imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid (3-methoxy-propyl)-amide, trans-isomer, (Compound A1445); 2-{4-(4-fluoro-phenyl)-5-[2-(4-methoxy-benzylamino)-pyrimidi n-4-yl]-111-imidazol-2-ylj-5 methyl-[1,3]dioxane-5-carboxylic acid (3-methoxy-propyl)-amide, trans-isomer, (Compound A1446); <BR> <BR> <BR> <BR> 2-[4-(4-fluoro-phenyl)-5-(2-methoxy-pyrimidin-4-yl)-lH-imida zol-2-yl]-5-methyl-[1,3]dioxane-5- carboxylic acid (3-methoxy-propyl)-amide, trans-isomer, (Compound A1447); <BR> <BR> <BR> <BR> 2-[5-(2-benzyloxy-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-111-im idazol-2-yl]-5-methyl-[1,3]dioxane- 5-carboxylic acid (3-methoxy-propyl)-amide, trans-isomer, (Compound A1448); <BR> <BR> <BR> <BR> 2-[4-(4-fluoro-phenyl)-5-(2-phenoxy-pyrimidin-4-yl)-111-imid azol-2-yl]-5-methyl-[1,3]dioxane-5- carboxylic acid (3-methoxy-propyl)-amide, trans-isomer, (Compound A1449); 2-{4-(4-fluoro-phenyl)-5-[2-(2-methoxy-ethoxy)-pyrimidin-4-y l]-1H-imidazol-2-yl}-5-methyl- [1,3]dioxane-5-carboxylic acid (3-methoxy-propyl)-amide, trans-isomer, (Compound A1450); 2-[5-[2-(2-dimethylamino-ethoxy)-pyrimidin-4-yl]-4-(4-fluoro -phenyl)-1H-imidazol-2-yl]-5- methyl-[1,3]dioxane-5-carboxylic acid (3-methoxy-propyl)-amide, trans-isomer, (Compound A1451); 2-[5-(2-cycloheXyloxy-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-lH -imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid (3-methoxy-propyl)-amide, trans-isomer, (Compound A1452); 2-[5-(2-Isopropoxy-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-im idazol-2-yl]-5-methyl-[1,3]dioxane- 5-carboxylic acid (3-methoxy-propyl)-amide, trans-isomer, (Compound A1453); 2-[4-(4-fluoro-phenyl)-5-(2-propoxy-pyrimidin-4-yl)-1H-imida zol-2-yl]-5-methyl-[1,3]dioxane-5- carboxylic acid (3-methoxy-propyl)-amide, trans-isomer, (Compound A1454); 2-{4-(4-fluoro-phenyl)-5-[2-(2-hydroxy-ethoxy)-pyrimidin-4-y l]-1H-imidazol-2-yl}-5-methyl- [1,3]dioxane-5-carboxylic acid (3-methoxy-propyl)-amide, trans-isomer, (Compound A1455); 2-{4-(4-fluoro-phenyl)-5-[2-(3-hydroxy-propoxy)-pyrimidin-4- yl]-1H-imidazol-2-yl}-5-methyl- [1,3]dioxane-5-carboxylic acid (3-methoxy-propyl)-amide, trans-isomer, (Compound A1456); 2-[4-(4-fluoro-phenyl)-5-(2-methylSulfanyl-pyrimidin-4-yl)-l H-imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid (3-methoxy-propyl)-amide, trans-isomer, (Compound A1457); 2-[5-(2-amino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)- lH-imidazol-2-yl]-5-methyl-[1,3]dioxane-5- carboxylic acid (2-methoxy-ethyl)-amide, trans-isomer, (Compound A1458); 2-[4-(4-fluoro-phenyl)-5-(2-methylamino-pyrimidin-4-yl)-1H-i midazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid (2-methoxy-ethyl)-amide, trans-isomer, (Compound A1459);

2-[5-(2-dimethylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-lH -imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid (2-methoxy-ethyl)-amide, trans-isomer, (Compound A1460); 2-[5-(2-cyclopropylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl) -lH-imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid (2-methoxy-ethyl)-amide, trans-isomer, (Compound A1461); <BR> <BR> <BR> 2-{4-(4-fluoro-phenyl)-5-[2-(piperidin-4-ylamino)-pyrimidin- 4-yl]-lH-imidazol-2-yl}-5-methyl- [1,3]dioxane-5-carboxylic acid (2-methoxy-ethyl)-amide, trans-isomer, (Compound A1462); 2-[5-(2-cyclohexylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)- 1H-imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid (2-methoxy-ethyl)-amide, trans-isomer, (Compound A1463); 2-{4-(4-fluoro-phenyl)-5- [2-(2-hydroxy-ethylamino) -pyrimidin-4-yl]- lH-imidazol-2-yl}-5-methyl- [1,3]dioxane-5-carboxylic acid (2-methoxy-ethyl)-amide, trans-isomer, (Compound A1464); 2-[5-[2-(amino-ethylamino)-pyrimidin-4-yl]-4-(4-fluoro-pheny l)-1H-imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid (2-methoxy-ethyl)-amide, trans-isomer, (Compound A1465); <BR> <BR> <BR> 2-(4-(4-fluoro-phenyl)-5-82-[3-(5H-imidazol- 1-yl)-propylamino]-pyrimidin-4-yl)-111-imidazol-2- yl)-5-methyl-[1,3]dioxane-5-carboxylic acid (2-methoxy-ethyl)-amide, trans-isomer, (Compound A1466); <BR> <BR> <BR> <BR> 2-{4-(4-fluoro-phenyl)-5-[2-(3-morpholin-4-yl-propylamino)-p yrimidin-4-yl]-lH-imidazol-2-yl}- 5-methyl-[1,3]dioxane-5-carboxylic acid (2-methoxy-ethyl)-amide, trans-isomer, (Compound A1467); 2-{4-(4-fluoro-phenyl)-5-[2-(3-hydroxy-propylamino)-pyrimidi n-4-yl]-1H-imidazol-2-yl}-5- methyl-[1,3]dioxane-5-carboxylic acid (2-methoxy-ethyl)-amide, trans-isomer, (Compound A1468); 2-[5-(2-benzylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-i midazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid (2-methoxy-ethyl)-amide, trans-isomer, (Compound A1469); 2-{4-(4-fluoro-phenyl)-5-[2-(1-phenyl-ethylamino)-pyrimidin- 4-yl]-1H-imidazol-2-yl}-5-methyl- [1,3]dioxane-5-carboxylic acid (2-methoxy-ethyl)-amide, R-isomer, trans-isomer, (Compound A1470); 2-{4-(4-fluoro-phenyl)-5-[2-(1-phenyl-ethylamino)-pyrimidin- 4-yl]-1H-imidazol-2-yl}-5-methyl- [1,3]dioxane-5-carboxylic acid (2-methoxy-ethyl)-amide, S-isomer, trans-isomer, (Compound A1471); 2-[4-(4-fluoro-phenyl)-5-(2-phenylamino-pyrimidin-4-yl)- lH-imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid (2-methoxy-ethyl)-amide, trans-isomer, (Compound A1472); 2-[4-(4-fluoro-phenyl)-5-(2-piperidin-1-yl-pyrimidin-4-yl)-1 H-imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid (2-methoxy-ethyl)-amide, trans-isomer, (Compound A1473); 2-(4-(4-fluoro-phenyl)-5-{2-[(pyridin-4-ylmethyl)-amino]-pyr imidin-4-yl}-1H-imidazol-2-yl)-5- methyl-[1,3]dioxane-5-carboxylic acid (2-methoxy-ethyl)-amide, trans-isomer, (Compound A1474);

2-(4-(4-fluoro-phenyl)-5-{2-[(pyridin-3-ylmethyl)-amino]-pyr imidin-4-yl}-1H-imidazol-2-yl)-5- methyl-[1,3]dioxane-5-carboxylic acid (2-methoxy-ethyl)-amide, trans-isomer, (Compound A1475); 2-(4-(4-fluoro-phenyl)-5-{2-[(pyridin-2-ylmethyl)-amino]-pyr imidin-4-yl}-1H-imidazol-2-yl)-5- methyl-[1,3]dioxane-5-carboxylic acid (2-methoxy-ethyl)-amide, trans-isomer, (Compound A1476); 2-(4-(4-fluoro-phenyl)-5-{2-[(furan-2-ylmetyl)-amino]-pyrimi din-4-yl}-1H-imidazol-2-yl)-5- methyl-[1,3]dioxane-5-carboxylic acid (2-methoxy-ethyl)-amide, trans-isomer, (Compound A1477); <BR> <BR> <BR> <BR> 2-(4-(4-fluoro-phenyl)-5-{2-[(thiophen-2-ylmethyl)-amino]-py rimidin-4-yl}-lH-imidazol-2-yl)-5- methyl-[1,3]dioxane-5-carboxylic acid (2-methoxy-ethyl)-amide, trans-isomer, (Compound A1478); <BR> <BR> <BR> 2-(4-(4-fluoro-phenyl)-5-{2-[(tetrahydro-furan-2-ylmethyl)-a mino]-pyrimidin-4-yl}-lH-imidazol- 2-yl)-5-methyl-[1,3]dioxane-5-carboxylic acid (2-methoxy-ethyl)-amide, trans-isomer, (Compound A1479); 2-{4-(4-fluoro-phenyl)-5-[2-(4-methyl-piperazin-1-yl)-pyrimi din-4-yl]-1H-imidazol-2-yl}-5- methyl-[1,3]dioxane-5-carboxylic acid (2-methoxy-ethyl)-amide, trans-isomer, (Compound A1480); 2-[4-(4-fluoro-phenyl)-5-(2-morpholin-4-yl-pyrimidin-4-yl)-1 H-imidazol-2-yl]-5-methyl [1,3]dioxane-5-carboxylic acid (2-methoxy-ethyl)-amide, trans-isomer, (Compound A1481); 2-{4-(4-fluoro-phenyl)-5-[2-(3-methoxy-propylamino)-pyrimidi n-4-yl]-1H-imidazol-2-yl}-5- methyl-[1,3]dioxane-5-carboxylic acid (2-methoxy-ethyl)-amide, trans-isomer, (Compound A1482); 2-{4-(4-fluoro-phenyl)-5-[2-(2-methoxy-ethylamino)-pyrimidin -4-yl]-1H-imidazol-2-yl}-5-methyl- [1,3]dioxane-5-carboxylic acid (2-methoxy-ethyl)-amide, trans-isomer, (Compound A1483); 2-[5-[2-(3-dimethylamino-propylamino)-pyrimidin-4-yl]-4-(4-f luoro-phenyl)-1H-imidazol-2-yl]- 5-methyl-[1,3]dioxane-5-carboxylic acid (2-methoxy-ethyl)-amide, trans-isomer, (Compound A1484); 2-[5-[2-(2-dimethylamino-ethylamino)-pyrimidin-4-yl]-4-(4-fL uoro-phenyl)-1H-imidazol-2-yl]-5- methyl-[1,3]dioxane-5-carboxylic acid (2-methoxy-ethyl)-amide, trans-isomer, (Compound A1485); (4-{5-(4-fluoro-phenyl)-2-[5-(2-methoxy-ethylcarbamoyl)-5-me thyl-[1,3]dioxan-2-yl]-3H- imidazol-4-yl)-pyrimidin-2-ylamino)-acetic acid, trans-isomer, (Compound A1486); 3-(4-{5-(4-fluoro-phenyl)-2-[5-(2-methoxy-ethylcarbamoyl)-5- methyl-[1,3]dioxan-2-yl]-3H- imidazol-4-yl}-pyrimidin-2-ylamino)-propionic acid, trans-isomer, (Compound A1487);

2-14-(4-fluoro-phenyl)-5- (2-isopropylamino-pyrimidin-4-yl)- lH-imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid (2-methoxy-ethyl)-amide, trans-isomer, (Compound A1488); <BR> <BR> <BR> 2-[5-(2-allylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-lH-im idazol-2-yl]-5-methyl-[1,3]dioxane- 5-carboxylic acid (2-methoxy-ethyl)-amide, trans-isomer, (Compound A1489); 2-[5-[2-(cyclopropylmethyl-amino)-pyrimidin-4-yl]-4-(4-fluor o-phenyl)-111-imidazol-2-yl]-5- methyl-[1,3]dioxane-5-carboxylic acid (2-methoxy-ethyl)-amide, trans-isomer, (Compound A1490); <BR> <BR> <BR> 2-[5-[2-(cyanomethyl-amino)-pyrimidin-4-yl]-4-(4-fluoro-phen yl)- lH-imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid (2-methoxy-ethyl)-amide, trans-isomer, (Compound A1491); <BR> <BR> <BR> 2-[5-[2-(2-cyano-ethylamino)-pyrimidin-4-ylj-4-(4-fluoro-phe nyl)-111-imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid (2-methoxy-ethyl)-amide, trans-isomer, (Compound A1492); 2-{4-(4-fluoro-phenyl)-5-[2-(pyridin-3-ylamino)-pyrimidin-4- yl]-lH-imidazol-2-yl}-5-methyl- [1,3]dioxane-5-carboxylic acid (2-methoxy-ethyl)-amide, trans-isomer, (Compound A1493); 2-{4-(4-fluoro-phenyl)-5-[2-(pyridin-4-ylamino)-pyrimidin-4- yl]-111-imidazol-2-yl)-5-methyl- [1,3]dioxane-5-carboxylic acid (2-methoxy-ethyl)-amide, trans-isomer, (Compound A1494); 2-[4-(4-fluoro-phenyl)-5-(2-propylamino-pyrimidin-4-yl)-lH-i midazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid (2-methoxy-ethyl)-amide, trans-isomer, (Compound A1495); 2-[4-(4-fluoro-phenyl)-5-(2-pyrrolidin-1-yl-pyrimidin-4-yl)- 1H-imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid (2-methoxy-ethyl)-amide, trans-isomer, (Compound A1496); <BR> <BR> <BR> 2-{4-(4-fluoro-phenyl)-5-[2-(4-fluoro-phenylamino)-pyrimidin -4-yl]- 1H-imidazol-2-yl)-5-methyl- [1,3]dioxane-5-carboxylic acid (2-methoxy-ethyl)-amide, trans-isomer, (Compound A1497); 2-[5-[2-(3m,4-difluro-phenylamino)-pyrimidin-4-yl]-4-(4-fluo ro-phenyl)-1H-imidazol-2-yl]-5- methyl-[1,3]dioxane-5-carboxylic acid (2-methoxy-ethyl)-amide, trans-isomer, (Compound A1498); 2-{4-(4-fluoro-phenyl)-5-[2-(3-methoxy-phenylamino)-pyrimidi n-4-yl]-1H-imidazol-2-yl}-5- methyl-[1,3]dioxane-5-carboxylic acid (2-methoxy-ethyl)-amide, trans-isomer, (Compound A1499); 2-[5-[2-(4-fluoro-benzylamino)-pyrimidin-4-yl]-4-(4-fluoro-p henyl)-1H-imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid (2-methoxy-ethyl)-amide, trans-isomer, (Compound A1500); 2-{4-(4-fluoro-phenyl)-5-{2-(4-methoxy-benzylamino)-pyrimidi n-4-yl]- lH-imidazol-2-yl}-5- methyl-[1,3]dioxane-5-carboxylic acid (2-methoxy-ethyl)-amide, trans-isomer, (Compound A1501); <BR> <BR> <BR> 2-{4-(4-fluoro-phenyl)-5-(2-methoxy-pyrimidin-4-yl)- 1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5- carboxylic acid (2-methoxy-ethyl)-amide, trans-isomer, (Compound A1502); 2-[5-(2-benzyloxy-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imi dazol-2-yl]-5-methyl-[1,3]dioxane- 5-carboxylic acid (2-methoxy-ethyl)-amide, trans-isomer, (Compound A1503);

2-[4-(4-fluoro-phenyl)-5-(2-phenoxy-pyrirnidin-yl) 111-imidazol-2-yl]-5-methyl- [1,3]dioxane-5- carboxylic acid (2-methoxy-ethyl)-amide, trans-isomer, (Compound A1504); 2-{4-(4-fluoro-phenyl)-5-[2-(2-methoxy-ethoxy)-pyrimidin-4-y l]-111-imidazol-2-yl}-5-methyl- [1,3]dioxane-5-carboxylic acid (2-methoxy-ethyl)-amide, trans-isomer, (Compound A1505); 2-{5-[2-(2-dimethylamino-ethoxy)-pyrimidin-4-yl]-4-(4-fluoro -phenyl)-lH-imidazol-2-yl]-5- methyl- [1,3]dioxane-5-carboxylic acid (2-methoxy-ethyl)-amide, trans-isomer, (Compound A1506); 2-[5-(2-cycloheXyloxy-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-lH -imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid (2-methoxy-ethyl)-amide, trans-isomer, (Compound A1507); 2-[5-(2-Isopropoxy-pyrimidin-4-yl)-4-(4-fluoro-phenyl)- lH-imidazol-2-yl]-5-methyl-[1,3]dioxane- 5-carboxylic acid (2-methoxy-ethyl)-amide, trans-isomer, (Compound A1508); <BR> <BR> <BR> 2-[4-(4-fluoro-phenyl)-5-(2-propoxy-pyrimidin-4-yl)-lH-imida zol-2-yl]-5-methyl-[1,3]dioxane-5- carboxylic acid (2-methoxy-ethyl)-amide, trans-isomer, (Compound A1509); 2-(4-(4-fluoro-phenyl) -5- [2-(2-hydroxy-ethoxy)-pyrimidin-4-yl]- 1H-imidazol-2-yl )-5-methyl- [1,3]dioxane-5-carboxylic acid (2-methoxy-ethyl)-amide, trans-isomer, (Compound A1510); <BR> <BR> <BR> 2-{4-(4-fluoro-phenyl)-5-[2-(3-hydroxy-propoxy)-pyrimidin-4- yl]-1H-imidazol-2-yl}-5-methyl- [1,3]dioxane-5-carboxylic acid (2-methoxy-ethyl)-amide, trans-isomer, (Compound A1511); 2-[4-(4-fluoro-phenyl)-5-(2-methylsulfanyl-pyrimidin-4-yl)-1 11-imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid (2-methoxy-ethyl)-amide, trans-isomer, (Compound A1512); 2-[5-(2.amino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)- lH-imidazol-2-yl]-5-methyl-[1,3]dioxane-5- carboxylic acid (3-dimethylamino-propyl)-amide, trans-isomer, (Compound A1513); 2-[4-(4-fluoro-phenyl)-5-(2-methylamino-pyrimidin-4-yl]-1H-i midazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid (3-dimethylamino-propyl)-amide, trans-isomer, (Compound A1514); 2-[5-(2-dimethylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-lH -imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid (3-dimethylamino-propyl)-amide, trans-isomer, (Compound A1515); 2-[5-(2-cyclopropylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl) -1H-imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid (3-dimethylamino-propyl)-amide, trans-isomer, (Compound A1516); 2-{4-(4-fluoro-phenyl)-5-[2-piperidin-4-ylamino)-pyrimidin-4 -yl]-1h-imidazol-2-yl}-5-methyl- [1,3]dioxane-5-carboxylic acid (3-dimethylamino-propyl)-amide, trans-isomer, (Compound A1517); 2-[5-(2-cycloheXylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)- lH-imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid (3-dimethylamino-propyl)-amide, trans-isomer, (Compound A1518);

2-{4-(4-fluoro-phenyl)-5- [2-(2-hydroxy-ethylamino)-pyrimidin-4-yl]- 1H-imidazol-2-yl)- 5-methyl- [1,3]dioxane-5-carboxylic acid (3-dimethylamino-propyl)-amide, trans-isomer, (Compound A1519); 2-[5-[2-(2-amino-ethylamino)-pyrimidin-4-yl]-4-(4-fluoro-phe nyl)-1H-imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid (3-dimethylamino-propyl)-amide, trans-isomer, (Compound A1520); <BR> <BR> <BR> <BR> 2-(4-(4-fluoro-phenyl)-5-{2-[3-(5H-imidazol-1-yl)-propylamin o]-pyrimidin-4-yl}-lH-imidazol-2- yl)-5-methyl-[1,3]dioxane-5-carboxylic acid (3-dimethylamino-propyl)-amide, trans-isomer, (Compound A1521); 2-{4-(4-fluoro-phenyl)-5-[2-(3-morpholin-4-yl-propylamino)-p yrimidin)-1H-imidazol-2-yl]-5-methyl- 5-methyl-[1,3]dioxane-5-carboxylic acid (3-dimethylamino-propyl)-amide, trans-isomer, (Compound A1522); 2-{4-(4-fluoro-phenyl)-5-[2-(3-hydroxy-propylamino)-pyrimidi n-4-yl]-lH-imidazol-2-yl}-5- methyl-[1,3]dioxane-5-carboxylic acid (3-dimethylamino-propyl)-amide, trans-isomer, (Compound A1523); 2-[5-(2-benzylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-i midazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid (3-dimethylamino-propyl)-amide, trans-isomer, (Compound A1524); 2-{4-(4-fluoro-phenyl)-5-[2-(1-phenyl-ethylamino)-pyrimidin- 4-yl]-1H-imidazol-2-yl}-5-methyl- [1,3]dioxane-5-carboxylic acid (3-dimethylamino-propyl)-amide, R-isomer, trans-isomer, (Compound A1525); 2-{4-(4-fluoro-phenyl)-5-[2-(1-phenyl-ethylamino)-pyrimidin- 4-yl]-1H-imidazol-2-yl}-5-methyl- [1,3]dioxane-5-carboxylic acid (3-dimethylamino-propyl)-amide, S-isomer, trans-isomer, (Compound A1526); 2-[4-(4-fluoro-phenyl)-5-(2-phenylamino-pyrimidin-4-yl) 111-imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid (3-dimethylamino-propyl)-amide, trans-isomer, (Compound A1527); 2-[4-(4-fluoro-phenyl)-5-(2-piperidin-1-yl-pyrimidin-4-yl)-1 H-imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid (3-dimethylamino-propyl)-amide, trans-isomer, (Compound A1528); 2-(4-(4-fluoro-phenyl)-5-{2-[(pyridin-4-ylmethyl)-amino]-pyr imidin-4-yl )-111-imidazol-2-yl)-5- methyl-[1,3]dioxane-5-carboxylic acid (3-dimethylamino-propyl)-amide, trans-isomer, (Compound A1529); 2-(4-(4-fluoro-phenyl)-5-{2-[(pyridin-3-ylmethyl)-amino]-pyr imidin-4-yl}-1H-imidazol-2-yl)-5- methyl-[1,3]dioxane-5-carboxylic acid (3-dimethylamino-propyl)-amide, trans-isomer, (Compound A1530);

2-(4-(4-fluoro-phenyl)-5-{2-[(pyridin-2-ylmethyl)-amino]~pyr imidin-4-yl}-1H-imidazol-2-yl)-5- methyl-[1,3]dioxane-5-carboxylic acid (3-dimethylamino-propyl)-amide, trans-isomer, (Compound A1531); 2-(4-(4-fluoro-phenyl)-5-{2-[(furan-2-ylmethyl)-amino]~pyrim idin-4-yl}-1H-imidazol-2-yl)-5- methyl-[1,3]dioxane-5-carboxylic acid (3-dimethylamino-propyl)-amide, trans-isomer, (Compound A1532); <BR> <BR> <BR> 2-(4-(4-fluoro-phenyl)-5-{2-[(thiophen-2-ylmethyl)-amino]-py rimidin-4-yl}-lH-imidazol-2-yl)-5- methyl-[1,3]dioxane-5-carboxylic acid (3-dimethylamino-propyl)-amide, trans-isomer, (Compound A1533); 2-(4-(4-fluoro-phenyl)-5-{2-[(tetrahydro-furan-2-ylmethyl)-a mino]-pyrimidin-4-yl}-1H-imidazol- 2-yl)-5-methyl-[1,3]dioxane-5-carboxylic acid (3-dimethylamino-propyl)-amide, trans-isomer, (Compound A1534); 2-{4-(4-fluoro-phenyl)-5-[2-(4-methyl-piperazin-1-yl)-pyrimi din-4-yl]-1H-imidazol-2-yl}-5- methyl-[1,3]dioxane-5-carboxylic acid (3-dimethylamino-propyl)-amide, trans-isomer, (Compound A1535); 2-[4-(4-fluoro-phenyl)-5-(2-morpholin-4-yl-pyrimidin-4-yl)-1 H-imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid (3-dimethylamino-propyl)-amide, trans-isomer, (Compound A1536); 2-{4-(4-fluoro-phenyl)-5-[2-(3-methoxy-propylamino)-pyrimidi n-4-yl]-1H-imidazol-2-yl}-5- methyl-[1,3]dioxane-5-carboxylic acid (3-dimethylamino-propyl)-amide, trans-isomer, (Compound A1537); 2-{4-(4-fluoro-phenyl)-5-[2-(2-methoxy-ethylamino)-pyrimidin -4-yl]-1H-imidazol-2-yl}-5-methyl- [1,3]dioxane-5-carboxylic acid (3-dimethylamino-propyl)-amide, trans-isomer, (Compound A1538); 2-[5-[2-(3-dimethylamino-propylamino)-pyrimidin-4-yl]-4-(4-f luoro-phenyl)-1H-imidazol-2-yl]- 5-methyl-[1,3]dioxane-5-carboxylic acid (3-dimethylamino-propyl)-amide, trans-isomer, (Compound A1539); 2-[5-[2-(2-dimethylamino-ethylamino)-pyrimidin-4-yl]-4-(4-fl uoro-phenyl)-1H-imidazol-2-yl]-5- methyl-[1,3]dioxane-5-carboxylic acid (3-dimethylamino-propyl)-amide, trans-isomer, (Compound A1540); {4-[2-[5-(3-dimethylamino-propylcarbmoyl)-5-methyl-[1,3]diox an-2-yl]-5-(4-fluoro-phenyl)-3H- imidazol-4-yl]-pyrimidin-2-ylamino)-acetic acid, trans-isomer, (Compound A1541); 3-{4-[2-[5-(3-dimethylamino-propylcarbamoyl)-5-methyl-[1,3]d ioxan-2-yl]--(4-fluoro-phenyl)- 3H-imidazol-4-yl]-pyrimidin-2-ylamino}-propionic acid, trans-isomer, (Compound A1542);

2-[4-(4-fluoro-phenyl)-5-(2-isopropylamino-pyrimidin-4-yl)-l H-imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid (3-dimethylamino-propyl)-amide, trans-isomer, (Compound A1543); <BR> <BR> <BR> 2-[5-(2-allylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)- lH-imidazol-2-yl]-5-methyl-[1,3]dioxane- 5-carboxylic acid (3-dimethylamino-propyl)-amide, trans-isomer, (Compound A1544); 2-[5-[2-(cyclopropylmethyl-amino)-pyrimidin-4-yl]-4-(4-fluor o-phenyl)-lH-imidazol-2-yl]-5- methyl-[1,3]dioxane-5-carboxylic acid (3-dimethylamino-propyl)-amide, trans-isomer, (Compound A1545); <BR> <BR> <BR> 2-[5-[2-(cyanomethyl-amino)-pyrimidin-4-yl]-4-(4-fluoro-phen yl)-lH-imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid (3-dimethylamino-propyl)-amide, trans-isomer, (Compound A1546); <BR> <BR> <BR> 2-[5-[2-(2-cyano-ethylamino)-pyrimidin-4-ylj-4-(4-fluoro-phe nyl)- lH-imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid (3-dimethylamino-propyl)-amide, trans-isomer, (Compound A1547); 2-{4-(4-fluoro-phenyl)-5-[2-(pyridin-3-ylamino)-pyrimidin-4- yl]-1H-imidazol-2-yl}-5-methyl- [1,3]dioxane-5-carboxylic acid (3-dimethylamino-propyl)-amide, trans-isomer, (Compound A1548); 2-{4-(4-fluoro-phenyl)-5-[2-(pyridin-4-ylamino)-pyrimidin-4- yl]-1H-imidazol-2-yl}-5-methyl- [1,3]dioxane-5-carboxylic acid (3-dimethylamino-propyl)-amide, trans-isomer, (Compound A1549); 2-[4-(4-fluoro-phenyl)-5-(2-propylamino-pyrimidin-4-yl)-1H-i midazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid (3-dimethylamino-propyl)-amide, trans-isomer, (Compound A1550); 2-[4-(4-fluoro-phenyl)-5-(2-pyrrolidin-1-yl-pyrimidin-4-yl)- 1H-imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid (3-dimethylamino-propyl)-amide, trans-isomer, (Compound A1551); 2-{4-(4-fluoro-phenyl)-5-[2-(4-fluoro-phenylamino)-pyrimidin -4-yl]-1H-imidazol-2-yl}-5-methyl- [1,3]dioxane-5-carboxylic acid (3-dimethylamino-propyl)-amide, trans-isomer, (Compound A1552); 2-[5-[2-(3,4-difluoro-phenylamino)-pyrimidin-4-yl]-4-(4-fluo ro-phenyl)-1H-imidazol-2-yl]-5- methyl-[1,3]dioxane-5-carboxylic acid (3-dimethylamino-propyl)-amide, trans-isomer, (Compound A1553); 2-{4-(4-fluoro-phenyl)-5-[2-(3-methoxy-phenylamino)-pyrimidi n-4-yl]-1H-imidazol-2-yl}-5- methyl-[1,3]dioxane-5-carboxylic acid (3-dimethylamino-propyl)-amide, trans-isomer, (Compound A1554);

2- [5- [2-(4-fluoro-benzylamino)-pyrimidin-4-yl]-4- (4-fluoro-phenyl)- lH-imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid (3-dimethylamino-propyl)-amide, trans-isomer, (Compound A1555); 2-{4-(4-fluoro-phenyl)-5-[2-(4-methoxy-benzylamino)-pyrimidi n-4-yl]-111-imidazol2yl}5 methyl-[1,3]dioxane-5-carboxylic acid (3-dimethylamino-propyl)-amide, trans-isomer, (Compound A1556); <BR> <BR> <BR> 2-[4-(4-fluoro-phenyl)-5-(2-methoxy-pyrimidin-4-yl)-lH-imida zol-2-yl]-5-methyl-[1,3]dioxane-5- carboxylic acid (3-dimethylamino-propyl)-amide, trans-isomer, (Compound A1557); 2-[5-(2-benzyloxy-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imi dazol-2-yl]-5-methyl-[1,3]dioxane- 5-carboxylic acid (3-dimethylamino-propyl)-amide, trans-isomer, (Compound A1558); 2-[4-(4-fluoro-phenyl)-5-(2-phenoxy-pyrimidin-4-yl)-1H-imida zol-2-yl]-5-methyl-[1,3]dioxane-5- carboxylic acid (3-dimethylamino-propyl)-amide, trans-isomer, (Compound A1559); 2-{4-(4-fluoro-phenyl)-5-[2-(2-methoxy-ethoxy)-pyrimidin-4-y l]-1H-imidazol-2-yl}-5-methyl- [1,3]dioxane-5-carboxylic acid (3-dimethylamino-propyl)-amide, trans-isomer, (Compound A1560); 2-[5-[2-(2-dimethylamino-ethoxy)-pyrimidin-4-yl]-4-(4-fluoro -phenyl)-1H-imidazol-2-yl]-5- methyl-[1,3]dioxane-5-carboxylic acid (3-dimethylamino-propyl)-amide, trans-isomer, (Compound A1561); 2-[5-(2-cyclohexyloxy-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H -imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid (3-dimethylamino-propyl)-amide, trans-isomer, (Compound A1562); 2-[5-(2-Isopropoxy-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-im idazol-2-yl]-5-methyl-[1,3]dioxane- 5-carboxylic acid (3-dimethylamino-propyl)-amide, trans-isomer, (Compound A1563); 2-[4-(4-fluoro-phenyl)-5-(2-propoxy-pyrimidin-4-yl)-1H-imida zol-2-yl]-5-methyl-[1,3]dioxane-5- carboxylic acid (3-dimethylamino-propyl)-amide, trans-isomer, (Compound A1564); 2-{4-(4-fluoro-phenyl)-5-[2-(2-hydroxy-ethoxy)-pyrimidin-4-y l]-1H-imidazol-2-yl}-5-methyl- [1,3]dioxane-5-carboxylic acid (3-dimethylamino-propyl)-amide, trans-isomer, (Compound A1565); 2-{4-(4-fluoro-phenyl)-5-[2-(3-hydroxy-propoxy)-pyrimidin-4- yl]-1H-imidazol-2-yl}-5-methyl- [1,3]dioxane-5-carboxylic acid (3-dimethylamino-propyl)-amide, trans-isomer, (Compound A1566); 2-[4-(4-fluoro-phenyl)-5-(2-methylsulfanyl-pyrimidin-4-yl)- 1H-imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid (3-dimethylamino-propyl)-amide, trans-isomer, (Compound A1567); <BR> <BR> <BR> <BR> 2-[5-(2-amino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)- lH-imidazol-2-yl]-5-methyl-[1,3]dioxane-5- carboxylic acid (2-dimethylamino-ethyl)-amide, trans-isomer, (Compound A1568);

2-[4-(4-fluoro-phenyl)-5-(2-methylamino-pyrimidin-4-yl)-1H-i midazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid (2-dimethylamino-ethyl)-amide, trans-isomer, (Compound A1569); 2-[5-(2-dimethylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H -imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid (2-dimethylamino-ethyl)-amide, trans-isomer, (Compound A1570); 2-[5-(2-cyclopropylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl) -1H-imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid (2-dimethylamino-ethyl)-amide, trans-isomer, (Compound A1571); <BR> <BR> <BR> 2-{4-(4-fluoro-phenyl)-5-[2-(piperidin-4-ylamino)-pyrimidin- 4-yl]-lH-imidazol-2-yl}-5-methyl- [1,3]dioxane-5-carboxylic acid (2-dimethylamino-ethyl)-amide, trans-isomer, (Compound A1572); 2-[5-(2-cyclohexylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)- 1H-imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid (2-dimethylamino-ethyl)-amide, trans-isomer, (Compound A1573); 2-{4-(4-fluoro-phenyl)-5-[2-(2-hydroxy-ethylamino)-pyrimdin- 4-yl]-1H-imidazol-2-yl}-5-methyl- [1,3]dioxane-5-carboxylic acid (2-dimethylamino-ethyl)-amide, trans-isomer, (Compound A1574); <BR> <BR> <BR> 2-[5-[2-(2-amino-ethylamino)-pyrimidin-4-yl]-4-(4-fluoro-phe nyl)-111-imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid (2-dimethylamino-ethyl)-amide, trans-isomer, (Compound A1575); 2-(4-(4-fluoro-phenyl)-5-{2-[3-(5H-imidazol-1-yl)-propylamin o]-pyrimidin-4-yl}-1H-imidazol-2- yl)-5-methyl-[1,3]dioxane-5-carboxylic acid (2-dimethylamino-ethyl)-amide, trans-isomer, (Compound A1576); 2-{4-(4-fluoro-phenyl)-5-[2-(3-morpholin-4-yl-propylamino)-p yrimidin-4-yl]-1H-imidazol-2-yl}- 5-methyl-[1,3]dioxane-5-carboxylic acid (2-dimethylamino-ethyl)-amide, trans-isomer, (Compound A1577); 2-{4-(4-fluoro-phenyl)-5-[3-(3-hydroxy-propylamino)-pyrimidi n-4-yl]-1H-imidazol-2-yl}-5- methyl-[1,3]dioxane-5-carboxylic acid (2-dimethylamino-ethyl)-amide, trans-isomer, (Compound A1578); 2-[5-(2-benzylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-i midazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid (2-dimethylamino-ethyl)-amide, trans-isomer, (Compound A1579); <BR> <BR> <BR> 2-{4-(4-fluoro-phenyl)-5-[2-(1-phenyl-ethylamino)-pyrimidin- 4-yl]-lH-imidazol-2-yl}-5-methyl- [1,3]dioxane-5-carboxylic acid (2-dimethylamino-ethyl)-amide, R-isomer, trans-isomer, (Compound A1580);

2-{4-(4-fluoro-phenyl)-5-[2-(1-phenyl-ethylamino)-pyrimidin- 4-yl]- 1H-imidazol-2yl )-9methyl- [1,3]dioxane-5-carboxylic acid (2-dimethylamino-ethyl)-amide, S-isomer, trans-isomer, (Compound A1581); 2-[4-(4-fluoro-phenyl)-5-(2-phenylamino-pyrimidin-4-yl)- lH-imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid (2-dimethylamino-ethyl)-amide, trans-isomer, (Compound A1582); 2-[4-(4-fluoro-phenyl)-5-(2-piperidin-1-yl-pyrimidin-4-yl)-1 H-imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid (2-dimethylamino-ethyl)-amide, trans-isomer, (Compound A1583); <BR> <BR> <BR> 2-(4-(4-fluoro-phenyl)-5-(2-[(pyridin-4-ylmethyl)-amino]-pyr imidin-4-yl l-111-imidazol-2-yl)-5- methyl-[1,3]dioxane-5-carboxylic acid (2-dimethylamino-ethyl)-amide, trans-isomer, (Compound A1584); 2-(4-(4-fluoro-phenyl)-5-{2-[(pyridin-2-ylmethyl)-amino]-pyr imidin-4-yl}-1H-imidazol-2-yl)-5- methyl- [1,3]dioxane-5-carboxylic acid (2-dimethylamino-ethyl)-amide, trans-isomer, (Compound A1585); 2-(4-(4-fluoro-phenyl)-5-{2-[(pyridin-2-ylmethyl)-amino]-pyr imidin-4-yl l-111-imidazol-2-yl)-5- methyl-[1,3]dioxane-5-carboxylic acid (2-dimethylamino-ethyl)-amide, trans-isomer, (Compound A1586); 2-(4-(4-fluoro-phenyl)-5-{2-[(furan-2-ylmethyl)-amino]-pyrim idin-4-yl}-1H-imidazol-2-yl)-5- methyl-[1,3]dioxane-5-carboxylic acid (2-dimethylamino-ethyl)-amide, trans-isomer, (Compound A1587); <BR> <BR> <BR> 2-(4-(4-fluoro-phenyl)-5-{2-[(thiophen-2-ylmethyl)-amino]-py rimidin-4-yl}-lH-imidazol-2-yl)-5- methyl-[1,3]dioxane-5-carboxylic acid (2-dimethylamino-ethyl)-amide, trans-isomer, (Compound A1588); 2-(4-(4-fluoro-phenyl)-5- (2-[(tetrahydro-furan-2-ylmethyl)-amino]-pyrimidin-4-yl)- 1H-imidazol- 2-yl)-5-methyl-[1,3]dioxane-5-carboxylic acid (2-dimethylamino-ethyl)-amide, trans-isomer, (Compound A1589); 2-{4-(4-fluoro-phenyl)-5-[2-(4-methyl-piperazin-1-yl)-pyrimi din-4-yl]-1H-imidazol-2-yl}-5- methyl-[1,3]dioxane-5-carboxylic acid (2-dimethylamino-ethyl)-amide, trans-isomer, (Compound A1590); 2-[4-(4-fluoro-phenyl)-5-(2-morpholin-4-yl-pyrimidin-4-yl)- 1H-imidazol-2-ylj-5-methyl- [1,3]dioxane-5-carboxylic acid (2-dimethylamino-ethyl)-amide, trans-isomer, (Compound A1591); 2-{4-(4-fluoro-phenyl)-5-[2-(3-methoxy-propylamino)-pyrimidi n-4-yl]-1H-imidazol-2-yl}-5 methyl-[1,3]dioxane-5-carboxylic acid (2-dimethylamino-ethyl)-amide, trans-isomer, (Compound A1592);

2-{4-(4-fluoro-phenyl)-5-[2-(2-methoxy-ethylamino)-pyrimidin -4-yl]-lH-imidazol-2-yl}-5-methyl- [1,3]dioxane-5-carboxylic acid (2-dimethylamino-ethyl)-amide, trans-isomer, (Compound A1593); <BR> <BR> <BR> <BR> 2-[5-[2-(3-dimethylamino-propylamino)-pyrimidin-4-yl]-4-(4-f luoro-phenyl)-lH-imidazol-2-yl]- 5-methyl-[1,3]dioxane-5-carboxylic acid (2-dimethylamino-ethyl)-amide, trans-isomer, (Compound A1594); 2-[5-[2-(2-dimethylamino-ethylamino)-pyrimidin-4-yl]-4-(4-fl uoro-phenyl)-1H-imidazol-2-yl]-5- methyl-[1,3]dioxane-5-carboxylic acid (2-dimethylamino-ethyl)-amide, trans-isomer, (Compound A1595); {4-[2-[5-(2-dimethylamino-ethylcarbamoyl)-5-methyl-[1,3]diox an-2-yl]-5-(4-fluoro-phenyl)-3H- imidazol-4-yl]-pyrimidin-2-ylamino)-acet acid, trans-isomer, (Compound A1596); 3-{4-[2-[5-(2-dimethylamino-ethylcarbamoyl)-5-methyl-[1,3]di oxan-2-yl]-5-(4-fluoro-phenyl)-3H- imidazol-4-yl]-pyrimidin-2-ylamino}-propionic acid, trans-isomer, (Compound A1597); 2-[4-(4-fluoro-phenyl)-5-(2-isopropylamino-pyrimidin-4-yl)-1 H-imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid (2-dimethylamino-ethyl)-amide, trans-isomer, (Compound A1598); 2-[5-(2-alkylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-im idazol-2-yl]-5-methyl-[1,3]dioxane- 5-carboxylic acid (2-dimethylamino-ethyl)-amide, trans-isomer, (Compound A1599); 2-[5-[2-(cyclopropylmethyl-amino)-pyrimidin-4-yl]-4-(4-fluor o-phenyl)-1H-imidazol-2-yl]-5- methyl-[1,3]dioxane-5-carboxylic acid (2-dimethylamino-ethyl)-amide, trans-isomer, (Compound A1600); 2-[5-[2-(cyanomethyl-amino)-pyrimdin-4-yl]-4-(4-fluoro-pheny l)-1H-imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid (2-dimethylamino-ethyl)-amide, trans-isomer, (Compound A1601); 2-[5-[2-(2-cyano-ethylamino)-pyrimidin-4-yl]--(4-fluoro-phen yl)-1H-imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid (2-dimethylamino-ethyl)-amide, trans-isomer, (Compound A1602); 2-{4-(4-fluoro-phenyl)-5-[2-(pyridin-3-ylamino)-pyrimidin-4- yl]-1H-imidazol-2-yl}-5-methyl- [1,3]dioxane-5-carboxylic acid (2-dimethylamino-ethyl)-amide, trans-isomer, (Compound A1603); 2-{4-(4-fluoro-phenyl)-5-[2-(pyridin-4-ylamino)-pyrimidin-4- yl]-1H-imidazol-2-yl}-5-methyl- [1,3]dioxane-5-carboxylic acid (2-dimethylamino-ethyl)-amide, trans-isomer, (Compound A1604); 2-[4-(4-fluoro-phenyl)-5-(2-propylamino-pyrimidin-4-yl)-1H-i midazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid (2-dimethylamino-ethyl)-amide, trans-isomer, (Compound A1605);

2-{4-(4-fluoro-phenyl)-5-(2-pyrrolidin- 1-yl-pyrimidin-4-yl)-lH-imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid (2-dimethylamino-ethyl)-amide, trans-isomer, (Compound A1606); <BR> <BR> <BR> 2-{4-(4-fluoro-phenyl)-5-[2-(4-fluoro-phenylamino)-pyrimidin -4-yli-111-imidazol-2-yl}-5-methyl- [1,3]dioxane-5-carboxylic acid (2-dimethylamino-ethyl)-amide, trans-isomer, (Compound A1607); 2-[5-[2-(3,4-difluoro-phenylamino)-pyrimidin-4-yl]-4-(4-fluo ro-phenyl)-111-imidazol-2-ylj-5- methyl-[1,3]dioxane-5-carboxylic acid (2-dimethylamino-ethyl)-amide, trans-isomer, (Compound A1608); 2-{4-(4-fluoro-phenyl)-5-[2-(3-methoxy-phenylamino)-pyrimidi n-4-yl]-lH-imidazol-2-yl}-5- methyl-[1,3]dioxane-5-carboxylic acid (2-dimethylamino-ethyl)-amide, trans-isomer, (Compound A1609); 2-[5-[2-(4-fluoro-benzylamino)-pyrimidin-4-yl]-4-(4-fluoro-p henyl)-1H-imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid (2-dimethylamino-ethyl)-amide, trans-isomer, (Compound A1610); 2-{4-(4-fluoro-phenyl)-5-[2-(4-methoxy-benzylamino)-pyrimidi n-4-yl]-1H-imidazol-2-yl}-5- methyl-[1,3]dioxane-5-carboxylic acid (2-dimethylamino-ethyl)-amide, trans-isomer, (Compound A1611); 2-[4-(4-fluoro-phenyl)-5-(2-methoxy-pyrimidin-4-yl)-1H-imida zol-2-yl]-5-methyl-[1,3]dioxane-5- carboxylic acid (2-dimethylamino-ethyl)-amide, trans-isomer, (Compound A1612); 2-[5-(2-benzyloxy-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imi dazol-2-yl]-5-methyl-[1,3]dioxane- 5-carboxylic acid (2-dimethylamino-ethyl)-amide, trans-isomer, (Compound A1613); <BR> <BR> <BR> 2-[4-(4-fluoro-phenyl)-5-(2-phenoxy-pyrimidin-4-yl)- lH-imidazol-2-yl]-5-methyl-[1,3]dioxane-5- carboxylic acid (2-dimethylamino-ethyl)-amide, trans-isomer, (Compound A1614); 2-{4-(4-fluoro-phenyl)-5-[2-(2-methoxy-ethoxy)-pyrimidin-4-y l]-1H-imidazol-2-yl}-5-methyl- [1,3]dioxane-5-carboxylic acid (2-dimethylamino-ethyl)-amide, trans-isomer, (Compound A1615); 2-[5-[2-(2-dimethylamino-ethoxy)-pyrimidin-4-yl]-4-(4-fluoro -phenyl)-1H-imidazol-2-yl]-5- methyl-[1,3]dioxane-5-carboxylic acid (2-dimethylamino-ethyl)-amide, trans-isomer, (Compound A1616); 2-[5-(2-cyclohexyloxy-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H -imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid (2-dimethylamino-ethyl)-amide, trans-isomer, (Compound A1617); <BR> <BR> <BR> <BR> 2-[5-(2-Isopropoxy-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-lH-im idazol-2-yl]-5-methyl-[1,3]dioxane- 5-carboxylic acid (2-dimethylamino-ethyl)-amide, trans-isomer, (Compound A1618);

2-[4-(4-fluoro-phenyl)-5-(2-propoxy-pyrimidin-4-yl)-1H-imida zol-2-yl]-5-methyl-[1,3]dioxane-5- carboxylic acid (2-dimethylamino-ethyl)-amide, trans-isomer, (Compound A1619); 2-{4-(4-fluoro-phenyl)-5-[2-(2-hydroxy-ethoxy)-pyrimidin-4-y l]-1H-imidazol-2-yl}-5-methyl- [1,3]dioxane-5-carboxylic acid (2-dimethylamino-ethyl)-amide, trans-isomer, (Compound A1620); 2-{4-(4-fluoro-phenyl)-5-[2-(3-hydroxy-propoxy)-pyrimidin-4- yl]-1H-imidazol-2-yl}-5-methyl- [1,3]dioxane-5-carboxylic acid (2-dimethylamino-ethyl)-amide, trans-isomer, (Compound A1621); 2-[4-(4-fluoro-phenyl)-5-(2-methylsulfanyl-pyrimidin-4-yl)-1 H-imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid (2-dimethylamino-ethyl)-amide, trans-isomer, (Compound A1622); {2-[5-(2-amino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidaz ol-2-yl]-5-methyl-[1,3]dioxan-5- yl}-(3-hydroxy-pyrrolidin-1-yl)-methanone, trans-isomer, (Compound A1623); {2-[4-(4-fluoro-phenyl)-5-(2-methylamino-pyrimidin-4-yl)-1H- imidazol-2-yl]-5-methyl- [1,3]dioxan-5-yl)-(3-hydroxy-pyrrolidin-1-yl)-methanone, trans-isomer, (Compound A1624); {2-[5-(2-dimethylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1 H-imidazol-2-yl]-5-methyl- [1,3]dioxan-5-yl l-(3-hydroxy-pyrrolidin-1-yl)-methanone, trans-isomer, (Compound A1625); (2-5-(2-cyclopropylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl) -111-imidazol-2-yl]-5-methyl [1,3]dioxan-5-yl)-(3-hydroxy-pyrrolidin- l-yl)-methanone, trans-isomer, (Compound A1626); <BR> <BR> <BR> (2-(4- (4-fluoro-phenyl)-5 - [2-(pip eridin-4-ylamino)-pyrimidin-4-yl] -1H-imidazol-2yl) -5-methyl- [1,3]dioxan-5-yl}-(3-hydroxy-pyrrolidin-1-yl)-methanone, trans-isomer, (Compound A1627); {2-[5-(2-cyclohexylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl) -1H-imidazol-2-yl]-5-methyl- [1,3]dioxan-5-yl )-(3-hydroxy-pyrrolidin-1-yl)-methanone, trans-isomer, (Compound A1628); (2-{4-(4-fluoro-phenyl)-5-[2-(2-hydroxy-ethylamino)-pyrimidi n-4-yl]-1H-imidazol-2-yl}-5- methyl-[1,3]dioxan-5-yl)-(3-hydroxy-pyrrolidin-1-yl)-methano ne, trans-isomer, (Compound A1629); {2-[5-[2-amino-ethylamino)-pyrimidin-4-yl]-4-(4-fluoro-pheny l)-1H-imidazol-2-yl]-5-methyl- [1,3]dioxan-5-yl}-(3-hydroxy-pyrrolidin-1-yl)-methanone, trans-isomer, (Compound A1630); [2-(4-(4-fluoro-phenyl)-5-{2-[3-(5H-imidazol-1-yl)-propylami no]-pyrimidin-4-yl}-1H-imidazol-2- yl)-5-methyl-[1,3]dioxan-5-yl]-(3-hydroxy-pyrrolidin- 1-yl)-methanone, trans-isomer, (Compound A1631); (2-{4-(4-fluoro-phenyl)-5-[2-(3-morpholin-4-yl-propylamino)- pyrimidin-4-yl]-1H-imidazol-2-yl}- 5-methyl- [1,3]dioxan-5-yl)-(3-hydroxy-pyrrolidin- 1-yl)-methanone, trans-isomer, (Compound A1632);

(2-{4-(4-fluoro-phenyl)-5- [2-(3-hydroxy-propylamino)-pyrimidin-4-yl]-lH-imidazol-2-yl} -5- methyl-[1,3]dioxan-5-yl)-(3-hydroxy-pyrrolidin-1-yl)-methano ne, trans-isomer, (Compound A1633); (2-[5-(2-benzylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-111 -imidazol-2-yl]-5-methyl- [1,3]dioxan-5-yl)-(3-hydroxy-pyrrolidin- 1-yl)-methanone, trans-isomer, (Compound A1634); (2-{4-(4-fluoro-phenyl)-5-[2-(1-phenyl-ethylamino)-pyrimidin -4-yl]-1H-imidazol-2-yl}-5-methyl- [1,3]dioxan-5-yl)-(3-hydroxy-pyrrolidin-1-yl)-methanone, R-isomer, trans-isomer, (Compound A1635); (2-{4-(4-fluoro-phenyl)-5-[2-(1-phenyl-ethylamino)-pyrimidin -4-yl]-1H-imidazol-2-yl}-5-methyl- [1,3]dioxan-5-yl)-(3-hydroxy-pyrrolidin-1-yl)-methanone, S-isomer, trans-isomer, (Compound A1636); {2-[4-(4-fluoro-phenyl)-5-(2-phenylamino-pyrimidin-4-yl)-1H- imidazol-2-yl]-5-methyl- [1,3]dioxan-5-yl)-(3-hydroxy-pyrrolidin-1-yl)-methanone, trans-isomer, (Compound A1637); (2-[4-(4-fluoro-phenyl)-5-(2-piperidin- 1-yl-pyrimidin-4-yl)- lH-imidazol-2-yl]-5-methyl- [1,3]dioxan-5-yl}-(3-hydroxy-pyrrolidin- 1-yl)-methanone, trans-isomer, (Compound A1638); [2-(4-(4-fluoro-phenyl)-5-{2-[(pyridin-4-ylmethyl)-amino]-py rimidin-4-yl}-1H-imidazol-2-yl)-5- methly-[1,3]dioxan-5-yl]-(3-hydroxy-pyrrolidin-1-yl)-methano ne, trans-isomer, (Compound A1639); [2-(4-(4-fluoro-phenyl)-5-{2-[(pyridin-3-ylmethyl)-amino]-py rimidin-4-yl}-1H-imidazol-2-yl)-5- methyl-[1,3]dioxan-5-yl]-(3-hydroxy-pyrrolidin- 1-yl)-methanone, trans-isomer, (Compound A1640); [2-(4-(4-fluoro-phenyl)-5-{[(pyridin-2-ylmethyl)-amino]-pyri midin-4-yl}-1H-imidazol-2-yl)-5- methyl-[1,3]dioxan-5-yl]-(3-hydroxy-pyrrolidin- 1-yl)-methanone, trans-isomer, (Compound A1641); [2-(4-(4-fluoro-phenyl)-5-{2- [(furan-2-ylmethyl)-amino]-pyrimidin-4-yl}- 111-imidazol-2-yl)-5- methyl-[1,3]dioxan-5-yl]-(3-hydroxy-pyrrolidin-1-yl)-methano ne, trans-isomer, (Compound A1642); [2-(4-(4-fluoro-phenyl)-5-{2-[(thiophen-2-ylmethyl)-amino]-p yrimidin-4-yl}-1H-imidazol-2-yl)-5- methyl-[1,3]dioxan-5-yl]-(3-hydroxy-pyrrolidin-1-yl)-methano ne, trans-isomer, (Compound A1643); [2-(4-(4-fluoro-penyl)-5-{2-[(tetrahydrofuran-2-ylmethyl)-am ino]-pyrimidin-4-yl}-1H- imidazol-2-yl)-5-methyl-[1,3]dioxan-5-yl]-(3-hydroxy-pyrroli din- 1-yl)-methanone, trans-isomer, (Compound A1644); (2-{4-(4-fluoro-phenyl)-5-[2-(4-methyl-piperazin- l-yl)-pyrimidin-4-yl]-1H-imidazol-2-yl)- methyl-[1,3]dioxan-5-yl)-(3-hydroxy-pyrrolidin-1-yl)-methano ne, trans-isomer, (Compound A1645);

(2- [4- (4-fluoro-phenyl)- 5- (2-morpholin-4-yl-pyrimidin-4-yl)- lH-imidazol-2-yl]-5-methyl- [1,3]dioxan-5-yl}-(3-hydroxy-pyrrolidin- 1-yl)-methanone, trans-isomer, (Compound A1646); (2-(4-(4-fluoro-phenyl)-5- [2-(3-methoxy-propylamino)-pyrimidin-4-yl]-111-imidazol-2-yl )-5- methyl-[1,3]dioxan-5-yl)-(3-hydroxy-pyrrolidin-1-yl)-methano ne, trans-isomer, (Compound A1647); (2-{4-(4-fluoro-phenyl)-5-[2-(2-methoxy-ethylamino)-pyrimidi n-4-yl]-lH-imidazol-2-yl}-5- methyl-[1,3]dioxan-5-yl)-(3-hydroxy-pyrrolidin-1-yl)-methano ne, trans-isomer, (Compound A1648); {2-[5-[2-(3-dimethylamino-propylamino)-pyrimidin-4-yl]-4-(4- fluoro-phenyl)-1H-imidazol-2-yl]- 5-methyl-[1,3]dioxan-5-yl}-(3-hydroxy-pyrrolidin-1-yl)-metha none, trans-isomer, (Compound A1649); [2-[5-[2-(2-dimethylamino-ethylamino)-pyrimidin-4-yl]-4-(4-f luoro-phenyl)-1H-imidazol-2-yl]-5- methyl-[1,3]dioxan-5-yl}-(3-hydroxy-pyrrolidin-1-yl)-methano ne, trans-isomer, (Compound A1650); <BR> <BR> <BR> <BR> (4-{5-(4-fluoro-phenyl)-2-[5-(3-hydroxy-pyrrolidine- 1-carbonyl)-5-methyl-[1,3]dioxan-2-yl]-3H- imidazol-4-yl)-pyrimidin-2-ylamino)-acetic acid, trans-isomer, (Compound A1651); 3-(4-{5-(4-fluoro-phenyl)-2-[5-(3-hydroxy-pyrrolidine-1-carb onyl)-5-methyl-[1,3]dioxan-2-yl]- 3H-imidazol-4-yl}-pyrimidin-2-ylamino)-propionic acid, trans-isomer, (Compound A1652); (2-[4- (4-fluoro-phenyl)-5 -(2-isopropylamino-pyrimidin-4-yl) - 1H-imidazol-2-yl]-5-methyl- [1,3]dioxan-5-yl)-(3-hydroxy-pyrrolidin-1-yl)-methanone, trans-isomer, (Compound A1653); {2[5-(2-allylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-im idazol-2-yl]-5-methyl-[1,3dioxan- 5-yl)-(3-hydroxy-pyrrolidin-1-yl)-methanone, trans-isomer, (Compound A1654); {2-[5-[2-cyclopropylmethyl-amino)-pyrimidin-4-yl]-4-(4-fluor o-phenyl)-1H-imidazol-2-yl]-5- methyl-[1,3]dioxan-5-yl )-(3-hydroxy-pyrrolidin-l -yl)-methanone, trans-isomer, (Compound A1655); (4-[5-(4-fluoro-phenyl)-2-[5-(3-hydroxy-pyrrolidine-1-carbon yl)-5-methyl-[1,3]dioxan-2-yl]-3H- imidazol-4-yll-pyrimidin-2-ylamino)-acetonitrile, trans-isomer, (Compound A1656); 3-(4-(5-(4-fluoro-phenyl)-2- [5-(3-hydroxy-pyrrolidine- l-carbonyl)-5-methyl- [1,3]dioxan-2-yl]- 3H-imidazol-4-yl}-pyrimidin-2-ylamino)-propionitrile, trans-isomer, (Compound A1657); (2-{4-(4-fluoro-phenyl) -5-[2-(pyridin-3-ylamino)-pyrimidin-4-yl]-lH-imidazol-2-yl}- 5-methyl- [1,3]dioxan-5-yl)-(3-hydroxy-pyrrolidin-1-yl)-methanone, trans-isomer, (Compound A1658); (2-{4-(4-fluoro-phenyl)-5-[2-pyridin-4-ylamino)-pyrimidin-4- yl]-1H-imidazol-2-yl}-5-methyl- [1,3]dioxan-5-yl)-(3-hydroxy-pyrrolidin-1-yl)-methanone, trans-isomer, (Compound A1659); {2-[4-4-(4-fluoro-phenyl)-5-(2-propylamino-pyrimidin-4-yl)-1 H-imidazol-2-yl]-5-methyl- [1,3]dioxan-5-yl}-(3-hydroxy-pyrrolidin-1-yl)-methanone, trans-isomer, (Compound A1660);

{2-[4-(4-fluoro-phenyl)-5-(2-pyrrolidin-1-yl-pyrimidin-4-yl) -lH-imidazol-2-yl]-5-methyl- [1,3]dioxan-5-yl)-(3-hydroxy-pyrrolidin-1-yl)-methanone, trans-isomer, (Compound A1661); (2-{4-(4-fluoro-phenyl)-5-[2-(4-fluoro-phenylamino)-pyrimidi n-4-yl]-1H-imidazol-2-yl}-5-methyl- [1,3]dioxan-5-yl)-(3-hydroxy-pyrrolidin-1-yl)-methanone, trans-isomer, (Compound A1662); {2-[5-[2-(3,4-difluoro-phenylamino)-pyrimidin-4-yl]-4-(4-flu oro-phenyl)-1H-imidazol-2-yl]-5- methyl-[1,3]dioxan-5-yl}-(3-hydroxy-pyrrolidin-1-yl)-methano ne, trans-isomer, (Compound A1663); (2-{4-(4-fluoro-phenyl)-5-[2-(3-methoxy-phenylamino)-pyrimid in-4-yl]-1H-imidazol-2-yl}-5- methyl-[1,3]dioxan-5-yl)-(3-hydroxy-pyrrolidin-1-yl)-methano ne, trans-isomer, (Compound A1664); {2-[5-[2-(4-fluoro-benzylamino)-pyrimidin-4-yl]-4-(4-fluoro- phenyl)-1H-imidazol-2-yl]-5-methyl- [1,3]dioxan-5-yl )-(3-hydroxy-pyrrolidin-1-yl)-methanone, trans-isomer, (Compound A1665); (2-{4-(4-fluoro-phenyl)-5-[2-(4-methoxy-benzylamino)-pyrimid in-4-yl]-1H-imidazol-2-yl}-5- methyl-[1,3]dioxan-5-yl)-(3-hydroxy-pyrrolidin-1-yl)-methano ne, trans-isomer, (Compound A1666); {2-[4-(4-fluoro-phenyl)-5-(2-methoxy-pyrimidin-4-yl)-1H-imid azol-2-yl]-5-methyl-[1,3]dioxan-5- yl}-(3-hydroxy-pyrrolidin-1-yl)-methanone, trans-isomer, (Compound A1667); {2-[5-(2-benzyloxy-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-im idazol-2-yl]-5-methyl-[1,3]dioxan- 5-yl}-(3-hydroxy-pyrrolidin-1-yl)-methanone, trans-isomer, (Compound A1668); {2-[4-(4-fluoro-phenyl)-5-(2-phenoxy-pyrimidin-4-yl)-1H-imid azol-2-yl]-5-methyl-[1,3]dioxan-5- yl}-(3-hydroxy-pyrrolidin- 1-yl)-methanone, trans-isomer, (Compound A1669); (2-{4-(4-fluoro-phenyl)-5-[2-(2-methoxy-ethoy)-pyrimidin-4-y l]-1H-imidazol-2-yl}-5-methyl- [1,3]dioxan-5-yl)-(3-hydroxy-pyrrolidin-1-yl)-methanone, trans-isomer, (Compound A1670); (2-[5-[2- (2-dimethylami no-ethoxy)-pyrimidi n-4-yl]-4- (4-fluoro-phenyl)-l H-imidazol-2yl]-5- methyl-[1,3]dioxan-5-yl]-(3-hydroxy-pyrrolidin-1-yl)-methano ne, trans-isomer, (Compound A1671); {2-[5-(2-cyclohexyloxy-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1 H-imidazol-2-yl]-5-methyl- [1,3]dioxan-5-yl )-(3-hydroxy-pyrrolidin 1-yl)-methanone, trans-isomer, (Compound A1672); {2-[5-(2-Isopropoxy-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-i midazol-2-yl]-5-methyl-[1,3]dioxan- 5-yl}-(3-hydroxy-pyrrolidin-1-yl)-methanone, trans-isomer, (Compound A1673); {2-[4-(4-fluoro-phenyl)-5-(2-propoxy-pyrimidin-4-yl)-1H-imid azol-2-yl]-5-methyl-[1,3]dioxan-5- yl}-(3-hydroxy-pyrrolidin-1-yl)-methanone, trans-isomer, (Compound A1674); (2-{4-(4-fluoro-phenyl)-5-[2-(2-hydroxy-ethoxy)-pyrimidin-4- yl]-1H-imidazol-2-yl]-5-methyl- [1,3]dioxan-5-yl)-(3-hydroxy-pyrrolidin- 1-yl)-methanone, trans-isomer, (Compound A1675); (2-{4-(4-fluoro-phenyl)-5-[2-(3-hydroxy-propoxy)-pyrimidin-4 -yl]-1H-imidazol-2-yl}-5-methyl- [1,3]dioxan-5-yl)-(3-hydroxy-pyrrolidin- 1-yl)-methanone, trans-isomer, (Compound A1676);

{2-[4-(4-fluoro-phenyl)-5-(2-methylsulfanyl-pyrimidin-4-yl)- lH-imidazol-2-yl]-5-methyl- [1,3]dioxan-5-yl )-(3-hydroxy-pyrrolidin- 1-yl)-methanone, trans-isomer, (Compound A1677); <BR> <BR> <BR> 2-[5-(2-amino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-lH-imidazo l-2-yl]-5-methyl-[1,3]dioxane-5- carboxylic acid isopropyl-amide, trans-isomer, (Compound A1678); 2-[4-(4-fluoro-phenyl)-5-(2-methylamino-pyrimidin-4-yl)-1H-i midazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid isopropyl-amide, trans-isomer, (Compound A1679); 2-[5-(2-dimethylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H -imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid isopropyl-amide, trans-isomer, (Compound A1680); 2-[5-(2-cyclopropylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl) -1H-imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid isopropyl-amide, trans-isomer, (Compound A1681); 2-{4-(4-fluoro-phenyl)-5-[2-(piperidin-4-ylamino]-pyrimidin- 4-yl]-1H-imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid isopropyl-amide, trans-isomer, (Compound A1682); 2-[5-(2-cyclohexylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)- 1H-imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid isopropyl-amide, trans-isomer, (Compound A1683); 2-{4-(4-fluoro-phenyl)-5-[2-(2-hydroxy-ethylamino)-pyrimidin -4-yl]-1H-imidazol-2-yl}-5-methyl- [1,3]dioxane-5-carboxylic acid isopropyl-amide, trans-isomer, (Compound A1684); 2-[5-[2-(2-amino-ethylamino)-pyrimidin-4-yl]-4-(4-fluoro-phe nyl)-1H-imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid isopropyl-amide, trans-isomer, (Compound A1685); 2-(4-(4-fluoro-phenyl)-5-{2-[3-(5H-imidazol-1-yl)-propylamin o]-pyrimidin-4-yl}-1H-imidazol-2- yl)-5-methyl-[1,3]dioxane-5-carboxylic acid isopropyl-amide, trans-isomer, (Compound A1686); 2-{4-(4-fluoro-phenyl)-5-[2-(3-morpholin-4-ylpropylamino)-py rimidin-4-yl]-1H-imidazol-2-yl}- 5-methyl-[1,3]dioxane-5-carboxylic acid isopropyl-amide, trans-isomer, (Compound A1687); 2-(4-(4-fluo ro-phenyl)-5 - E2- (3-hydroxy-propyl amino) -pyrimidin4-yl] -1H-imidazol -2-yl)-5- methyl-[1,3]dioxane-5-carboxylic acid isopropyl-amide, trans-isomer, (Compound A1688); 2-[5-(2-benzylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-i midazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid isopropyl-amide, trans-isomer, (Compound A1689); 2-{4-(4-fluoro-phenyl)-5-[2-(1-phenyl-ethylamino)-pyrimidin- 4-yl]-1H-imidazol-2-yl}-5-methyl- [1,3]dioxane-5-carboxylic acid isopropyl-amide, R-isomer, trans-isomer, (Compound A1690); 2-{4-(4-fluoro-phenyl)-5-[2-(1-phenyl-ethylamino)-pyrimidin- 4-yl]-1H-imidazol-2-yl}-5-methyl- [1,3]dioxane-5-carboxylic acid isopropyl-amide, S-isomer, trans-isomer, (Compound A1691); 2-[4-(4-fluoro-phenyl)-5-(2-phenylamino-pyrimidin-4-yl)-1H-i midazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid isopropyl-amide, trans-isomer, (Compound A1692); 2-[4-(fluoro-phenyl)-5-(2-piperidin-1-yl-pyrimidin-4-yl-5-me thyl- [1,3]dioxane-5-carboxylic acid isopropyl-amide, trans-isomer, (Compound A1693); 2-(4-(4-fluoro-phenyl)-5-{2-[(pyridin-4-ylmethyl)-amino]-pyr imidin-4-yl}-1H-imidazol-2-yl)-5- methyl-[1,3]dioxane-5-carboxylic acid isopropyl-amide, trans-isomer, (Compound A1694);

2-(4-fluoro-phenyl)-5-{2-[(pyridin-3-ylmethyl)-amino]-pyrimi din-4-yl]-1H-imidazol-2-yl)-5- methyl-[1,3]dioxane-5-carboxylic acid isopropyl-amide, trans-isomer, (Compound A1695); 2-(4-(4-fluoro-phenyl)-5-{2-[(pyridin-2-ylmethyl)-amino]-pyr imidin-4-yl}-1H-imidazol-2-yl)-5- methyl- [1,3]dioxane-5-carboxylic acid isopropyl-amide, trans-isomer, (Compound A1696); 2-(4-(4-fluoro-phenyl)-5-{2-[(furan-2-ylmethyl)-amino]-pyrim idin-4-yl}-1H-imidazol-2-yl)-5- methyl-[1,3]dioxane-5-carboxylic acid isopropyl-amide, trans-isomer, (Compound A1697); 2-(4-(4-fluoro-phenyl)-5-{2-{thiophen-2-ylmethyl)-amino]-pyr imidin-4-yl}-1H-imidazol-2-yl)-5- methyl-[1,3]dioxane-5-carboxylic acid isopropyl-amide, tran-isomer, (Compound A1698); <BR> <BR> <BR> 2-(4-(4-fluoro-phenyl)-5-{2-[(tetrahydro-furan-2-ylmethyl)-a mino]pyrimidin-4-yl}-lH-imidazol- 2-yl)-5-methyl-[1,3]dioxane-5-carboxylic acid isopropyl-amide, trans-isomer, (Compound A1699); 2-{2-(4-fluoro-phenyl)-5-[2-(4-methyl-piperazin-1-yl)-pyrimi din-4-yl]-1H-imidazol-2-yl}-5- methyl-[1,3]dioxane-5-carboxylic acid isopropyl-amide, trans-isomer, (Compound A1700); 2-[4-(4-fluoro-phenyl)-5-(2-morpholin-4-yl-pyrimidin-4-yl)-1 H-imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid isopropyl-amide, trans-isomer, (Compound A1701); 2-{4-(4-fluoro-phenyl)-5-[2-(3-methoxy-propylamino)-pyrimidi n-4-yl]-1H-imidazol-2-yl}-5- methyl-[1,3jdioxane-5-carboxylic acid isopropyl-amide, trans-isomer, (Compound A1702); 2-{4-(4-fluoro-phenyl)-5-[2-(2-methoxy-ethylamino)-pyrimidin -4-yl]-1HJ-imidazol-2-yl}-5-methyl- [1,3]dioxane-5-carboxylic acid isopropyl-amide, trans-isomer, (Compound A1703); 2-[5-[2-(3-dimethylamino-propylamino)-pyrimidin-4-yl]-4-(4-f luoro-phenyl)-1H-imidazol-2-yl]- 5-methyl-[1,3]dioxane-5-carboxylic acid isopropyl-amide, trans-isomer, (Compound A1704); 2-[5-[2-(2-dimethylamino-ethylamino)-pyrimidin-4-yl]-4-(4-fl uoro-phenyl)-1H-imidazol-2-yl]-5- methyl-[1,3]dioxane-5-carboxylic acid isopropyl-amide, trans-isomer, (Compound A1705); {4-[5-(4-fluoro-phenyl)-2-(5-isopropylcarbamoyl-5-methyl-[1, 3]dioxan-2-yl)-3H-imidazol-4-yl]- pyrimidin-2-ylamino}-acetic acid, trans-isomer, (Compound A1706); 3-{4-[5-(4-fluoro-phenyl)-2-(5-isopropylcarbmoyl-5-methyl-[1 ,3]dioxan-2-yl)-3H-imidazol-4-yl]- pyrimidin-2-ylamino)-propionic acid, trans-isomer, (Compound A1707); 2-[4-(4-fluoro-phenyl)-5-(2-isopropylamino-pyrimidin-4-yl)-1 H-imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid isopropyl-amide, trans-isomer, (Compound A1708); 2-[5-(2-allylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-im idazol-2-yl]-5-methyl-[1,3]dioxane- 5-carboxylic acid isopropyl-amide, trans-isomer, (Compound A1709); 2- [5-[2-(cyclopropylmethyl-amino)-pyn.midin-4-yl]-4-(4-fluoro- phenyl) 111-imidazol-2-yl]-5 methyl-[1,3]dioxane-5-carboxylic acid isopropyl-amide, trans-isomer, (Compound A1710); 2-[5-[2-(cyanomethyl-amino)-pyrimidin-4-yl]-4-(4-fluoro-phen yl)-1H-imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid isopropyl-amide, trans-isomer, (Compound A1711);

2-[5-[2-(2-cyano-ethylamino)-pyrimidin-4-yl]-4-(4-fluoro-phe nyl)-lH-imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid isopropyl-amide, trans-isomer, (Compound A1712); 2-{4-(4-fluoro-phenyl)-5-[2-(pyridin-3-ylamino)-pyrimidin-4- yl]-lH-imidazol-2-yl}-5-methyl- [1,3]dioxane-5-carboxylic acid isopropyl-amide, trans-isomer, (Compound A1713); 2-{4-(4-fluoro-phenyl)-5-[2-(pyridin-4-ylamino)-pyrimidin-4- yl]-lH-imidazol-2-yl}-5-methyl- [1,3]dioxane-5-carboxylic acid isopropyl-amide, trans-isomer, (Compound A1714); 2-[4-(4-fluoro-phenyl)-5-(2-propylamino-pyrimidin-4-yl)- lH-imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid isopropyl-amide, trans-isomer, (Compound A1715); 2-[4-(4-fluoro-phenyl)-5-(2-pyrrolidin-1-yl-pyrimidin-4-yl)- lH-imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid isopropyl-amide, trans-isomer, (Compound A1716); <BR> <BR> <BR> 2-{4-(4-fluoro-phenyl)-5-[2-(4-fluoro-phenylamino)-pyrimidin -4-yl]-lH-imidazol-2-yl}-5-methyl- [1,3]dioxane-5-carboxylic acid isopropyl-amide, trans-isomer, (Compound A1717); 2-[5-[2-(3,4-difluoro-phenylamino)-pyrimidin-4-yl]-4-(4-fluo ro-phenyl)-1H-imidazol-2-yl]-5- methyl-[1,3]dioxane-5-carboxylic acid isopropyl-amide, trans-isomer, (Compound A1718); 2-{4-(4-fluoro-phenyl)-5-[2-(3-methoxy-phenylamino)-pyrimidi n-4-yl]-1H-imidazol-2-yl]-5- methyl-[1,3]dioxane-5-carboxylic acid isopropyl-amide, trans-isomer, (Compound A1719); 2-[5-[2-(4-fluoro-benzylamino)-pyrimidin-4-yl]-4-(4-fluoro-p henyl)-1H-imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid isopropyl-amide, trans-isomer, (Compound A1720); 2-{4-(4-fluoro-phenyl)-5-[2-(4-methoxy-benzylamino)-pyrimidi n-4-yl]-1H-imidazol-2-yl}-5- methyl-[1,3]dioxane-5-carboxylic acid isopropyl-amide, trans-isomer, (Compound A1721); 2-[4-(4-fluoro-phenyl)-5-(2-methoxy-pyrimidin-4-yl)-1H-imida zol-2-yl]-5-methyl-[1,3]dioxane-5- carboxylic acid isopropyl-amide, trans-isomer, (Compound A1722); 2-[5-(2-benzyloxy-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imi dazol-2-yl]-5-methyl-[1,3]dioxane- 5-carboxylic acid isopropyl-amide, trans-isomer, (Compound A1723); 2-[4-(4-fluoro-phenyl)-5-(2-phenoxy-pyrimidin-4-yl)-1H-imida zol-2-yl]-5-methyl-[1,3]dioxane-5- carboxylic acid isopropyl-amide, trans-isomer, (Compound A1724); 2-{4-(4-fluoro-phenyl)-5-[2-(2-methoxy-ethoxy)-pyrimidin-4-y l]-1H-imidazol-2-yl}-5-methyl- [1,3]dioxane-5-carboxylic acid isopropyl-amide, trans-isomer, (Compound A1725); 2-[5-[2-(2-dimethylamino-ethoxy)-pyrimidin-4-yl]-4-(4-fluoro -phenyl)-1H-imidazol-2-yl]-5- methyl-[1,3]dioxane-5-carboxylic acid isopropyl-amide, trans-isomer, (Compound A1726); 2-[5-(2-cyclohexyloxy-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H -imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid isopropyl-amide, trans-isomer, (Compound A1727); 2-[5-(2-Isopropoxy-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-im idazol-2-yl]-5-methyl-[1,3]dioxane- 5-carboxylic acid isopropyl-amide, trans-isomer, (Compound A1728); 2-[4-(4-fluoro-phenyl)-5-(2-propoxy-pyrimidin-4-yl)-1H-imida zol-2-yl]-5-methyl-[1,3]dioxane-5- carboxylic acid isopropyl-amide, trans-isomer, (Compound A1729);

2-{4-(4-fluoro-phenyl)-5-[2-(2-hydroxy-ethoxy)-pyrimidin-4-y l]-1H-imidazol-2-yl}-5-methyl- [1,3]dioxane-5-carboxylic acid isopropyl-amide, trans-isomer, (Compound A1730); 2-{4-(4-fluoro-phenyl)-5-[2-(3-hydroxy-propoxy)-pyrimidin-4- yl]-1H-imidazol~-2-yl}-5-methyl- [1,3]dioxane-5-carboxylic acid isopropyl-amide, trans-isomer, (Compound A1731); 2-[4-(4-fluoro-phenyl)-5-(2-methylsulfanyl-pyrimidin-4-yl)-1 H-imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid isopropyl-amide, trans-isomer, (Compound A1732); 2-[5-(2-amino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazo l-2-yl]-5-methyl-[1,3]dioxane-5- carboxylic acid allylamide, trans-isomer, (Compound A1733); 2-[4-(4-fluoro-phenyl)-5-(2-methylamino-pyrimidin-4-yl)-1H-i midazol-2-yl]-5-methyl [1,3]dioxane-5-carboxylic acid allylamide, trans-isomer, (Compound A1734); 2-[5-(2-dimethylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H -imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid allylamide, trans-isomer, (Compound A1735); 2-[5-(2-cyclopropylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl) - 1H-imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid allylamide, trans-isomer, (Compound A1736); 2-{4-(4-fluoro-phenyl)-5-[2-(piperidin-4-ylamino)-pyrimidin- 4-yl]-1H-imidazol-2-yl}-5-methyl- [1,3]dioxane-5-carboxylic acid allylamide, trans-isomer, (Compound A1737); 2-[5-(2-cyclohexylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)- 1H-imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid allylamide, trans-isomer, (Compound A1738); 2-{4-(4-fluoro-phenyl)-5-[2-(2-hydroxy-ethylamino)-pyrimidin -4-yl]-1H-imidazol-2-yl}-5-methyl- [1,3]dioxane-5-carboxylic acid allylamide, trans-isomer, (Compound A1739); 2-[5-[2-(2-amino-ethylamino)-pyrimidin-4-yl]-4-(4-fluoro-phe nyl)-1H-imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid allylamide, trans-isomer, (Compound A1740); 2-(4-(4-fluoro-phenyl)-5-{2-[3-(5H-imidazol-1-yl)-propylamin o]-pyrimidin-4-yl}-1H-imidazol-2- yl)-5-methyl-[1,3]dioxane-5-carboxylic acid allylamide, trans-isomer, (Compound A1741); 2-{4-(4-fluoro-phenyl)-5-[2-(3-morpholin-4-yl-propylamino)-p yrimidin-4-yl]-1H-imidazol-2-yl}- 5-methyl-[1,3]dioxane-5-carboxylic acid allylamide, trans-isomer, (Compound A1742); 2-{4-(4-fluoro-phenyl)-5-[2-(3-hydroxy-propylamino)-pyrimidi n-4-yl]-1H-imidazol-2-yl}-5- methyl-[1,3]dioxane-5-carboxylic acid allylamide, trans-isomer, (Compound A1743); 2-[5-(2-benzylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-i midazol-2yl]-5-methyl- [1,3]dioxane-5-carboxylic acid allylamide, trans-isomer, (Compound A1744); <BR> <BR> <BR> 2-{4-(4-fluoro-phenyl)-5-[2-(1-phenyl-ethylamino)-pyrimidin- 4-yl]-lH-imidazol-2-yl}-5-methyl- [1,3]dioxane-5-carboxylic acid allylamide, R-isomer, trans-isomer, (Compound A1745); <BR> <BR> <BR> 2-{4-(4-fluoro-phenyl)-5-[2-(1-phenyl-ethylamino)-pyrimidin- 4-yl]-lH-imidazol-2-yl}-5-methyl- [1,3]dioxane-5-carboxylic acid allylamide, S-isomer, trans-isomer, (Compound A1746); 2[4-(4-fluoro-phenyl)-5-(2-phenylamino-pyrimidin-4-yl)-1H-im idazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid allylamide, trans-isomer, (Compound A1747);

2-[4-(4-fluoro-phenyi)-5-(2-piperidin- 1-yl-pyrimidin-4-yl)-lH-imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid allylamide, trans-isomer, (Compound A1748); 2-(4-(4-fluoro-phenyl)-5-{2-[(pyridin-4-ylmethyl)-amino]-pyr imidin-4-yl}-1H-imidazol-2-yl)-5- methyl-[1,3]dioxane-5-carboxylic acid allylamide, trans-isomer, (Compound A1749); <BR> <BR> <BR> 2-(4-(4-fluoro-phenyl)-5-{2-[(pyridin-3-ylmethyl)-amino]-pyr imidin-4-yl}-lH-imidazol-2-yl)-5- methyl-[1,3]dioxane-5-carboxylic acid allylamide, trans-isomer, (Compound A1750); 2-(4-(4-fluoro-phenyl)-5-{2-[(pyridin-2-ylmethyl)-amino]-pyr imidin-4-yl}-1H-imidazol-2-yl)-5- methyl-[1,3]dioxane-5-carboxylic acid allylamide, trans-isomer, (Compound A1751); 2-(4-(4-fluoro-phenyl)-5-{2-[(furan-2-ylmethyl)-amino]-pyrim idin-4-yl}-lH-imidazol-2-yl)-5- methyl-[1,3]dioxane-5-carboxylic acid allylamide, trans-isomer, (Compound A1752); 2-(4-(4-fluoro-phenyl)-5-{2-[(thiophen-2-ylmethyl)-amino]-py rimidin-4-yl}-1H-imidazol-2-yl)-5- methyl-[1,3]dioxane-5-carboxylic acid allylamide, trans-isomer, (Compound A1753); 2-(4-(4-fluoro-phenyl)-5-{2-[(tetrahydro-furan-2-ylmethyl)-a mino]-pyrimidin-4-yl}-1H-imidazol- 2-yl)-5-methyl-[1,3]dioxane-5-carboxylic acid allylamide, trans-isomer, (Compound A1754); 2-{4-(4-fluoro-phenyl)-5-[2-(4-methyl-piperazin-1-yl)-pyrimi din-4-yl]-1H-imidazol-2-yl}-5- methyl-[1,3]dioxane-5-carboxylic acid allylamide, trans-isomer, (Compound A1755); 2-[4-(4-fluoro-phenyl)-5-(2-morpholin-4-yl-pyrimidin-4-yl)-1 H-imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid allylamide, trans-isomer, (Compound A1756); 2-{4-(4-fluoro-phenyl)-5-[2-(3-methoxy-propylamino)-pyrimidi n-4-yl]-1H-imidazol-2-yl}-5- methyl-[1,3]dioxane-5-carboxylic acid allylamide, trans-isomer, (Compound A1757); <BR> <BR> <BR> 2-{4-(4-fluoro-phenyl)-5-[2-(2-methoxy-ethylamino)-pyrimidin -4-yl]-lH-imidazol-2-yl}-5-methyl- [1,3]dioxane-5-carboxylic acid allylamide, trans-isomer, (Compound A1758); 2-[5-[2-(3-dimethylamino-propylamino)-pyrimidin-4-yl]-4-(4-f luoro-phenyl)-1H-imidazol-2-yl]- 5-methyl-[1,3]dioxane-5-carboxylic acid allylamide, trans-isomer, (Compound A1759); 2- [5-[2-(2-dimethylamino-ethylamino)-pyrimidin-4-yl]-4-(4-fluo ro-phenyl)- lH-imidazol-2-yl]-5- methyl-[1,3]dioxane-5-carboxylic acid allylamide, trans-isomer, (Compound A1760); (4-[2-(5-allylcarbamoyl-5-methyl-[1,3]dioxan-2-yl)-5-(4-fluo ro-phenyl)-311-imidazol-4-yl]- pyrimidin-2-ylamino)-acetic acid, trans-isomer, (Compound A1761); 3-{4-[2-(5-allylcarbamoyl-5-methyl-[1,3]dioxan-2-yl)-5-(4-fl uoro-phenyl)-3H-imidazol-4-yl]- pyrimidin-2-ylamino}-propionic acid, trans-isomer, (Compound A1762); 2-[4-(4-fluoro-phenyl)-5-(2-(isopropylamino-pyrimidin-4-yl)- 1H-imdiazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid allylamide, trans-isomer, (Compound A1763); 2-[5-(2-allylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)- lH-imidazol-2-yl]-5-methyl-[1,3]dioxane- 5-carboxylic acid allylamide, trans-isomer, (Compound A1764); 2-[5-[2-(cyclopropylmethyl-amino)-pyrimidin-4-yl]-4-(4-fluor o-phenyl)-1H-imidazol-2-yl]-5- methyl-[1,3]dioxane-5-carboxylic acid allylamide, trans-isomer, (Compound A1765);

2-[5-[2-(cyanomethyl-amino)-pyrimidin-4-yl]-4-(4-fluoro-phen yl)-lH-imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid allylamide, trans-isomer, (Compound A1766); 2-[5-[2-(2-cyano-ethylamino)-pyrimidin-4-yl]-4-(4-fluoro-pen yl)-1H-imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid allylamide, trans-isomer, (Compound A1767); 2-(4-(4-fluoro-phenyl)-5-F2-(pyridin-3-ylamino)-pyrimidin-4- ylj-1Himidazol2yl)5methyl [1,3]dioxane-5-carboxylic acid allylamide, trans-isomer, (Compound A1768); 2-{4-(4-fluoro-phenyl)-5-[2-(pyridin-4-ylamino)~pyrimidin-4- yl]-1H-imidazol-2-yl}-5-methyl- [1,3]dioxane-5-carboxylic acid allylamide, trans-isomer, (Compound A1769); 2-[4-(4-fluoro-phenyl)-5-(2-propylamino-pyrimidin-4-yl)-1H-i midazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid allylamide, trans-isomer, (Compound A1770); 2-[4-(4-fluoro-phenyl)-5-(2-pyrrolidin-yl-pyrimidin-4-yl)-1H -imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid allylamide, trans-isomer, (Compound A1771); <BR> <BR> <BR> 2-{4-(4-fluoro-phenyl)-5-[2-(4-fluoro-phenylamino)-pyrimidin -4-yl]- 1H-i mid azol -2-yl)-5-methyl - [1,3]dioxane-5-carboxylic acid allylamide, trans-isomer, (Compound A1772); 2-[5-[2-(3,4-difluoro-phenylamino)-pyrimidin-4-yl]-4-(4-fluo ro-phenyl)-1H-imidazol-2-yl]-5- methyl-[1,3]dioxane-5-carboxylic acid allylamide, trans-isomer, (Compound A1773); 2-{4-(4-fluoro-phenyl)-5-[2-(3-methoxy-phenylamino)-pyrimidi n-4-yl]-1H-imidazol-2-yl}-5- methyl-[1,3]dioxane-5-carboxylic acid allylamide, trans-isomer, (Compound A1774); 2-[5-[2-(4-fluoro-benzylamino)-pyrimidin-4-yl]-4-(4-fluoro-p henyl)-1H-imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid allylamide, trans-isomer, (Compound A1775); 2-{4-(4-fluoro-phenyl)-5-[2-(4-methoxy-benzylamino)-pyrimidi n-4-yl]- 111-imidazol-2-yl)-5- methyl-[1,3]dioxane-5-carboxylic acid allylamide, trans-isomer, (Compound A1776); 2-[4-(4-fluoro-phenyl)-5-(2-methoxy-pyrimidin-4-yl)-1H-imida zol-2-yl]-5-methyl-[1,3]dioxane-5- carboxylic acid allylamide, trans-isomer, (Compound A1777); 2-[5-(2-benzyloxy-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imi dazol-2-yl]-5-methyl-[1,3]dioxane- 5-carboxylic acid allylamide, trans-isomer, (Compound A1778); 2-[4-(4-fluoro-phenyl)-5-(2-phenoxy-pyrimidin-4-yl)-1H-imida zol-2-yl]-5-methyl-[1,3]dioxane-5- carboxylic acid allylamide, trans-isomer, (Compound A1779); 2-{4-(4-fluoro-phenyl)-5-[2-(2-methoxy-ethoxy)-pyrimidin-4-y l]-1H-imidazol-2-yl}-5-methyl- [1,3]dioxane-5-carboxylic acid allylamide, trans-isomer, (Compound A1780); 2-[5-[2-(2-dimethylamino-ethoxy)-pyrimidin-4-yl]-4-(4-fluoro -phenyl)-1H-imidazol-2-yl]-5- methyl-[1,3]dioxane-5-carboxylic acid allylamide, trans-isomer, (Compound A1781); 2-[5-(2-cyclohexyloxy-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H -imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid allylamide, trans-isomer, (Compound A1782); 2-[5-(2-Isopropoxy-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-im idazol-2-yl]-5-methyl-[1,3]dioxane- 5-carboxylic acid allylamide, trans-isomer, (Compound A1783);

2-[4-(4-fluoro-phenyl)-5-(2-propoxy-pyrimidin-4-yl)- lH-imidazol-2-yl]-5-methyl-[1,3]dioxane-5- carboxylic acid allylamide, trans-isomer, (Compound A1784); 2-{4-(4-fluoro-phenyl)-5-[2-(2-hydroxy-ethoxy)-pyrimidin-4-y l]-lH-imidazol-2-yl}-5-methyl- [1,3]dioxane-5-carboxylic acid allylamide, trans-isomer, (Compound A1785); 2-{4-(4-fluoro-phenyl)-5-[2-(3-hydroxy-propoxy)-pyrimidin-4- yl]-lH-imidazol-2-yl}-5-methyl- [1,3]dioxane-5-carboxylic acid allylamide, trans-isomer, (Compound A1786); 2-[4-(4-fluoro-phenyl)-5-(2-methylsulfanyl-pyrimidin-4-yl)-l H-imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid allylamide, trans-isomer, (Compound A1787); 2-[5-(2-amino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazo l-2-yl]}-5-methyl-[1,3]dioxane-5- carboxylic acid cyclopropylmethyl-amide, trans-isomer, (Compound A1788); 2-[4-(4-fluoro-phenyl)-5-(2-methylamino-pyrimidin-4-yl)-1H-i midazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid cyclopropylmethyl-amide, trans-isomer, (Compound A1789); 2-[5-(2-dimethylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H -imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid cyclopropylmethyl-amide, trans-isomer, (Compound A1790); 2-[5-(2-cyclopropylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl) -1H-imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid cyclopropylmethyl-amide, trans-isomer, (Compound A1791); 2-{4-(4-fluoro-phenyl)-5-[2-(piperidin-4-ylamino)-pyrimidin- 4-yl]-1H-imidazol-2-yl}-5-methyl- [1,3]dioxane-5-carboxylic acid cyclopropylmethyl-amide, trans-isomer, (Compound A1792); 2-[5-(2-cyclohexylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)- 1H-imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid cyclopropylmethyl-amide, trans-isomer, (Compound A1793); 2-{4-(4-fluoro-phenyl)-5-[2-(2-hydroxy-ethylamino)-pyrimidin -4-yl]-1H-imidazol-2-yl}-5-methyl- [1,3]dioxane-5-carboxylic acid cyclopropylmethyl-amide, trans-isomer, (Compound A1794); 2-[5-[2-(2-amino-ethylamino)-pyrimidin-4-yl]-4-(4-fluoro-phe nyl)-1H-imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid cyclopropylmethyl-amide, trans-isomer, (Compound A1795); 2-(4-(4-fluoro-phenyl)-5-{2-[3-(5H-imidazol-1-yl)-propylamin o]-pyrimidin-4-yl}-1H-imidazol-2- yl)-5-methyl-[1,3]dioxane-5-carboxylic acid cyclopropylmethyl-amide, trans-isomer, (Compound A1796); 2-{4-(4-fluoro-phenyl)-5-[2-(3-morpholin-4-yl-propylamino)-p yrimidin-4-yl]-1H-imidazol-2-yl}- 5-methyl-[1,3]dioxane-5-carboxylic acid cyclopropylmethyl-amide, trans-isomer, (Compound A1797); 2-{4-(4-fluoro-phenyl)-5-[2-(3-hydroxy-propylamino)-pyrimidi n-4-yl]-1H-imidazol-2-yl}-5- methyl-[1,3]dioxane-5-carboxylic acid cyclopropylmethyl-amide, trans-isomer, (Compound A1798); 2-[5-(2-benzylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-i midazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid cyclopropylmethyl-amide, trans-isomer, (Compound A1799);

2-(4-(4-fluoro-phenyl)-5- [2-(l-phenyl-ethylamino)-pyrimidin-4-yl] H-imidazol-2-yl)-5-methyl- [1,3]dioxane-5-carboxylic acid cyclopropylmethyl-amide, R-isomer, trans-isomer, (Compound A1800); <BR> <BR> <BR> <BR> 2-{4-(4-fluoro-phenyl)-5-[2-(1-phenyl-ethylamino)-pyrimidin- 4-yl]-lH-imidazol-2-yl}-5-methyl- [1,3]dioxane-5-carboxylic acid cyclopropylmethyl-amide, S-isomer, trans-isomer, (Compound A1801); 2-[4-(4-fluoro-phenyl)-5-(2-phenylamino-pyrimidin-4-yl)-1H-i midazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid cyclopropylmethyl-amide, trans-isomer, (Compound A1802); 2-[4-(4-fluoro-phenyl)-5-(2-piperidin-1-yl-pyrimidin-4-yl)-1 H-imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid cyclopropylmethyl-amide, trans-isomer, (Compound A1803); 2-(4-(4-fluoro-phenyl)-5-{2-[(pyridin-4-ylmethyl)-amino]-pyr imidin-4-yl}-1H-imidazol-2-yl)-5- methyl-[1,3]dioxane-5-carboxylic acid cyclopropylmethyl-amide, trans-isomer, (Compound A1804); <BR> <BR> <BR> <BR> 2-(4-84-fluoro-phenyl)-5-{2- [(py ridin- 3-ylme thyl)-amino]- pyrimidin-4-yl)- lH-imidazol-2-yl)-5- methyl-[1,3]dioxane-5-carboxylic acid cyclopropylmethyl-amide, trans-isomer, (Compound A1805); 2-(4-(4-fluoro-phenyl)-5-{2-[(pyridin-2-ylmethyl)-amino]-pyr imidin-4-yl}-1H-imidazol-2-yl)-5- methyl-[1,3]dioxane-5-carboxylic acid cyclopropylmethyl-amide, trans-isomer, (Compound A1806); 2-(4-(4-fluoro-phenyl)-5-(2-[(furan-2-ylmethyl)-amino]-pyrim idin-4-yl )- lH-imidazol-2-yl)-5- methyl-[1,3]dioxane-5-carboxylic acid cyclopropylmethyl-amide, trans-isomer, (Compound A1807); 2-(4-(4-fluoro-phenyl)-5-{2-[(thiophen-2-ylmethyl)-amino]-py rimidin-4-yl )-111-imidazol-2-yl)-5- methyl-[1,3]dioxane-5-carboxylic acid cyclopropylmethyl-amide, trans-isomer, (Compound A1808); <BR> <BR> <BR> <BR> 2-(4-(4-fluoro-phenyl)-5-{2-[(tetrahydro-furan-2-ylmethyl)-a mino]-pyrimidin-4-yl}-lH-imidazol- 2-yl)-5-methyl-[1,3]dioxane-5-carboxylic acid cyclopropylmethyl-amide, trans-isomer, (Compound A1809); 2-{4-(4-fluoro-phenyl)-5-[2-(4-methyl-piperazin-1-yl)-pyrimi din-4-yl]-1H-imidazol-2-yl}-5- methyl-[1,3]dioxane-5-carboxylic acid cyclopropylmethyl-amide, trans-isomer, (Compound A1810); 2-[4-(4-fluoro-phenyl)-5-(2-morpholin-4-yl-pyrimidin-4-yl)-1 H-imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid cyclopropylmethyl-amide, trans-isomer, (Compound A1811); 2-{4-(4-fluoro-phenyl)-5-[2-(3-methoxy-propylamino)-pyrimidi n-4-yl]-1H-imidazol-2-yl}-5- methyl-[1,3]dioxane-5-carboxylic acid cyclopropylmethyl-amide, trans-isomer, (Compound A1812);

2-{4-(4-fluoro-phenyl)-5-[2-(2-methoxy-ethylamino)-pyrimidin -4-yl]-1H-imidazol-2-yl}-5-methyl- [1,3]dioxane-5-carboxylic acid cyclopropylmethyl-amide, trans-isomer, (Compound A1813); 2-[5-[2-(3-dimethylamino-propylamino)-pyrimidin-4-yl]-4-(4-f luoro-phenyl)-1H-imidazol-2-yl]- 5-methyl-[1,3]dioxane-5-carboxylic acid cyclopropylmethyl-amide, trans-isomer, (Compound A1814); 2-[5-[2-(2-dimethylamino-propylamino)-pyrimidin-4-yl]-4-(4-f luoro-phenyl)-1H-imidazol-2-yl]-5- methyl-[1,3]dioxane-5-carboxylic acid cyclopropylmethyl-amide, trans-isomer, (Compound A1815); {4-[2-[5-(cyclopropylmethyl-carbamoyl)-5-methyl-[1,3]dioxan- 2-yl]-5-(4-fluoro-phenyl)-3H- imidazol-4-yl]-pyrimidin-2-ylamino}-acetic acid, trans-isomer, (Compound A1816); 3-{4-[2-[5-(cyclopropylmethyl-carbamoyl)-5-methyl-[1,3]dioxa n-2-yl]-5-(4-fluoro-phenyl)-3H- imidazol-4-yl]-pyrimidin-2-ylamino}-propionic acid, trans-isomer, (Compound A1817); 2-[4-(4-fluoro-phenyl)-5-(2-isopropylamino-pyrimidin-4-yl)- lH-imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid cyclopropylmethyl-amide, trans-isomer, (Compound A1818); 2-[5-(2-allylamino-pyrimidin-4-yl]-4-(4-fluoro-phenyl)-1H-im idazol-2-yl]-5-methyl-[1,3]dioxane- 5-carboxylic acid cyclopropylmethyl-amide, trans-isomer, (Compound A1819); 2-[5-[2-(cyclopropylmethyl-amino)-pyrimidin-4-yl]-4-(4-fluor o-phenyl)-1H-imidazol-2-yl]-5- methyl-[1,3]dioxane-5-carboxylic acid cyclopropylmethyl-amide, trans-isomer, (Compound A1820); 2-[5-[2-(cyanomethyl-amino)-pyrimidin-4-yl]-4-(4-fluoro-phen yl)- 111-imidazol-2-ylj-5-methyl- [1,3]dioxane-5-carboxylic acid cyclopropylmethyl-amide, trans-isomer, (Compound A1821); 2-[5-[2-(2-cyano-ethylamino)-pyrimidin-4-yl]-4-(4-fluoro-phe nyl)-1H-imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid cyclopropylmethyl-amide, trans-isomer, (Compound A1822); 2-{4-(4-fluoro-phenyl)-5-[2-(pyridin-3-ylamino)-pyrimidin-4- yl]-1H-imidazol-2-yl}-5-methyl- [1,3]dioxane-5-carboxylic acid cyclopropylmethyl-amide, trans-isomer, (Compound A1823); 2-(4-(4-fluoro-phenyl) -5-[2-(pyridin-4-ylamino)-pyrimidin-4-yl la-imidazol-2yl )-5-methyl- [1,3]dioxane-5-carboxylic acid cyclopropylmethyl-amide, trans-isomer, (Compound A1824); 2-[4-(4-fluoro-phenyl)-5-(2-propylamino-pyrimidin-4-yl)-1H-i midazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid cyclopropylmethyl-amide, trans-isomer, (Compound A1825); 2-[4-(4-fluoro-phenyl)-5-(2-pyrrolidin-1-yl-pyrimidin-4-yl)- 1H-imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid cyclopropylmethyl-amide, trans-isomer, (Compound A1826); <BR> <BR> <BR> 2-{4-(4-fluoro-phenyl)-5-[2-(4-fluoro-phenylamino)-pyrimidin -4-yl]-lH-imidazol-2-yl}-5-methyl- [1,3]dioxane-5-carboxylic acid cyclopropylmethyl-amide, trans-isomer, (Compound A1827); 2-[5-[2-(3,4-difluoro-phenylamino)-pyrimidin-4-yl]-4-(4-fluo ro-phenyl)-1H-imidazol-2-yl]-5- methyl-[1,3]dioxane-5-carboxylic acid cyclopropylmethyl-amide, trans-isomer, (Compound A1828);

2-{4-(4-fluoro-phenyl)-5-[2-(3-methoxy-phenylamino)-pyrimidi n-4-yli-111-imidazol-2-yl}-5 methyl-[1,3]dioxane-5-carboxylic acid cyclopropylmethyl-amide, trans-isomer, (Compound A1829); <BR> <BR> <BR> 2-[5-[2-(4-fluoro-benzylamino)-pyrimidin-4-yl]-4-(4-fluoro-p henyl)- lH-imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid cyclopropylmethyl-amide, trans-isomer, (Compound A1830); 2-(4-(4-fluoro-phenyl)-5-[2-(4-methoxy-benzylamino)-pyrimidi n-4-yl]-111.imidazol-2-yl}-5- methyl-[1,3]dioxane-5-carboxylic acid cyclopropylmethyl-amide, trans-isomer, (Compound A1831); <BR> <BR> <BR> <BR> 2-[4-(4-fluoro-phenyl)-5-(2-methoxy-pyrimidin-4-yl)- 1H-imidazol-2-yl]-5-methyl- [1,3]dioxane-5- carboxylic acid cyclopropylmethyl-amide, trans-isomer, (Compound A1832); <BR> <BR> <BR> <BR> 2-[5-(2-benzyloxy-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-lH-imi dazol-2-yl]-5-methyl-[1,3]dioxane- 5-carboxylic acid cyclopropylmethyl-amide, trans-isomer, (Compound A1833); <BR> <BR> <BR> <BR> 2-[4-(4-fluoro-phenyl)-5-(2-phenoxy-pyrimidin-4-yl)- lH-imidazol-2-yl]-5-methyl-[1,3]dioxane-5- carboxylic acid cyclopropylmethyl-amide, trans-isomer, (Compound A1834); 2-{4-(4-fluoro-phenyl)-5-[2-(2-methoxy-ethoxy)-pyrimidin-4-y l]-lH-imidazol-2-yl}-5-methyl- [1,3]dioxane-5-carboxylic acid cyclopropylmethyl-amide, trans-isomer, (Compound A1835); 2-[5-[2-(2-dimethylamino-ethoxy)-pyrimidin-4-ylj-4-(4-fluoro -phenyl)-111-imidazol-2-yl]-5- methyl-[1,3]dioxane-5-carboxylic acid cyclopropylmethyl-amide, trans-isomer, (Compound A1836); 2-[5-(2-cyclohexyloxy-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H -imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid cyclopropylmethyl-amide, trans-isomer, (Compound A1837); 2-[5-(2-Isopropoxy-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-im idazol-2-yl]-5-methyl-[1,3]dioxane- 5-carboxylic acid cyclopropylmethyl-amide, trans-isomer, (Compound A1838); <BR> <BR> <BR> 2-[4-(4-fluoro-phenyl)-5-(2-propoxy-pyrimidin-4-yl)-lH-imida zol-2-yl]-5-methyl-[1,3]dioxane-5- carboxylic acid cyclopropylmethyl-amide, trans-isomer, (Compound A1839); 2-{4-(4-fluoro-phenyl)-5-[2-(2-hydroxy-ethoxy)-pyrimidin-4-y l]-1H-imidazol-2-yl}-5-methyl- [1,3]dioxane-5-carboxylic acid cyclopropylmethyl-amide, trans-isomer, (Compound A1840); 2-{4-(4-fluoro-phenyl)-5-[2-(3-hydroxy-propoxy)-pyrimidin-4- yl]-1H-imidazol-2-yl}-5-methyl- [1,3]dioxane-5-carboxylic acid cyclopropylmethyl-amide, trans-isomer, (Compound A1841); 2-[4-(4-fluoro-phenyl)-5-(2-methylsulfanyl-pyrimidin-4-yl)-1 H-imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid cyclopropylmethyl-amide, trans-isomer, (Compound A1842); <BR> <BR> <BR> <BR> 2-[5-(2-amino-pyrimidin-4-yl)-4-(4-fiuoro-phenyl).1H-imidazo l-2-yl]-5-methyl-[1,3]dioxane-5- carboxylic acid cyanomethyl-amide, trans-isomer, (Compound A1843); 2-[4-(4-fluoro-phenyl)-5-(2-methylamino-pyrimidin-4-yl)-lH-i midazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid cyanomethyl-amide, trans-isomer, (Compound A1844);

2-[5-(2-dimethylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H -imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid cyanomethyl-amide, trans-isomer, (Compound A1845); 2-[5-(2-cyclopropylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl) -1H-imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid cyanomethyl-amide, trans-isomer, (Compound A1846); 2-{4-(4-fluoro-phenyl)-5-[2-(piperidin-4-ylamino)-pyrimidin- 4-yl]-1H-imidazol-2-yl}-5-methyl- [1,3]dioxane-5-carboxylic acid cyanomethyl-amide, trans-isomer, (Compound A1847); 2-[5-(2-cyclohexylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)- 1H-imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid cyanomethyl-amide, trans-isomer, (Compound A1848); 2-{4-(4-fluoro-phenyl)-5-[2-(2-hydroxy-ethylamino)-pyrimidin -4-yl]-1H-imidazol-2-yl}-5-methyl- [1,3]dioxane-5-carboxylic acid cyanomethyl-amide, trans-isomer, (Compound A1849); 2-[5-[2-(2-amino-ethylamino)-pyrimidin-4-yl]-4-(4-fluoro-phe nyl)-1H-imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid cyanomethyl-amide, trans-isomer, (Compound A1850); <BR> <BR> <BR> 2-(4-(4-fluoro-phenyl)-5-{2-[3-(5H-imidazol-1-yl)-propylamin o]-pyrimidin-4-yl}-lH-imidazol-2- yl)-5-methyl-[1,3]dioxane-5-carboxylic acid cyanomethyl-amide, trans-isomer, (Compound A1851); 2-{4-(4-fluoro-phenyl)-5-[2-(3-morpholin-4-yl-propylamino)-p yrimidin-4-yl]-1H-imidazol-2-yl}- 5-methyl-[1,3]dioxane-5-carboxylic acid cyanomethyl-amide, trans-isomer, (Compound A1852); 2-{4-(4-fluoro-phenyl)-5-[2-(3-hydroxy-propylamino)-pyrimidi n-4-yl]-1H-imidazol-2-yl}-5- methyl-[1,3]dioxane-5-carboxylic acid cyanomethyl-amide, trans-isomer, (Compound A1853); 2-[5-(2-benzylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-i midazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid cyanomethyl-amide, trans-isomer, (Compound A1854); 2-{4-(4-fluoro-phenyl)-5-[2-(1-phenyl-ethylamino)-pyrimidin- 4-yl]-1H-imidazol-2-yl}-5-methyl- [1,3]dioxane-5-carboxylic acid cyanomethyl-amide, R-isomer, trans-isomer, (Compound A1855); <BR> <BR> <BR> 2-{4-(4-fluoro-phenyl)-5-[2-(1-phenyl-ethylamino)-pyrimidin- 4-yl]-lH-imidazol-2-yl}-5-methyl- [1,3]dioxane-5-carboxylic acid cyanomethyl-amide, S-isomer, trans-isomer, (Compound A1856); 2-[4-(4-fluoro-phenyl)-5-(2-phenylamino-pyrimidin-4-yl)-1H-i midazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid cyanomethyl-amide, trans-isomer, (Compound A1857); 2-[4-(4-fluoro-phenyl)-5-(2-piperidin-1-yl-pyrimidin-4-yl)-1 H-imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid cyanomethyl-amide, trans-isomer, (Compound A1858); 2-(4-(4-fluoro-phenyl)-5-{2-[(pyridin-4-ylmethyl)-amino]-pyr imidin-4-yl}-1H-imidazol-2-yl)-5- methyl-[1,3]dioxane-5-carboxylic acid cyanomethyl-amide, trans-isomer, (Compound A1859); 2-(4-(4-fluoro-phenyl)-5-{2-[(pyridin-3-ylmethyl)-amino]-pyr imidin-4-yl )-111-imidazol-2-yl)-5- methyl-[1,3]dioxane-5-carboxylic acid cyanomethyl-amide, trans-isomer, (Compound A1860); 2-(4-(4-fluoro-phenyl)-5-{2-[(pyridin-2-ylmethyl)-amino]-pyr imidin-4-yl}-1H-imidazol-2-yl)-5- methyl-[1,3]dioxane-5-carboxylic acid cyanomethyl-amide, trans-isomer, (Compound A1861);

2-(4-(4-fluoro-phenyl)-5-{2-[(furan-2-ylmethyl)-amino]-pyrim idin-4-yl}-1H-imidazol-2-yl)-5- methyl-[1,3]dioxane-5-carboxylic acid cyanomethyl-amide, trans-isomer, (Compound A1862); <BR> <BR> <BR> 2-(4-(4-fluoro-phenyl)-5-{2-[(thiophen-2-ylmethyl)-amino]-py rimidin-4-yl}-lH-imidazol-2-yl)-5- methyl-[1,3]dioxane-5-carboxylic acid cyanomethyl-amide, trans-isomer, (Compound A1863); 2-(4-(4-fluoro-phenyl)-5-{2-[(tetrahydro-furan-2-ylmethyl)-a mino]-pyrimidin-4-yl}-1H-imidazol- 2-yl)-5-methyl-[1,3]dioxane-5-carboxylic acid cyanomethyl-amide, trans-isomer, (Compound A1864); 2-{4-(4-fluoro-phenyl)-5-[2-(4-methyl-piperazin- l-yl)-py rimidin4-yl]-l H-imidazol -2-yl)-5- methyl-[1,3]dioxane-5-carboxylic acid cyanomethyl-amide, trans-isomer, (Compound A1865); 2-[4-(4-fluoro-phenyl)-5-(2-morpholin-4-yl-pyrimidin-4-yl)-1 H-imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid cyanomethyl-amide, trans-isomer, (Compound A1866); 2-{4-(4-fluoro-phenyl)-5-[2-(3-methoxy-propylamino)-pyrimidi n-4-yl]-1H-imidazol-2-yl}-5- methyl-[1,3]dioxane-5-carboxylic acid cyanomethyl-amide, trans-isomer, (Compound A1867); 2-{4-(4-fluoro-phenyl)-5-[2-(2-methoxy-ethylamino)-pyrimidin -4-yl]-1H-imidazol-2-yl}-5-methyl- [1,3jdioxane-5-carboxylic acid cyanomethyl-amide, trans-isomer, (Compound A1868); 2-[5-[2-(3-dimethylamino-propylamino)-pyrimidin-4-yl]-4-(4-f luoro-phenyl)-1H-imidazol-2-yl]- 5-methyl-[1,3]dioxane-5-carboxylic acid cyanomethyl-amide, trans-isomer, (Compound A1869); 2-[5-[2-(2-dimethylamino-ethylamino)-pyrimidin-4-yl]-4-(4-fl uoro-phenyl)-1H-imidazol-2-yl]-5- methyl-[1,3]dioxane-5-carboxylic acid cyanomethyl-amide, trans-isomer, (Compound A1870); {4-[2-[5-(cyanomethyl-carbamoyl)-5-methyl-[1,3]dioxan-2-yl]- 5-(4-fluoro-phenyl)-3H-imidazol-4- yl]-pyrimidin-2-ylamino}-acetic acid, trans-isomer, (Compound A1871); 3-{4-[2-[5-(cyanomethyl-carbamoyl)-5-methyl-[1,3]dioxan-2-yl ]-5-(4-fluoro-phenyl)-3H-imidazol- 4-yl]-pyrimidin-2-ylamino}-propionic acid, trans-isomer, (Compound A1872); 2-[4-(4-fluoro-phenyl)-5-(2-isopropylamino-pyrimidin-4-yl)-1 H-imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid cyanomethyl-amide, trans-isomer, (Compound A1873); 2-[5-(2-allylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-im idazol-2-yl]-5-methyl-[1,3]dioxane- 5-carboxylic acid cyanomethyl-amide, trans-isomer, (Compound A1874); 2-[5-[2-(cyclopropylmethyl-amino)-pyrimidin-4-yl]-4-(4-fluor o-phenyl)-1H-imidazol-2-yl]-5- methyl-[1,3]dioxane-5-carboxylic acid cyanomethyl-amide, trans-isomer, (Compound A1875); 2-[5-[2-(cyanomethyl-amino)-pyrimidin-4-yl]-4-(4-fluoro-phen yl)-1H-imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid cyanomethyl-amide, trans-isomer, (Compound A1876); 2-[5-[2-(2-cyano-ethylamino)-pyrimidin-4-yl]-4-(4-fluoro-phe nyl)-1H-imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid cyanomethyl-amide, trans-isomer, (Compound A1877); 2-{4-(4-fluoro-phenyl)-5-[2-(pyridin-3-ylamino)-pyrimidin-4- yl]-1H-imidazol-2-yl}-5-methyl- [1,3]dioxane-5-carboxylic acid cyanomethyl-amide, trans-isomer, (Compound A1878);

2-{4-(4-fluoro-phenyl)-5-[2-(pyridin-4-ylamino)-pyrimidin-4- yl]- lH-imidazol-2-yl}-5-methyl- [1,3]dioxane-5-carboxylic acid cyanomethyl-amide, trans-isomer, (Compound A1879); 2-[4-(4-fluoro-phenyl)-5-(2-propylamino-pyrimidin-4-yl)-111- imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid cyanomethyl-amide, trans-isomer, (Compound A1880); 2-[4-(4-fluoro-phenyl)-5-(2-pyrrolidin-1-yl-pyrimidin-4-yl)- 1H-imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid cyanomethyl-amide, trans-isomer, (Compound A1881); <BR> <BR> <BR> <BR> 2-{4-(4-fluoro-phenyl)-5-[2-(4-fluoro-phenylamino)-pyrimidin -4-yl]-111-imidazol-2-yl}-5-methyl- [1,3]dioxane-5-carboxylic acid cyanomethyl-amide, trans-isomer, (Compound A1882); 2-[5-[2-(3,4-difluoro-phenylamino)-pyrimidin-4-yl]-4-(4-fluo ro-phenyl)-111-irnidazol-2-yl]-5- methyl-[1,3]dioxane-5-carboxylic acid cyanomethyl-amide, trans-isomer, (Compound A1883); 2-(4-(4-fluoro-phenyl)-5-[2-(3-methoxy-phenylamino)-pyrimidi n-4-yl]-111-imidazol-2-yl}-5- methyl-[1,3]dioxane-5-carboxylic acid cyanomethyl-amide, trans-isomer, (Compound A1884); <BR> <BR> <BR> <BR> 2-[5-[2-(4-fluoro-benzylamino)-pyrimidin-4-yl]-4-(4-fluoro-p henyl)- lH-imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid cyanomethyl-amide, trans-isomer, (Compound A1885); 2-{4-(4-fluoro-phenyl)-5-[2-(4-methoxy-benzylamino)-pyrimidi n-4-yl]-111-imidazol-2-yl}-5- methyl-[1,3]dioxane-5-carboxylic acid cyanomethyl-amide, trans-isomer, (Compound A1886); <BR> <BR> <BR> <BR> 2-[4-(4-fluoro-phenyl)-5-(2-methoxy-pyrimidin-4-yl)- lH-imidazol-2-yl]-5-methyl-[1,3]dioxane-5- carboxylic acid cyanomethyl-amide, trans-isomer, (Compound A1887); <BR> <BR> <BR> <BR> 2-[5-(2-benzyloxy-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-lH-imi dazol-2-yl]-5-methyl-[1,3]dioxane- 5-carboxylic acid cyanomethyl-amide, trans-isomer, (Compound A1888); <BR> <BR> <BR> <BR> 2-[4-(4-fluoro-phenyl)-5-(2-phenoxy-pyrimidin-4-yl)-lH-imida zol-2-yl]-5-methyl-[1,3]dioxane-5- carboxylic acid cyanomethyl-amide, trans-isomer, (Compound A1889); 2-{4-(4-fluoro-phenyl)-5-[2-(2-methoxy-ethoxy)-pyrimidin-4-y l]-1H-imidazol-2-yl}-5-methyl- [1,3]dioxane-5-carboxylic acid cyanomethyl-amide, trans-isomer, (Compound A1890); 2-[5-[2-(2-dimethylamino-ethoxy)-pyrimidin-4-yl]-4-(4-fluoro -phenyl)-1H-imidazol-2-yl]-5- methyl-[1,3]dioxane-5-carboxylic acid cyanomethyl-amide, trans-isomer, (Compound A1891); 2-[5-(2-cyclohexyloxy-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H -imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid cyanomethyl-amide, trans-isomer, (Compound A1892); <BR> <BR> <BR> <BR> 2-[5-(2-Isopropoxy-pyrimidin-4-yl)-4-(4-fluoro-phenyl)- lH-imidazol-2-yl] -5-methyl-[1,3]dioxane- 5-carboxylic acid cyanomethyl-amide, trans-isomer, (Compound A1893); 2-[4-(4-fluoro-phenyl)-5-(2-propoxy-pyrimidin-4-yl)-1H-imida zol-2-yl]-5-methyl-[1,3]dioxane-5- carboxylic acid cyanomethyl-amide, trans-isomer, (Compound A1894); 2-{4-(4-fluoro-phenyl)-5- [2-(2-hydroxy-ethoxy)-pyrimidin-4-yl]- lH-imidazol-2-yl )-5-methyl- [1,3]dioxane-5-carboxylic acid cyanomethyl-amide, trans-isomer, (Compound A1895); 2-{4-(4-fluoro-phenyl)-5-[2-(3-hydroxy-propoxy)-pyrimidin-4- yl]-1H-imidazol-2-yl}-5-methyl- [1,3]dioxane-5-carboxylic acid cyanomethyl-amide, trans-isomer, (Compound A1896);

2-[4-(4-fluoro-phenyl)-5-(2-methylsulfanyl-pyrimidin-4-yl)-1 H-imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid cyanomethyl-amide, trans-isomer, (Compound A1897); 2-[5-(2-amino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazo l-2-yl]-5-methyl-[1,3]dioxane-5 carboxylic acid (2-cyano-ethyl)-amide, trans-isomer, (Compound A1898); 2-[4-(4-fluoro-phenyl)-5-(2-methylamino-pyrimidin-4-yl)-1H-i midazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid (2-cyano-ethyl)-amide, trans-isomer, (Compound A1899); 2-[5-(2-dimethylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H -imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid (2-cyano-ethyl)-amide, trans-isomer, (Compound A1900); 2-[5-(2-cyclopropylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl) -1H-imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid (2-cyano-ethyl)-amide, trans-isomer, (Compound A1901); <BR> <BR> <BR> <BR> 2-(4-(4-fluoro-phenyl)-5- [2-(piperidin-4-ylamino)-pyrimidin-4-yl] ZH-imidazol-2-yl)-5-methyl- [1,3]dioxane-5-carboxylic acid (2-cyano-ethyl)-amide, trans-isomer, (Compound A1902); 2-[5-(2-cyclohexylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)- 1H-imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid (2-cyano-ethyl)-amide, trans-isomer, (Compound A1903); <BR> <BR> <BR> 2-{4-(4-fluoro-phenyl)-5-[2-(2-hydroxy-ethylamino)-pyrimidin -4-yl]-lH-imidazol-2-yl}-5-methyl- [1,3]dioxane-5-carboxylic acid (2-cyano-ethyl)-amide, trans-isomer, (Compound A1904); 2-[5-[2-(2-amino-ethylamino)-pyrimidin-4-yl]-4-(4-fluoro-phe nyl)-1H-imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid (2-cyano-ethyl)-amide, trans-isomer, (Compound A1905); 2-(4-(4-fluoro-phenyl)-5-{2-[3-(5H-imidazol-1-yl)-propylamin o]-pyrimidin-4-yl}-1H-imidazol-2- yl)-5-methyl-[1,3]dioxane-5-carboxylic acid (2-cyano-ethyl)-amide, trans-isomer, (Compound A1906); <BR> <BR> <BR> <BR> 2-{4-(4-fluoro-phenyl)-5-[2-(3-morpholin-4-yl-propylamino)-p yrimidin-4-yl]-lH-imidazol-2-yl}- 5-methyl-[1,3]dioxane-5-carboxylic acid (2-cyano-ethyl)-amide, trans-isomer, (Compound A1907); 2-{4-(4-fluoro-phenyl)-5-[2-(3-hydroxy-propylamino)-pyrimidi n-4-yl]-1H-imidazol-2-yl}-5- methyl-[1,3]dioxane-5-carboxylic acid (2-cyano-ethyl)-amide, trans-isomer, (Compound A1908); 2-[5-(2-benzylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-i midazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid (2-cyano-ethyl)-amide, trans-isomer, (Compound A1909); 2-{4-(4-fluoro-phenyl)-5-[2-(1-phenyl-ethylamino)-pyrimidin- 4-yl]-1H-imidazol-2-yl}-5-methyl- [1,3]dioxane-5-carboxylic acid (2-cyano-ethyl)-amide, R-isomer, trans-isomer, (Compound A1910); 2-{4-(4-fluoro-phenyl)-5-[2-(1-phenyl-ethylamino)-pyrimidin- 4-yl]-1H-imidazol-2-yl}-5-methyl- [1,3]dioxane-5-carboxylic acid (2-cyano-ethyl)-amide, S-isomer, trans-isomer, (Compound A1911); 2-[4-(4-fluoro-phenyl)-5-(2-phenylamino-pyrimidin-4-yl)-1H-i midazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid (2-cyano-ethyl)-amide, trans-isomer, (Compound A1912);

2-[4-(4-fluoro-phenyl)-5-(2-piperidin- 1-yl-pyrimidin-4-yl)- lH-imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid (2-cyano-ethyl)-amide, trans-isomer, (Compound A1913); 2-(4-(4-fluoro-phenyl)-5-{2-[(pyridin-4-ylmethyl)-amino]-pyr imidin-4-yl}-1H-imidazol-2-yl)-5- methyl-[1,3]dioxane-5-carboxylic acid (2-cyano-ethyl)-amide, trans-isomer, (Compound A1914); <BR> <BR> <BR> 2-(4-(4-fluoro-phenyl)-5-{2-[(pyridin-3-ylmethyl)-amino]-pyr imidin-4-yl}-lH-imidazol-2-yl)-5- methyl-[1,3]dioxane-5-carboxylic acid (2-cyano-ethyl)-amide, trans-isomer, (Compound A1915); 2-(4-(4-fluoro-phenyl)-5-{2-[(pyridin-2-ylmethyl)-amino]-pyr imidin-4-yl}-1H-imidazol-2-yl)-5- methyl-[1,3]dioxane-5-carboxylic acid (2-cyano-ethyl)-amide, trans-isomer, (Compound A1916); 2-(4-(4-fluoro-phenyl)-5-{2-[(furan-2-ylmethyl)-amino]-pyrim idin-4-yl}-1H-imidazol-2-yl)-5- methyl-[1,3]dioxane-5-carboxylic acid (2-cyano-ethyl)-amide, trans-isomer, (Compound A1917); 2-(4-(4-fluoro-phenyl)-5-{2-[(thiophen-2-ylmethyl)-amino]-py rimidin-4-yl}-1H-imidazol-2-yl)-5- methyl-[1,3]dioxane-5-carboxylic acid (2-cyano-ethyl)-amide, trans-isomer, (Compound A1918); <BR> <BR> <BR> 2-(4-(4-fluoro-phenyl)-5-{2-[(tetrahydro-furan-2-ylmethyl)-a mino]-pyrimidin-4-yl}-lH-imidazol- 2-yl)-5-methyl-[1,3]dioxane-5-carboxylic acid (2-cyano-ethyl)-amide, trans-isomer, (Compound A1919); 2-{4-(4-fluoro-phenyl)-5-[2-(4-methyl-piperazin-1-yl)-pyrimi din-4-yl]-1H-imidazol-2-yl}-5- methyl-[1,3]dioxane-5-carboxylic acid (2-cyano-ethyl)-amide, trans-isomer, (Compound A1920); 2-[4-(4-fluoro-phenyl)-5-(2-morpholin-4-yl-pyrimidin-4-yl)-1 H-imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid (2-cyano-ethyl)-amide, trans-isomer, (Compound A1921); 2-{4-(4-fluoro-phenyl)-5-[2-(3-methoxy-propylamino)-pyrimidi n-4-yl]-1H-imidazol-2-yl}-5- methyl-[1,3]dioxane-5-carboxylic acid (2-cyano-ethyl)-amide, trans-isomer, (Compound A1922); <BR> <BR> <BR> 2-{4-(4-fluoro-phenyl)-5-[2-(2-methoxy-ethylamino)-pyrimidin -4-yl]-lH-imidazol-2-yl}-5-methyl- [1,3]dioxane-5-carboxylic acid (2-cyano-ethyl)-amide, trans-isomer, (Compound A1923); 2-[5-[2-(3-dimethylamino-propylamino)-pyrimidin-4-yl]-4-(4-f luoro-phenyl)-1H-imidazol-2-yl]- 5-methyl-[1,3]dioxane-5-carboxylic acid (2-cyano-ethyl)-amide, trans-isomer, (Compound A1924); <BR> <BR> <BR> 2-[5-[2-(2-dimethylamino-ethylamino)-pyrimidin-4-yl]-4-(4-fl uoro-phenyl)- lH-imidazol-2-yl]-5- methyl-[1,3]dioxane-5-carboxylic acid (2-cyano-ethyl)-amide, trans-isomer, (Compound A1925); {4-[2-[5-(2-cyano-ethylcarbamoyl)-5-methyl-[1,3]dioxan-2-yl] -5-(4-fluoro-phenyl)-3H-imidazol-4- yl]-pyrimidin-2-ylamino}-acetic acid, trans-isomer, (Compound A1926); 3-{4-[2-[5-(2-cyano-ethylcarbamoyl)-5-methyl-[1,3]dioxan-2-y l]-5-(4-fluoro-phenyl)-3H-imidazol- 4-yl]-pyrimidin-2-ylamino}-propionic acid, trans-isomer, (Compound A1927); 2-[4-(4-fluoro-phenyl)-5-(2-isopropylamino-pyrimidin-4-yl)- 1H-imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid (2-cyano-ethyl)-amide, trans-isomer, (Compound A1928); 2-[5-(2-allylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-im idazol-2-yl]-5-methyl-[1,3]dioxane- 5-carboxylic acid (2-cyano-ethyl)-amide, trans-isomer, (Compound A1929);

2-[5-[2-(cyclopropylmethyl-amino)-pyrimidin-4-yl]-4-(4-fluor o-phenyl)- lH-imidazol-2-yl]-5- methyl-[1,3]dioxane-5-carboxylic acid (2-cyano-ethyl)-amide, trans-isomer, (Compound A1930); <BR> <BR> <BR> <BR> 2-[5-[2-(cyanomethyl-amino)-pyrimidin-4-yl]-4-(4-fluoro-phen yl)-111-imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid (2-cyano-ethyl)-amide, trans-isomer, (Compound A1931); <BR> <BR> <BR> <BR> 2-[5-[2-(2-cyano-ethylamino)-pyrimidin-4-yl]-4-(4-fluoro-phe nyl)-111-imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid (2-cyano-ethyl)-amide, trans-isomer, (Compound A1932); 2-(4-(4-fluoro-phenyl)-5-[2-(pyridin-3-ylamino)-pyrimidin-4- yl]-111-imidazol-2-yl)-5-methyl- [1,3]dioxane-5-carboxylic acid (2-cyano-ethyl)-amide, trans-isomer, (Compound A1933); 2-(4-(4-fluoro-phenyl)-5- [2-(pyridin-4-ylamino)-pyrimidin-4-yl]- 1H-imidazol-2-yl)-S-methyl- [1,3]dioxane-5-carboxylic acid (2-cyano-ethyl)-amide, trans-isomer, (Compound A1934); 2-[4-(4-fluoro-phenyl)-5-(2-propylamino-pyrimidin-4-yl)-lH-i midazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid (2-cyano-ethyl)-amide, trans-isomer, (Compound A1935); 2-[4-(4-fluoro-phenyl)-5-(2-pyrrolidin-1-yl-pyrimidin-4-yl)- lH-imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid (2-cyano-ethyl)-amide, trans-isomer, (Compound A1936); <BR> <BR> <BR> <BR> 2-(4-(4-fluoro-phenyl)-5-[2-(4-fluoro-phenylamino)-pyrimidin -4-yli-111-imidazol-2-yl)-5-methyl- [1,3]dioxane-5-carboxylic acid (2-cyano-ethyl)-amide, trans-isomer, (Compound A1937); 2-[5-[2-(3,4-difluoro-phenylamino)-pyrimidin-4-yl]-4-(4-fluo ro-phenyl)-111-imidazol-2-yl]-5- methyl-[1,3]dioxane-5-carboxylic acid (2-cyano-ethyl)-amide, trans-isomer, (Compound A1938); 2-{4-(4-fluoro-phenyl)-5-[2-(3-methoxy-phenylamino)-pyrimidi n-4-yl]-lH-imidazol-2-yl}-5- methyl-[1,3]dioxane-5-carboxylic acid (2-cyano-ethyl)-amide, trans-isomer, (Compound A1939); 2-[5-[2-(4-fluoro-benzylamino)-pyrimidin-4-yl]-4-(4-fluoro-p henyl)-1H-imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid (2-cyano-ethyl)-amide, trans-isomer, (Compound A1940); 2-{4-(4-fluoro-phenyl)-5-[2-(4-methoxy-benzylamino)-pyrimidi n-4-yl]-1H-imidazol-2-yl}-5- methyl-[1,3]dioxane-5-carboxylic acid (2-cyano-ethyl)-amide, trans-isomer, (Compound A1941); 2-[4-(4-fluoro-phenyl)-5-(2-methoxy-pyrimidin-4-yl)-1H-imida zol-2-yl]-5-methyl-[1,3]dioxane-5- carboxylic acid (2-cyano-ethyl)-amide, trans-isomer, (Compound A1942); 2-[5-(2-benzyloxy-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imi dazol-2-yl]-5-methyl-[1,3]dioxane- 5-carboxylic acid (2-cyano-ethyl)-amide, trans-isomer, (Compound A1943); 2-[4-(4-fluoro-phenyl)-5-(2-phenoxy-pyrimidin-4-yl)-1H-imida zol-2-yl]-5-methyl-[1,3]dioxane-5- carboxylic acid (2-cyano-ethyl)-amide, trans-isomer, (Compound A1944); 2-{4-(4-fluoro-phenyl)-5-[2-(2-methoxy-ethoxy)-pyrimidin-4-y l]-1H-imidazol-2-yl}-5-methyl- [1,3]dioxane-5-carboxylic acid (2-cyano-ethyl)-amide, trans-isomer, (Compound A1945); 2-[5-[2-(2-dimethylamino-ethoxy)-pyrimidin-4-yl]-4-(4-fluoro -phenyl)- 1H-imidazol-2-yl]-5- methyl-[1,3]dioxane-5-carboxylic acid (2-cyano-ethyl)-amide, trans-isomer, (Compound A1946); 2-[5-(2-cyclohexyloxy-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H -imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid (2-cyano-ethyl)-amide, trans-isomer, (Compound A1947);

2-[5-(2-Isopropoxy-pyrimidin-4-yl)-4-(4-fluoro-phenyl)- 1H-imidazol- 2-yl]-5-methyl- E1,3] dioxane- 5-carboxylic acid (2-cyano-ethyl)-amide, trans-isomer, (Compound A1948); <BR> <BR> <BR> 2-[4-(4-fluoro-phenyl)-5-(2-propoxy-pyrimidin-4-yl)-111-imid azol-2-yl]-5-methyl-[1,3]dioxane-5- carboxylic acid (2-cyano-ethyl)-amide, trans-isomer, (Compound A1949); 2-{4-(4-fluoro-phenyl)-5-[2-(2-hydroxy-ethoxy)-pyrimidin-4-y l]-lH-imidazol-2-yl}-5-methyl- [1,3]dioxane-5-carboxylic acid (2-cyano-ethyl)-amide, trans-isomer, (Compound A1950); <BR> <BR> <BR> 2-(4-(4-fluoro-phenyl)-5-[2-(3-hydroxy-propoxy)-pyrimidin-4- yli-111-imidazol-2-yl)-5-methyl- [1,3]dioxane-5-carboxylic acid (2-cyano-ethyl)-amide, trans-isomer, (Compound A1951); 2-[4-(4-fluoro-phenyl)-5-(2-methylsulfanyl-pyrimidin-4-yl)-l H-imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid (2-cyano-ethyl)-amide, trans-isomer, (Compound A1952); 2-[5-(2-amino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-lH-imidazo l-2-yl]-5-methyl-[1,3]dioxane-5- carboxylic acid pyridin-3-ylamide, trans-isomer, (Compound A1953); 2-[4-(4-fluoro-phenyl)-5-(2-methylamino-pyrimidin-4-yl)-lH-i midazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid pyridin-3-ylamide, trans-isomer, (Compound A1954); 2-[5-(2-dimethylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-lH -imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid pyridin-3-ylamide, trans-isomer, (Compound A1955); 2-[5-(2-cyclopropylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl) -lH-imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid pyridin-3-ylamide, trans-isomer, (Compound A1956); 2-{4-(4-fluoro-phenyl)-5-[2-(piperidin-4-ylamino)-pyrimidin- 4-yl]-1H-imidazol-2-yl}-5-methyl- [1,3]dioxane-5-carboxylic acid pyridin-3-ylamide, trans-isomer, (Compound A1957); 2-[5-(2-cyclohexylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)- 1H-imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid pyridin-3-ylamide, trans-isomer, (Compound A1958); <BR> <BR> <BR> <BR> 2-(4-(4-fluoro-phenyl)-5-[2-(2-hydroxy-ethylamino)-pyrimidin -4-yl]- lH-imidazol-2-yl}-5-methyl- [1,3]dioxane-5-carboxylic acid pyridin-3-ylamide, trans-isomer, (Compound A1959); <BR> <BR> <BR> 2-[5-[2-(2-amino-ethylamino)-pyrimidin-4-yl]-4.(4-fluoro-phe nyl)-1H-imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid pyridin-3-ylamide, trans-isomer, (Compound A1960); 2-(4-(4-fluoro-phenyl)-5-{2-[3-(5H-imidazol-1-yl)-propylamin o]-pyrimidin-4-yl}-1H-imidazol-2- yl)-5-methyl-[1,3]dioxane-5-carboxylic acid pyridin-3-ylamide, trans-isomer, (Compound A1961); <BR> <BR> <BR> 2-{4-(4-fluoro-phenyl)-5-[2-(3-morpholin-4-yl-propylamino)-p yrimidin-4-yl]- 1H-imidazol-2-yl)- 5-methyl-[1,3]dioxane-5-carboxylic acid pyridin-3-ylamide, trans-isomer, (Compound A1962); 2-{4-(4-fluoro-phenyl)-5-[2-(3-hydroxy-propylamino)-pyrimidi n-4-yl]-1H-imidazol-2-yl}-5- methyl-[1,3]dioxane-5-carboxylic acid pyridin-3-ylamide, trans-isomer, (Compound A1963); 2-[5-(2-benzylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-i midazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid pyridin-3-ylamide, trans-isomer, (Compound A1964);

2-{4-(4-fluoro-phenyl)-5-[2-(1-phenyl-ethylamino)-pyrimidin- 4-yl]-1H-imidazol-2-yl}-5-methyl- [1,3]dioxane-5-carboxylic acid pyridin-3-ylamide, R-isomer, trans-isomer, (Compound A1965); 2-{4-(4-fluoro-phenyl)-5-[2-(1-phenyl-ethylamino)-pyrimidin- 4-yl]-1H-imidazol-2-yl}-5-methyl- [1,3]dioxane-5-carboxylic acid pyridin-3-ylamide, S-isomer, trans-isomer, (Compound A1966); 2-14-(4-fluoro-phenyl)-5-(2-phenylamino-pyrimidin-4-yl)-lH-i midazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid pyridin-3-ylamide, trans-isomer, (Compound A1967); 2-[4-(4-fluoro-phenyl)-5-(2-piperidin-1-yl-pyrimidin-4-yl)-1 H-imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid pyridin-3-ylamide, trans-isomer, (Compound A1968); 2-(4-(4-fluoro-phenyl)-5-{2-[(pyridin-4-ylmethyl)-amino]-pyr imidin-4-yl}-1H-imidazol-2-yl)-5- methyl-[1,3]dioxane-5-carboxylic acid pyridin-3-ylamide, trans-isomer, (Compound A1969); 2-(4-(4-fluoro-phenyl)-5-{2-[(pyridin-3-ylmethyl)-amino]-pyr imidin-4-yl}-1H-imidazol-2-yl)-5- methyl-[1,3]dioxane-5-carboxylic acid pyridin-3-ylamide, trans-isomer, (Compound A1970); 2-(4-(4-fluoro-phenyl)-5-{2-[(pyridin-2-ylmethyl)-amino]-pyr imidin-4-yl}-1H-imidazol-2-yl)-5- methyl-[1,3]dioxane-5-carboxylic acid pyridin-3-ylamide, trans-isomer, (Compound A1971); 2-(4-(4-fluoro-phenyl)-5-{2-[(furan-2-ylmethyl)-amino]-pyrim idin-4-yl}-1H-imidazol-2-yl)-5- methyl-[1,3]dioxane-5-carboxylic acid pyridin-3-ylamide, trans-isomer, (Compound A1972); 2-(4-(4-fluoro-phenyl)-5-{2-[(thiophen-2-ylmethyl)-amino]-py rimidin-4-yl}-1H-imidazol-2-yl)-5- methyl-[1,3]dioxane-5-carboxylic acid pyridin-3-ylamide, trans-isomer, (Compound A1973); <BR> <BR> <BR> 2-(4-(4-fluoro-phenyl)-5-{2-[(tetrahydro-furan-2-ylmethyl)-a mino]-pyrimidin-4-yl}-lH-imidazol- 2-yl)-5-methyl-[1,3]dioxane-5-carboxylic acid pyridin-3-ylamide, trans-isomer, (Compound A1974); 2-(4-(4-fluoro-phenyl)-5- [2- (4-methyl-piperazin- l-yl) -pyrimidin4-yl]- IH-imidazol-2-yl )-5- methyl-[1,3]dioxane-5-carboxylic acid pyridin-3-ylamide, trans-isomer, (Compound A1975); 2-[4-(4-fluoro-phenyl)-5-(2-morpholin-4-yl-pyrimidin-4-yl)-1 H-imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid pyridin-3-ylamide, trans-isomer, (Compound A1976); 2-{4-(4-fluoro-phenyl)-5-[2-(3-methoxy-propylamino)-pyrimidi n-4-yl]-1H-imidazol-2-yl}-5- methyl-[1,3]dioxane-5-carboxylic acid pyridin-3-ylamide, trans-isomer, (Compound A1977); 2-{4-(4-fluoro-phenyl)-5-[2-(2-methoxy-ethylamino)-pyrimidin -4-yl]-1H-imidazol-2-yl}-5-methyl- [1,3]dioxane-5-carboxylic acid pyridin-3-ylamide, trans-isomer, (Compound A1978); 2-[5-[2-(3-dimethylamino-propylamino)-pyrimidin-4-yl]-4-(4-f luoro-phenyl)-1H-imidazol-2-yl]- 5-methyl-[1,3]dioxane-5-carboxylic acid pyridin-3-ylamide, trans-isomer, (Compound A1979); 2-[5-[2-(2-dimethylamino-ethylamino)-pyrimidin-4-yl]-4-(4-fl uoro-phenyl)-1H-imidazol-2-yl]-5- methyl-[1,3]dioxane-5-carboxylic acid pyridin-3-ylamide, trans-isomer, (Compound A1980); (4-{5-(4-fluoro-phenyl)-2-[5-methyl-5-(pyridin-3-ylcarbamoyl )-[1,3]dioxan-2-yl]-3H-imidazol-4- yl}-pyrimidin-2-ylamino)-acetic acid, trans-isomer, (Compound A1981);

3-(4-(5-(4-fluoro-phenyl)-2- [5-methyl-5- (pyridin-3-ylcarbamoyl)-[ 1,3]dioxan-2-yl]-3H-imidazoi- 4-yl}-pyrimidin-2-ylamino)-propionic acid, trans-isomer, (Compound A1982); 2-[4-(4-fluoro-phenyl)-5-(2-isopropylamino-pyrimidin-4-yl)-1 H-imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid pyridin-3-ylamide, trans-isomer, (Compound A1983); 2-[5-(2-allylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-im idazol-2-yl]-5-methyl-[1,3]dioxane- 5-carboxylic acid pyridin-3-ylamide, trans-isomer, (Compound A1984); 2- [5- [2-(cyclop ropylmethyl- amino)-py rimidin4-yl ] -4-(4-fluoro- phenyl)-l H-imidazol-Zyl] -5 - methyl-[1,3]dioxane-5-carboxylic acid pyridin-3-ylamide, trans-isomer, (Compound A1985); 2-[5-[2-(cyanomethyl-amino)-pyrimidin-4-yl]-4-(4-fluoro-phen yl)-1H-imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid pyridin-3-ylamide, trans-isomer, (Compound A1986); <BR> <BR> <BR> 2-[5- [2-(2-cyano-ethylamino)-pyrimidin-4-yl] -4-(4-fluoro-phenyl)- IH-imidazol-Zyl] -5-methyl- [1,3]dioxane-5-carboxylic acid pyridin-3-ylamide, trans-isomer, (Compound A1987); 2-{4-(4-fluoro-phenyl)-5-[2-(pyridin-3-ylamino)-pyrimidin-4- yl]-1H-imidazol-2-yl}-5-methyl- [1,3]dioxane-5-carboxylic acid pyridin-3-ylamide, trans-isomer, (Compound A1988); 2-{4-(4-fluoro-phenyl)-5-[2-(pyridin-4-ylamino)-pyrimidin-4- yl]-1H-imidazol-2-yl}-5-methyl- [1,3]dioxane-5-carboxylic acid pyridin-3-ylamide, trans-isomer, (Compound A1989); 2-[4-(4-fluoro-phenyl)-5-(2-propylamino-pyrimidin-4-yl)-lH-i midazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid pyridin-3-ylamide, trans-isomer, (Compound A1990); 2-[4-(4-fluoro-phenyl)-5-(2-pyrrolidin-1-yl-pyrimidin-4-yl)- 1H-imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid pyridin-3-ylamide, trans-isomer, (Compound A1991); 2-{4-(4-fluoro-phenyl)-5-[2-(4-fluoro-phenylamino)-pyrimidin -4-yl]-1H-imidazol-2-yl}-5-methyl- [1,3]dioxane-5-carboxylic acid pyridin-3-ylamide, trans-isomer, (Compound A1992); 2-[5-[2-(3,4-difluoro-phenylamino)-pyrimidin-4-yl]-4-(4-fluo ro-phenyl)-1H-imidazol-2-yl]-5- methyl-[1,3]dioxane-5-carboxylic acid pyridin-3-ylamide, trans-isomer, (Compound A1993); 2-{4-(4-fluoro-phenyl)-5-[2-(3-methoxy-phenylamino)-pyrimidi n-4-yl]-1H-imidazol-2-yl}-5- methyl-[1,3]dioxane-5-carboxylic acid pyridin-3-ylamide, trans-isomer, (Compound A1994); 2-[5-[2-(4-fluoro-benzylamino)-pyrimidin-4-yl]-4-(4-fluoro-p henyl)-1H-imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid pyridin-3-ylamide, trans-isomer, (Compound A1995); 2-{4-(4-fluoro-phenyl)-5- [2-(4-methoxy-benzylamino)-pyrimidin-4-yl]-lH-imidazol-2-yl} -5- methyl-[1,3]dioxane-5-carboxylic acid pyridin-3-ylamide, trans-isomer, (Compound A1996); 2-[4-(4-fluoro-phenyl)-5-(2-methoxy-pyrimidin-4-yl)-1H-imida zol-2-yl]-5-methyl-[1,3]dioxane-5- carboxylic acid pyridin-3-ylamide, trans-isomer, (Compound A1997); 2-[5-(2-benzyloxy-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imi dazol-2-yl]-5-methyl-[1,3]dioxane- 5-carboxylic acid pyridin-3-ylamide, trans-isomer, (Compound A1998); 2-[4-(4-fluoro-phenyl)-5-(2-phenoxy-pyrimidin-4-yl)-1H-imida zol-2-yl]-5-methyl-[1,3]dioxane-5- carboxylic acid pyridin-3-ylamide, trans-isomer, (Compound A1999);

2-{4-(4-fluoro-phenyl)-5- [2-(2-methoxy-ethoxy)-pyrimidin-4-yl]- lH-imidazol-2-yl}-5-methyl- [1,3]dioxane-5-carboxylic acid pyridin-3-ylamide, trans-isomer, (Compound A2000); 2-[5-[2-(2-dimethylamino-ethoxy)-pyrimidin-4-yl]-4-(4-fluoro -phenyl)- lH-imidazol-2-yl]-5- methyl-[1,3]dioxane-5-carboxylic acid pyridin-3-ylamide, trans-isomer, (Compound A2001); 2-[5-(2-cycloheXyloxy-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-lH -imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid pyridin-3-ylamide, trans-isomer, (Compound A2002); <BR> <BR> <BR> <BR> 2-[5-(2-Isopropoxy-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-lH-im idazol-2-yl]-5-methyl-[1,3]dioxane- 5-carboxylic acid pyridin-3-ylamide, trans-isomer, (Compound A2003); 2-[4-(4-fluoro-phenyl)-5-(2-propoxy-pyrimidin-4-yl)- lH-imidazol-2-yl]-5-methyl-[1,3]dioxane-5- carboxylic acid pyridin-3-ylamide, trans-isomer, (Compound A2004); 2-{4(4-fluoro-phenyl)-5-[2-(2-hydroxy-ethoxy)-pyrimidin-4-yl i-111-imidazol-2-yl)-5-methyl- [1,3]dioxane-5-carboxylic acid pyridin-3-ylamide, trans-isomer, (Compound A2005); 2-{4-(4-fluoro-phenyl)-5-[2-(3-hydroxy-propoxy)-pyrimidin-4- yl]-1H-imidazol-2-yll-5-methyl- [1,3]dioxane-5-carboxylic acid pyridin-3-ylamide, trans-isomer, (Compound A2006); 2-[4-(4-fluoro-phenyl)-5-(2-methylsulfanyl-pyrimidin-4-yl)-1 H-imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid pyridin-3-ylamide, trans-isomer, (Compound A2007); 2-[5-(2-amino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazo l-2-yl]-5-methyl-[1,3]dioxane-5- carboxylic acid pyridin-4-ylamide, trans-isomer, (Compound A2008); 2-[4-(4-fluoro-phenyl)-5-(2-methylamino-pyrimidin-4-yl)-1H-i midazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid pyridin-4-ylamide, trans-isomer, (Compound A2009); 2-[5-(2-dimethylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H -imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid pyridin-4-ylamide, trans-isomer, (Compound A2010); 2-[5-(2-cyclopropylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl) -lH-imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid pyridin-4-ylamide, trans-isomer, (Compound A2011); <BR> <BR> <BR> <BR> 2-{4-(4-fluoro-phenyl)-5-[2-(piperidin-4-ylamino)-pyrimidin- 4-yl]- 1H-imidazol-2-yl)-5-methyl- [1,3]dioxane-5-carboxylic acid pyridin-4-ylamide, trans-isomer, (Compound A2012); 2-[5-(2-cyclohexylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)- 1H-imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid pyridin-4-ylamide, trans-isomer, (Compound A2013); 2-{4-(4-fluoro-phenyl)-5-[2-(2-hydroxy-ethylamino)-pyrimidin -4-yl]-1H-imidazol-2-yl}-5-methyl- [1,3]dioxane-5-carboxylic acid pyridin-4-ylamide, trans-isomer, (Compound A2014); 2-[5-[2-(2-amino-ethylamino)-pyrimidin-4-yl]-4-(4-fluoro-phe nyl)-1H-imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid pyridin-4-ylamide, trans-isomer, (Compound A2015); 2-(4-(4-fluoro-phenyl)-5-{2-[3-(5H-imidazol-1-yl)-propylamin o]-pyrimidin-4-yl}-1H-imidazol-2- yl)-5-methyl-[1,3]dioxane-5-carboxylic acid pyridin-4-ylamide, trans-isomer, (Compound A2016);

2-{4-(4-fluoro-phenyl)-5-[2-(3-morpholin-4-yl-propylamino)-p yrimidin-4-yl]-1H-imidazol-2-yl}- 5-methyl-[1,3]dioxane-5-carboxylic acid pyridin-4-ylamide, trans-isomer, (Compound A2017); 2-{4-(4-fluoro-phenyl)-5-[2-(3-hydroxy-propylamino)-pyrimidi n-4-yl]-1H-imidazol-2-yl}-5- methyl-[1,3]dioxane-5-carboxylic acid pyridin-4-ylamide, trans-isomer, (Compound A2018); 2-[5-(2-benzylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-i midazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid pyridin-4-ylamide, trans-isomer, (Compound A2019); 2-{4-(4-fluoro-phenyl)-5-[2-(1-phenyl-ethylamino)-pyrimidin- 4-yl]-1H-imidazol-2-yl}-5-methyl- [1,3]dioxane-5-carboxylic acid pyridin-4-ylamide, R-isomer, trans-isomer, (Compound A2020); 2-{4-(4-fluoro-phenyl)-5-[2-(1-phenyl-ethylamino)-pyrimidin- 4-yl]-1H-imidazol-2-yl}-5-methyl- [1,3]dioxane-5-carboxylic acid pyridin-4-ylamide, S-isomer, trans-isomer, (Compound A2021); 2-[4-(4-fluoro-phenyl)-5-(2-phenylamino-pyrimidin-4-yl)-1H-i midazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid pyridin-4-ylamide, R-isomer, trans-isomer, (Compound A2022); 2-[4-(4-fluoro-phenyl)-5-(2-piperidin-1-yl-pyrimidin-4-yl)-1 H-imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid pyridin-4-ylamide, S-isomer, trans-isomer, (Compound A2023); 2-(4-(4-fluoro-phenyl)-5-{2-[(pyridin-4-ylmethyl)-amino]-pyr imidin-4-yl}-1H-imidazol-2-yl)-5- methyl-[1,3]dioxane-5-carboxylic acid pyridin-4-ylamide, trans-isomer, (Compound A2024); 2-(4-(4-fluoro-phenyl)-5-{2-[(pyridin-3-ylmethyl)-amino]-pyr imidin-4-yl}-1H-imidazol-2-yl)-5- methyl-[1,3]dioxane-5-carboxylic acid pyridin-4-ylamide, trans-isomer, (Compound A2025); <BR> <BR> <BR> 2-(4-(4-fluoro-phenyl)-5-{2-[(pyridin-2-ylmethyl)-amino]-pyr imidin-4-yl}-lH-imidazol-2-yl)-5- methyl-[1,3]dioxane-5-carboxylic acid pyridin-4-ylamide, trans-isomer, (Compound A2026); 2-(4-(4-fluoro-phenyl)-5-{2-[(furan-2-ylmethyl)-amino]-pyrim idin-4-yl}-1H-imidazol-2-yl)-5- methyl-[1,3]dioxane-5-carboxylic acid pyridin-4-ylamide 2-(4-(4-fluoro-phenyl)-5-(2-[(thiophen- 2-ylmethyl)-amino]-pyrimidin-4-yl )-1H-imidazol-2-yl)-5-methyl- [1,3]dioxane-5-carboxylic acid pyridin-4-ylamide, trans-isomer, (Compound A2027); 2-(4-(4-fluoro-phenyl)-5-{2-[(thiophen-2-ylmethyl)-amino]-py rimidin-4-yl}-1H-imidazol-2-yl)-5- methyl-[1,3]dioxane-5-carboxylic acid pyridin-4-ylamide, trans-isomer, (Compound A2028); <BR> <BR> <BR> 2-(4-(4-fluoro-phenyl)-5-{2-[(tetrahydro-furan-2-ylmethyl)-a mino]-pyrimidin-4-yl}-lH-imidazol- 2-yl)-5-methyl-[1,3]dioxane-5-carboxylic acid pyridin-4-ylamide, trans-isomer, (Compound A2029); 2-{4-(4-fluoro-phenyl)-5-[2-(4-methyl-piperazin-1-yl)-pyrimi din-4-yl]-1H-imidazol-2-yl}-5- methyl-[1,3]dioxane-5-carboxylic acid pyridin-4-ylamide, trans-isomer, (Compound A2030); 2-[4-(4-fluoro-phenyl)-5-(2-morpholin-4-yl-pyrimidin-4-yl)-1 H-imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid pyridin-4-ylamide, trans-isomer, (Compound A2031); 2-{4-(4-fluoro-phenyl)-5-[2-(3-methoxy-propylamino)-pyrimidi n-4-yl]-1H-imidazol-2-yl}-5- methyl-[1,3]dioxane-5-carboxylic acid pyridin-4-ylamide, trans-isomer, (Compound A2032);

2-{4-(4-fluoro-phenyl)-5 -[2-(2-methoxy-ethylamino)-pyrimidin-4-yl]-lH-imidazol-2-yl} -5-methyl- [1,3]dioxane-5-carboxylic acid pyridin-4-ylamide, trans-isomer, (Compound A2033); <BR> <BR> <BR> 2-[5-[2-(3-dimethylamino-propylamino)-pyrimidin-4-yl]-4-(4-f luoro-phenyl)-lH-imidazol-2-yl]- 5-methyl-[1,3]dioxane-5-carboxylic acid pyridin-4-ylamide, trans-isomer, (Compound A2034); <BR> <BR> <BR> 2-[5-[2-(2-dimethylamino-ethylamino)-pyrimidin-4-yl]-4-(4-fl uoro-phenyl)-lH-imidazol-2-yl]-5- methyl-[1,3]dioxane-5-carboxylic acid pyridin-4-ylamide, trans-isomer, (Compound A2035); <BR> <BR> <BR> (4-{5-(4-fluoro-phenyl)-2-[5-methyl-5-(pyridin-4-ylcarbamoyl )-[1,3]dioxan-2-yl]-3H-imidazol-4- yl}-pyrimidin-2-ylamino)-acetic acid, trans-isomer, (Compound A2036); 3-(4-{5-(4-fluoro-phenyl)-2-[5-methyl-5-(pyridin-4-ylcarbamo yl)-[1,3]dioxan-2-yl]-3H-imidazol- 4-yl)-pyrimidin-2-ylamino)-propionic acid, trans-isomer, (Compound A2037); 2-[4-(4-fluoro-phenyl)-5(2-isopropylamino-pyrimidin-4-yl)-1H -imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid pyridin-4-ylamide, trans-isomer, (Compound A2038); 2-[5-(allylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imid azol-2-yl]-5-methyl-[1,3]dioxane- 5-carboxylic acid pyridin-4-ylamide, trans-isomer, (Compound A2039); 2-[5-[2-(cyclopropylmethyl-amino)-pyrimidin-4-yl]-4-(4-fluor o-phenyl)-1H-imidazol-2-yl]-5- methyl-[1,3]dioxane-5-carboxylic acid pyridin-4-ylamide, trans-isomer, (Compound A2040); 2-[5-[2-(cyanomethyl-amino)-pyrimidin-4-yl]-4-(4-fluoro-phen yl)-1H-imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid pyridin-4-ylamide, trans-isomer, (Compound A2041); 2-[5-[2-(cyano-ethylamino)-pyrimidin-4-yl]-4-(4-fluoro-pheny l)-1H-imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid pyridin-4-ylamide, trans-isomer, (Compound A2042); 2-{4-(4-fluoro-phenyl)-5-(2-(pyridin-3-ylamino)-pyrimidin-4- yl]-1H-imidazol-2-yl}-5-methyl- [1,3]dioxane-5-carboxylic acid pyridin-4-ylamide, trans-isomer, (Compound A2043); 2-{4-(4-fluoro-phenyl)-5-(2-(pyridin-4-ylamino)-pyrimidin-4- yl]-1H-imidazol-2-yl}-5-methyl- [1,3]dioxane-5-carboxylic acid pyridin-4-ylamide, trans-isomer, (Compound A2044); 2-[4-(4-fluoro-phenyl)-5(2-propylamino-pyrimidin-4-yl)-1H-im idazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid pyridin-4-ylamide, trans-isomer, (Compound A2045); 2-[4-(4-fluoro-phenyl)-5(2-pyrroldin-1-yl-pyrimidin-4-yl)-1H -imidazol-2-yl]-5-methyl- [1,3idioxane-5-carboxylic acid pyridin-4-ylamide, trans-isomer, (Compound A2046); 2-{4-(4-fluoro-phenyl)-5-(2-(4-fluoro-phenylamino)-pyrimidin -4-yl]-1H-imidazol}-2-yl}-5-methyl- [1,3]dioxane-5-carboxylic acid pyridin-4-ylamide, trans-isomer, (Compound A2047); 2-[5-[2-(3,4-difluoro-phenylamino)-pyrimidin-4-yl]-4-(4-fluo ro-phenyl)-1H-imidazol-2-yl}-5-methyl- methyl-[1,3]dioxane-5-carboxylic acid pyridin-4-ylamide, trans-isomer, (Compound A2048); 2-{4-(4-fluoro-phenyl)-5-(2-(3-methoxy-phenylamino)-pyrimidi n-4-yl]-1H-imidazol}-2-yl}-5- methyl-[1,3]dioxane-5-carboxylic acid pyridin-4-ylamide, trans-isomer, (Compound A2049); 2-[5-[2-(4-fluoro-benzylamino)-pyrimidin-4-yl]-4-(4-fluoro-p henyl)-1H-imidazol-2-yl}-5-methyl- [1,3]dioxane-5-carboxylic acid pyridin-4-ylamide, trans-isomer, (Compound A2050);

2-{4-(4-fluoro-phenyl)-5-[2-(4-methoxy-benzylamino)-pyrimidi n-4-yl]-lH-imidazol-2-yl}-5- methyl-[1,3]dioxane-5-carboxylic acid pyridin-4-ylamide, trans-isomer, (Compound A2051); <BR> <BR> <BR> 2-[4-(4-fluoro-phenyl)-5-(2-methoxy-pyrimidin-4-yl)- lH-imidazol-2-yl]-5-methyl-[1,3]dioxane-5- carboxylic acid pyridin-4-ylamide, trans-isomer, (Compound A2052); 2-[5-(2-benzyloxy-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imi dazol-2-yl]-5-methyl-[1,3]dioxane- 5-carboxylic acid pyridin-4-ylamide, trans-isomer, (Compound A2053); 2-[4-(4-fluoro-phenyl)-5-(2-phenoxy-pyrimidin-4-yl)-1H-imida zol-2-yl]-5-methyl[1,3]dioxane-5- carboxylic acid pyridin-4-ylamide, trans-isomer, (Compound A2054); 2-{4-(-fluoro-phenyl)-5-[2-(2-methoxy-ethoxy)-pyrimidin-4-yl ]-1H-imidazol-2-yl}-5-methyl- [1,3]dioxane-5-carboxylic acid pyridin-4-ylamide, trans-isomer, (Compound A2055); 2-[5-[2-(2-dimethylamino-ethoxy)-pyrimidin-4-yl)-4-(4-fluoro -phenyl)-1H-imidazol-2-yl]-5- methyl-[1,3]dioxane-5-carboxylic acid pyridin-4-ylamide, trans-isomer, (Compound A2056); 2-[5-(2-cyclohexyloxy-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H -imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid pyridin-4-ylamide, trans-isomer, (Compound A2057); <BR> <BR> <BR> 2-[5-(2-Isopropoxy-pyrimidin-4-yl)-4-(4-fluoro-phenyl) 1H-imidazol-2-yl]-5-methyl-[1,3]dioxane 5-carboxylic acid pyridin-4-ylamide, trans-isomer, (Compound A2058); 2-[4-(4-fluoro-phenyl)-5-(2-propoxy-pyrimidin-4-yl)-1H-imida zol-2-yl]-5-methyl-[1,3]dioxane-5- carboxylic acid pyridin-4-ylamide, trans-isomer, (Compound A2059); 2-{4-(4-fluoro-phenyl)-5-[2-(2-hydroxy-ethoxy)-pyrimidin-4-y l]-1H-imidazol-2-yl}-5-methyl- [1,3]dioxane-5-carboxylic acid pyridin-4-ylamide, trans-isomer, (Compound A2060); 2-{4-(4-fluoro-phenyl)-5-[2-(2-hydroxy-propoxy)-pyrimidin-4- yl]-1H-imidazol-2-yl}-5-methyl- [1,3]dioxane-5-carboxylic acid pyridin-4-ylamide, trans-isomer, (Compound A2061); 2-[4-(4-fluoro-phenyl)-5-(2-methylsulfanyl-pyrimidin-4-yl)-1 H-imidazol-2-yl]-5-methyl- [1,3]dioxane-5-carboxylic acid pyridin-4-ylamide, trans-isomer, (Compound A2062); (c) By proceeding in a similar manner to Example 40 (b) but using 2-[4-(4-fluorophenyl)-5- (2-methylsulpheonylpyrimidin-4-yl)-1H-imidazol-2-yl]-5-methy l-[1,3]dioxan-5-carboxylic acid methyl ester, cis isomer (Compound LN) there is prepared the corresponding cis-isomers of Compound GT and Compounds A557 to A2062.

REFERENCE EXAMPLE 1 <BR> <BR> <BR> 4- r5-(4-Fluoro-phenvl )-2formvl-l- r(2-(trimethvlsilvl)ethoxv)methvll- 1H-imidazol-4-vll-psridine A solution of 4-[5-(4-fluoro-phenyl)-1-[(2-(trimethylsilyl)ethoxy)methyl]- lH-imidazol-4-yl]- pyridine (8.15g, reference Example 2) in tetrahydrofuran (100ml) was treated with a solution of n-butyllithium in hexane (10.6ml, 2.1M) to give a dark green solution. The solution was stirred at -78~C for 15 minutes then treated with a solution of N-formylmorpholine (2.45ml) in tetrahydrofuran (10ml). After stirring for 15 minutes at -780C, the mixture was allowed to warm to room temperature then stirred at this temperature for a further 1 hour. The reaction mixture was quenched with water (50ml) and then extracted four times with ethyl acetate (50ml).

The combined extracts were dried over magnesium sulphate and evaporated. The residual oil was subjected to flash chromatography on silica, eluting with ethyl acetate, to give the title compound (7.86g) as a yellow oil.

REFERENCE EXAMPLE 2 4-r5-(4-Fluoro-phenvl)-l-r(2-(trimethvlsilvl)ethoxv)methvll- lH-imidazol-4-vll-pvridine A stirred solution of 5-(4-fluoro-phenyl)-4-(4-pyridyl)-imidazole [BOEHM ET AL.,] (12.86g, prepared according to the procedure of Boehm et. al., J.Med.Chem., 1996, 39, page 3829-3937) in dry dimethylformamide (150ml) was treated portionwise with sodium hydride (2.58g, 60% dispersion in mineral oil). The mixture was stirred at room temperature until the evolution of hydrogen stopped, then treated dropwise with 2-(trimethylsilyl)ethoxymethyl chloride (10.66ml).

After stirring at room temperature for 1.5 hours, the reaction mixture was treated with water (10ml) then evaporated. The residual oil was then partitioned between ethyl acetate and water (lOOml). The aqueous phase was extracted three times with ethyl acetate (100ml). The combined organic phases were washed with brine (50ml), then dried over magnesium sulphate, then evaporated. The residual yellow oil was subjected to flash chromatography on silica eluting with a mixture of methanol and dichloromethane (98:2, v/v) to give the title compound.

REFERENCE EXAMPLE 3 4- r2-Dimethoxvmethvl-5-(4-fluoro- phenvl)- 1H-imidazo~l-4-vll-pvridine Method A: A solution of 4-[2-formyl-5-(4-fluoro-phenyl)-1-{(2-(trimethylsilyl)ethoxy )-methyl}- lH-imidazol-4-yl]-pyridine (0.525g, Reference Example 1) in methanol (10ml) was treated with trimethylorthoformate (5ml) then with 4-toluenesulphonic acid (0.39g). The reaction mixture was refluxed for 5 hours, then cooled to room temperature, then evaporated. The residue was partitioned between ethyl acetate and saturated aqueous sodium bicarbonate solution (30ml).

The aqueous phase was extracted four times with ethyl acetate (20ml). The combined organic phases were washed with water (15ml), then with brine (15ml), then dried over magnesium

sulphate and then evaporated. The residual oil was subjected to flash chromatography on silica eluting with a mixture of dichloromethane and methanol (8:1, v/v) to give the title compound (0.344g) as a white solid, m.p. 186-189"C.

Method B: A stirred suspension of 1-(4-fluorophenyl)-2-(4-pyridyl)-1,2-ethandione (162.74g, Reference Example 10) in tert-butylmethyl ether (735ml), at 20-25"C, was treated with a solution of glyoxal 1,1-dimethylacetal in tert-butylmethyl ether (244.4ml, 45 %) followed by a solution of ammonium acetate (140.75g) in methanol (260ml) over a period of 30 minutes, during which time the suspension dissolved to form an orange solution. After stirring for 1 hour at 20-25~C, the resulting suspension was cooled to 5-10"C, then stirred for a further 1 hour, then filtered. The damp filter cake was slurry washed three times with water (350ml) and then the pressed cake washed twice with tert-butylmethyl ether (350ml). The air-dry cake was then dried in vacuo at 60-650C for 16 hours, to afford the title compound, as a cream coloured, free-flowing solid, m.p.

204-206"C. 111 NMR [6, (CD3)2SO]: 8.35 (d, 2H); 7.43 (dt, 2H); 7.36 (d, 2H); 7.19 (dt, 2H); 5.39 (s, 1H); 3.34 (s, 6H).

REFERENCE EXAMPLE 4 2-methvl-2-trifluoroacetamido-1.3-propanediol A stirred solution of 2-amino-2-methyl-1,3-propanediol (1.05g) in dry dimethylformamide (20ml), at room temperature, was treated with potassium carbonate (1.52g). After stirring at room temperature for 15 minutes the mixture was treated dropwise with trifluoroacetic anhydride (1.55ml) and stirring was then continued for a further 18 hours. The reaction mixture was evaporated and the residue was subjected to flash chromatography on silica eluting with a mixture of dichloromethane and methanol (95:5, v/v) to give the title compound (lug) as a white solid.

REFERENCE EXAMPLE 5 2-azidomethvl-2-methvl-1 3-propanediol A mixture of 5-azidomethyl-2-dimethyl-5-methyl-1,3-dioxane [1.48g, prepared according to the procedure in J.Org.Chem., 1992, page 6080] concentrated hydrochloric acid (0.3ml), water (0.8ml) and tetrahydrofuran (10ml) was heated at reflux for 1 hour. After cooling to room temperature the reaction mixture was evaporated. The residue was dried under vacuum to give the title compound (1.3g) as a colourless oil.

REFERENCE EXAMPLE 6 3-hvdroxv-2-hvdroxvmethvl-2-methvl-1-morpholino-1-propanone A stirred mixture of diisopropylethylamine (339.67ml) and morpholine (141.71ml) in acetonitrile (500ml), at 20-25"C, was treated with 2,2-bis(hydroxymethyl)propionic acid (87.18g) and 1-hydroxybenzotriazole (43.92g). The resulting suspension was warmed to 55-600C then treated dropwise with a solution of 1,3-dicyclohexylcarbodiimide (147.62g) in acetonitrile (232.2ml) over 30 minutes. The resulting solution was then stirred at 55-600C for a further 2 hours then filtered to remove the dicyclohexylurea (131.88g) by-product. The filter cake was washed twice with acetonitrile (250ml). The filtrate was evaporated and the residue was treated with warm ethyl acetate (500ml). The resultant solution was allowed to cool for 16 hours then the 1-hydroxybenzotriazole (42.04 g) which crystallised was removed by filtration. Further cooling of the filtrate over 5 hours and filtration gave the title compound (44.82g), m.p. 95-97"C. lH NMR (d, CD Cl3): 4.02 (d, 2H); 3.70 (m, 10H); 3.30 (bs, 2H); 1.08 (s, 3H).

A further quantity of the title compound (41.33g) was obtained following evaporation of the filtrate from the first crop of product, then treating the residue with ethyl acetate (1000ml), then passing the solution through a silica gel pad (4cm high x 11cm diameter), then evaporating the filtrate and then crystallising the residue from n-butyl acetate (1000ml) over 16 hours.

REFERENCE EXAMPLE 7 <BR> <BR> <BR> 4-r2-Dimethoxvmethvl-5(4)-(4-fluoro-Phenvl)-lH-imidazol-4(5) -vll-2-methanesulphanyl- <BR> <BR> <BR> <BR> <BR> pvrimidine A solution of 1-(4-fluorophenyl)-2-(2-methylsulphanylpyrimidin-4-yl)- 1,2-ethandione (18.7g, Reference Example 8) in t-butyl methyl ether (75ml) and glyoxal dimethylacetal in t-butylmethyl ether (36ml, 40%), at room temperature, was treated dropwise over 30 minutes with a solution of ammonium acetate (21.7g) in methanol (40ml) to give an orange solution.

After stirring for 2 hours at room temperature the resulting suspension was filtered to give the title compound (15.6g) as a colourless solid, m.p. 180-182"C. MH+ 361.

REFERENCE EXAMPLE 8 1-(4-fluorophenvl)-2-(2-methvlsulPhanvlpvrimidin-4-vl)-1.2-e thandione A solution of 1-(4-fluorophenyl)-2-(2-methylsulphanylpyrimidin-4-yl)-1-eth anone(65.5g, Reference Example 9) in dimethylsulphoxide, at 55-700C, was treated dropwise with an aqueous solution of hydrogen bromide (48%). After stirring at 600C for 3 hours, the reaction mixture was cooled to room temperature, then poured into water and the pH of the mixture adjusted to p118 by addition of sodium bicarbonate. The reaction mixture was extracted with ethyl acetate and the extracts were evaporated to give the title compound (40.87g), m.p. 74-76"C. MH+ 277.

REFERENCE EXAMPLE 9 1-(4-fluorophenvl)-2-(2-methvlsulphanylpyrimidin-4-yl)-1-eth anone A solution of lithium hexamethyldisilazane in tetrahydrofuran (1.221, 1M), at -400C, was treated with a solution of 4-methyl-2-methylsulphanylpyrimidine (76.03g) in tetrahydrofuran (100ml).

The solution was warmed to OOC, then stirred for 15 minutes, then cooled to -400C, then treated with a solution of ethyl 4-fluorobenzoate (91.32g) in tetrahydrofuran (200ml). After stirring at -40~C for 15 minutes the reaction mixture was allowed to warm to room temperature over 2 hours, then treated with ammonium chloride solution. The organic phase was separated and the aqueous phase was extracted with ethyl acetate. The combined organic phases were evaporated to give the title compound (136.19g), m.p. 212-214"C. MH+ 263.

REFERENCE EXAMPLE 10 1-(4-fluorophenvl)-2-(4-pvridvl)-1 2-ethandione A mixture of 1-(4-fluorophenyl)-2-(4-pyridyl)-1-ethanone (247.69g, Reference Example 11) was mixed with dimethylsulfoxide (500ml) then warmed on a rotary evaporator (no vacuum). The resulting solution was transferred to a reaction vessel with two rinses of dimethylsulfoxide (500ml and 240ml) incorporated to ensure complete transfer. The resulting solution was then warmed to 55 - 65"C and hydrogen bromide (581.47g) was added at such a rate so as to maintain the solution temperature in the range 55 - 65"C, without the need for any external heating. The solution was stirred at 55 - 65"C for a further 2 hours, when thin layer chromatography on silica indicated the reaction to be complete. The reaction mixture was added to water (4000ml) a separate vessel, with external cooling to maintain a solution temperature in the range 15-25"C.

The residual contents of the reaction vessel were transferred using a further aliquot of water (2000ml). The aqueous solution was then treated with a solution of sodium acetate (600g) in water (2000ml), over 15 minutes, and the resulting suspension was stirred for 2 hours at ambient temperature, then filtered. The filter cake was washed three times with water (500ml), then air-dried for 1 hour, then dried in vacuo for 16 hours at 15-250C to give the title compound (296.93g) as a free-flowing yellow-orange powder, m.p. 84-86"C. 1H NMR (CDCl3): 6 8.81 (d, 2H); 7.98 (dd, 2H); 7.74 (d, 2H); 7.18 (t, 2H).

REFERENCE EXAMPLE 11 1-(4-fluoroPhenvl)-2-(4-pvridvl)- 1 -ethanone A stirred solution of sodium bis(trimethylsilyl)amide in tetrahydrofuran (720ml, 2M), under nitrogen, was treated with 4-picoline (64.7ml). After 5 minutes a solution of ethyl

4-fluorobenzoate (111.7g) was added over 30 minutes whilst maintaining the temperature at 18-20"C by occasional cooling. After stirring at 20-21"C for 30 minutes, the resultant slurry was cooled in an ice-bath then treated with toluene (500ml). When the temperature reached 15"C a solution of acetic acid (82ml) in water (300ml) was added over 15 minutes maintaining the temperature below 25"C. After a further 30 minutes stirring at 20-25~C, the organic phase was separated and then evaporated. The oily residue was triturated with heptane to give the title compound (133g) as a yellow solid, m.p. 80-84"C. 1H NMR (8, CDCl3): 8.42 (d, 2H); 7.88 (dd, 2H); 7.06 (d, 2H, ); 7.01 (t, 2H); 4.12 (s, 2H).

IN VITRO AND IN VIVO TEST PROCEDURES 1. In Vitro Inhibitory Effects on TNF-alpha Release bv Human Monocvtes The effects of compounds on TNF-alpha production by human peripheral blood monocytes (PBMs) are examined as follows.

1.1. Preparation of human peripheral blood monocytes Freshly drawn blood from normal healthy donors was mixed (4:1, v/v) with sodium citrate (3.8%, w/v). Mononuclear cells were prepared by centrifugation of the blood on Histopaque-1077 (Sigma Diagnostics) according to manufacturers instructions. The fraction enriched with mononuclear cells was washed and resuspended in Hank's balanced salts solution (HBSS) supplemented with deoxyribonuclease (37.5 U/ml) and human serum albumin (0.3%).

Differential (cytospin) cell counts revealed that the mononuclear cell fraction routinely comprised 70-80% monocytes.

Cells from the mononuclear leukocyte fraction were centrifuged (200g, 10mien, 20"C), resuspended, at a density of 106 cells/ml, in RPMI 1640 containing foetal calf serum (FCS) (1% ), penicillin (50 U/ml) and streptomycin (50 pLg/ml) and allowed to adhere in 96 well plates.

Following incubation (5% C02, 37"C) for 90min, medium containing non-adherent cells was removed, the cells were washed once with fresh medium and fresh medium was added.

1.2. Measurement of monocvte TNF-alpha release Adherent cells in culture medium were incubated for 1 h (5% C02, 37"C) with fresh medium containing compounds or vehicle (0.1 % dimethylsulphoxide). Compounds were tested within the concentration range of 3x10-9M to 3x10-6M. LPS (10 ng/ml) was then added to the

cells and the incubation continued for a further 18 hours. Cell supernatants were removed into 96 well, 0.22 Rm filtration plates for storage at -200C.

TNF-alpha concentrations in cell supernatants were quantified by sandwich ELISA. Briefly, ELISA plates were coated overnight with 2pg/ml of mouse anti-human TNF-alpha antibody in bicarbonate buffer (pH 9.9). After washing the wells with wash buffer (0.05% (v/v) Tween in PBS),and blocking unoccupied sites (1% BSA in PBS), monocyte supernatant samples or human recombinant TNF-alpha standards were vacuum filtered into the corresponding wells of the ELISA plate. Biotinylated rabbit polyclonal anti-human TNF-alpha antibody (3,ug/ml) was used as the second antibody and streptavidin-horseradish peroxidase was used as the detection antibody. The peroxidase substrate was 3,3',5,5'-tetramethylbenzidine (TMB), in the presence of hydrogen peroxide.

TNFa concentrations in supernatants from control and LPS-stimulated monocyte incubations were calculated by interpolation from a standard (log/log) curve (0.125-16 ng/ml) fitted by linear regression using a Multicaic software program (Wallac U.K., Ltd).

1.3. Results Compounds within the scope of the invention produce 50% inhibition of LPS induced TNF-alpha release from human monocytes at concentrations within the range of 10 9 M to 10 4 M, preferably within the range of 10 9 M to 10 7 M.

2. Inhibitorv effects of compounds on serum TNF-alpha levels in LPS-challenged mice 2.1. Treatment of animals and measurement of murine TNF-alpha.

Female Balb/c mice (age 6-8 weeks, weight 20-22g from Charles River, U.K.) in groups of five or more animals were dosed p.o. with compounds (1 to 100mg/kg) suspended in 1.5% (w/v) carboxymethyl cellulose then challenged after a minimum period of 30 minutes with 30mg of LPS i.p. After 90 minutes, the animals were killed by carbon dioxide asphyxiation and bled by cardiac puncture. Blood was allowed to clot at 4"C, centrifuged (12,000 g for 5 minutes) and serum taken for TNF-alpha analysis. TNF-alpha levels are measured using a commercially available murine TNF-alpha ELISA kit, purchased from Genzyme (Cat. no. 1509.00), as recommended by the manufacturer. Values for TNF-alpha were calculated from a recombinant murine TNF-alpha standard curve as above.